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Abstract
Background
Methadone maintenance treatment has been shown to be the most beneficial and cost 
effective treatment in decreasing heroin dependence and the health and social consequences 
associated with it. Provision of methadone treatment in Australia varies between 
jurisdictions due to the federal and state structure of health service delivery.
There has been limited research comparing outcomes for urban and rural methadone 
clients. Recent research has shown that rural Injecting Drug Users (IDUs) and new entrants 
to methadone treatment programme have poorer outcomes in relation to availability, access, 
cost and confidentiality associated with health service provision and delivery.
Hepatitis C Virus (HCV) has emerged as a major health issue amongst IDUs and it is 
estimated that 60 to 80 per cent are HCV positive. HCV is most effectively transmitted 
through blood and approximately 90 per cent of infections in Australia are associated with 
unsafe injecting drug use. It is thus important for IDUs to be aware of their HCV status and 
to practice behaviours that minimise HCV transmission. Available research suggests that 
IDUs have inaccurate knowledge of actual status, resulting in poor validity of HCV self- 
report as an indicator of true status.
Aims
The study had two aims. Firstly, to measure and compare health outcomes and Blood Borne 
Virus (BBV) transmission risk amongst urban and rural methadone clients, and to identify 
factors significantly associated with these outcomes within the two groups. BBVs of 
interest were Human Immune Deficiency Virus (HIV), Hepatitis B Virus (HBV) and HCV. 
My focus was on BBV risk due to injecting as methadone being orally administered aims to 
decrease the frequency of injecting. The second aim of the study was to investigate the 
validity of HCV self-reported status amongst IDUs by comparing it to serological status.
Methods
The Australian Capital Territory (ACT) methadone treatment programme was chosen to 
represent the urban study group, while the Southern New South Wales (SNSW) programme 
was chosen to represent the rural study group.
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A cross sectional study design and a random sampling strategy were used to minimise 
selection bias into the study. One hundred clients per study group were needed to elicit a 
significant difference of 20 per cent in health and BBV risk outcomes between groups 
(p< 0.05, power=80%). The Opiate Treatment Index (OTI) and Blood Borne Virus Risk 
Assessment TraQ (BBV TraQ) were used to measure health and BBV risk outcomes 
respectively. Sensitivity, specificity, positive and negative predictive values and likelihood 
ratios were used to measure validity of HCV and HIV self-reported status. Serological 
status of the participant at the time of the study was used as the gold standard to ascertain 
HCV status. Validity of HIV self-reported status was measured for comparison.
Results
A total of 118 clients were recruited into the study; 62 in the urban study group (ACT) and 
56 in the rural study group (SNSW). The two study groups were not significantly different 
in relation to most sociodemographic characteristics, previous drug use and risk factors, 
treatment history and BBV serological status. However, programme policy and delivery 
characteristics (such as cost of methadone, cost of travel to dose, takeaway dose policy, and 
access to case managers) significantly differed between the study groups (p<0.05). Overall, 
51 per cent of participants had injected in the month prior to interview. Many participants 
continued to use heroin and other drugs and practice some risky behaviour.
Urban and rural groups did not differ in the magnitude of health outcomes as measured by 
the OTI mean Total Health Score (urban: 13.98, SD 7.72; rural 15.43, SD 7.48, p=0.31) and 
psychological adjustment score (urban: 8.10, SD=7.40; rural: 9.61, SD=8.76, p=0.51). 
However, factors significantly associated with health outcomes in the study groups 
differed. In the urban group, having to pay for their methadone dose was significantly 
associated with poorer health outcomes, while in the rural group, being female, using a 
greater number of other drugs in the month prior to interview and being unsatisfied with 
their programme were significant factors.
Being an urban or rural client was not significantly associated with injecting while on 
treatment. The factors significantly associated with injecting were similar for the two study 
groups. These included living with someone who injected, number of drugs used in the 
month prior to interview and employment being the main income source in the last six 
months prior to interview.
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Like health outcomes, there was no significant difference between the two study groups in 
the magnitude of BBV risk due to injecting as measured by the BBV TraQ injecting risk 
scores (rural=7.75, SD 9.68; urban=5.78, SD 8.93; p=0.42). Factors that were significantly 
associated with injecting with a BBV risk were similar for both study groups (unlike health 
outcomes). These were younger age, frequency of injecting in the month prior to interview, 
number of takeaway doses, number of missed doses per week, and methadone dose. Being 
a rural client was also significantly associated with injecting with a BBV risk.
Overall, 70 per cent (n=76) of all participants who had provided a blood sample (n=l 10) 
had positive HCV serology. A higher proportion of rural participants were positive as 
compared to urban, but this difference was not significant (urban=63%, rural=76%, 
p=0.16). For HIV, all but one participant (108 of 109) had negative serology. Factors 
significantly associated with having a HCV positive serological status were being older 
(40+ years), having a tertiary education, having injected methadone, previous incarceration, 
and not being on methadone treatment while in prison. Overall, validity of HCV positive 
self-reports (sensitivity=87%, positive predictive value=83%, positive likelihood 
ratio=2.12) was better than validity of HCV negative self-reports (specificity=59%, 
negative predictive value=64%, negative likelihood ratio=0.23). Validity of HCV self- 
reports (positive and negative) were better for rural participants, but not significantly 
different to urban participants. Duration between last serological test and provision of self- 
report appeared to affect the validity of self-report.
Conclusion/Implications
Although the magnitude of health and BBV risk outcomes were not significantly different 
for urban and rural study groups, the factors influencing these outcomes differed and were 
either dependent on treatment policy or client characteristics and behaviour. Common 
factors contributing to poorer outcomes within both study groups should be considered in 
the planning and delivery of methadone treatment services in general. Risk factors that 
differed should be considered within urban and rural programmes. Risk factors relevant to 
client characteristics should be addressed at the individual level during enrolment and 
review. Results from the study suggest that validity of HCV self-report continues to be poor 
and reasons should be investigated further. Increased education and more frequent testing 
may be needed within programmes that target IDUs.
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Preface
Preface
This thesis evolved out of working with the SNSW Public Health Unit (PHU), between 
April 1998 and March 2001, where I coordinated the Sexual Health and HCV 
programmes. The HCV programme was introduced as a new national programme with 
the release of the National HCV Strategy in 1999. It was included into the portfolio of 
Sexual Health programmes throughout Australia even though HCV has not been 
conclusively shown to be transmitted sexually. This arrangement although appropriate 
for resource management purposes, made delivery of HCV services to IDUs who were 
the main target group difficult. IDUs accessed the sexual health services for procuring 
clean injecting equipment through the Needle and Syringe Programmes (NSPs). For 
issues related to drug use and dependency, they accessed the Alcohol and other Drug 
(AOD) services. For HCV services to be delivered and utilised appropriately I 
developed linkages with the SNSW AOD programme, and thus became closely 
involved with the methadone treatment programme.
Delivery of HCV services within SNSW were further complicated by rural area specific 
issues such as availability and access to services, cost to the client, client 
confidentiality, and stigmatisation associated with injecting drug use. These issues were 
emphasised more within the methadone treatment programme where policy and service 
delivery varied according to jurisdictional priorities and was not always flexible to the 
needs of the client. Trying to implement and manage the new HCV programme 
instigated my interest in rural health service delivery. The research for my PhD gave me 
the opportunity to examine if differences in delivery of urban and rural methadone 
treatment programmes affected outcomes.
While working with the SNSW PHU, I became involved in a study researching the 
effect of withdrawal of large bore syringes from NSPs on methadone injecting in NSW. 
The study recruited methadone injectors from urban and rural areas. I coordinated the 
rural arm of the study and as an extension to the study I examined the accuracy of HCV 
self-reported status in this group by comparing it to serological antibody status. The 
study found that only 64 per cent of participants who reported their status as positive 
were serologically positive, while only 54 per cent of participants who reported their 
status as negative were serologically negative. The research for my PhD also gave me 
the opportunity to examine the accuracy of HCV self-reported status as a true indicator 
of actual status further, and compare it for urban and rural IDUs.
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Thesis outline
Thesis outline
The thesis has eight chapters in which I aim to take the reader through the study in a 
systematic way. I begin the thesis with an introduction to the history of heroin 
dependency, BBV transmission, and methadone treatment globally and in Australia.
In Chapter 1 ,1 explain the Australian health system structure to enable better 
understanding of methadone treatment service provision and delivery. This background 
assists with explaining the aims and rationale for my study. I also describe my study 
locations and the management and service delivery of the programmes within these 
locations in this chapter.
In Chapter 2 ,1 provide a literature review into the origins and effectiveness of 
methadone treatment particularly in relation to health and BBV risk outcomes. This 
includes a review of previous studies that examined accuracy of BBV self-reported 
status.
Methods used to conduct the study including study design, instruments used, sampling, 
recruitment, data collection and analyses processes are described in Chapter 3.
Chapters 4, 5, 6, and 7 present the results of my study in relation to the aims. Chapter 4 
describes and compares socio-demographic characteristics, treatment characteristics, 
client risk characteristics (previous and current), BBV status and client satisfaction and 
outcome perceptions for the two study groups. Any differences identified were taken 
into consideration for measurement and comparison of health and BBV risk outcomes 
for urban and rural methadone clients. These results are presented in Chapters 5 and 6, 
which also describe the instruments used for measurement of health and BBV risk 
outcomes. Chapter 7 presents results of the validity study of HCV self-reported status 
and uses HIV as a comparator. Chapter 7 also identifies factors associated with being 
HCV positive as diagnosed through serological status and compares this to factors 
identified through HCV self-reported status.
Chapter 8 brings together all the results and discusses them in the broader context of 
public health and implications for future policy and service delivery.
I discuss the implications of the results and compare them to other relevant studies 
through a summary and/or discussion section at the end of each chapter.
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“All things appear and disappear because of the concurrence of causes and conditions. 
Nothing ever exists entirely alone; everything is in relation to everything else”.
Buddha
Chapter 1: Introduction, aims, rationale and locations
Chapter 1
Introduction, aims, rationale, and locations for the study
In this chapter I describe the history of heroin dependency, BBV (HIV, HBV and HCV) 
aetiology, prevalence and transmission risk, the history of methadone treatment, and 
service provision and delivery of methadone treatment in Australia. The chapter also 
details the aims and rationale for the study, describes the locations of the study and 
service provision and delivery of methadone treatment within the locations.
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Chapter 1: Introduction, aims, rationale and locations
1.1: History of heroin dependency in Australia
Illegal heroin use in Australia escalated in the 1970s [1], A review of methadone 
treatment in Australia conducted in 1995 indicated that there were approximately 
60,000 heroin dependent users [2]. In 2000, Hall and colleagues estimated the 
prevalence of dependent or daily heroin users in Australia to be between 67-92,000, 
with a median estimate of 74,000 users. The population prevalence was calculated at 6.9 
per 1,000 persons aged 15-54 years [3]. As part of the Australian National Drug 
Strategy (NDS), house-hold surveys to monitor trends of alcohol and other drug usage 
have been conducted every two to three years in Australia since 1985. The survey 
conducted in 1998 indicated that one per cent of males and 0.6 per cent of females aged 
14 years or older injected illicit drugs in the 12 months preceding the survey, and one 
per cent of persons aged 14-19 years injected in the month prior to the survey. Twenty 
eight per cent of illicit injectors in the 1998 house-hold survey reported overdosing at 
least once after injecting heroin in that period [4], The survey conducted in 2001 
indicated that although heroin use in Australia is relatively low, it is a significant cause 
of death, injury and illness for younger people and in the last decade was the third 
commonest cause of death in the 25-35 year age group [5]. The most recent survey 
conducted in 2004 indicated that heroin had been used by 1.4 per cent of the population 
aged 14 years and over with the highest proportion of users being in the 20-29 year age 
group. Males were more likely to have used heroin than females [6], Results from these 
surveys are best interpreted with caution as these surveys are dependent on an 
individuals’ willingness to participate. Participants may not always provide accurate 
information due to the sensitive nature of these surveys and the possibility of 
identification. Another limitation is that many drug users are not always in regular 
house-holds and the results may be underestimated.
The rate of opioid related overdose deaths increased steadily between 1964 to 1997, 
with a study showing that mortality rates increased 55-fold from 1.3 to almost 71.5 per 
million for persons aged 15-54 years. The study also showed that death rates increased 
more substantially for the older birth cohorts with an incidence rate ratio of 20.70 (95% 
Cl, 13.60-31.46) for the 1940-44 birth cohort as compared with the 1975-79 cohort 
indicating that older dependent users were more at risk of death related to overdose [1].
20
Chapter 1: Introduction, aims, rationale and locations
There was an exponential increase in mortality between 1995-1999 with approximately 
500 deaths per annum [7], A report published by the National Drug and Alcohol 
Research Centre (NDARC) showed that mortality rates have since decreased, and there 
were 347 deaths recorded in 2004 (31.3 per million population) [8]. This decrease was 
attributed to a shortage of heroin in the early 2000s [9]. Although there has been a 
reduction in opioid related mortality, rates amongst older injectors (45-54 years) 
continue to increase. Males comprise the majority of deaths (up to 78%) and the highest 
proportion of deaths (43%) continue to occur in the 25-34 year age group [8].
Figure 1.1 illustrates mortality rates related to opioid overdose between 1988 to 2004 
for persons aged 15-45 in Australia.
Figure 1.1: Rate of accidental deaths due to opioids per million by age group: 
Australia 1988-2004
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Courtesy of NDARC ‘Opioid Overdose Deaths in Australia: 2004 Edition’
Australia has experienced similar problems associated with heroin dependency to the 
rest of the world in relation to health, BBV transmission, crime, and social problems. 
Australia, however, has been fortunate in relation to transmission of HIV and the related 
health care and social support issues being much less prevalent in comparison to some 
other countries. This is due to the introduction of harm minimisation policies (such as 
NSPs) in the early to mid 1980s, and the availability of treatment and support services 
for IDUs. In 1986, Drucker noted that approximately 50 per cent of IDUs were infected 
with HIV in New York city [10]. He outlined the health and social consequences 
associated with this rate of infection and the implications this would have on health care 
utilisation and need [10].
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Quantifiable costs associated with illegal drug use in Australia were estimated to be 
$1,700 million in 1992; law enforcement cost at $450 million and net health costs at 
$43 million [11]. A further report published in 2002 estimated costs for 1988-99 to be 
$59 million for health and $2,500 million for law enforcement [12]. There are many 
social costs that cannot be quantified. For the heroin dependent individual this includes 
diminished quality of life, financial hardship, employment instability, broken 
relationships and stigmatisation in the community. For the general community there are 
costs associated with drug related crime including financial loss and sometimes physical 
harm [13].
1.2: BBV (HIV, HBV and HCV) transmission and prevalence amongst 
IDUs in Australia
The three viruses that are of major concern for blood borne transmission amongst IDUs 
are HIV, HBV and HCV [14-17], HIV and HBV are also known to have other routes of 
transmission apart from blood. HIV is transmitted through sexual intercourse and 
vertical transmission from mother to baby during pregnancy, while HBV is known to be 
transmitted through sexual intercourse and during the perinatal period (four weeks after 
delivery) [18, 19]. HCV has been shown to be transmitted most effectively through 
blood with uncertainty about sexual transmission [20, 21]. Transmission of BBVs can 
occur while injecting drugs, through the sharing of injecting equipment, and other 
unhygienic and un-sterile practices [22-24], Transmission of BBVs through injecting 
drugs is now recognised as a major public health problem [25-27],
With the advent of HIV and AIDS in the 1980s, the non-availability of a vaccine for 
HIV, the high mortality rate associated with AIDS and the high possibility of 
transmission of the virus through injecting drug use, many countries recognised IDUs as 
a serious threat to contributing to increased prevalence not only through blood borne 
transmission but also through sexual transmission to the general population. For this 
reason, many developed countries introduced policies and programmes for IDUs to 
have access to sterile injecting equipment at no cost, with the aim of minimising sharing 
of injecting equipment and preventing transmission of HIV [28-31],
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This was a policy adopted by Australia in the early stages of the HIV and AIDS 
epidemic, and for the past two decades Australia has been very successful in keeping 
the prevalence of HIV amongst injecting drug users to a minimum with only one per 
cent of the population infected [30, 32, 33]. Methadone treatment has assisted further as 
it is administered orally and decreases risk of transmission through injecting. The policy 
has also assisted with minimising other BBV transmission (HBV and HCV). In 
countries that did not adopt policies to provide clean injecting equipment, the 
prevalence of HIV is higher amongst IDUs in comparison to countries that did [34].
For example, in Russia which did not adopt the policy, HIV prevalence in 2004 was 
found to be anywhere between 3-14 per cent amongst IDUs [35, 36].
The global prevalence of HBV varies widely and there are three demarcated prevalence 
zones: high, medium and low. Despite vaccination programmes being available, global 
incidence of HBV continues to rise and is mainly due to transmission in high risk 
groups such as IDUs. Australia is considered to be a low prevalence zone and minimal 
data is available about the true prevalence of HBV in the general population [37, 38].
A recent study conducted in 2005 to gain information about seroprevalence of HBV in 
the Australian general population revealed that only two per cent of the sample 
(45/2115 persons) either had current infection or were chronic carriers of the virus. 
However, the adjusted Odds Ratio (OR) for HBV infection was significantly increased 
in persons who had injected drugs between 1980 and 1990 (4.4-fold), persons who had 
household contact with someone diagnosed with HBV between 1980 and 1990 
(3.9-fold) and persons who had never been vaccinated for HBV (2.8-fold) [38]. These 
results indicate that, although the prevalence in Australia for HBV may be low, HBV 
transmission still poses a risk for IDUs and there is a continuing need to check and 
immunise IDUs against the virus.
HBV vaccination has been included into the Australian National Immunisation 
Programme (NIP)1 as a routine childhood vaccine since 2000, as recommended by the 
National Health and Medical Research Council (NHMRC). Prior to this (since 1988) it 
was only available as a routine childhood vaccination to Australian children whose 
ethnic origins were from highly endemic areas for HBV [39].
' All vaccines on the NIP are funded through the Pharmaceutical Benefits Schedule and are provided free 
o f  charge to eligible people.
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HBV vaccination for IDUs has been recommended by the NHMRC immunisation 
guidelines, but is not provided free of charge. Although vaccination is available and 
recommended, many IDUs may not be immunised either due to the vaccine not being 
available during their childhood or due to the schedule. This makes them vulnerable to 
acquiring HBV. A recent study amongst 118 Australian drug and alcohol users found 
that only 21 per cent had immunity to HBV determined through serology. Of these 118 
participants, 22 per cent were current IDUs and 48 per cent had injected in the past [40]
Even with the provision of clean injecting equipment, the prevalence of HCV is high 
amongst IDUs in Australia, with an estimated 60-90 per cent being diagnosed with the 
virus [17, 41], One of the reasons for this could be that although HCV was only 
identified in 1989 (after introduction of NSPs), the virus existed prior to this as one of 
the collective group of non-A non-B hepatitis viruses, and knowledge about 
transmission of the virus was limited [42, 43]. By the time HCV was identified, its 
aetiology established, and programmes for provision of clean injecting equipment were 
instituted in Australia, the virus had already spread amongst IDUs and was common in 
this population [44]. This is supported by a recent Australian study that was conducted 
amongst IDUs in opioid replacement therapy. The study showed that persons above 40 
years had higher HCV prevalence as compared to persons in the 19-30 year age group 
(93.9% vs. 60.8%). This suggests that the virus has been present in the Australian IDU 
population for many years and older IDUs who have been injecting for longer were 
more likely to have been exposed to it [45].
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1.3: Methadone treatment for heroin dependency in Australia
Methadone has been used in Australia for treatment of heroin dependency since 1969. It 
was first prescribed for heroin dependency by a physician from the United Kingdom 
(UK), Dr. Stella Dalton, who was practising as a General Practitioner (GP) in New 
South Wales (New South Wales) [2, 46]. By 1970, most Australian States and 
Territories offered methadone as a treatment for heroin dependency.
1.3.1: History
The use of methadone treatment for heroin dependency grew gradually between 1969 to 
the early 1980s when there were approximately 3000 clients nationwide [13]. With an 
apparent rise in illness, death, social instability and crime associated with heroin 
dependency, and the advent of HIV in the early 1980s, methadone was endorsed as an 
effective treatment by the Australian Government in 1985 [2]. National Guidelines to 
provide a framework for jurisdictions to formulate policies and procedures for 
methadone treatment were endorsed by the Australian Health Ministers conference of 
1985 [2, 13]. The Guidelines were endorsed as National Policy in 1993 to provide a 
common set of standards for methadone treatment within Australia; this policy was 
revised in 1997 [2, 13]. The number of clients on methadone increased rapidly from 
6,500 in 1989 to 17,000 clients by mid-1995 [2, 13]. There were approximately 32,000 
methadone clients Australia wide in June 2001, with an average annual growth rate of 
14 per cent since 1985 [46]. Currently (in 2007), there are an estimated 38,000 people 
receiving opioid replacement therapy [47].
Since I commenced this study other forms of opioid replacement therapy have been 
registered as treatments for heroin dependency in Australia. Buprenorphine in tablet 
form (subutex) was registered in October 2000, while a combination of buprenorphine 
and naltrexone as a sublingual tablet (suboxone) was registered in 2005. Methadone 
however, still continues to be used as the main opioid replacement therapy in Australia.
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1.3.2: Australian Government Framework for methadone treatment
Australia has a Federal system of Government, with the Constitution establishing a 
Commonwealth Government and six State and two Territory governments. The 
Australian Health Care System follows this pattern of governance giving the 
Commonwealth Government certain powers in specified fields of Health, and the State 
and Territory Governments powers in other areas. The Commonwealth Government has 
a leadership role in policy making, particularly in the areas of Public Health, Research 
and Health Information Management. State and Territory Governments are responsible 
for delivery and management of public health services, such as acute care services and a 
wide range of public and community health services including the methadone treatment 
programme. State and Territory Governments are also responsible for liaison with 
health care providers and the regulation of health professionals. The Australian health 
care system contracts the provision of health services both at the Commonwealth and 
State and Territory levels through a large network of health providers in the private and 
non-government sector. Consultation and administration of the health care system is 
managed between the Commonwealth and State and Territories through the Australian 
Health Ministers Council (AHMC). There are several ministerial advisory councils with 
representation from the Commonwealth and State and Territory Governments on 
various health issues that are responsible for development of policy and strategies that 
inform the AHMC [48, 49].
Based on this system of health care, the Commonwealth Government is responsible for 
the formulation of national strategic directions, national policy and clinical guidelines 
for methadone treatment, under the auspices of the NDS. States and Territories are 
responsible to adopt the broad policy context framework and principles of these 
guidelines for service delivery and regulation of service provision. There is a National 
Structure in place that provides the information and advice necessary to inform national 
strategic direction and policy. This structure is presented in Figure 1.2. All alcohol, 
tobacco and other drug treatment policies fall under this structure and are the 
responsibility of the various committees that form this structure. Policies and guidelines 
for methadone treatment are developed under the auspices of this structure.
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Figure 1.2: Australian National Drug Strategy Structure
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There are three key strategic documents which provide the guiding principles and 
philosophies under which treatment for heroin dependence is delivered. These are:
1) The National Drug Strategy (currently 2004-2009) [5].
2) The National Pharmacotherapy Policy for People Dependent on Opioids (2004) [46].
3) The National Policy on Methadone Treatment (1997) [13].
The NDS is the ultimate responsibility of the Ministerial Council on Drug Strategy 
(MCDS), which receives advice from the Australian National Council on Drugs 
(ANCD) and the Inter Governmental Committee on Drugs (IGCD). The ANCD 
represents stakeholders interested in drug strategy and involves the private and non­
government sector, and the general community. The IGCD represents stakeholders and 
experts from the Commonwealth and State and Territory Governments [5].
The National Pharmacotherapy Policy for People Dependent on Opioids was produced 
under the auspices of the NDS and was prepared by the methadone subcommittee of 
the IGCD. This policy provides States and Territories with guidelines for the different 
types of treatment available for heroin dependency in Australia. Opioid replacement 
therapies currently recognised and used in Australia for heroin dependency under these 
guidelines are methadone, buprenorphine and naltrexone [46].
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Methadone is the most commonly used treatment for heroin dependence in Australia 
and is administered orally [13]. Injectable methadone and heroin have not been used 
and are not available in Australia for the treatment of opioid dependency unlike the UK 
[50]. There is a range of options available to manage heroin dependence in addition to 
opioid replacement therapies. These include in-patient and out-patient withdrawal 
services, day programmes, therapeutic communities and self-help groups [13].
The National Policy on Methadone Treatment is also produced under the auspices of 
the NDS and is the key document for methadone treatment objectives and principles. 
States and Territories provide and deliver methadone treatment services according to 
the broad policy context and framework set out in these guidelines [13].
1.3.3: The goals and objectives of the methadone treatment programme
The goal of methadone treatment and the objectives of the programme in Australia as 
established by the National Policy on Methadone Treatment (pg 6) are quoted below [13].
The goal of methadone treatment is to reduce the health, social and economic 
harms to individuals and the community associated with unsanctioned opioid use.
The objectives of methadone treatment are:
• To reduce harmful opioid and other drug use;
• To improve the health of clients;
• To help reduce the spread of blood-borne communicable diseases associated 
with injecting opioid use;
• To reduce deaths associated with opioid use;
• To reduce crime associated with opioid use; and
• To facilitate an improvement in social functioning.
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1.3.4: Service delivery and regulation
The methadone treatment programme is regulated through the Australian Health 
System. Service delivery of methadone treatment in Australia is the responsibility of 
States and Territories and jurisdictional policy is developed based on national polices 
and guidelines. Some aspects of the programme are funded at the national level, while 
others are funded at the State and Territory level. Service delivery occurs through a 
combination of public and private sector providers; most clients are treated either 
completely or partially through the public health system [13].
Clients in most States and Territories are inducted into the programme through the 
public sector, where assessment and treatment schedules are drawn up by Medical 
Officers employed by public sector methadone clinics. Dosing also occurs through the 
public sector until the client is considered stable, after which they can be transferred 
into the private sector. Clinical assessment and management in the private sector is 
usually conducted by GPs who are registered as methadone prescribers, and dosing 
occurs at participating community pharmacies. Criteria for induction into the 
programme and transfer between public and private sectors can vary according to 
jurisdictional guidelines within States and Territories [13].
The prescription and administration of methadone is highly controlled and most people 
on the programme have to access their dosing site to get their regular dose. Methadone 
treatment requires daily dosing, and until deemed stable clients are required to present at 
their dosing centre on a daily basis. Dosing times are restricted and can vary between 
sites. Most clients pay a nominal fee (either on a weekly or daily basis) for their 
methadone. There are some instances where clients may get their methadone free, for 
example at the commencement of the programme during a short induction period. Once 
clients are relatively stable they may be eligible for Takeaway Doses (TAs). The criteria 
for eligibility for TAs and the number of TAs once again vary according to 
jurisdictional guidelines. Payment for assessment services and methadone also varies 
between jurisdictions [13].
It is recommended by the National Policy on Methadone Treatment that clients be 
encouraged to have testing for HIV, HBV and HCV at the time of induction into the 
programme. The availability and access to support systems such as counsellors, case 
managers, social welfare services and follow-up support after treatment completion is 
also recommended but is at the discretion of jurisdictional policy [13].
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1.3.5: Current state of play
Methadone treatment in Australia has been proven to be successful in improving health 
status, minimising harm from injecting and reducing some BBV transmission amongst 
opioid dependent users [51, 52]. Treatment programmes have grown immensely since 
commencement in 1969. Programmes have seen many changes in relation to service 
provision and delivery with the aim of maximising outcomes for clients. A review of the 
administration and service delivery of the methadone treatment programme in Australia 
in 1995 indicated that treatment philosophies and principles were similar between States 
and Territories and were basically dictated by national policy. There were, however, 
considerable differences in development and delivery of programmes between States 
and Territories [2], Growth and changes to methadone treatment programmes within 
different jurisdictions have occurred at different rates and within different aspects of the 
programme. Changes have included a shift from methadone withdrawal to maintenance 
treatment, a shift from being a completely public programme to having a combination 
of service provision through public and private sectors, and an increase in the number of 
available places and decrease in waiting lists to be admitted to programmes [2].
Although there have been several changes that have enhanced the methadone treatment 
programme in Australia over the years, there have been difficulties in meeting treatment 
needs for all dependent heroin users [51]. This could be associated with jurisdictional 
policy relating to service provision and delivery, and rural area specific issues. There 
has been minimal evaluation of these changes and about the way differences in service 
delivery could affect outcomes for rural clients.
The methadone treatment programme and NSPs do not seem to have had an impact on 
transmission and incidence of HCV (unlike HIV and HBV) in Australia [24, 53]. Dore 
and colleagues estimated an incidence of 10-20/100 person years and prevalence of 50- 
55 per cent amongst IDUs in 2003. Levels of HCV transmission were found to be 
particularly high in both younger IDUs and incarcerated IDUs [54]. A more recent study 
in Sydney, NSW which followed up 215 HCV negative IDUs at 3-6 monthly intervals, 
observed a total of 61 seroconversions with an incidence of 45.8/100 person years. [55]. 
Depending on future IDU patterns and practices, it is projected that there could be 300- 
800,000 infected people in Australia by 2020 [17].
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Reasons for the continuing transmission of HCV even with successful harm reduction 
strategies are not completely understood. Crofts suggested in 1999, that the higher 
prevalence and infectiousness of HCV (in comparison to that of HIV), combined with 
risk factors related to injecting (including contamination of equipment other than 
needles and syringes, such as tourniquets, spoons, water and swabs) as contributing 
factors [24], Lack of accurate knowledge of HCV status and aetiology could also be 
contributing factors. Studies conducted amongst methadone treatment clients in the UK 
and the United States (US) indicated that clients lacked knowledge about their status, 
risk factors for transmission, consequences of infection and treatment [56, 57]. A study 
that I was involved with while working in SNSW PHU in relation to methadone 
injecting amongst a rural population, found that accuracy of HCV self-report was 
relatively low amongst participants. Forty four of 64 participants in this study provided 
a blood sample, of whom 66 per cent (n=25) were serologically positive for HCV. Sixty 
per cent (n=15) reported their positive status correctly, while 54 per cent (n=7) reported 
their negative status correctly [58]. This study suggested that knowledge of actual HCV 
status amongst IDUs can be inaccurate.
These issues instigated my interest in whether policy and service delivery in rural areas 
could affect methadone treatment outcomes for rural clients differently to urban clients, 
whether lack of knowledge of HCV status amongst IDUs could be a contributing factor 
to continuing HCV transmission, and whether rural IDUs knowledge was different to 
that of urban IDUs. This formed the basis for my PhD and the development of the 
following aims.
1.4: Aims of the study
1) To measure and compare health status and BBV risk (HIV, HBV, and HCV) 
between urban and rural methadone clients, and to identify factors that affect 
these outcomes.
2) To establish the validity of HCV self-reported status amongst IDUs by 
comparing it to serological status, and to compare HCV self-report validity 
between urban and rural areas.
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1.5: Rationale for comparing health and BBV risk outcomes for urban 
and rural methadone programme clients
There are two perspectives from which conclusions about effectiveness of methadone 
treatment can be drawn: 1) from the perspective of the general community and 2) from 
the perspective of the heroin dependent individual. The general community would be 
interested in methadone treatment effectiveness in decreasing drug use and antisocial 
behaviour including crimes related to drug use. From the heroin dependent individual’s 
perspective, one would be interested in decreasing the chance of acquiring BBVs 
through injecting and improving health and social well-being [44], As I am interested in 
comparing outcomes for urban and rural individuals on the programme, I have chosen 
to concentrate on health and BBV risk outcomes. In addition to this, these are the two 
outcome areas that I have clinical experience and knowledge in. I have chosen to focus 
on BBV risk outcomes related to injecting risk practices as methadone treatment aims to 
minimise BBV transmission by decreasing injecting.
The benefits of methadone maintenance treatment are at their optimum when 
programmes are easily available, accessible and clients are retained on treatment as long 
as possible [13, 44, 59]. Factors that have been shown to influence programme entry, 
participation and retention include: number and/or location of treatment programmes, 
cost to clients, opening hours of dosing centres, methadone dose, assessment 
procedures, attitudes of treating clinicians, and relevant access to other allied health and 
social welfare support services [13, 44]. The National Policy on Methadone Treatment 
stipulates four principles that should be part of treatment programmes to optimise 
benefits of treatment: availability, access, acceptability and quality of care [13]. These 
four principles can be compromised in rural areas as shown in other rural health 
outcomes studies (mental health, dental health, sexual health and youth health) [60-65],
The 1996 Australian census estimated that 14 per cent of the Australian population lived 
in rural areas [66]. In 2002, 14 per cent of opioid maintenance therapy patients in NSW 
were classified as rural clients [67], Access to services has been shown to be the major 
barrier for better health outcomes for rural populations. This was recognised in 2002 at 
a joint conference of the World Health Organization (WHO) and the World 
Organization of Family Doctors (WONCA) which initiated ‘The Global Initiative on 
Rural Health’ and the ‘Health for All’ vision for rural people [68],
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Limited access to methadone treatment for rural people could be due to decreased 
availability of services, smaller choice of service provider, and longer travel time and 
distance to services. Confidentiality and stigmatisation are also issues that could 
contribute to poorer access for rural people resulting in poorer health outcomes [69,
70]. It has been shown that people will travel longer distances in rural and small 
communities to seek treatment if confidentiality is an issue [71]. These issues have been 
shown to affect the rural young to a greater extent, and health seeking behaviour in 
relation to sexual health and drug use (including alcohol, tobacco and illicit drugs) [72, 
73].
Cost of services in rural areas can be a contributory factor to health seeking behaviour 
and outcomes [74, 75]. Cost for rural clients that could affect methadone treatment 
outcomes might include the cost of the service, cost associated with travel, and costs of 
seeking other allied health services support if these are not provided through the 
programme. Cost in its own right could compromise compliance and retention on the 
programme.
At the time of commencement of my study in 2000, there had been very little research 
conducted into evaluating outcomes for rural clients on methadone treatment. An article 
written in 1998 by Richards highlighted some strengths and weaknesses of methadone 
treatment in rural Australia based on his experience as a rural GP in Victoria. Lack of 
proper public transport systems, confidentiality and lack of support from health 
professionals and the community were identified as factors that contributed to barriers 
for effective treatment outcomes. Richards highlights that rural IDUs and methadone 
treatment clients faced greater barriers to accessing harm minimisation and treatment 
services than their urban counterparts [76]. Another article in 2002 by Edwards and 
Donnermeyer suggested that due to very little research conducted in rural areas, 
methadone treatment policy and delivery had been based on research conducted in 
urban centres [77].
From my own experience working with a rural PHU between 1998 to 2001,1 noticed 
that availability, access, cost and confidentiality of services were relevant to outcomes 
for clients in the sexual health and methadone treatment programmes. Jurisdictional 
policy and service delivery of methadone treatment in this rural area may have further 
compromised outcomes for clients.
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As methadone is at present the most preferred and cost effective option for treatment of 
heroin dependency, it is important to evaluate its effectiveness particularly where 
optimal level of service provision can be compromised such as in rural areas. My study 
takes this first step to investigate if differences in relation to sociodemographics, risk 
practices, and service delivery and policy, affect outcomes for rural methadone clients 
in comparison to urban clients.
1.6: Rationale for establishing validity of HCV self-report amongst ID Us
The term validity is used in reference to the validity of a screening test to pick up actual 
disease as used in clinical epidemiology. In my study validity of HCV self-reported 
status refers to the accuracy of self-reported status as a screening test to determine 
whether a person is truly HCV positive as indicated by serology [78, 79].
HCV has emerged as a major health issue amongst IDUs globally and in Australia. 
Injecting drug use has been shown to be a major risk factor for acquiring HCV as it is 
primarily transmitted through blood. Studies have shown that 60-80 per cent of IDUs in 
Australia are HCV positive [17, 80-82], State and Territory PHUs received 
approximately 160,000 notifications of HCV infections between 1990-2000 making it 
the most commonly notified communicable disease in Australia [54]. It has been 
estimated that there were 242,000 Australians living with hepatitis C by the end of 2003 
with 16,000 new infections occurring every year. The evidence suggests that 80 per cent 
of past infections and 90 per cent of currently occurring infections in Australia are 
associated with unsafe injecting drug use [17].
Seventy five per cent of people infected with HCV will develop chronic disease and the 
25 per cent who clear the virus will still have detectable antibodies present indicating 
past exposure [17], Common symptoms of chronic HCV are lethargy, nausea, 
headaches, joint pains and depression. Symptoms can take many years to develop. An 
estimated 7-20 per cent of persons with chronic HCV will develop cirrhosis over a 
20-40 year period if therapeutic intervention is not sought. Another four per cent may 
develop hepatocellular carcinoma or liver failure [17, 54], Currently, HCV-related liver 
disease is the primary reason for liver transplants in Australia. People co-infected with 
other BBVs such as HIV and HBV have been shown to progress more quickly to 
develop liver disease [17].
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Past infection with HCV does not provide immunity from being re-infected [17, 20]. 
There are six major genotypes of HCV with several subtypes, and re-infection with a 
different genotype can occur [83]. It has been shown that IDUs can be infected with 
several genotypes at the same time [84], There is no vaccine available for HCV. 
Treatment has been available for a few years and the effectiveness is improving, but 
only a small proportion (<10%) of people with HCV access treatment [47, 85]. Reasons 
for this are not clearly understood, but access issues (such as location of clinics), side 
effects of treatment and lack of knowledge of the criteria to be eligible for treatment and 
their outcomes may be deterrents [17, 20, 85].
In addition to physical illness, people infected with HCV suffer many social and 
economic consequences of the illness [86]. Due to physical symptoms, many people are 
forced to reduce working hours. As HCV is known to be strongly associated with 
injecting drug use, many infected people can be discriminated against [17, 87].
Due to the health and social consequences associated with HCV it is important for IDUs 
to have accurate knowledge of their status. Lack of accurate knowledge of HCV status 
could be a reason for the high incidence and transmission of HCV that is continuing to 
occur in Australia and also a reason for not seeking treatment and support. It could also 
be responsible for unnecessary stigmatisation by the general community. In addition to 
this, many studies investigating socio-demographic and risk factors associated with 
HCV use self-reported status as an indicator of HCV status.
At the commencement of my research, I found only five studies that had investigated 
knowledge about HCV status amongst IDUs: two in Australia [88, 89], and three 
overseas [56, 57, 90]. The objectives of these studies were mainly to identify risk 
factors for HCV, but some findings suggested that knowledge of actual HCV status may 
be poor. For these reasons I decided to examine the validity of HCV self-reported status 
as an indicator of true status amongst a sample of IDUs in Australia further. I also 
decided to compare accuracy between urban and rural IDUs, as the accuracy of HCV 
self-reported status in the NSW rural methadone injectors study was poor. I chose to 
measure the validity of HIV self-report as a comparison to HCV self-report as when 
HIV was discovered there was a huge momentum towards education, testing and harm 
minimisation, and people at risk were made very aware of the consequences of HIV 
and AIDS.
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1.7: Locations for the study
Having worked closely with the SNSW methadone treatment programme and gaining 
knowledge of the practicalities of delivering the programme within the area, I chose this 
area to represent the rural group for my study. The ACT programme was chosen as the 
comparable urban study group as it had a similar population size to SNSW and was 
located within the boundaries of SNSW. Geographical location of the two study areas 
are represented in Figure 1.3.
At the time of data collection (2002), the ACT had a population of 307,053 [91]. SNSW 
had a population of 239,993 within three statistical subdivisions; these being the 
Southern Highlands (population 68,045), South Coast (66,731) and Southern Tablelands 
(population 105,217) [91]. The SNSW population was spread out in population groups 
of 5,000 persons upwards. The largest population group was in the city of Queanbeyan 
(population 41,378), which is within the Southern Tablelands and shares a boundary 
with the ACT.
Although the two areas were similar in population size and located within the same 
regional area of Australia, they varied in relation to some aspects. The ACT had a 
higher average annual income of $55,000 per annum compared to $35,000 per annum in 
SNSW. The two areas also differed geographically with SNSW being spread over a 
large and diverse area with mountain ranges and coastal areas, with a three hour travel 
radius from its administrative centre, Queanbeyan. In contrast, the ACT although 
elevated 570 metres above sea level is basically flat with a 30 minute travel radius from 
the city centre with all residents closely located to central services. The two areas also 
varied in terms of health service provision, delivery and management, based on policy 
that applied within their State and Territory governments and for reasons specific to 
urban and rural areas. These factors have been considered in the comparison of the two 
groups in relation to my research questions.
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1.8: The ACT and SNS W methadone programme structure
The methadone programmes in both the ACT and SNSW were managed and delivered 
according to national frameworks with State and Territory policy articulating service 
delivery within these frameworks. The National Drug Strategic Framework 1998-99 to 
2002-03 provided the national framework under which the two programmes developed 
strategies for delivery of AOD Programmes [4], The National Policy on Methadone 
Treatment provided the guidelines for delivery of the methadone treatment programme 
within the overall national framework [4, 13].
The ACT and SNSW programmes were managed through a combination of the public 
and private health systems. Each programme had three tiers (Tier 1, Tier 2, and Tier 3). 
Clients were registered into these tiers dependent on whether they were a new client or 
not, and for existing clients their stability in their current programme. Clients could be 
moved in and out of the tiers depending on their stability and adherence to criteria 
within each tier. Movement between tiers was also dependent on the availability of 
places within the tiers. Table 1.1 (at the end of the chapter) compares service delivery 
and management of the two programmes and the three tiers within the programmes.
1.8.1: Tier 1 (Public)
Tier 1 was completely managed through the public health system and all services were 
delivered through the public sector. All persons who were new to the methadone 
programme were registered into this tier for assessment and management of their opioid 
dependence. Clients were clinically assessed and managed through public methadone 
clinics and were dosed at public outlets based at the public clinics, hospitals or 
community health centres. Cost of clinical assessment and management was covered by 
the public health system (Medicare system) and was thus free to the client. Most new 
clients were dosed on a daily basis in this tier and payment for methadone depended on 
jurisdiction programme policy. If there was a payment for methadone this was a flat rate 
that was to be paid on a weekly basis.
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1.8.2: Tier 2 (Partly Public/Partly Private)
Tier 2 was partly public and partly private in relation to client assessment, management 
and delivery of the service. Clinical assessment and management of clients was 
conducted through the public system similar to Tier 1, but dosing was conducted 
through the private sector at community pharmacies registered with the programme as 
service providers. All clients in Tier 2 paid a weekly fee for methadone which was a flat 
rate not dependent on dose. In some instances payment was partly subsidised by the 
programme. In most instances clients could only be registered in Tier 2 after being 
stabilised in Tier 1.
1.8.3: Tier 3 (Private)
Tier 3 was referred to as the private tier where client assessment, management and 
delivery of services were completely through the private health sector. All clients who 
were registered with Tier 3 were most likely to enter the programme through Tier 1 for 
initial clinical assessment and management. They would either have progressed through 
Tier 2 into Tier 3 or on some occasions directly from Tier 1 to Tier 3 depending on their 
stability. GPs registered as methadone prescribes (GP prescriber) on a State and 
Territory Registry were responsible for clinical assessment and management of clients 
in this tier. Tier 3 clients had to pay for their clinical assessments, according to general 
practice rates; some GP prescribers bulk-billed 2 through the Medicare system, which 
meant no out-of-pocket expense for the client. Clients dosed at community pharmacies 
and paid for their weekly methadone dose on a similar basis to Tier 2 clients.
1.8.4: TA and transfer policy
The availability and number of TAs per week depended on the tier the client was in, 
stability of the client, time on the programme and TA policy within each programme. 
Tier 2 and 3 clients were more likely to get TAs on a regular basis as they were usually 
more stable than Tier 1 clients. Transfer between State and Territory programmes 
required negotiation and availability of an appropriate place on the programme in which 
a client was transferring into. Clients moving away temporarily or travelling for a 
period longer than for which they could get TAs also required a transfer to another 
programme.
2 The Medicare system in Australia pays a rebate for a GP consultation. Most GP consultations (and some 
other medical services) are above this rate, meaning an out-of-pocket expense to a client. In some 
instances a GP will only charge the cost o f the rebate which is referred to as bulk-billing. This means no 
out-of-pocket expense to the client.
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1.9: The ACT programme
The first formal ACT methadone treatment programme started in 1979 as a completely 
publicly managed and delivered programme at the Woden Valley Hospital. Between 
1986 to 1994, the number of clients on methadone increased from 64 to 323 [2], For 
many years the programme had approximately 80 places (A. Faden 2007, [ACT 
Methadone Programme] pers.comm., 10 January). In 1993, the programme was still 
completely run through the public sector and there were three dosing points, one in 
Woden Valley Hospital (south-side of Canberra), one in Civic (north-side of Canberra, 
city centre) and one operating out of a pharmacy in Queanbeyan 3 [92], In 1995, the 
methadone programme instituted dosing through the private sector via community 
pharmacies. All clinical assessment of clients was still conducted through the public 
sector by two medical officers employed by the ACT Department of Health and there 
were no private methadone prescribers. Ninety per cent of cases dosed at the clinics in 
Woden and Civic, while the rest dosed at five community pharmacies and the pharmacy 
at Queanbeyan that were approved for dosing [2],
By 2002 when I conducted my study, the ACT programme had considerably expanded 
since 1993 and had a total of 755 places available at any one time. The programme had 
evolved to having three tiers with public and private sector management and service 
delivery components. Tier 1 had a total of 270 places, Tier 2 had 330 places and Tier 3 
had 155 places. Strictly speaking a potential client had to be a resident of the ACT 
(residential address with ACT postcode) to be eligible to register on the programme.
At the time of the study the ACT had two public methadone clinics, one based in Civic 
in the north-side of Canberra and one based at The Canberra Hospital (TCH) in Woden 
in the south-side of Canberra (the old Woden Valley Hospital). The clinic in the north- 
side provided some clinical assessment and management services, and provided a public 
outlet for dosing in the north side. This clinic closed down during the course of my 
study, which left the ACT with one public clinic and dosing outlet for the entire 
population. The south-side clinic provided the bulk of the clinical assessment and 
management services, particularly with assessment of new clients, and provided a 
public outlet for dosing. It also functioned as the administrative centre for the 
management of the ACT programme.
3 Queanbeyan centre was part o f  the ACT programme as the SNSW programme did not exist at this time.
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1.9.1: ACT Tier 1
All new clients were initiated into the programme through Tier 1. All Tier 1 clients 
were clinically assessed and managed at the public clinic in TCH, Woden. Services 
were bulk-billed through the Medicare system with no cost to the client. Clients were 
provided with prescriptions for methadone at regular intervals based on their clinical 
assessment by medical officers within the clinic. Clients in this tier received their daily 
methadone dose at the public clinic in Woden at two designated time periods; one in the 
morning and one in the afternoon. Methadone was provided cost-free for the first six 
months in this tier, after which all clients paid $15.00 per week, regardless of magnitude 
of dose.
Clients in this tier were allowed a maximum of two TAs per week. The number of TAs 
per week was dependent on the length of time the client had been on the programme, 
results of random urine tests for opioids and other drugs, indicating stability of the 
client. Clients were not allowed TAs in the first three months, after which they were 
allowed one TA if they had four clear random urine tests in the first four months of 
treatment. If clients progressed over the next four months with clear random urine tests, 
they would be eligible to have two TAs per week.
1.9.2: ACT Tier 2
Once clients were stabilised in Tier 1, they could be moved into Tier 2. Clients in this 
tier were clinically assessed and managed by medical officers in the public clinic at 
TCH with no cost to the client, similar to Tier 1. Dosing of clients in this Tier was 
through the private health sector at community pharmacies registered as service 
providers with the ACT programme. Community Pharmacies had fixed time periods for 
dosing similar to the public clinic. Most dosing pharmacies had only one time slot per 
day, which was usually as soon as the pharmacy opened in the morning. The cost of 
methadone dosing (regardless of magnitude of dose) was $30.00 per week; the client 
paid $15.00 and the ACT programme subsidised the remaining $15.00 payment. Clients 
were allowed TAs if four of six random urine tests were drug free, and were allowed a 
maximum of three TAs per week dependent on stability.
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1.9.3: ACT Tier 3
Clients in Tier 3 were clinically assessed and managed through GPs who were 
registered with the ACT programme as prescribers. Most clients were usually charged a 
fee to see the GP prescriber for assessment and provision of prescriptions due to the 
limited level of bulk-billing within the ACT. Clients in this tier dosed at community 
pharmacies with a similar set-up as Tier 2 clients. Payment policy for these clients was 
that they paid the full $30.00 per week for methadone, but in practice, they paid $15.00 
per week like all other tiers (with a subsidy of $15.00 from the ACT methadone 
programme). TA policy was also the same as for clients in Tier 2.
1.9.4: ACT programme policies common to all tiers
Case managers were allocated to ACT Tier 1 and 2 methadone clients on a needs basis 
when they had complex clinical assessment management issues; this arrangement was 
extended to Tier 3 clients in some instances. ACT methadone programme clients were 
also subject to a missed dose policy. If a client missed one or two doses consecutively, a 
quick assessment was made by the dosing staff. If there were no significant issues and 
the client appeared stable, they would continue to be dosed. If a client missed three or 
more doses consecutively, they would need to be reviewed by a medical officer for re­
assessment of dose. If a client missed seven doses consecutively (i.e. a week of dosing), 
they would be removed from the programme and would need to be assessed as a new 
client to re-enter the programme.
There was a total of 18 community pharmacies that dosed methadone clients and a total 
of 23 GP prescribers through the ACT at the time of my study. All clients (regardless of 
which tier they were in) were registered with the public programme. There were two 
databases for registration purposes; one database for Tier 1 and a second database for 
Tier 2 and 3 clients. Tier 2 and 3 clients were on one database for purposes of 
registration with community pharmacies.
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1.10: The SNSWprogramme
The SNSW methadone programme is a relatively new programme, having commenced 
in 1994. The methadone programme was introduced to NSW in the 1970s but the 
programme was not rolled out to smaller centres and rural areas until some time later. 
This does not mean that methadone treatment was not available within SNSW until 
1994. Prior to 1994, there were approximately 20 clients being case managed by AOD 
service workers in one of SNSW’s cities (Goulburn). These clients were prescribed 
methadone by a GP in Campbelltown on the outskirts of Sydney (about 175kms from 
Goulburn). There were a handful of GPs in the south-coast who had patients on 
methadone as well. This system of being managed by GPs continued on as Tier 3 of the 
SNSW programme when it commenced in 1994, but without any formal links 
(B. Callahan [SNSW Methadone Programme] 2007, pers.comm., 15 January).
In 2002, the SNSW methadone programme had a total of 300 places. The programme 
had three tiers with a combination of public health and private health sector 
management and service delivery. The three tiers had 100 places each and to be eligible 
to enter the programme a client had to be a resident of SNSW (SNSW residential 
postcode). This was similar to the ACT’s residential criteria.
1.10.1: SNSW Tier 1
Unlike the ACT programme, clinical assessment, management and prescribing 
methadone for clients Tier 1 was done by medical officers from the private sector who 
were contracted by the programme (most being GPs, others being locum medical 
officers). These medical officers conducted assessment and prescription clinics for the 
SNSW programme at the Queanbeyan public clinic. Rooms in the public clinic were 
rented by the medical officers, and clients were bulk-billed for the service (i.e. no cost 
to them). The end result was similar to the ACT programme with clinical assessment 
and management being provided by default through the public health system. Clients 
were dosed at public dosing outlets based within community health centres (CHC) and 
one hospital through the area. Methadone was completely subsidised by the programme 
and provided free of charge in Tier 1. Unlike the ACT programme, clients in this tier 
were not eligible for any TAs. This was different to the rest of NSW’s TA policy [93]. 
This was mainly put in place to decrease demand for dosing within the public system 
(B. Callahan [SNSW Methadone Programme] 2002, pers. comm., 15 March).
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1.10.2: SNSW Tier 2
Clients entered Tier 2, once stabilised in Tier 1, similar to the ACT programme. Clinical 
assessment, management and prescription of methadone in this tier were as per Tier 1. 
Dosing of clients was at community pharmacies, thus making this part of service 
delivery through the private system. In contrast to the ACT programme, clients in this 
tier did not receive a subsidy for the cost of methadone and paid the full-cost for their 
weekly dosing, which was $35.00 per week. Clients in this tier were eligible for a 
maximum of four TAs per week dependent on their time on the programme and 
stability. Clients were not eligible for TAs in the first three months on the programme. 
After this they were eligible for a maximum of two TAs between 3-12 months on the 
programme, a maximum of three TAs between 12 months to two years on the 
programme and a maximum of four TAs after two years on the programme.
1.10.3: SNSW Tier 3
Unlike the ACT program, clients could register into Tier 3 in SNSW directly without 
having to go through Tier 1. As Tier 3 of the programme had no formal links to the 
SNSW programme (due to the history of its development), these clients were the sole 
responsibility of the GP prescribcr managing them. They could enter and exit the 
programme without having to register with the SNSW methadone programme. These 
clients could approach a GP prescriber within the area and at the discretion of the 
prescriber could be initiated into the programme. This arrangement was developed to 
particularly assist persons seeking treatment for opioid dependence in areas within 
SNSW where there was limited access to the public programme. Clinical assessment 
and management was provided through the private health sector without subsidy from 
the programme and the client usually paid the full cost for it. Similar to Tier 2 clients, 
clients in this tier dosed at community pharmacies and paid the full-cost of methadone 
of $35.00 per week with no subsidy from the programme. The number of TAs a client 
received per week was at the discretion of the GP prescriber managing the client.
Clients in this tier were only registered on the NSW Pharmaceutical Registry for 
identification and provision of methadone at nominated community pharmacies.
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1.10.4: SNSW programme policies common to all tiers
All clients in Tiers 1 and 2 of the SNSW programme were allocated case managers 
routinely for the time that they were on the programme regardless of whether they had 
complex management issues or not. This was in contrast to the ACT programme. Tier 3 
clients did not have access to case managers. In rare instances this could be negotiated 
between a GP prescriber and the SNSW programme. If there was a prolonged need for a 
case manager, a transfer from Tier 3 to Tier 1 or 2 would most likely be negotiated. The 
SNSW programme also had a missed dose policy which was similar to the ACT 
programme policy.
At the time of the study, there were eight public dosing outlets in SNSW which 
included seven community health centres and one hospital. There were 25 community 
pharmacies through the area that dosed methadone clients and eight GP prescribers 
registered with the programme.
Management and service delivery policies for the ACT and SNSW methadone treatment 
programmes are described and compared in Table 1.1.
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1.11: Summary
Australia has an identified problem of heroin dependency and associated health and 
social problems. Prevention of BBV transmission related to injecting drug use is an 
integral part of public health policy and harm reduction.
Methadone has been identified as an effective treatment to curtail heroin use and assist 
with reducing health and social problems associated with heroin dependency.
Methadone treatment services are delivered under the auspices of State and Territory 
Policy within the broad contextual framework of the NDS, The National 
Pharmacotherapy Policy for People Dependent on Opioids and the National Policy on 
Methadone Treatment. All States and Territories are required to provide access to 
methadone treatment which includes assessment and clinical management, access to 
suitable dosing centres, support systems such as crisis counselling, appropriate referrals 
for other medical services and the need to provide a confidential and informative 
service. Criteria and policy of service provision may differ according to State and 
Territory and jurisdictional policy. For this reason, availability, access, cost and support 
services may vary between jurisdictions. Differing service delivery policy, along with 
rural specific issues such as availability, access, cost and confidentiality of services, can 
contribute to differences in outcomes for urban and rural methadone clients.
HCV has emerged as a major health issue for Australian IDUs. Due to its high 
prevalence HCV poses a greater threat than HIV and HBV amongst IDUs. Lack of 
accurate knowledge of HCV status could affect HCV transmission amongst IDUs and 
treatment seeking behaviour. Findings from studies investigating demographic and risk 
factors associated with HCV using self-report as an indicator of HCV status may also be 
compromised due to this. For these reasons it is important to ascertain the validity of 
HCV self-report amongst IDUs.
The two methadone programmes chosen as study groups for urban and rural comparison 
of health and BBV risk taking behaviour outcomes were the ACT and SNSW. The two 
study areas were comparable in terms of population size, but differed in terms of annual 
average income and geography.
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The management of the urban and rural programmes was basically similar, with both 
programmes having three tiers for service delivery and management. Services in Tier 1 
in both areas were completely managed and delivered through the public sector, even if 
the mechanisms for service delivery differed in the two areas. Tier 2 for the two 
programmes was also similar with services being partly public and partly privately 
managed and delivered. Tier 3 for the two areas, although completely delivered through 
the private sector, differed in relation to its links to the Area programme. There were 
differences identified in relation to access to service delivery and policy such as access 
to TAs, cost of methadone, and allocation of cases managers.
Both programmes continue to be managed and delivered in the same way to date.
(A. Faden 2007, [ACT Methadone Programme] pers.comm., 10 January; B. Callahan 
[SNSW Methadone Programme] 2007, pers.comm., 15 January).
1.12: Implications of the study
Through this thesis I aim to contribute towards knowledge about urban and rural 
outcomes for opioid users on methadone treatment and a better understanding of HCV 
self-report accuracy amongst IDUs.
It is envisaged that results from this study will:
1) Identify if there are differences in health and BBV risk outcomes for urban and rural 
methadone clients and identify the factors associated with these outcomes.
2) Provide further information about validity of HCV self-report amongst IDUs.
3) Inform policy making and service delivery for methadone treatment clients and 
IDUs not on treatment according to urban and rural needs.
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Chapter 2 
Literature review
In this chapter I present a literature review about the inception of the methadone 
programme, its goals and expected outcomes, its effectiveness in curtailing heroin use 
and improving health and decreasing BBV risk behaviours. I also include an overview 
of literature on rural health and BBV risk outcomes and research findings on accuracy 
of HCV and other BBV self-report.
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2.1: History of heroin dependency
Heroin (diacetylmorphine) is a semi-synthetic drug derived from opium. The opium 
poppy was cultivated as early as 3400 BC in lower Mesopotamia and was used for 
many reasons including medicinal, cultural and social4 reasons. Morphine, the principle 
active opiate extracted from the opium poppy was known for its ‘addictive” properties 
from early times of use [94, 95]. Heroin was synthesised from morphine in 1874 by a 
British chemist C.R. Alder Wright, by combining morphine with acetic anhydride acid 
after experimenting with combining morphine with various acids. This compound was 
further analysed by F.M. Pierce who confirmed that its properties included production 
of analgesia, euphoria and a sense of well-being [95]. Heroin was released as a 
medicinal product by the pharmaceutical company Bayer in 1898 and was marketed as a 
cough medicine for children as a supposed non-‘addictive’ substitute for morphine until 
1910 [96, 97]. Heroin was also marketed as a treatment for morphine ‘addiction’ prior 
to the discovery that it was in fact ‘addictive’ as it is converted to morphine in the brain 
[97].
Heroin mimics endorphins which are produced regularly by the body and induce a sense 
of well-being and attenuate pain [98]. When heroin is introduced to the body, the body 
responds by reducing the production of endogenous endorphins as heroin substitutes 
their effect [99]. Frequent use can lead to tolerance of its effects, and the need for higher 
doses to experience its effects. As heroin replaces endogenous endorphins, the body can 
also become dependent on it. Once a stage of dependency is reached, non-use of the 
drug can cause severe withdrawal effects within 6-24 hours of the last dose [99].
Withdrawal effects include sweating, malaise, anxiety, depression, cramping, muscle 
and bone aches, sleep problems, cold sweats, nausea, vomiting, diarrhoea, priapism in 
males (persistent and intense penile erection) and genital hypersensitivity in females. 
Sometimes symptoms can be severe enough to be life threatening if not treated; for 
example dehydration from vomiting and diarrhoea [99] .
4 By social use, I refer to non-dependent heroin use to experience a euphoric state.
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Heroin can be injected (intramuscular, subcutaneous, and intravenous) smoked, snorted 
or consumed orally. The onset of its effect depends on route of administration. 
Intravenous injection results in an almost immediate rush and a state of euphoria and is 
the most common route of administration [100]. International studies have shown that 
about 55 per cent of users inject it [100, 101]. Injecting is more common in Australia, 
and a recent study in 2006 showed that 86 per cent of study participants injected their 
opioids [67].
In the early 1900s heroin became popular as a social drug due to its euphoric properties 
[102], As heroin use and the likelihood of dependency and its associated consequences 
increased, many countries passed laws to monitor its production and availability for 
medicinal purposes only. By the mid-1920s most countries had made the production of 
heroin for non-medicinal purposes illegal and by the 1930s heroin trafficking became 
more prevalent because of these laws. In the 1940s most western countries declared 
heroin to be a controlled substance due to its high level of non-prescribed use, and high 
potential for dependency and associated health risks.
Making heroin a controlled substance increased the potential for black market supplies 
and as is the case with all black market supplies, the cost of heroin soared. This became 
an issue particularly for users who were dependent on the drug [103]. Maintaining a 
heroin dependency needed large sums of money on a regular basis which led many 
users to a life of crime and sex work. The bulk of a dependent individual’s finances 
went towards maintaining their heroin dependency, which led to other social issues such 
as unemployment, lack of proper housing, nutrition and antisocial behaviours. Heroin 
dependency also led to many health issues such as malnutrition, infections related to 
injecting and general poor health [97, 104-107], The illegality of use made it difficult 
for dependent persons to seek help for these problems. The 1950s and 60s saw a huge 
increase in heroin dependent individuals in the US with the numbers continuing to rise 
in the 1970s along with the health and social issues that accompanied it [97, 104, 108].
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2.2: The inception of methadone treatment to combat heroin dependency
The main opium supply for manufacture of heroin in the US and Europe between the 
1940s to the 1970s was from Iran. In the 1940s due to World War II and temporary 
trade disruptions (including the engagement of Iran in anti-opium policies under 
pressure from the US) heroin trafficking was virtually eliminated in the US and parts of 
Europe. Due to this allied effort threatening heroin supply from Iran, the Germans 
developed methadone in their laboratories in 1939, alongside many other synthetic 
opioids (including pethidine) for medicinal purposes. Methadone was known initially as 
Amidon and was not used extensively in the early years of discovery. This new 
synthetic opioid was recognised to have strong analgesic properties and a long duration 
of action. It was given the name methadone in 1947, but only marketed as a drug in 
1949 and patented in 1953. It has been marketed under other names including 
Dolophine, Phenadone and Physeptone [97, 109].
The health and social problems associated with heroin use and dependency became 
widely recognised in the US in the 1950s, and a number of abstinence related treatment 
programmes were developed to combat it [97]. In the early 1960s, Marie Nyswander a 
New York based psychiatrist who had worked in these abstinence based programmes, 
and her husband Vincent Dole (a biochemist), noticed that there were limited results 
achieved through abstinence in relation to health and social well-being for heroin 
dependent users. In an initial trial of treating 307 heroin dependent individuals with 
methadone, they observed that individuals not only stopped their heroin-seeking 
behaviour, but did remarkably well in relation to health and social well-being without 
counselling support even though available. This observation made them question the 
theory of ‘addictive’ personalities contributing to heroin dependency. They considered 
it more likely to be associated with a metabolic deficiency that could be managed by 
administering a sufficient amount of an appropriate substitute opioid [110]. Based on 
this argument they decided to substitute heroin with other opioids in the quest to treat 
heroin dependency and carried out trials using different opioids [111].
In 1964, after numerous trials using short acting opioids, Dole and Nyswander found 
that methadone had the best outcome amongst heroin users in curtailing use, and 
improving health and social well-being [112, 113]. The advantages of methadone were 
that it could be taken orally and had a longer half-life then most other synthetic opioids. 
This meant that it needed to be administered only once a day (one dose in 24 hours).
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Dole and Nyswander noticed that with this one dose in 24 hours, heroin dependent 
persons were able to regain control of their lives, improve their health and nutrition, 
social circumstances and move away from a life of crime and sex work [113].
With the success of this first trial of methadone treatment in reducing heroin use, 
criminal activity and improving health, its use to curtail heroin dependency and 
associated problems became quite common, and the methadone treatment programme 
was bom [44], Since then, methadone treatment has been adopted in many countries to 
treat heroin dependency. There have been many changes to the management of the 
programme over the years in relation to objectives, dosage and support services 
provided for rehabilitation [44, 114].
The use of methadone became even more important with the advent of HIV in the early 
1980s as one of the transmission routes for HIV was identified to be through blood, thus 
making injecting drug use a major risk category for transmission [115]. The role that 
methadone treatment could play in preventing transmission of BBVs in general became 
even more obvious in the latter part of the 1980s with the identification of HCV, which 
was shown to be most effectively transmitted through blood [20]. With these two 
milestones in the 1980s, the importance of using methadone as an oral opioid substitute 
for decreasing heroin injecting and managing dependency became even more 
magnified. The importance of keeping the prevalence of HIV low amongst IDUs to 
prevent transmission to the general population through other routes (i.e. sexual and 
vertical) was also a factor in driving the need to decrease injecting drug use related to 
heroin dependency [44].
Over the years methadone has been used to treat heroin dependency both as a 
withdrawal and maintenance treatment. The ultimate aim of withdrawal programmes 
was abstinence from use of heroin, and this was to be achieved through administering 
decreasing doses of methadone over the course of treatment. In contrast methadone 
maintenance programmes aim to reduce heroin dependency to enable a dependent user 
to improve their health and social well-being [44], Research has shown that heroin 
dependent users on methadone withdrawal programmes are more likely to relapse to 
heroin use, and that methadone maintenance programmes are much more effective in 
reducing heroin use and allowing for a return to normal life [51, 116-118]. Most 
methadone treatment programmes in Australia today are maintenance programmes.
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2.3: The effectiveness of methadone treatment
The main goal of methadone treatment is to improve health status, and psychological 
and social well being of the opioid dependent person [119]. The initial aim of 
methadone treatment was to reduce heroin use and associated crime, which is why 
methadone treatment programmes were supported by governments and the public [44], 
From the heroin dependent individual’s point of view, the aim is to improve health and 
social functioning (e.g. housing, employment, relationships) and decrease the chances 
of acquiring BBVs [44]. Effectiveness of methadone treatment is usually measured 
under five outcome headings: 1) decreased drug use, 2) decreased BBV risk, 3) 
improved physical and psychological health, 4) decreased criminal activity and 
5) improved social adjustment and functioning [13, 120]. Researchers have studied the 
effectiveness of methadone in achieving single outcomes or a combination of outcomes.
Research since the inception of methadone treatment has shown that methadone is 
particularly effective in reducing heroin use and associated crime. There are three 
Randomised Controlled Trials (RCT) quoted in most methadone literature assessing the 
effectiveness of methadone treatment in relation to decreased heroin use and crime, two 
of which are reviewed here [121, 122]. The third study is not reported here as it 
concentrates on the effect of methadone dose and retention in the programme [123].
The first RCT was conducted by Dole and colleagues in 1969 [121]. The study was 
conducted amongst 32 male prisoners who had been dependent on heroin for at least 
four years and were eligible for release over a four month period at the time of 
commencement of the study. The prisoners were randomly assigned to methadone 
treatment and non-treatment groups with 16 participants in each group. Of the 16 
prisoners randomly assigned to the methadone treatment group, 12 took part in the 
study and commenced on methadone before leaving jail. The 16 prisoners in the non­
treatment group were put on a waiting list. The two groups were followed up after 12 
months of release from prison; there was one member in each group lost to follow-up. 
Of the 12 participants in the methadone treatment group, none returned to daily heroin 
use (although 10 of 12 had used heroin at least once since their release) and only three 
returned to jail. In contrast, all 16 participants in the control group had returned to daily 
heroin use and prison. The non-treatment group had a 2.67 times greater risk of being 
re-imprisoned and four times greater risk of returning to daily heroin use as compared to 
the treatment group [121].
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A previous publication by Dole and Colleagues reported results of their first trial 
conducted in 1965, which indicated that methadone curtailed heroin use, decreased 
crime and increased social functioning [111]. The results were cautiously accepted and 
supported by the medical fraternity but did not receive support from law enforcement 
agencies and the general community [44, 97]. The RCT conducted later in 1969 showed 
similar results but had a greater impact on law enforcement agencies and community 
groups as it showed a clear association between methadone use and decreased 
incarceration suggesting a decrease in crime.
The second RCT was conducted in 1981 by Gunne and Gronbladh in Sweden, and 
compared patients on methadone in an in-patient setting with intensive vocational 
rehabilitation, and persons with referral to drug-free treatment [122], The criteria for 
entry into the study were similar to the RCT conducted by Dole and colleagues in 1969, 
with participants having to be opioid dependent for at least four years and having tried 
rehabilitation before. The study design was such that participants were recruited into the 
two groups until a statistically significant difference was elicited between outcomes for 
the groups. Outcomes were assessed at the end of two years. In total, 36 persons were 
recruited to the study, 17 of whom were placed in the methadone treatment group.
When the two groups were compared, 12 of the 17 participants in the treatment group 
no longer used other opioids. In the non-treatment group only one participant had 
ceased using opioids; two had died and two were in prison [122].
Similar results were seen in an Australian observational study, which compared crime 
rates while on treatment as opposed to when not on treatment as one of its objectives 
[124], Three hundred and four methadone clients from three different private clinics 
were recruited into the study and interviewed on three occasions over a twelve month 
period. Crime rates on treatment and off treatment were measured through self-report 
and by checking police records on the three interview occasions. Crime rates through 
self-report while on treatment were one-eighth the level of when the person was not on 
treatment (i.e. prior to entry into their current treatment programme). Police records 
corroborated self-report results. Participants who had committed crimes while on 
treatment were more likely to have used illegal drugs, particularly cannabis. The study 
concluded that crime rates are lower while on methadone treatment than when 
dependent on illegal opioids [124],
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Results from these three studies indicate that participants on methadone treatment had 
decreased their heroin use and associated crime as compared to participants who were 
not on methadone treatment.
Improved social functioning is another recognised outcome of methadone treatment [97, 
125]. The RCT conducted by Dole and colleagues in 1969 showed improved social 
functioning for participants who were in the methadone treatment group. Of the 12 
participants in the methadone treatment group, six were employed or studying [121]. In 
the Gunne and Gronbladh study of 1989, 12 of the 17 participants in methadone 
treatment were either employed or studying [122]. A more recent study published in 
1999 by Dore and colleagues examined the effectiveness of methadone treatment by 
comparing outcomes for 112 clients before and after six months in treatment in a New 
Zealand clinic. The study found that during treatment the number of clients on 
government benefits reduced by almost 30 per cent, employment rates doubled from 19 
to 40 per cent (including attendance at educational programmes) [126].
Cost effectiveness of methadone treatment for heroin dependency is another factor that 
makes it attractive to governments as well as to the general community [44, 97], A 
literature review into the cost-effectiveness of methadone maintenance as a health care 
intervention for heroin use was conducted in 1999 [127]. The aim was to measure the 
mortality associated with opioid use. Life-years of survival were used as the measure of 
treatment benefit. Cost effectiveness was calculated through cost for every life-year 
saved. The study found that providing opioid dependent persons with access to 
methadone incurred an additional treatment cost of $5915 for every year of life saved 
(incremental cost-effectiveness ratio of $5915 per life-year gained). This ratio is much 
lower than many other medical therapies and well below the $50, 000 threshold for 
every life year saved used forjudging cost-effectiveness of a treatment [127].
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2.3.1: Effectiveness of methadone treatment in improving health outcomes 
and decreasing BBV risk
Dole and Nyswander, recorded an improvement in appearance, attitude and general 
health amongst heroin dependent individuals with their first trial of methadone 
treatment in the 1960s [97, 113]. It has been shown that heroin dependent individuals 
entering methadone treatment suffer from both physical and psychological health 
problems [44], Physical health problems include infectious diseases such as respiratory 
illness, dermatological problems, sexually transmissible infections, BBVs, infective 
endocarditis, osteomyelitis and septicaemia. BBV risk associated with heroin 
dependency is related to HCV, HIV and HBV. Additional health problems that have 
been noted to be associated with heroin dependency are malnutrition, dental caries, 
menstrual irregularities, accidents, overdose and injecting associated risks such as 
emboli and cellulitis [128, 129]. Most common psychological disorders seen in heroin 
dependent individuals are mood disturbances and personality disorders, but can range to 
severe psychiatric disorders. Whether psychological problems are a cause or 
consequence of illicit drug use, still remains unclear [130, 131].
Many health and BBV risk problems are directly related to risky injecting behaviour 
(such as sharing equipment) leading to transmission of an infection (e.g. BBVs, 
endocarditis, pneumonia, septicaemia) [44], Other health problems are related to the 
physical act of unhygienic and unsafe injecting as a route of drug administration 
(e.g. localised infection around the injecting site, collapse of veins, and emboli) [129]. 
By replacing heroin with methadone, the need to inject and use heroin and the 
associated financial strain has decreased. This is turn has assisted with improving the 
physical, mental, psychological and social health of these individuals as defined by the 
WHO [104, 132].
The following summary of studies show that methadone treatment is effective in 
improving health outcomes, decreasing mortality associated with heroin dependency, 
and decreasing injecting and associated BBV risk.
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2.3.1.a: Effectiveness of methadone treatment in decreasing mortality
Gearing and Schweitzer measured changes in mortality rates amongst heroin dependent 
individuals as part of an evaluation of long-term methadone maintenance treatment 
[133], The evaluation was done in four cohorts and conducted amongst 17,500 patients 
admitted to New York city methadone treatment programmes between 1964 and 1971. 
Ninety per cent were still in treatment after one year, while 80 per cent remained after 
two years and 75 per cent after 3 years. The study found that mortality rates of people 
who remained in treatment (7.6 deaths per 1000) were lower than those observed among 
methadone clients who had left treatment (28.2 per thousand), and were not much 
higher than the general New York population at that time (5.6 per thousand).
A case control-study conducted amongst 4200 methadone treatment clients in Rome 
between 1980 to 1988, found that those who left treatment were over three times more 
likely to die from heroin overdose than those who stayed in treatment (OR=3.55, Cl: 
1.82-6.90) [134], The risk was higher for those who left treatment in the first 12 
months. These individuals were eight times more likely to die from an overdose 
(OR=7.98, Cl: 3.40-18.73). In the following 12 months, those who left treatment were 
two times more likely to die from overdose as those who remained (OR=2.54, Cl: 1.25- 
5.15).
Heroin dependent individuals in Australia have also been shown to have higher 
mortality rates than the general population. This is usually associated with overdose [1]. 
A long-term follow-up study of a cohort of 307 study heroin dependent persons 
admitted to methadone treatment in Australia, showed that those who left treatment 
were there times more likely to die than those in treatment (Cl: 1.45-5.61) [135].
2.3.1.b: Effectiveness of methadone treatment in decreasing injecting
Ball and Ross (1991) investigated the effectiveness of methadone treatment in 
decreasing frequency of injecting and sharing of equipment. A total of 633 male patients 
from six methadone maintenance programmes in the US were recruited over a three- 
year period [136]. Of 506 patients interviewed at the end of the study period, 388 
remained in treatment. Of these, 36 per cent had not injected since the first month on 
methadone treatment, 22 per cent had not injected in the past year and 13 per cent had 
not injected in the one to 11 months prior to interview. The rate of injection in the 
remainder was less than before entry into treatment.
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An Australian study conducted by Baker and colleagues in 1995 compared injecting and 
sexual risk-taking behaviour among IDUs who were currently, previously and never 
enrolled in methadone treatment [137]. All participants had to have injected in the six 
months prior to interview to be eligible to enter the study. The OTI was used to measure 
injecting and sexual risk [120], Results indicated that the three groups were similar for 
age, age at first injection and number of years at school. IDUs who were currently on 
methadone treatment had significantly lower (pO.OOl) injecting risk behaviour than the 
group who had been on methadone treatment previously, and the group who had never 
been in treatment. IDUs on current treatment also differed significantly from the other 
two groups in the frequency of injecting (pO.OOl) and cleaning of injecting equipment 
with bleach (p<0.01). For sexual risk behaviour there was no difference between the 
IDUs on methadone treatment and the other two study groups.
The study by Dore and colleagues (1999) examining effectiveness of methadone 
treatment amongst clients in a New Zealand clinic, found that of 89 clients injecting 
opioids daily prior to treatment, 64 per cent reported no opioid use in the three months 
prior to review (at six months after commencement of treatment). Sharing of injecting 
equipment was also reduced by almost 90 per cent [126].
2.3.l.c: Effectiveness of methadone treatment in decreasing BBV transmission
Methadone treatment has been shown to be very effective in decreasing new HIV 
infections [44]. There have been two prospective cohort studies conducted in the US 
that examined the effectiveness of methadone treatment in reducing HIV transmission 
through injecting. In the first study, 255 heroin injectors (inclusive of injectors in 
treatment and not in treatment) were followed over a period of 18 months to determine 
incidence of HIV in the two groups [138]. One hundred and fifty two injectors in 
treatment were recruited from a methadone clinic in north-central Philadelphia and 103 
injectors not in treatment were recruited from surrounding areas. HIV serology and 
other behavioural assessments were conducted at six monthly intervals over the follow­
up period and results were available for 89 per cent of the sample. At baseline, the HIV 
seroprevalence rate for the total sample was 12 per cent; 10 per cent for injectors on 
methadone and 16 per cent for injectors not on methadone. Seroconversion rates were 
calculated for the HIV-negative injectors in both groups. At the end of the follow-up 
period, injectors on methadone showed a seroconversion rate of 3.5 per cent, while 
injectors not on methadone showed a seroconversion rate of 22 per cent.
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Moss and colleagues conducted the second cohort study, which aimed to examine HIV 
seroconversion rate, risk factors for seroconversion, and changes in risk behaviour over 
time amongst IDUs admitted to methadone treatment in San Francisco between 1985- 
1990 [139]. A total of 2351 heterosexual IDUs were recruited into the study, of whom 
681 were HIV sero-negative at first visit. At the end of the study period, results showed 
that of these 681 participants, those who stayed in methadone treatment for over a year 
were almost three times less likely (risk ratio of 2.7) to have sero-converted for HIV as 
opposed to those who had stayed in treatment for less than one year.
Some countries that were initially opposed to methadone treatment for heroin 
dependency (as it was seen as supporting continued drug use), changed their position to 
combat escalating HIV prevalence amongst IDUs when studies showed that methadone 
treatment assisted with decreasing incidence of HIV. Drucker in his ‘Notes from the 
Drug Wars: On the European Front’ describes France as an example of this 
phenomenon, where 20-40 per cent of heroin injectors were infected with HIV and the 
need to use methadone in this group to decrease injecting and minimise transmission of 
HIV was finally recognised [140].
With HCV, methadone treatment has not been as effective in minimising new infections 
as most methadone clients are already HCV positive when they start on treatment [44], 
This could be due to the higher infectiousness and higher prevalence of HCV amongst 
IDUs as compared to HIV. The higher infectiousness of HCV may mean that 
transmission could occur with exposure to smaller amounts of contaminated blood [24, 
55, 82]. The higher prevalence of HCV amongst IDUs also means that transmission of 
the virus can occur with fewer risk exposures compared to HIV. The lack of knowledge 
about the aetiology and transmission of HCV until the late 1980s may have also 
promoted unsafe injecting practices [7, 44, 53]. In addition to this, as discussed in 
Chapter 1, a person who is HCV positive can be re-infected with a different genotype 
and can thus have multiple infections unlike HIV [83, 84], Due to its high prevalence 
amongst IDUs, the higher infectiousness, and the potential for re-infection with other 
genotypes, methadone treatment may be ineffective in preventing new infections of 
HCV but may be more effective in minimising re-infection with a different genotype.
This literature review indicates that methadone maintenance treatment over the years 
has been effective in improving health outcomes and decreasing mortality, in reducing 
injecting and transmission of HIV associated with heroin dependency.
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2.4: Factors associated with health and BBV risk for rural IDUs
At the time of commencement of my study there was very little research that had been 
conducted into investigating factors that could be associated with health outcomes and 
BBV risk amongst rural IDUs (such as drug use and associated risk factors, access to, 
and delivery, of harm minimisation services). This paucity of research in rural areas has 
been recognised in recent years. Two studies in 2005 and 2006 have aimed to 
specifically compare risk practices between urban and rural IDUs related to injecting, 
and explore the relationship with service delivery in rural areas [67, 141].
The first study conducted by Day and colleagues (2005) aimed to compare patterns of 
drug use, associated harms, and service access and utilisation among rural and urban 
IDUs in Australia [141]. The study was conducted in NSW, where 164 rural and 96 
urban IDUs were recruited. Urban and rural participants were found to be similar for 
sociodemographic factors such as age, gender, education and employment. Range of 
drugs used and drug use patterns were also similar for urban and rural participants. 
However, rural participants were less likely to have used heroin on a daily basis as 
compared to urban participants (rural: 2%; urban 10%), and were more likely to have 
injected morphine in the six months prior to interview (rural: 50%; urban: 21%). Rural 
participants were also less likely than urban participants to have used NSPs (rural: 36%; 
urban: 80%), and reported that access to NSPs and other drug treatment services was an 
issue [141].
The most recent study in 2006 by Lawrinson and colleagues examined if there were 
regional differences amongst entrants to opioid treatment in NSW in relation to 
sociodemographics, injecting practices and risk behaviours related to other substance 
use [67]. A total of 1512 consecutive entrants to opioid maintenance therapy in NSW 
were enrolled into the study between November 2000 and July 2003. There were three 
study groups; urban, regional and rural methadone treatment clients as designated by the 
NSW Department of Health (the demarcation between these groups is population 
dependent).
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Data for this study were collected using the Brief Treatment Outcome Measure 
(BTOM)5 when clients first entered into their methadone treatment programme. Results 
indicated that there were some sociodemographic differences between the study groups, 
with rural participants being significantly more likely to be older (p=<0.001), to have 
dependent children (pO.OOl) and to be unemployed (pO.OOl) in comparison to their 
urban and regional counterparts. Rural and regional participants were significantly more 
likely (pO.OOl) and almost two times more likely to have shared injecting equipment 
as compared to urban participants (urban: 16%, regional: 31%, rural: 29%). The 
researchers conclude that there is a need to investigate the reasons for these differences 
in BBV risk, so that harm reduction and treatment services can be developed 
accordingly [67].
These two recent studies conducted after commencement of my study, suggest that there 
are differences between urban and rural IDUs in relation to sociodemographics, BBV 
risk exposures and access to harm minimisation and treatment services. The studies 
highlight that these differences need to be investigated further and taken into account 
when planning and delivering treatment services for heroin dependency. The findings 
from these two studies corroborate and support my study objectives to investigate if 
there are differences in outcomes for urban and rural methadone treatment clients and 
the factors affecting them. The differences identified in these two studies were included 
as possible factors that could affect health and BBV risk outcomes for urban and rural 
methadone clients in my study.
5 The BTOM is a relatively new validated questionnaire that collects baseline information about 
dependency issues, BBV exposure risk, drug use, health/psychological functioning and social functioning 
at the commencement of opioid replacement therapy. Information is collected for client behaviour for the 
three months prior to interview.
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2.5: Validity of HCVself-reported status
As discussed in Chapter 1, 60-80 per cent of IDUs in Australia are positive for HCV 
and it has been projected that there could be between 300,000 to 800,000 IDUs living 
with HCV by 2020 (1.5-4% of the Australian population). HCV is associated with many 
health and social consequences that impact on daily living and quality of life.
A literature search conducted at the time of commencement of my study found five 
previous studies that compared HCV self-report with serology [56, 57, 88-90], These 
studies had other main objectives but blood samples were collected for BBV serology 
and information on self-reported status was also gathered. Four studies compared 
serology done at the time of the study with participant’s recall of previous tests [57, 88- 
90], while the fifth study compared serology done within two years of the interview date 
and self-report [56]. Two studies were conducted amongst prisoners [88, 90]; one study 
amongst IDUs [89]; and two studies amongst methadone programme clients [56, 57], 
The five studies used different population groups, and validity of self-report per se was 
not actively measured. I calculated the validity of HCV self-report from results 
published in the studies using clinical epidemiology measures, including sensitivity, 
specificity, positive and negative predictive values (PPV and NPV), and positive and 
negative likelihood ratios (PLR and NLR) [78]. These validity measures are 
summarised in Appendix 1.
Both prison studies were conducted for the purpose of determining BBV prevalence 
based on serology and to identify associated risk factors for BBV amongst prisoners.
The first prison study was conducted amongst Irish prisoners and measured 
seroprevalence for HCV, HBV and HIV through salivary antibody status [90]. The 
second prison study was amongst Australian prisoners in NSW and serology was done 
through blood samples. Participants were asked to provide self-report of BBV status and 
the study provided the proportion of correct positive self-reports [88]. The study 
amongst Australian IDUs was a multi-city study comparing seroprevalence for HCV, 
HIV and HBV, associated risk factors and the effectiveness of available harm 
minimisation strategies between cities. Serology and self-reports for HCV, HBV and 
HIV were compared [89]. The first study amongst methadone programme clients was 
conducted amongst English methadone clients who were still injecting opioids and 
aimed to examine the accuracy of self-report of HBV and HCV status compared to 
serology [57]. The second study amongst US methadone clients compared HCV self- 
report with results of serology performed within two years of the self-report [56].
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All five studies were conducted in differing settings with different study groups, and 
sociodemographic descriptions are presented in Table 2.1. The validity study amongst 
rural methadone injectors in NSW in 2000 was included as the sixth study in this 
description [58]. For these comparisons the entire study samples were used and not just 
the samples that aimed to compare HCV serology to self-report. The comparison found 
some sociodemographic differences between the study groups.
Studies conducted amongst methadone treatment clients had higher mean ages [56-58]. 
The male to female ratio was much higher amongst the prison studies [88, 90]. Only 
three studies (Australian IDUs study, the English methadone programme study and the 
NSW rural methadone injectors study) had information on education level [56, 58, 89]. 
A large proportion (72%) of the participants in the Australian IDUs study had not 
completed secondary school [89], while two-thirds in the English methadone 
programme study and the rural methadone injectors study had [56, 58]. All of the 
participants in the studies (other than the prison studies) had injected drugs. This was to 
be expected as they were studies amongst IDUs or methadone clients. These differences 
may affect risk exposure for HCV but would not affect the validity measurement of 
HCV self-report as this is dependent on testing and presumed knowledge of the 
individual.
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Chapter 2: Literature review
2.5.1: Validity of HCV self-reported status from the six studies
Findings in the published papers of these studies were used to measure validity of HCV 
self-reported status. Results are based on the sample in each study where both HCV self- 
report and serology were available. Some studies did not have all the necessary information 
to calculate all parameters of validity. Table 2.2 presents results for HCV self-report and 
serology status for participants of the six studies. For all studies, a greater proportion of 
participants were serologically positive than compared to self-report and a smaller 
proportion were serologically negative as compared to self-report.
Table 2.2: Comparison of correct self-reports (positive and negative) for the HCV validity studies 
reviewed
+ve self-report +ve serology -ve self-report -ve serology
Study
n % n % n % n %
Thornton & Barry 
(Irish prisoners) 
(n=304) 229 75 246 81 75 25 58 19
Butler et al
(NSW prisoners) 
(n=738) NA* NA 288 39
NA NA NA NA
Loxley et al 
(Australian IDUs) 
(n=599) 319 53 367 61 280 47 232 39
Best et al
English methadone clients 
(n=79) 58 73 66 84 16 20 8 10
Stein et al
(US methadone clients) 
(n=149) 104 70 132 89 45 30 17 11
Southgate et al 
(Australian rural 
methadone injectors) 
(n=38)
21 55 25 65 17 45 13 34
*  NA: Not Available
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Results of the validity analysis of HCV self-report for the six studies reviewed are 
presented in Table 2.3. This table has been reported once again in Chapter 7 inclusive of 
validity results from my study to compare and discuss the results from my study with these 
six studies. The proportion of participants who reported their status as positive and were 
HCV positive as elicited through serology (sensitivity) ranged between 60-90 per cent. 
These results suggest that between 10-40 per cent of people who are infected with HCV can 
report a false negative status. The positive predictive value ranged between 70-100 per cent 
suggesting that up to 30 per cent of people who are HCV positive can self-report a positive 
status when actually serologically negative. The likelihood of self-reporting a positive 
status when serologically positive as opposed to when negative (as measured by the PLR) 
ranged between 1.30 to 7.43. This suggests that people who are HCV positive are between 
one to seven times more likely to report a positive status when actually positive as 
compared to those who are negative.
The proportion of participants who truly did not have HCV and reported their negative 
status correctly (specificity) ranged between 54-100 per cent for the five studies where 
specificity could be calculated. Of these, three of the four studies had specificity of greater 
than 80 per cent; the NSW rural methadone injectors study had a very low specificity at 54 
per cent in comparison. Taking into consideration the low specificity in the NSW 
methadone injectors study, the results suggest that up to 46 per cent of persons who are not 
infected with HCV can provide a false positive result. The negative predictive value had a 
very wide range, between 33-74 per cent, suggesting that predicting a correct negative 
result can vary widely for persons who are HCV negative, and can be as low as 33 per cent. 
The likelihood of self-reporting a negative HCV status while positive as opposed to when 
negative also varied widely and ranged between 0.13 to 0.74. This suggests that the 
likelihood of a negative self-report in persons who were HCV positive in comparison to 
those who were HCV negative could be up to three of four persons (0.74). This is a very 
high proportion of incorrect negative self-reports.
Results of these validity calculations for HCV self-report (positive or negative) from the six 
studies suggest that knowledge and awareness of HCV status is poor amongst people at risk 
of acquiring HCV. The results also suggest that validity of positive self-report is better than 
negative self-report.
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Chapter 2: Literature review
I compared associations of possible risk factors with HCV serological and self-reported 
status in the NSW rural methadone injectors study [58]. This could not be done for the 
other studies reviewed due to lack of availability of results for this comparison. I did this to 
examine if the risk factors found to be significantly associated with HCV as determined by 
serology were the same as those elicited through self-report. I considered this to be 
important as one in four studies have been shown to use HCV self-report as an indicator of 
HCV status. The analysis conducted with HCV serological status (n=44) showed that men 
were significantly more likely to test positive than women, and those who had been in 
prison were significantly more likely to test positive (p<0.05). When the same analysis was 
conducted based on HCV self-reported status (n=64), these associations were no longer 
significant (p>0.05).
2.6: Summary
In this chapter I reviewed available literature about heroin dependency, the advent of 
methadone treatment to curtail heroin dependency and the accuracy of HCV self-reported 
status. Research has shown that methadone is effective in improving health, decreasing 
mortality, and decreasing BBV transmission associated with heroin use and injecting. 
Although there has not been an evaluation comparing methadone treatment outcomes for 
urban and rural clients in Australia, there has been recent research which suggests that rural 
IDUs and entrants to methadone treatment differ in relation to sociodemographic 
characteristics, risk behaviours and access to, and utilisation of harm minimisation 
treatment services, which could affect outcomes. The few studies that have examined the 
accuracy of self-report of BBVs prior to and after commencement of my study, suggest that 
the validity of HCV self-report is poor.
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Chapter 3 
Methods
In this chapter I describe the study design, ethical considerations, sampling methods, 
recruitment processes, data collection and handling, data analyses and limitations 
associated with the methods used.
Most alcohol and other drug research has been conducted using opportunistic or 
convenience sampling particularly with IDUs. As convenience sampling can introduce 
selection bias and confounding into study results, I attempted to recruit participants into 
this study through the use of random sampling [79]. Although this had limited success (as 
will be shown in this chapter), by using this methodology I explored the possibility of 
increasing validity of AOD research results by attempting to decrease selection bias. The 
outcomes of using random sampling in my study indicate that it is very difficult to do in 
research amongst IDU populations for logistic reasons and due to the unpredictable nature 
of IDU lifestyles.
Another feature of my study design was the use of verbal consent in the presence of an 
appropriate witness to gain informed consent from participants. This assisted in increasing 
the chances of participation by removing the need to identify individuals for random 
sampling.
I consider the attempt to increase validity of results and participation in my study by using 
these two methods to be a major contribution towards AOD research methodology.
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3.1: Study design
The first aim of my study was to investigate if there was a difference in health and BBV 
risk outcomes for urban and rural methadone clients, and identify factors that were 
associated with these outcomes. The best study design to explore this was a cross sectional 
study design where data were collected at one point in time [79]. This study design was 
also suitable for my second aim to examine the validity of HCV self-report as compared to 
serology at one point in time. The study design was also the most practical in terms of time 
and resources available for a PhD thesis.
3.2: Instruments used for data collection
I developed a partly self-administered and partly interviewer administered questionnaire to 
collect data required for the study. The questionnaire was mainly quantitative (close ended 
questions) with questions developed specifically for the study. It included two validated 
questionnaires; the OTI [120, 142] and the BBV TraQ [143]. There were three parts to the 
questionnaire, the first part concentrated on gathering socio-demographic data and specific 
information on programme policy and service delivery factors that could be associated with 
the outcomes of interest (health, BBV risk, and validity of HCV self-report status). Most of 
the questions in this part were developed for the purpose of my study. Some questions from 
a short questionnaire used for a study conducted by Dr Gabriele Bammer in 1993 
investigating the feasibility of controlled availability of opioids in Australia (ACT 1993 
Feasibility study) were included in the first part, as they were relevant to the first aim of my 
study [92]. The second two parts consisted of the two validated questionnaires which were 
used to measure health and BBV risk outcomes. A finger prick blood spot test was used for 
serological diagnosis of HCV and HIV status of the participants [144].
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3.2.1: The Questionnaire (Appendix 2)
The three parts to the questionnaire are described below.
Part 1: General questions
Part 1 of the questionnaire was self-administered. There were four sections to this part. 
Section 1: General questions
Included questions regarding socio-demographics, participant methadone treatment and 
programme management characteristics, participant perceptions of outcomes and 
satisfaction related to being on methadone treatment.
Section 2: Prison history
Collected data on prison history of participants and whether drug use and risk practices 
for BBV transmission occurred whilst in prison.
Section 3: Drug history
Collected information on drug use history, including first drugs used and injected, age 
when regular drug use commenced, and injecting practices. This section also collected 
information on methadone injecting.
Section 4: Serostatus
Participants were asked to self-report their perceived status for HIV, HBV, HCV and 
Hepatitis A Virus (HAV); details of when their last serological tests were done were 
also collected. Immunisation details were collected for HBV.
Part 11: The BBV TraQ [143]
The BBV TraQ is a validated questionnaire developed by Fry, Rumbold and Lintzeris in 
1998 under the auspices of the Turning Point Alcohol and Drug Centre [143]. It was 
developed for the sole purpose of measuring BBV risk. The TraQ measures risk in three 
domains; injecting risk, sexual risk and skin penetration risk (e.g. tattooing, body piercing 
and sharing of razors or toothbrushes). Additionally, it measures protective behaviours that 
may be used to minimise a risk practice while injecting. One of the criteria for use of the 
BBV TraQ is that participants need to be current injectors, which is described as having 
injected in the month prior to interview.
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The BBV TraQ uses a numerical scale that calculates scores for each domain, and a total 
BBV risk score that combines the scores for the three domains. These scores indicate the 
magnitude of risk experienced by an individual in the three risk domains by quantifying it 
through the numerical score. Individual scores and group mean scores can be calculated 
within each domain as well as for the total BBV risk score. A zero score indicates no risk 
and any score above zero indicates risk; the higher the score the greater the risk.
I used the BBV TraQ as the questionnaire of choice for measuring BBV risk. Although my 
main focus was on risk associated with injecting, I also measured BBV risk from sexual 
and other skin penetration practices to examine how much of BBV risk amongst 
methadone clients in my study groups was contributed from these sources. The reasoning 
for using the BBV TraQ, and further description of how it measures BBV risk is described 
in Chapter 6 (results chapter measuring and comparing BBV risk).
Part 111: The OTI
The OTI is a validated questionnaire which was developed in 1991 by Darke et al under the 
auspices of the National Drug and Alcohol Research Centre (NDARC) at the University of 
New South Wales [120]. The OTI was designed to measure and evaluate the outcomes of 
methadone treatment based on the five expected outcome measures described in Chapter 1. 
The OTI has also been extensively used for research purposes widely through Australia and 
other countries, including in a modified form in the UK [137, 142, 145-150].
The OTI has seven sections, six of which measure expected outcomes from methadone 
treatment as listed in the goals of treatment (Chapter 1). The first section gathers 
demographic information about participants. Sections II to VI measure outcomes related to 
drug use, BBV risk (injecting and sexual practices), social functioning (including housing, 
employment and relationships), involvement in crime, and health (general and in specific 
systems). Section VII uses the General Health Questionnaire-28 (GHQ-28) to measure 
psychological adjustment [151]. As demographic details were collected in Part 1 of my 
study questionnaire, the demographics section in the OTI (Section I) was not used in my 
study questionnaire. OTI information was collected from Sections II to VII only, which 
were re-labelled as I to VI for the purposes of my study.
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The OTI also uses a numerical scale to measure the expected outcomes similar to the BBV 
TraQ. For sections relating to drug use history, BBV risk, crime, health and psychological 
adjustment (GHQ-28), risk or dysfunction is measured for the month prior to interview.
For social functioning risk is measured for the six months prior to interview. A participant 
will have a numerical score for each of the section outcomes and a total score combining 
all section outcome scores (OTI total score). Mean scores can be calculated for study 
groups (group mean scores) in each section and for the OTI total score. Like the BBV 
TraQ a zero score indicates no risk or dysfunction in relation to the expected outcome, any 
score above zero indicates risk or dysfunction, and the higher the score the greater the risk 
or dysfunction.
I used the OTI to measure health outcomes in my study. The health section consisted of 
eight health areas/systems, and outcomes were measured through the presence or absence 
of symptoms within these. Scores for the eight areas/systems can be calculated and a Total 
Health Score (THS) can be calculated by combining the eight areas/system scores. Like 
the BBV TraQ, THS scores indicate the magnitude of health risk or dysfunction 
experienced by an individual. Although information was collected for all sections of the 
OTI, only measurement scores for health outcomes (THS scores) are presented in this 
thesis. Details of the measurement process for health outcomes are explained further in 
Chapter 5 (results chapter measuring and comparing health outcomes). Appendix 3 
describes OTI measurement of all the outcome sections. Although the OTI measures BBV 
risk, I chose not to use the OTI for my study for reasons explained in Chapter 6.
3.2.2. Finger prick blood spot
Capillary blood collected through a finger prick blood spot test was used to establish 
serological HCV and HIV status. Venous blood samples were not collected as interview 
locations did not have appropriate facilities for collecting or storing large amounts of blood. 
Blood collected was stored on blotting paper at room temperature and couriered to the 
pathology laboratory for analysis at regular weekly intervals. Blood samples were tested for 
HCV antibody using a modified third generation enzyme immunoassay (Abbott HCV 3.0, 
Chicago II). HIV antibody was detected using Genetic Systems HIV-1 ELISA tests. These 
assays have been shown to have a high correlation with venous blood samples [144].
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The National Centre for HIV Epidemiology and Clinical Research (NCHECR) in Sydney 
provided the test kits for serology and carried out the analysis. This support was provided 
to my study as the results of HCV and HIV status would contribute to the on-going 
Australian NSP Survey conducted by NCHECR [33].
3.3: Outcome measures
1) Health: Health outcomes were measured through group mean scores for urban and rural 
study groups in the following categories as calculated by the OTI.
a. THS (Sum of systems score).
b. Each systems score:
• general health,
• injection related problems,
• cardio/respiratory,
• genito-urinary,
• gynaecological,
• musculo-skeletal,
• neurological,
• gastrointestinal systems,
• GHQ scores for psychological adjustment.
c. Factors associated with THS within urban and rural study groups.
2) BBV risk: BBV risk was measured through group mean scores for urban and rural 
study groups in the following categories as calculated by the BBV TraQ.
a. Total BBV score (sum of injecting, sexual and skin penetration risk score).
b. Each section score:
• injecting risk,
• sexual risk,
• other skin penetration risk.
c. BBV risk in injectors and non-injectors.
d. Factors associated with BBV risk due to injecting within urban and rural study 
groups.
76
Chapter 3: Methods
3) Validity of HCV self-reported status: In my study, validity of HCV self-reported 
status refers to the accuracy of self-reported status as a screening test as used in clinical 
epidemiology, to determine whether a person is truly HCV positive as indicated by 
serology [79]. Validity of HCV self reported status compared to serological status was 
calculated for urban and rural study groups using the following epidemiological validity 
measures:
a. sensitivity and specificity,
b. positive and negative predictive values,
c. positive and negative likelihood ratios.
Validity of HIV self-reported status was measured as a comparator to validity of HCV 
self-reported status.
3.4: Factors that could be associated with study outcomes
Factors that could be potentially associated with the outcomes of interest in my study 
(health, BBV risk, validity of HCV self-report) were identified from previous studies and 
through my experience working with the SNSW PHU and methadone treatment 
programme. They were categorised under the following broad headings for which 
information was collected.
• Socio-demographic characteristics
• Participant risk factors
o Previous drug and prison history 
o Current risk factors
• Methadone programme policy and service delivery
• Client programme characteristics
• Client satisfaction and perception of outcomes
• HCV self-reported and serological status
• HIV self-reported and serological status
Actual factors within these categories are outlined in Figure 3.2.
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Figure 3.1: Factors that could be associated with study outcomes
Socio-demographic factors
• Age
• Gender
• Education
• Employment
• Main income last 6mths
• Prison status
Previous drug and prison 
history
• Age first injected drugs
• Age first injected drugs regularly
• Other drug treatments
• Prison history
• Prison risk factors (drug use, 
injecting, tattooing)
• Prison methadone treatment
Current risk factors
• Drugs used in the last month
• Methadone injecting
• NSP access
• Re-use of injecting equipment
• Living with someone who injects
• Self-report of BBV
Programme policy and service 
delivery
• Programme tier
• Cost of methadone
• Access to takeaway methadone
• Number of takeaway doses
• Case Management
• Time between prescriber 
appointments
• Cost of prescriber appointments
Client programme characteristics
• Previous methadone treatment history
• Reasons for getting on methadone
• Time on program
• Referral source
• Methadone dose
• Time travelled to dose
• Travel costs to dose
Client satisfaction and perceptions
• Perceived client outcomes
• Satisfaction with programme
HCV and HIV status
• Self-reported status
• Serological status
78
Chapter 3: Methods
3.5: Ethics Committee approval and ethical considerations
As this study involved two methadone programmes, ethics approval had to be obtained 
from the Ethics Committees responsible for the two programmes. Approval was also 
needed from the Australian National University (ANU) Human Research Ethics Committee 
(HREC), as the study was being conducted under the auspices of ANU. Ethics applications 
were prepared and submitted to the following three bodies at the end of September 2001:
• ANU HREC,
• ACT Department of Health and Community Care HREC,
• South Western Sydney Area Health Service HREC (proxy for SNSW Area Health 
Service).
Approval from all three committees was granted by the end of February 2002.
3.5.1: Main conditions for approval granted by Ethics Committees
1) All three HRECs required that the study should not have access to, collect or keep any 
identifying details that would allow a participant in the study to be traced. This was 
done to protect confidentiality and prevent identification of participants under the 
Federal Privacy Act 1988 [152].
2) A second ethical issue raised was the dissemination of HIV and HCV blood test results 
as a diagnosis. All three HRECs agreed that this could not be done for two reasons. 
Firstly, although the finger prick blood spot test used was recognised to have a high 
correlation with assays of venous blood samples, it was designed for research purposes 
only. A venous sample would be needed for confirmatory diagnosis and the participant 
would need to have pre and post test counselling as required by law [153]. Secondly, to 
disseminate results to participants, records of their identity and contact details would 
have to be kept, which was not allowed under the conditions granted for the study by 
the three HRECs. All HRECs required that participants be made aware of this and 
alternatives for diagnostic testing be provided. Every participant was given an 
information sheet (Appendix 4) at the time of the interview explaining the study, the 
process of the interview, protection of their identity and that results of blood tests would 
not be given to them. Participants were given the opportunity to have diagnostic testing 
done through their respective methadone programmes.
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3) Informed verbal consent
Acquiring written consent from participants was not possible, as HRECs required that 
no identifying information of the client be kept. Instead, verbal consent was gained with 
a clinic/community health centre staff member present as a witness. This process for 
consent was included in the information sheet (Appendix 4) given to participants at the 
beginning of the interview and was read out to participants in the presence of the 
witness after the study had been explained. The witness was present until participants 
consented verbally to taking part in the study. The verbal consent process has been used 
in other AOD studies and is seen to be acceptable to fulfil ethics committees criteria in 
keeping the identity of participants anonymous [154]. Verbal consent was documented 
on the information/consent sheet and stored with the completed questionnaire. The 
study record number of participants was also noted on this information sheet and a copy 
of the sheet was given to participants. If a participant wished to withdraw from the 
study at any time, they were asked to call me or the ANU HREC Secretariat, quote their 
record number and asked to be removed from the study.
3.6: The sample
As mentioned in the introduction, most AOD research has used convenience sampling to 
maximise recruitment and increase sample sizes. One of the reasons for lesser numbers of 
individuals recruited into AOD research is the fear of being identified. Many studies require 
admission of illegal activity such as illicit drug use and criminal activity on the part of 
participants to be able to measure risk or outcomes. Acknowledgement of performing 
illegal activities could compromise participants’ eligibility to remain on treatment 
programmes and also increase the chance of being identified by law enforcement agencies. 
There may also be social and professional implications such as loss of employment and 
stigmatisation by the community. These issues are particularly relevant amongst IDUs who 
are in general a hard to reach group. Thus research with IDUs grasps every opportunity to 
recruit participants into studies, and convenience sampling makes this much more possible 
through recruiting all voluntary and self-referred participants.
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Convenience sampling has both advantages and disadvantages. The advantages are that 
larger numbers can be recruited and participants do not need to be identified for recruitment 
purposes. A major disadvantage is that the sample may not be a representative sample of 
the study group and could thus introduce selection bias and confounding into the study 
results [79]. For these reasons I designed a random sampling strategy to recruit a 
representative sample for my study.
3.6.1: Sampling frame and method
A multistage process of stratified systematic simple random sampling was used to minimise 
bias and confounding associated with recruitment of the study sample. Sampling of 
participants for the study was conducted from the ACT and SNSW methadone registers. As 
HRECs’ approvals required that identifying factors of the client could not be accessed, 
sampling was done with a de-identified register. The sample was initially stratified by study 
group (urban and rural), then by methadone programme tier, followed by systematic 
selection of every nth client within each tier to add up to the required sample size within 
each study group. Equal numbers were selected from each programme tier to ensure equal 
representation from all tiers. Table 3.1 illustrates the sampling frame and method and how 
participants were to be selected into the study.
Table 3.1: Sampling frame and method
Sampling
Frame
Urban: ACT Methadone Treatment Programme Clients 
Rural: SNSW Methadone Treatment Programme Clients
Three tiers of the programmes
- Tier 1: Public (public programme management and dosing)
- Tier 2: Partly public/partly private (public programme management/ pharmacy dosing)
- Tier 3: Private (GP management/pharmacy dosing)
Sampling
Method
Multistage sampling
- Stratified by urban/rural
- Stratified by tier of programme
- Systematic simple random sample (every nth client from each Tier of the programme, 
to have equal numbers from each tier)
Eligibility
Criteria
Determined by the programme the client was registered on
- ACT client for urban sample
- SNSW client for rural sample
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3.6.2: Sample size calculations
Group mean scores as measured by the OTI in the ACT 1993 feasibility study conducted by 
Bammer and colleagues were used as baseline health scores to calculate the sample size 
required to elicit a 20 per cent difference in health outcome scores between urban and rural 
study groups at the p<0.05 level with 80 per cent power [92]. The ACT 1993 study group 
mean score for health status was 14.6 (SD: 7.3)
Group mean scores from the validation study of the BBV TraQ were used for calculation of 
sample size required to elicit a 20 per cent difference in total BBV risk and injecting risk 
scores between urban and rural study groups at the p<0.05 level with 80 per cent power. I 
used the standard deviations (SD) of total BBV risk and injecting risk scores from the ACT 
1993 study as measured by the OTI instead of the BBV TraQ. This was done as participants 
in my study were methadone treatment clients and the ACT 1993 study was conducted 
amongst methadone treatment clients. The BBV TraQ validation study was conducted 
amongst IDUs not on methadone treatment and by using the BBV TraQ SDs for sample 
size calculations, risk may have been overestimated for participants in my study.
The following were the mean scores from the BBV TraQ validation study and SDs as 
measured by the OTI in the ACT 1993 study:
• Total BBV risk: Group mean score=29.4; SD=6.6.
• Injecting risk: Group mean score= 16.1; SD=3.9.
STATA statistical software package was used for sample size calculations [155]. Using the 
baseline mean scores and SDs from previous studies, the following sample sizes were 
required to establish a 20 per cent difference (p<0.05 level, power=80%) between urban 
and rural study groups for health outcomes and BBV risk associated with injecting:
• Total BBV risk: 20% difference in group mean scores = 20 per group
• BBV risk (injecting): 20% difference in group mean scores = 24 per group
• Health Status: 20% difference in group mean scores = 100 per group
To calculate the sample size required to determine the validity of self-reported HIV and 
HCV status, a 95 per cent confidence interval length of 0.2 for sensitivity and specificity 
was used for precision. Based on these calculations a sample size of 100 per group was 
required.
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A final sample size of 100 per comparison group was reached for the study. To have equal 
representative samples from each of the three tiers of the two programmes, at least 34 
clients from each of the tiers were required to be sampled to make up a total of 100 
participants per study group. Systematic sampling was going to be based on the number of 
methadone clients registered within each tier of the programme at the time of sampling.
3.7: Random sampling for selection o f participants into the study
Sampling, recruitment and data collection processes for the two study groups were done 
separately and at different times. The processes commenced within the ACT in April 2002. 
Sampling, recruitment and data collection processes for SNSW were planned to occur after 
those of the ACT and to commence in July 2002. Figure 3.2 outlines the stratified 
systematic random sampling process, recruitment process and final study numbers.
3.7.1: Procurement of a de-identified database for random sampling
To enable random sampling, I had to obtain a de-identified database to keep in line with the 
confidentiality requirements of the HRECs. All clients in the ACT were listed on one of 
two ACT methadone programme registers (public and community programme registers), 
which were maintained by the programme. These registers were used for sampling to select 
clients into the urban study group. ACT Tier 1 clients were kept on a separate register to 
Tier 2 and 3 clients. This was because Tier 1 clients were managed as public clinic clients, 
while Tier 2 and 3 clients were grouped and managed as community programme clients, as 
they were dosed through community pharmacies. The ACT methadone programme 
coordinator produced a de-identified database by removing all identifying variables such as 
name, address, phone number and workplace. This database was sorted by tier. Each client 
was assigned a database number in place of his or her name. The database numbers were 
sequential for the entire database and were not sequential within each tier. I was provided 
with a copy of this de-identified database for the purposes of random sampling.
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Only Tier 1 and 2 clients were listed on the SNSW methadone programme register. As 
Tier 3 clients could get on the programme directly at the discretion of GP prescribers, they 
were not on the SNSW programme register and were only registered on the NSW 
Department of Health’s Pharmaceutical register (as explained in Chapter 1). The process 
that was used to procure a de-identified database for sampling in the ACT was replicated 
for Tiers 1 and 2 in SNSW.
Sampling for Tier 3 clients in SNSW proved to be more complicated as these clients were 
not registered with the SNSW programme. The methadone coordinator could not access a 
client list from the NSW Pharmaceutical Department of Health’s register to enable Tier 3 
clients to be added to the Tier 1 and 2 database for sampling, as these were private patients. 
Procuring a de-identified database for random sampling of Tier 3 clients could only be done 
with the assistance of GP prescribers.
There were two options considered for random sampling of Tier 3 clients within SNSW.
The first was for the GP prescribers to provide a list of clients registered at their practices to 
the SNSW methadone coordinator to collate and add to the Tiers 1 and 2 de-identified 
database. This was only possible if clients gave their consent. Getting consent from Tier 3 
clients could only be done when the clients visited the GP as contact details of clients kept 
in GP practices were not reliable. Client GP visits were usually at three monthly intervals or 
greater and this timeframe for the purposes of the study was not reasonable.
The second option was for GP prescribers to compile a list of their clients in alphabetical 
order and do the random sampling process for the study by selecting every nth client as 
required to produce a total Tier 3 sample of 34 clients. Although this process did not 
provide a random sample similar to that of Tier 1 and 2 of SNSW and the ACT, there 
would still be an element of randomisation within each GP practice. This was seen as being 
the best option at obtaining a SNSW Tier 3 database for random sampling without 
compromising confidentiality and the process of random sampling.
84
e 
3.
2:
 S
um
m
ar
y 
of
 sa
m
pl
in
g 
an
d 
re
cr
ui
tm
en
t 
pr
oc
es
:
r
j
3
CM
CJ
3
z z s
Chapter 3: Methods
3.7.2: Random sampling process for selecting clients into the study
Random sampling to select participants into the urban study group (ACT) was done on 
2 April 2002. There was a total of 620 clients (three tiers combined) registered for 
treatment on the day of sampling, out of a total of 755 available places on the 
programme.
Random sampling to select participants from Tiers 1 and 2 for the rural study group 
(SNSW) was done on 1 July 2002 after completion of recruitment and data collection in 
the ACT as planned. There was a total of 152 clients registered for treatment in the two 
tiers on the day of sampling, out of a total of 200 available places on the programme. 
The number of Tier 3 clients registered in SNSW at this time was 95, out of a total 100 
available places (this information was accessed from the NSW Department of Health by 
the methadone coordinator). Due to the complexity of access to a Tier 3 client list, 
sampling of this tier was left until Tiers 1 and 2 sampling, recruitment and data 
collection was completed. The distribution of clients by tiers in the two study areas at 
the time of sampling to select participants into the study is displayed in Table 3.2.
Table 3.2: Numbers on the ACT and SNSW programme by tier at time of sampling
T ie r
Urban study group (ACT) Rural study group (SNSW)
Total
places
No.
registered
% Places 
occupied
Total places No.
registered
% Places 
occupied
Tier 1 270 235 87 100 62 62
Tier 2 330 234 62 100 90 90
Tier 3 155 151 97 100 95 100
Total 755 620 82 300 247 82.3
To recruit the required sample size of 100 for the urban study group with equal 
sampling of approximately 34 in each tier, the following clients were systematically 
selected from each Tier in the ACT:
Every 6th client was selected in Tier 1; with 39 of 235 clients selected.
Every 6th client was selected in Tier 2; with 39 of 234 clients selected.
Every 4th client was selected in Tier 3; with 37 of 151 clients selected.
A total of 115 clients were selected from the ACT programme through this process.
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In SNSW, systematic random sampling as per the ACT process was done for Tiers 1 
and 2. The following clients were selected into the rural study group to have 
approximately 34 participants from each tier:
Every 2nd client in Tier 1 was selected; with 31 of 62 clients selected.
Every 3rd client in Tier 2 was selected; with 30 of 90 clients selected.
In total, sixty-one clients were selected from Tiers 1 and 2 through the sampling process 
to represent Tiers 1 and 2 of the rural study group.
Sampling of SNSW Tier 3 clients was done by enlisting the assistance of GP prescribers 
and their practice managers. Out of 17 GP prescribers in SNSW, there were nine GPs 
who managed Tier 3 clients in their practices at the time of the study. All nine GPs were 
contacted and sent information detailing the study with a covering letter from the 
director of the SNSW AOD Programme. Two GPs had no patients registered for 
treatment at the time of sampling, one refused to participate and one had withdrawn 
from the programme. This left five GPs who were on the programme and willing to 
participate in the study. Of the 95 clients on the NSW pharmaceutical register, the five 
GPs who were willing to participate had 88 clients between them, while the GP who 
had refused to participate in the study had seven patients at that point in time. This 
meant that 93 per cent of Tier 3 clients could be accessed through the five GPs willing 
to participate in the study. I visited these five GP to finalise details of random sampling 
of clients within their practice for recruitment into the study. A total of 35 clients were 
selected through this process in Tier 3.
Randomly selected clients were to be contacted by the methadone coordinators in each 
programme to be recruited into the study. For this to occur, clients selected needed to be 
identified by the methadone coordinators. Every client randomly selected was allocated 
a sample number, separate to his or her database number. The sample number was 
allocated sequentially within tiers unlike the database number. This number indicated 
which tier selected clients belonged to, and their chronological number in the random 
sampling process within the tier (example: second client randomly picked in Tier 1 
would have a sample number of 1 [2]). The sample number along with the database 
number allowed for the methadone coordinators to identify clients for recruitment into 
the study according to tier.
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3.7.3: ‘Sample waves’ and non-respondents
It was intended that all clients who were selected through the sampling process to be 
recruited into the study were to be given one month to respond to the invitation to 
participate. If they did not respond within this period they were to be deemed as non­
respondents. Clients who refused at the time of invitation were also classified as non­
respondents. To ensure that enough numbers were recruited and random selection into 
the study was maintained, the next person to the non-respondent on the methadone 
register replaced the non-respondent. These new samples were to be created on a 
monthly basis as this was the timeframe for selected clients to respond and were termed 
‘sample waves’ for the purpose of this study. The sample number remained the same 
for participants in each sample wave.
3.7.3. a: Non-respondents
Non-respondents were asked to fill in a non-respondent questionnaire (Appendix 5), 
with 14 questions relating to demographics, selected programme characteristics, 
satisfaction with the programme and why they did not wish to participate. This was 
done to establish if non-respondents differed to respondents in the study. Non­
respondent response was very poor. Overall there were only 19 non-respondents who 
participated, 17 of 156 non-respondents in the ACT and two of 145 non-respondents in 
SNSW. Non-respondent numbers and participation rates by tier are presented in Table
3.3.
Table 3.3: Non-respondent participation rate
Urban (ACT) Rural (SNSW)
No.
sampled
No.
recruited
Participation 
rate (%)
No.
Sampled
No.
recruited
Participation 
rate (%)
Tier 1 26 9 35 35 1 3
Tier 2 69 3 4 38 1 3
Tier 3 61 5 8 72 0 0
Total 156 17 11 145 2 1
As the response was so poor and sample size was small, further analyses of non­
respondents would not have been useful.
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3.8: Recruitment
Advertising of the study through posters (Appendix 6) was timed to occur a month prior 
to recruitment and data collection commencing in the two study areas. Posters were 
distributed to all methadone clients in the urban and rural study areas at their point of 
dosing, informing them about the study and that they may be randomly selected to 
participate. The poster was not an open invitation, but was intended to raise awareness 
and provide information to potential participants of the study. Copies of these posters 
were sent to all ACT and SNSW public methadone clinics and medical officers, 
community pharmacies, CHCs, other AOD services and all participating GP methadone 
prescribers in the two study areas.
As randomly selected participants had to be identified to be recruited, and due to Ethics 
Committees’ requirements that the study could not have access to identifying details of 
clients, the methadone programme coordinators of the urban and niral programmes were 
to recruit selected participants into the study. Recruitment sheets for the coordinators to 
use were created for each tier in each study group with the randomly selected clients’ 
database number and sample number (Appendix 7). A third column on the recruitment 
sheet indicated whether the randomly selected client was willing to participate or not.
The coordinators in each programme area used the recruitment sheets to cross reference 
the selected participants against their identification details on the methadone registers. 
Once selected participants were identified, the coordinators were to contact them, 
briefly describe the study and invite them to participate. Contact was to be made 
through client details available on the register. A schedule of interview times was 
organised. If a selected client agreed to participate the coordinators were to set up 
interviews according to the convenience of the client, and time slots available on the 
schedule (Appendix 8). This recruitment process was applicable to all urban participants 
and Tier 1 and 2 participants of the rural study group. Selected Tier 3 clients of the rural 
study group were to be contacted through the practice managers of their GP methadone 
prescribers.
Each participant was to be given AUDI 5.00 as re-imbursement for out of pocket 
expenses (such as bus fares and childcare) related to participating in the study. The 
poster did not advertise this as it was perceived that advertising a monetary re­
imbursement would encourage unnecessary self-referral for participation in the study.
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3.8.1: Recruitment process in the ACT
Advertisement of the study to recruit urban participants commenced in the ACT in the 
first week of March 2002. Recruitment started with Tier 1, and as per the recruitment 
plan, the methadone coordinator tried to contact and recruit selected clients through 
contact details available in the methadone registers. This process was not successful as 
contact details of many clients were not recorded or incorrect. Consequently another 
strategy was needed.
It was decided that the best way to contact Tier 1 clients was through their dosing 
centres, which were the Civic Methadone Clinic (north-side) and TCH Methadone 
Clinic (south-side). The Tier 1 recruitment sheet along with interview schedules were 
sent to these dosing points for selected clients to be recruited by dosing staff. If the 
client agreed to participate they were asked to choose a time from the interview 
schedule. If they declined they were asked to fill in the non-respondent questionnaire. 
The non-responders were replaced with the next client on the database by the 
methadone coordinator. The sample number for the new client selected remained the 
same but the database number changed and the sample sheet was modified accordingly.
Recruitment of clients for Tiers 2 and 3 ran into the same problem as Tier 1. Once again 
it was decided that the best method for recruitment was at the point of dosing, which in 
the case of Tiers 2 and 3 was at community pharmacies. The recruitment sheets created 
for Tiers 2 and 3 were not usable any more for the new recruitment strategy as each 
selected client had to be identified by the pharmacy they dosed at. A recruitment sheet 
of selected clients with database number, sample number and pharmacy where they 
dosed was compiled for Tiers 2 and 3 from the de-identified database (Appendix 9).
Recruitment sheets for each pharmacy were compiled combining Tiers 2 and 3 clients 
onto the one sheet with a blank column for client name to be entered by the methadone 
coordinator (Appendix 10). The methadone coordinator identified randomly selected 
clients by database number, filled their names on the sheet and forwarded it to the 
nominated pharmacy for recruitment when they came in to dose. To protect the identity 
of the clients the study did not have access to these lists. Selected clients were to contact 
me on a mobile number and identify themselves by their sample number to make time 
for an interview. Information sheets detailing these processes were given to selected 
clients at the time of recruitment (Appendix 11). This recruitment strategy maintained 
the confidentiality of the client since no identifying details were accessible.
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All randomly selected clients were given one month to respond after which they were 
deemed as non-respondents and were replaced with the next person on the database 
within their tier for recruitment into the study.
As the methodology for recruitment had changed significantly, HRECs needed to be 
informed and for me to seek permission to use the new methods for recruitment. As the 
same recruitment issues were envisaged in SNSW as well, and to ensure that 
methodology was consistent in both study groups, all three HRECs were contacted at 
the same time to seek permission to modify recruitment processes in both study areas.
All HRECs gave permission for the new recruitment process to be adopted immediately. 
Permission was also obtained from the ACT and SNSW Pharmacy Guilds, and the ACT 
and SNSW methadone programmes, to use participating methadone pharmacies and 
public programme dosing outlets as recruitment points.
3.8.2: Recruitment process in SNSW
All clients on the SNSW methadone programme were sent the poster advertising the 
study through their dosing points in June 2002, a month before data collection began.
All Tier 3 clients were also sent the poster advertising the study through participating 
GP practices. All public clinics, participating pharmacies and GP prescribers were sent 
the poster and further information detailing the study and processes involved, by the 
SNSW methadone coordinator.
Recruitment of Tier 1 and 2 randomly selected participants was done as per the process 
used to recruit for the urban study group through public dosing points. Selected clients 
called me directly to make appointments (similar to clients in Tiers 2 and 3 in the urban 
study group). As it was going to cost more than the cost of a local phone call (since 
SNSW was out of the ACT region), all clients recruited through SNSW pharmacies 
were sent a phone card via their dosing point to ensure that participants did not have any 
further out-of-pocket expenses, and to maximise the chances of recruitment into the 
study. Selected clients were given an information sheet detailing all these processes by 
the recruiting pharmacist (similar to those used in the ACT) (Appendix 12). Similar 
sampling sheets to those used for the ACT were created for SNSW Tiers 1 and Tier 2 
recruitment processes.
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Randomly selected Tier 3 clients were to be recruited by practice managers at the GP 
practice that the client attended. Contact details for SNSW Tier 3 clients were also 
found to be unreliable and the practice managers had to recruit clients when they visited 
the practice. As clients’ visits were at three monthly intervals or more, recruiting only 
selected participants into the study was not going to be possible within the timeframe 
for data collection. For this reason, any client who visited the GP practice was invited to 
participate, which made the Tier 3 sample in the rural study group a convenience 
sample. There was still an element of randomisation to this process, as clients did not 
self-refer themselves into the study. Practice managers made the appointment with the 
client at the time of the visit, based on a schedule I had provided them with. All rural 
Tier 3 clients were also supplied with phone cards to enable them to contact me to 
schedule an appointment. An information sheet with these details was given to recruited 
clients (Appendix 13).
As per the ACT recruitment strategy randomly selected participants in SNSW were also 
given one month to respond before a new sample wave was created. Non-respondents 
were asked to fill in the non-respondent questionnaire.
3.9: Data collection
Two research assistants were employed for 10 hours per week, to assist with the data 
collection process. The research assistants were employed to collect data only within the 
urban study area and areas with minimal travelling time in the rural area, which was 
mainly Queanbeyan. I conducted all other interviews in SNSW outside of the 
ACT/Queanbeyan region; thus in total there were three people (including myself) 
collecting data. A training session was conducted a week prior to the commencement of 
data collection, to familiarise the research assistants with the questionnaire, the process 
of administering the questionnaire, blood sample collection, ethical considerations and 
personal safety issues. All interviewers were trained to collect finger prick blood 
samples and were provided with gloves, disinfectants and sharps disposal bins that fit 
into a backpack for easy carriage.
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3.9.1: Locations used for data collection in the ACT
Appropriate interview locations had to be identified to ensure easy access, comfort and 
confidentiality for participants, and at the same time provide personal safety for 
interviewers. Public places such as coffee shops would have been suitable for 
administration of the questionnaire but were not considered suitable for blood sample 
collection.
As the urban study area (ACT) is divided by Lake Burley Griffin into the south-side and 
the north-side it was decided that the study would have a centrally located interview 
venue within each area to maximise access for clients. The best option for the south-side 
location was at TCH clinic dosing point for the following reasons:
• it was centrally located,
• it had private interview rooms that could be made available for the study,
• public transport stopped in front of the clinic,
• the clinic was open on weekends enabling interviews on weekends,
• the clinic was a secure location for interviewers as desk phones and Duress alarms6 
were provided and fitted in each interview room,
• there were hand washing facilities and sharps disposal equipment within the rooms.
The Civic methadone clinic was chosen as the interview point for the north-side for 
similar reasons. However, soon after data collection commenced in mid-April 2002 the 
north-side clinic shut down (in the first week of May 2002). To ensure access for the 
north-side participants, a non-govemmental organisation, Canberra Alliance for Harm 
Minimisation and Advocacy (CAHMA), which had a drop in centre for drug users in 
the north-side was approached to request use of their premises. CAHMA was centrally 
located in the ACT Business District (ACT CBD). CAHMA staff were willing to 
support the study and provided a room to use for interview purposes during centre 
opening hours, which were normal business hours (Monday to Friday). Most methadone 
clients were familiar and comfortable with the centre, which provided privacy and 
helped to maintain confidentiality, security and easy access for both interviewers and 
participants. The only disadvantage of this location was that it was closed on weekends.
6 A Duress alarm system is a network o f transmitters linked to a central location within large facilities and 
is designed to provide a means o f alerting security personnel to potential personal safety problems within 
the site. Every patient consultation room in TCH had a Duress alarm.
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3.9.1.a: Changes and problems with recruitment and data collection in the ACT
Once data collection commenced, it became apparent that most selected clients were not 
going to keep their interview times. Selected clients turned up for interviews at 
unscheduled times either due to confusion with timeslots or just forgetting interview 
times. As selected clients were interested and were turning up but not necessarily at the 
appointed time, it was decided that rather than having set appointment slots, 
interviewers would be available between 9.30 am and 4.30 pm, most days at both 
interview locations (north and south). This was to allow selected clients to come in for 
the interview according to their convenience.
The first week of data collection for Tier 1, with interviewers being available at all 
times (first week in April 2002), was a dismal failure as there was not a single interview 
conducted in the first four days of the week. When the process was reviewed it came to 
light that some recruiting staff at dosing points were not aware of the study, were not 
briefed that there was an interviewer available through the day, or were just forgetting 
to recruit as dosing times could be very busy. This could have been due to a number of 
staff working part-time or being casual workers, or working different shifts, thus 
missing briefing meetings. It was decided that receptionists at the clinics who were 
fulltime workers and worked normal business hours including dosing times, were 
probably more likely to be able to recruit clients consistently. This process worked 
more efficiently and numbers interviewed in Tier 1 increased substantially in the weeks 
following (mid April-June 2002). The recruitment plan for Tiers 2 and 3 clients 
continued as planned and recruitment was done by pharmacists at dosing points, and 
selected clients called me directly to make an appointment.
3.9.2: Locations used for data collection in SNSW
As clients in SNSW were so widely dispersed, there needed to be many locations for 
interviews for ease of access, to minimise travel time, and have sufficient privacy for 
participants to feel that their confidentiality was protected. For interviewers the 
locations needed to be accessible, secure and practical to conduct interviews. As CHCs 
are available in most rural towns, it was decided to use their facilities in SNSW for 
interviews. These locations were the most practical as they had confidential private 
interview rooms, with phones, Duress alarms and hand washing facilities (needed for 
blood sample collection).
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Permission was sought and granted by the SNSW Health Services to use interview 
rooms in the CHCs as necessary. Clients from all tiers were interviewed at these 
locations. For Queanbeyan clients, interview rooms in the AOD clinic were used instead 
of the CHC, as this was more accessible for clients and was also the dosing point for 
Tier 1 clients.
As recruitment and data collection for SNSW was done after the ACT processes were 
almost completed, lessons learned in the ACT made the processes in SNSW flow more 
smoothly and according to plan. The main problem with recruitment and data collection 
in SNSW was the limited numbers available in Tier 1 for random selection into the 
study (i.e. every second client was selected to have approximately 34 clients in the 
study). There were a few minor logistic problems, such as selected clients who had 
received phone cards, not knowing how to use them. Recruiting staff were asked to 
inform clients on how to use them.
Data collection for both study groups was stopped on the 30th November 2002 even 
though the required sample size was not reached. This was done for the following 
reasons:
• There were no more clients to be sampled in Tier 1 of SNSW (Tier 1 had only 50% 
of places full and all 62 clients were approached through two sample waves).
• It was getting difficult to recruit more participants and in the last few weeks of data 
collection, there were only one or two interviews being conducted.
• Time limit in terms of completing a doctoral study.
3.10: Data coding and entry
Data were directly coded on the questionnaire. Data from the coded questionnaire were 
entered into an Access database, which had four tables, representing the four parts of the 
questionnaire. I entered all data onto the Access database after all data collection was 
completed. Where possible screen input validation checks were incorporated for 
questions. Data already entered were re-checked against each questionnaire. This 
ensured that the error rate in data entry was minimal.
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3.11: Data storage
Once an interview was completed, the questionnaire and blood sample were sealed in an 
interview package and stored under lock and key at the National Centre for 
Epidemiology and Population Health (NCEPH). All questionnaire packages were only 
opened to mail the blood samples to NCHECR for analysis at weekly intervals. The 
interview packages were then re-sealed and locked at NCEPH. All data (questionnaires 
and databases) will be stored under lock and key at NCEPH for at least seven years after 
completion of the PhD, as per ANU requirements.
3.12: Data analysis
Data were transferred from the Access database to SPSS and STATA databases for 
analysis, which were used interchangeably [155, 156]. Missing variables were removed 
for analysis but are presented in final tables. There were three types of analyses 
conducted. These are described in detail below.
1) Descriptive analysis (Chapter 4)
Pearson chi-square two sided tests (p<0.05) were used to measure and compare factors 
that could be associated with outcomes for urban and rural study groups. Where 
numbers were less than five in any cell, a Fishers exact test was used.
2) Measurement and comparison of health and BBV risk outcomes for urban and 
rural study groups (Chapters 5 and 6)
As the samples were independent, t-tests were used to compare the mean score of health 
outcomes (THS) and BBV risk outcomes (BBV TraQ risk scores) for the study groups, 
where sample sizes were large enough and the test statistic had an approximate normal 
distribution (>30 degrees of freedom) [157]. A non-parametric test (Mann-Whitney test) 
was used for comparison of mean scores when sample sizes were small and normal 
distributions could not be assumed.
Factors identified as having a potential association (Figure 3.2) with health and BBV 
risk outcomes were entered into stepwise (backward elimination) multiple regression 
models to identify the best combination of factors that were significantly associated 
(p<0.05) with the outcomes within the two study groups. Linear regression analysis was 
used where the outcome was an approximately continuous variable and logistic 
regression analysis was done where the outcome variables of interest were binary.
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As there were several factors identified as having the potential to be associated to the 
outcomes, I first used univariate analyses to examine the association of individual 
factors with the outcomes within each study group, to select a subset of factors to enter 
into the stepwise regression model. I chose a p-value of 0.10 as the cut-off to maximise 
the chances of picking up significant associations. All factors that were significantly 
associated with outcomes at the p< 0.10 in this univariate analyses were entered into the 
stepwise (backward elimination) multiple regression models. Possible confounders were 
entered into the model regardless of whether or not they were significantly associated 
with the outcomes in the univariate analysis.
ß coefficients in the linear regression models represent the change in mean score of the 
outcomes associated with factors. Odds Ratios (ORs) in the logistic regression models 
represent the strength of the association between factors and the outcomes. These 
measures also indicate the direction of the association between factors and outcomes 
(positive measures=detrimental relationship, negative measures^ beneficial 
relationship). P-values and confidence intervals (Cl) indicate whether the associations 
were significant or not. Likelihood Ratio tests (LR tests) were used to determine if 
categorical factors (> two categories) were significantly associated with outcomes as a 
whole factor. The variance of outcome scores within the study groups explained by 
factors significantly associated with the outcome is indicated by R2 in the univariate 
analysis and adjusted R2 in the multivariate models [157],
3) Validity of HCV and HIV self report (Chapter 7)
There were two parts to this analysis. The first part aimed to determine validity of HCV 
self-reported status as an indicator of true HCV status and compared it for urban and 
rural individuals. This was done by calculating sensitivity, specificity, PPV and NPV, 
and PLR and NLR for HCV self-reported status as a screening test for true status as 
determined by serology (Appendix 1). Validity of HIV self-reported status was used a 
comparator.
The second part of the analysis compared factors associated with HCV serological 
status as opposed to self-reported status to examine if significant associations differed. 
As this analysis was not aimed at comparing urban and rural factors associated with 
HCV, the study samples were combined to have greater power to pick up any 
significant associations that may exist. Univariate analyses were used for this purpose 
with level of significance set at p<0.05, as these were final analyses.
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3.13: Numbers recruited, response and participation rates
A total of 118 participants were recruited into the study; 62 in the ACT and 56 in 
SNSW. Tables 3.4 and 3.5 describe the recruitment and response rates and the final 
sample numbers by study groups and tier. Recruitment rate for the purposes of my study 
is the proportion of the sample size needed for the study, while response rate is the 
proportion of randomly selected participants who took part in the study.
There were three waves of sampling conducted in the ACT; sampled on the 02/04/2002, 
27/05/2002 and 05/07/2002. There were two sample waves in SNSW for Tiers 1 and 2, 
sampled on the 01/07/2002 and the 10/09/2002 respectively. Only two sample waves 
were created in SNSW for Tiers 1 and 2 due to lack of numbers in the tiers. There was a 
total of 40 clients recruited from Tiers 1 and 2 into the rural study group from these 
sample waves. There were 16 clients recruited from Tier 3 in SNSW through GP 
practices into the rural study group. Although sample waves were to be created on a 
monthly basis, for logistic reasons participants were given longer to respond.
Table 3.4: Numbers recruited by tier and by study group
T i e r
Urban study group (ACT) Rural study group (SNSW)
No. No. Recruitment No. No. Recruitment
Needed recruited rate (%) Needed recruited rate (%)
Tier 1 34 26 76 34 27 79
Tier 2 33 21 64 33 13 39
Tier 3 33 15 45 33 16 48
Total 100 62 62 100 56 56
Table 3.5: Response rate by tier and by study group
Tier
Urban study group (ACT) Rural study group (SNSW)
No.
sampled
No.
recruited
Response 
rate (%)
No.
sampled
No.
recruited
Response 
rate (%)
Tier 1 62 26 42 62 27 44
Tier 2 90 21 23 51 13 25
Tier 3 76 15 20 88 16 18
Total 228 62 27 201 56 28
98
Chapter 3: Methods
Recruitment into the study was lower than was needed for the required sample size of 
100 participants per study group. Overall the recruitment into both study groups was 
greater than 50 per cent. The achieved recruitment rate of 62 per cent (n=62) into the 
urban study group and 56 per cent (n=56) into the rural study group was only possible 
because of creating sample waves to replace non-responders. Recruitment rates in Tier 1 
were higher than those of Tiers 2 and 3 for both study groups. This may have been due 
to better compliance on the part of drug and alcohol staff recruiting at Tier 1 dosing 
points. Recruitment rates into Tiers 1 and 3 were similar for both study groups but 
Tier 2 rates were higher for the urban study group as compared to the rural study group. 
Tier 2 and 3 recruiting in the ACT and Tier 2 recruiting in SNSW received poorer 
compliance from pharmacists as compared to public dosing points. Although 
recruitment for Tier 3 in SNSW was complex and dependent on clients presenting at GP 
practices to be recruited, recruitment rate for Tier 3 in SNSW was similar to that of the 
ACT.
The overall response rates for urban and rural study groups were approximately the 
same at 27 and 28 per cent respectively. Response rates for the three tiers were 
comparable between study groups. The response rates in Tier 1 for both study groups 
was almost approximately double that of Tiers 2 and 3. Lack of Tier 2 and 3 recruiting 
compliance and interest on the part of community pharmacists may have contributed 
towards poor response rates in these tiers.
3.14: Sources of bias and confounding 
3.14.1: Selection bias
Random sampling was used as a method to minimise selection bias into the study.
This was however, compromised due to the following reasons:
• Tier 1 in SNSW had a total of 62 clients only at the time of sampling. As at least 34 
participants were required from each tier, this meant that with two sample waves, all 
Tier 2 clients in SNSW had been selected and asked to participate in the study, 
making this a convenience sample.
• Not being able to include SNSW Tier 3 clients on to the same database as Tier 1 and 
2 clients and having to recruit Tier 3 clients into the study as they presented at GP 
practices, made Tier 3 sampling of the rural study group a convenience sample.
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• Knowledge of re-imbursement of $15.00 for out-of-pocket expenses through word- 
of-mouth communication amongst methadone clients (even though not advertised 
through the study), may have introduced an incentive for randomly selected clients 
to participate.
Although serious attempts were made to minimise selection bias, due to the issues noted 
above there was a certain degree of self-selection and convenience sampling introduced 
into the study.
3.14.2: Measurement Bias
Measurement bias can occur in a study through recall bias (inaccurate responses from 
participants), interviewer bias, and measurement and analysis of outcomes [79]. These 
biases were reduced in my study at two levels: firstly through the study design used and 
secondly through analytical methods used. Recall bias was decreased through the use 
of a cross sectional study design and most questions were limited to behaviours 
affecting outcomes in the one-month prior to interview. The use of validated 
questionnaires, training interviewers in the use of the questionnaire, and standardisation 
of information collected and recorded decreased the likelihood of interviewer bias. 
Measurement bias was also decreased through the measurement of outcome variables 
being standard through the use of validated questionnaires.
The use of a de-identified database for sampling and the use of verbal consent to 
participate assisted in lowering measurement bias. As the questionnaire covered some 
illegal activities (such as illicit drug use and other criminal activities), if identification 
was required from participants, they may have provided inaccurate responses due to fear 
of their methadone treatment being compromised or being pursued by the legal system.
3.14.3: Potential Confounders
Information was collected for potential confounders identified through literature 
(e.g. age, sex, socio-economic status) and other confounders identified at the time of the 
study (e.g. tiers of programmes as they were managed differently). Methods used to 
control for these confounders were through the study design (random sampling) and 
analysis (stratification and inclusion of potential confounders in multiple regression 
models).
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3.15: Validity of study results
Internal validity of results depends on controlling for sources of error; these being 
chance, bias and confounding [79]. Sampling, recruitment, and data collection and 
analysis methods used in the study were designed to minimise these sources of error to 
increase internal validity of results.
3.16: Generalisability
The final sample size recruited was smaller than required and mainly a convenience 
sample. This may not have been truly representative of urban and rural participants of 
the areas chosen for the study, or Australian urban and rural methadone clients in 
general. However, 13 per cent of the total study population was recruited (118 of 867 
registered methadone clients in both programmes), with 10 per cent recruited in the 
urban programme (56 of 620 registered clients) and 23 per cent in the rural programme 
(56 of 247 registered clients). These proportions of the actual study populations 
recruited should provide a representative sample of urban and rural methadone clients, 
thus improving the generalisability of results.
3.17: Limitations:
The limitations of the methods employed were that random sampling was not 
completely achieved and this may have contributed to selection bias. The sample size 
needed to elicit significant differences was also not reached which may have resulted in 
actual significant differences not being detected.
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3.18: Summary
This chapter described the methods used to address the aims of the study. A cross- 
sectional study design was considered to be the most appropriate and a random 
sampling strategy was used to minimise selection bias. A questionnaire that was partly 
self-administered and partly interviewer-administered was used to collect relevant data. 
The OTI and BBV TraQ were part of the questionnaire and were used to measure health 
and BBV risk outcomes respectively. A finger prick blood spot test was used to collect 
blood for HCV and HIV serology. Ethics approval was sought from ANU, ACT and 
SNSW HRECs.
Random sampling was used to decrease selection bias, but there were several problems 
encountered with the sampling and recruitment processes. Random sampling was not 
achieved properly due to issues normally associated with AOD research and logistic 
factors (such as available numbers on the programmes for sampling, and time). The 
required sample size to elicit significant differences between study groups for health and 
BBV risk outcomes was not reached.
An Access database was created to enter data. Data were transferred to SPSS and 
STATA for analysis. A combination of univariate and multivariate analyses were 
employed to measure and compare health and BBV risk outcomes for the two study 
groups. Standard clinical epidemiology validity measures were used to measure validity 
of HCV self-reported status as a screening test for true HCV status as indicated by 
serology. The methods employed were not completely successful in minimising 
selection bias but were able to minimise measurement bias.
The smaller sample size and not achieving random sampling properly may have affected 
the representativeness of the sample, which in turn could affect the generalisability of 
the results. However, approximately 13 per cent of the overall study population was 
recruited into the study, which should provide a representative sample for 
generalisability of the results to other urban and rural methadone treatment groups in 
Australia. Validity of study results was increased by minimising bias and confounding 
both in the study design and analysis wherever possible.
The following chapters (Chapters 4, 5, 6 and 7) provide the results of the study by 
application of these methods. Relevant results are in the process of being submitted to 
participating organisations.
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RESULTS
“However beautiful the strategy, you should occasionally look at the results”
Winston Churchill
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Evaluation is
The process of determining whether an item or activity meets specified criteria.’
('soarc.ttirtime.co.uk/users/wvsvwitt/eloss.htm)
And aims to
‘(1) Assess the effectiveness of an ongoing program in achieving its objectives, 
(2) Relies on the standards of project design to distinguish a programme’s effects 
from those of other forces, and
(3) Program improvement through a modification of current operations'.
(www.ojp.usdoj.gov/BJA/evaluation/ctlossary/Qlossary e.htm)
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Chapter 4
Description o f the sample
In this chapter I describe and compare the urban and rural study groups in relation to 
sociodemographic characteristics, previous and current drug use history and risk factors, 
methadone treatment characteristics and other factors that could affect health and BBV 
risk outcomes (as described in Chapter 3). These analyses were done to examine if the 
two study groups differed in relation to these factors. Results for the whole sample as 
well as comparisons between urban and rural samples are also reported.
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4.1: Socio-demographics
Table 4.1 presents socio-demographic comparisons for the two study groups. Overall, 
the majority of participants (44%) were aged between 30-39 years and 59 per cent were 
male. Only four participants (3.3%) identified as being of Aboriginal or Torres Strait 
Islander background7. Although only small proportions of participants had completed 
Year 10 and Year 12, completion of tertiary education was relatively high at 35 per 
cent. Only twenty one per cent of participants were employed either full-time or part- 
time. Twenty five percent were unemployed. Fifty per cent were on government 
pensions (relating to home duties and sickness benefits) and four per cent identified as 
students. A high proportion of participants (66%) lived in rented accommodation. These 
factors were not significantly different between urban and rural samples.
The main source of income in the six months prior to interview was the only socio­
demographic factor found to be significantly different for the two study groups. The 
urban study group was more likely to have been in paid employment as compared to the 
rural study group (p=0.01). Interestingly this did not contribute to a significant 
difference in employment status at the time of the study.
7 In order to maintain anonymity no further information related to Indigenous status will be presented.
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Table 4.1: Sociodemographic characteristics of study groups
Characteristic ACT
N=62
SNSW
N=56
Total
N=118 p-values 
(Pearson X2)
n % n % n %
Age group
<20 1 1.6 0 0 1 0.9
20-29 17 27.9 11 20.0 28 24.1 0.32
30-39 28 45.9 23 41.8 51 44.0
40 + 15 24.6 21 38.2 36 31.0
Total 61* 100 55* 100 116b 100
Sex
Male 35 56.5 34 60.7 69 58.5
Female 27 43.5 22 39.3 49 41.5 0.64
Total 62 100 56 100 118 100
Education completed
Under Year 10 11 18.0 18 33.3 29 25.2
Completed Year 10 14 23.0 12 22.2 26 22.6 0.25
Completed Year 12 13 21.3 7 13.0 20 17.4
Tertiary 23 37.7 17 31.5 40 34.8
Total 61* 100 54b 100 115C 100
Employment at time of study
Unemployed 16 25.8 13 23.2 29 24.6
Employed (fulltime/part-time/casual) 15 24.2 10 17.9 25 21.2 0.75
Student 2 3.2 3 5.4 5 4.2
Other (home duties/sick leave) 29 46.8 30 53.6 59 50
Total 62 100 56 100 118 100
Accommodation type
Own accommodation 9 14.5 11 19.6 20 16.9
Rented accommodation 43 69.4 35 62.5 78 66.1 0.70
Other (boarding house, live with 
parents/govt housing/shelters)
10 16.1 10 17.1 20 16.9
Total 62 100 56 100 118 100
Main income last 6mths
Paid employment 18 29.5 6 10.7 24 20.5
Non-employment sources 
(Government benefits/ dependent on 
spouse/illegal sources)
43 70.5 50 89.3 93 79.5 0.01
Total 61* 100 56 100 117* 100
a One missing value, b two missing values,c three missing values
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The socio-demographic characteristics of participants in my study were similar to those 
found in the first Australian national census of clients of AOD treatment agencies 
conducted in 1990 as well as the most recent census of 2001 [158, 159], For 6175 
clients surveyed in the first census, the mean age was 34 years, 66 per cent were male 
and the majority were not in paid employment. There were 10 per cent who identified as 
Aboriginal or Torres Strait Islander people [158]. In the most recent census of 2001 the 
mean age of clients was 33 years, 63 per cent were male and the majority (82%) were 
unemployed or in unpaid employment [159]. Opioid dependency was the second most 
common reason for being in treatment after alcohol in both surveys.
Education levels were not reported in the two censuses. A high proportion of my study 
participants had completed tertiary education (35%) and this could possibly be 
explained by the inclusion of TAFE (Technical and Further Education) qualifications in 
the tertiary education category. The ACT population having higher levels of education 
may also explain the urban study group having a higher level of tertiary education in 
comparison to the rural study group (38% vs. 32%). The 2001 census data indicate that 
46 per cent of ACT residents had a tertiary qualification (inclusive of TAFE and 
university degrees) [160].
4.2: Previous drug injecting history
In this section I compare drug injecting history for the two study groups. This includes 
age of first injection, age of starting to inject regularly, first drug injected and 
methadone injecting.
4.2.1: Age of first drug injection
The mean age of first drug injection for the overall sample was 19.8 years (SD 5.7, 
range 12-45) with a median age of 19.0 years. The mean age of first injection for the 
urban sample was 19.8 (SD 6.7, range 12-45) with a median age of 19.0 years. The 
mean age of first injection for the rural sample was 19.7 (SD 5.3, range 12-37) with 
median age of 18.0 years. There was no significant difference in mean age of first 
injection between the study groups (p=0.42). The mean age and age range of first 
injection are represented in Figure 4.1.
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Figure 4.1: Mean age and age range of first drug injection for study groups
ACT
Mean age=19.8 
(SD 6.7) 
Range=12-45
SNSW
Mean age=19.7 
(SD 5.3) 
Range=12-37
Study group
The mean age of first drug injection in my study (19.8 years) was slightly higher than 
another Australian study amongst IDUs in Sydney between 1996-2000 (mean age 18.8 
years) [161]. It was slightly lower than another Australian study in 2005 conducted 
amongst 399 heroin users also in Sydney (mean age 21.0 years). It was also lower than 
the NDS household survey of 2004 (mean age 21.0 years) [6, 162].
4.2.2: Age of starting to inject drugs regularly
The mean age of starting to inject regularly for the total sample was 21.6 years
(SD 5.7, range 12-40), with a similar median age of 21.0 years. The mean age of regular
injecting for the urban sample was 22.2 (SD 5.8, range 12-40) with a median age of
21.0 years; for the rural sample it was 20.9 (SD 5.6, range 12-37) with a median age of
19.0 years. There was no significant difference between urban and rural study groups 
for mean age of starting to inject regularly (p=0.24).
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When categorised into age groups, 80 per cent of the participants started injecting drugs 
regularly between the ages of 16-29 years. A higher proportion of rural participants 
(46%) started injecting regularly in their teenage years (16-19 years), while a higher 
proportion of urban participants (50%) started injecting regularly in their twenties. This 
difference was not statistically significant (p=0.16). These results are summarised in 
Table 4.2.
Age group when first injected 
regularly
ACT
N = 62
S N S W
N = 5 6
Total
N = 1 1 8 p-values
(Pearson
x 2)
n % n % n %
10-15 6 10.3 4 7.4 10 8.9 0.16
16-19 15 25.9 25 46.3 40 35.7
20-29 29 50.0 20 37.0 49 43.8
30 and above 8 13.8 5 9.3 13 11.6
Total 58* 100 5 4 b 100 1 12c 100
Mean age of starting to inject 22.2 + 5.8 20.9 ±5.6 21.6 + 5.7 0.24
regularly (range 12-40) (range 12-37) (range 12-40)
Table 4.2: Age group of starting regular drug injecting
° Four missing values,b two missing values, c six missing values
Overall, the mean age of starting to inject regularly was approximately a year and a half 
higher than that of first injection. Rural participants appeared to commence regular 
injecting within a shorter period after their first injection (about one year) compared to 
urban participants (a little over two years after their first injection).
(Rural: first injection 19.7 years, regular injecting 20.9 years; Urban: first injection 19.8 
years: regular injecting 22.2 years).
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4.2.3: Drug first injected
For the overall sample, heroin was the first drug ever injected by a large proportion of 
participants (46%), followed by amphetamines and methamphetamines 8 (38%). Table 
4.3 summarises and compares type of drug first injected for the urban and rural study 
groups. Urban participants seemed more likely to have injected amphetamines and 
methamphetamines as their first drug ever injected (44%), with heroin following closely 
(43%). In comparison, heroin was the first drug ever injected for almost half of the rural 
participants (49%), followed by amphetamines (31%). Rural participants had a higher 
frequency of injecting other drugs such as ecstasy, benzodiazepines and steroids. There 
was no significant difference between choice of first drug ever injected between urban 
and rural participants (p=0.29).
4.2.4: Methadone injecting history
The methadone injecting history of the two study groups is also summarised in Table 
4.3. Although methadone was the least likely drug of choice for first drug ever injected, 
two thirds (67%) of the total sample had injected it at some point during their drug 
injecting careers. This pattem was similar for urban and rural participants (p=0.51).
Table 4.3: Drug first injected and methadone injecting history
ACT
Characteristic
SNSW
N=56
Total
N=118 p-values 
(Pearson X2)
n % n % n %
Drug first injected
Heroin 26 42.6 27 49.1 53 45.7 0.29
Amphetamines 27 44.3 17 30.9 44 37.9
Other drugs * 8 13.1 11 20.0 19 16.4
Total 61" 100 55’ 100 116b 100
Ever injected methadone
Yes 39 63.9 39 69.6 78 66.7 0.51
No 22 36.1 17 30.4 39 33.3
Total 61* 100 56 100 117* 100
a One missing value,b two missing values
* Urban: cocaine = 2, methadone = 1, other opioids = 1, ecstasy, benzodiazepines, steroids = 4 
Rural: cocaine = 1, methadone = 0, other opioids = 3, ecstasy, benzodiazepines, steroids = 7 
Total: cocaine = 3, methadone = 1, other opioids = 4, ecstasy, benzodiazepines, steroids = 11
8 Other amphetamine type substances such as ecstasy and cocaine are grouped under ‘other drugs’.
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The practice of injecting methadone while on methadone treatment has been identified 
to be prevalent in Australia since the mid 1990s. An Australian study in 1995 found that 
of 312 heroin IDUs surveyed, 50 per cent had injected methadone at least once while on 
a methadone programme [163], A more recent study conducted between 1999-2000 
found that of 205 methadone injectors recruited, 80 per cent (n=164) were on 
methadone treatment This study also found that the mean age of first injecting 
methadone was 26 years and the mean age of first injecting any drug was 18 years [58].
There are not many studies that have been conducted overseas in relation to methadone 
injecting. Robinson and colleagues conducted a study in New Zealand which aimed to 
identify patterns of methadone injecting, and reasons and perceived risks of this 
behaviour over a two month period between December 1995 to January 1996 [164]. 
Nineteen of 36 possible methadone injectors were recruited through a NSP, 17 (89%) of 
whom had been in methadone treatment for an average duration of four years. Of the 19 
recruits, 26 per cent (n=5) had injected methadone daily, 16 per cent (n=3) had injected 
three times a week, 26 per cent (n=5) had injected one to two times a week and 32 per 
cent (n=6) had injected less than weekly in the three months prior to interview. The 
main reasons for injecting methadone stated by the participants were to get an 
immediate effect of the drug (80%), and ‘needle fixation’9 (47%) [165]. These reasons 
were supported by another study in Australia by Sunjic and Howard in 1996 [166],
From other available overseas reports, it appears that methadone injecting is not as 
common as it appears to be in Australia. For example, a recent Swiss survey on 
methadone injecting amongst methadone treatment clients of a state-run clinic, found 
that of 80 patients, 32 per cent (n=26) had ever injected methadone, but only five per 
cent (n=4) had injected in the last month prior to the survey despite the relative leniency 
of the clinic’s TA policy [167].
9 Defined by Mcbride and colleagues as the repetitive puncturing o f the skin with or without injection o f  
psychoactive drugs via intravenous, subcutaneous or intramuscular routes irrespective o f the drug or 
drugs injected or the anticipated effects o f  the drug’ [165].
112
Chapter 4: Description o f  the Sample
4.3: Prison history: drug use and associated risk factors
Injecting drugs and increased risk of BBV transmission while incarcerated has been 
shown to occur quite frequently in Australia and overseas [27, 88, 168-170], In 
Australia, not having NSPs or providing bleach for cleaning injecting equipment in 
prisons may be contributing to risky injecting behaviours and associated BBV 
transmission [171, 172], Overseas studies have shown that in prisons with NSPs there is 
decreased sharing of syringes translating into decreased transmission of BBVs. Dolan 
and colleagues conducted a review of journal publications and conference presentations 
on prison-based NSPs overseas in 2003. This review found six evaluations of prison 
based NSPs, which all showed that syringe sharing decreased dramatically and there 
were no new cases of HIV, HCV or HBV reported after the introduction of the NSPs. 
Negative events such as the use of needles as weapons had also decreased [173].
Another study in Germany in 2006 evaluated the impact of prison based NSPs in two 
prisons in Berlin. Prior to commencement of the programme, 71 per cent of injectors 
within these two prisons shared syringes. This declined to 11 per cent during the first 
four months of the programme. After commencement of the programme no HIV 
seroconversions were noted, and there were just four HCV seroconversions [174].
Table 4.4 summarises prison history and risk behaviours while incarcerated for 
participants in my study. Overall, 50 per cent (n=58) of participants in my study had 
been in prison at least once, and this was similar for the two study groups. This is 
comparable to other studies that have found that between 20-50 per cent of IDUs have 
been previously imprisoned, mainly due to illegal activities associated with injecting 
drug use [44]. In an Australian study of prison entrants in 2004, 59 per cent had a 
history of injecting drug use [175].
Of participants in my study who had been previously incarcerated, 48 per cent (n=28) 
were on methadone treatment while in prison. Urban clients were much more likely to 
have been on treatment than rural clients (57% vs. 39%), but this was not statistically 
significant (p=0.19). Twenty eight per cent (n=16) had injected in prison, and 24 per 
cent (n=14) were tattooed; these proportions were similar for both study groups.
Overall, males were significantly more likely to be incarcerated than females (60% vs. 
37%, p=0.02). When adjusted for study groups, the significant gender difference was 
found to be only amongst rural participants (64% vs. 32%, p=0.02). These results 
relating to gender differences have not been tabulated.
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Table 4.4: Prison history
Characteristic
ACT
N=62
SNSW
N=56
Total
N=118 p-values 
(Pearson X2)
n % n % n %
Been in prison
- Yes 30 49.2 28 50.9 58 50 0.85
(includes remand/police cells) 
- No 31 50.8 27 49.1 58 50
- Total 61* 100 55* 100 116b 100
Prison factors (n=58)
Methadone treatment while in prison 
- Yes 17 56.7 11 39.3 28 48.3 0.19
- No 13 43.3 17 60.7 30 51.7
- Total 30 100 28 100 58 100
Inject drugs while in prison
- Yes 9 30.0 7 25.0 16 27.6 0.67
- No 21 70.0 21 75.0 42 72.4
- Total 30 100 28 100 58 100
Tattooed while in prison
- Yes 7 23.3 7 25.0 14 24.1 0.88
- No 23 76.7 21 75.0 44 75.9
- Total 30 100 28 100 58 100
°  One missing value, h two missing values
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4.4: Other treatments sought for opioid dependence
Table 4.5 details all drug treatments10 other than methadone sought for opioid 
dependence by the participants prior to their current methadone programme. For the 
overall sample, the most common other treatment sought (apart from previous 
methadone treatment) was withdrawal services* 11 followed by drug-free counselling. 
Urban participants were more likely to have accessed withdrawal services and in-patient 
rehabilitation12 than their rural counterparts. For rural participants drug-free counselling 
was the most highly accessed form of other treatment. Approximately one third of the 
sample had not accessed any other form of drug treatment. Rural participants were 
marginally more likely to have not accessed other treatments in comparison to their 
urban counterparts (30% as opposed to 26%). There were no significant differences 
between the two study groups in terms of other treatments accessed.
Table 4.5: Other drug treatments accessed for opioid dependence
Other drug treatment
ACT
N=62*
SNSW
N=56*
Total 
N=118* p-values 
(Pearson X2)n % n % n %
Withdrawal service 38 61.3 29 51.8 67 56.8 0.30
Drug free counselling 32 51.6 30 53.6 62 52.5 0.83
In-patient rehabilitation 23 37.1 14 25.0 37 31.4 0.16
Narcotics anonymous 19 30.6 18 32.1 37 31.4 0.86
No previous treatment 16 25.8 17 30.4 33 28.0 0.58
Other (Narcotics Anonymous/ 
psychotherapy/family support/religion)
11 17.7 5 8.9 16 13.6 0.16
*  Total for each treatment does not tally to total sample as participants could pick more than one option
Although these results were not statistically significant they indicate that a greater 
proportion of urban clients accessed withdrawal and in-patient rehabilitation services in 
comparison to their rural counterparts. This could be due to these services mainly being 
based in urban centres. Rural participants in my study who accessed these services 
would have accessed them through the ACT AOD programme or through services 
elsewhere.
lu These treatments could also have been sought outside the ACT and SNSW.
11 ACT: 5-7 days on a combination of Valium and Doloxene; could be done as in-patient or out patient. 
SNSW: Admission to hospital and symptomatic relief.
12 ACT: Abstinence and supportive therapy as an in-patient for 3, 6 to 12 months. In-patient rehabilitation 
could be done after withdrawal.
SNSW: No in-patient rehabilitation, could access ACT or other NSW services.
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4.5: Methadone treatment history
Forty seven per cent of the overall sample (n=55) were on their current methadone 
programme for the first time. There was a slightly higher proportion of rural participants 
on their programme for the first time as compared to urban participants (50% vs.44%) 
as seen in Table 4.6. Of the 62 participants who had been on the programme before, the 
majority (78%) had been on the programme between 1-3 times previously. The rural 
sample had a higher proportion of participants who had been on the programme in this 
category (82% and 75% respectively); while there was a higher proportion of urban 
participants who had been on the programme 3-6 times (25 % and 11% respectively). 
These findings were not significantly different for the two study groups (possibly due to 
numbers in the groups being small).
Table 4.6: Methadone treatment history
Characteristic
ACT
N=62
SNSW
N=56
Total 
N=118 p-values 
(Pearson X2)n % n % n %
First time on programme
Yes 27 44.3 28 50 55 47.0 0.53
No 34 55.7 28 50 62 53.0
Total 61* 100 56 100 117’ 100
Number of other times on a 
programme
(ACTn=34, SNSW n=28)
1-3 times 24 75.0 23 82.1 47 78.3 0.24
3-6 times 8 25.0 3 10.7 11 18.3
> 6 times 0 0 2 7.1 2 3.3
Total 32b 100 28 100 60b 100
° One missing value, b two missing values
Overall, people who were on the programme for the first time were relatively evenly 
distributed through the three tiers with no significant difference between tiers (p=0.1). 
There was also no significant difference between the two study groups in relation to the 
number of participants who were on the programme for the first time within each tier 
(Tier 1 p=0.88, Tier 2 p=0.93, Tier 3 p=0.26). These results are not tabulated.
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4.5.1: Reasons for leaving previous methadone programmes
Of participants who had been on a previous programme (n=62), it was interesting to 
note that most (76%, n= 47) had left their previous methadone programme for reasons 
such as completing or transferring to another programme rather than for issues related to 
access, financial or confidentiality. Table 4.7 tabulates reasons for leaving previous 
programmes. There were relatively small numbers who stated that travel distance (10%, 
n=6), cost associated with the programme (5%, n=3) and confidentiality (3%, n=2) were 
reasons for leaving previous programmes. Although numbers were small, and the 
findings were not statistically significant there was a higher proportion of rural 
participants who left their previous programmes for these reasons. This was to be 
expected as rural people can have poorer access to services and access can be affected 
by confidentiality within services as shown in the literature review (Chapter 2). A 
higher proportion of urban participants had left the previous programme as it was not 
suited for them as opposed to the rural sample (urban: 24%, n=8; rural:7%, n=2 ). These 
differences were, however, not significant, most likely due to the small numbers in each 
category. Both urban and rural study groups had similar small numbers of people stating 
that the programme did not fit their schedule as a reason for leaving it (urban 13%, n=4; 
rural 11%, n=3).
Table 4.7: Reasons for leaving previous methadone programme
Reasons for leaving the last
ACT
N=34*
SNSW
N=28*
Total
N=62* p-values 
(Pearson X2)methadone program n % n % n %
Completed/transferred programme 26 76.3 21 75.0 47 75.8 0.74
Did not suit (“was not for me”) 8 23.5 2 7.1 10 16.0 0.09"
Did not fit schedule 4 12.5 3 10.7 7 11.3 1.00+
Too far to travel 2 5.9 4 14.3 6 9.7 0.40"
Too expensive 1 2.9 2 7.1 3 4.8 0.59"
Confidentiality 1 2.9 1 3.6 2 3.2 1.00"
*  Total for each reason does not tally to actual sample numbers as participants could pick more than one option 
+  Fishers exact test
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Studies have shown that retention rates are greater with methadone maintenance rather 
than withdrawal treatment, and when methadone dose is higher [117, 176-178]. The 
results from my study suggest that service delivery factors such as programme 
suitability and time-related issues could affect retention, while issues such as access, 
cost and confidentiality may not. These results should, however, be interpreted with 
caution as the numbers are small. A literature search revealed there were no studies 
conducted to date to examine the association between methadone programme service 
delivery factors and retention. Further research in this area may be warranted.
4.6: Current methadone programme treatment and management 
characteristics
This section describes and compares characteristics related to participants in the urban 
and rural study group that are associated with their current methadone treatment. It 
includes reasons for accessing the programme, referral source to the programme, 
dosing, cost associated with the programme and clinical management.
4.6.1: Reasons for accessing the current methadone treatment programme.
Table 4.8 summarises the reasons for study participants accessing their current 
methadone treatment programme. Overall, the main reasons were, financial (82%), a 
need to get out of the drug scene (79%), health related issues (76%), to stop drug usage 
(71%), and general relationship issues (65%). Whilst the five main reasons were the 
same for both study groups, they differed in priority within each group.
For urban clients the five main reasons in order of highest to lowest priority were:
• health issues,
• financial issues,
• to get out of the drug scene,
• general relationship issues,
• to stop drug usage.
For rural clients the five main reasons in order of highest to lowest priority were:
• getting out of the drug scene
• financial issues,
• to stop drug usage,
• health issues,
• general relationship issues.
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Table 4.8: Reasons for accessing the current methadone programme
Reasons for getting on the current 
programme
ACT
N=62*
n %
SNSW
N=56*
n %
Total
N=118*
n %
p-values 
(Pearson X2)
To improve financial situation 50 87.7 35 74.5 85 81.7 0.08
To get out of the drug scene 43 81.1 37 77.1 80 79.2 0.62
To improve health status 51 87.9 30 61.2 81 75.7 0.001
To stop illegal drug usage completely 35 70.0 35 71.4 70 70.7 0.88
To improve general relationships 41 75.9 25 53.2 66 65.3 0.02
To improve employment prospects 31 60.8 17 38.6 48 50.5 0.03
To decrease injecting 26 49.1 20 47.6 46 48.4 0.89
To decrease criminal activity 23 46.9 19 42.2 42 44.7 0.65
*  Total for each reason does not tally to actual sample numbers as participants could pick more than one option
Urban participants were significantly more likely to have accessed their current 
programme than rural participants for health reasons (88% vs. 61%, p=0.001), general 
relationship issues (76% vs. 53%, p=0.02), and to improve employment prospects 
(61% vs. 39%, p=0.03). A higher proportion of urban participants also accessed the 
programme for financial reasons, and this was marginally significantly different to rural 
participants (88% vs. 75%, p=0.08). Overall, less than 50 per cent cited the need to 
decrease criminal activity as a reason. This was similar for both study groups (p=0.65).
Ward and colleagues note that there has been very little research into the reasons why 
heroin dependent users decide to access treatment. They suggest that factors such as the 
increased risk of HIV and HCV amongst IDUs, and the price and purity of heroin 
related to law enforcement strategies may play a role in accessing treatment [44]. A 12 
year follow-up study in the US (1969 onwards) of various aspects of drug dependency 
examined the reasons for accessing methadone treatment as one of its outcomes. The 
researchers interviewed 490 people who were opioid dependent over the course of 12 
years. The following factors rated highly as reasons for accessing methadone treatment:
- Tired of the ‘hustle’ involved in maintaining a heroin habit (83%).
- Needed to make a dramatic change in their lives (82%).
- A major personal event, such as a new relationship, childbirth (66%).
- Fear of incarceration (57%).
Rating under 50 per cent were reasons such as high cost of heroin (40%), poor quality 
of heroin (36%), other financial issues (34%), and fearing a drug overdose (31%) [179].
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A more recent study was conducted in Italy between September 1998 and March 2001 
amongst 565 heroin users who were on the programme for the first time [180]. The 
study found the following factors to be associated with accessing methadone treatment:
• age (< 25 years),
• injecting heroin more than twice a day,
• recent imprisonment,
• living with a partner,
• having sex without a condom in the previous six months,
• being HIV positive,
• being enrolled at a National Health Centre where a psychiatrist was available.
4.6.2: Referral source to the current methadone programme
The two study groups were found to be significantly different in relation to referral 
source to the methadone programme (p=0.04). Referral to the programme for 
individuals in both study groups was through three sources; self referral, referral by a 
health care worker and transfer from another programme. Although the majority (70%) 
had referred themselves to their current programme, urban participants were 
significantly more likely to have been self-referred than their rural counterparts (79% 
vs. 61%). Rural participants were significantly more likely to have been referred by a 
health care worker in comparison to their urban counterparts (30% vs. 11%). These 
results are presented in Table 4.9.
Table 4.9: Referral sources to the current methadone programme
Referral source
ACT
N=62
SNSW
N=56
Total
N=118 p-values
n % n % n % (Pearson X2)
Self-referred 49 79.0 34 60.7 83 70.3
Health care worker referred 
(GP, D&A worker)
7 11.3 17 30.4 24 20.3 0.04
Other (transfer from other programme/ 
started in jail or hospital)
6 9.7 5 8.9 11 9.3
Total 62 100 56 100 118 100
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4.6.3: Time and dosage on current programme
Overall, most participants (58%) had been on their current methadone programme 
between 1-5 years and this was similar for both study groups. Table 4.10 outlines time 
on the current programme and methadone dosage of participants. Although there were 
relatively similar proportions of participants in the two study groups who had been on 
the programme for one year or less, the rural sample had a larger proportion of 
participants (16%, n=9) who had been on the programme for less than six months as 
opposed to the urban area (7%, n=4). There was only one participant who had been on 
the programme for greater than 10 years (results not tabulated).
A larger proportion of rural study participants being on the programme for less than six 
months could be associated with methadone being free for the first six months of the 
rural programme regardless of whether it was the client’s first time on the programme or 
not. In the urban programme methadone is also free for the first six months but only for 
first time clients. A study conducted in 1999 amongst 112 methadone programme 
clients in Otago, New Zealand found that 86 per cent of clients had a treatment retention 
rate of six months or more [126].
The range of the daily methadone dose was large and participants received anywhere 
between one to > lOOmgs of methadone as shown in Table 4.10. The majority (65%) 
had a daily of dose of 21-80mgs.
Table 4.10: Time and dosage on current methadone programme
Characteristic
ACT
N=62
SNSW
N=56
Total
N=118 p-values 
(Pearson X2)n % n % n %
Time on current programme
12 months and under 13 21.3 11 20.0 24 20.7
13-24 months 19 31.1 17 30.9 36 31.0 0.96
25-60 months 17 27.9 14 25.5 31 26.7
>60 months 12 19.7 13 23.6 25 21.6
Total 61“ 100 55“ 100 116b 100
Methadone dose (mgs)
1-20 9 14.8 10 18.2 19 16.4
21-40 12 19.7 14 25.5 26 22.4 0.94
41-60 16 26.2 11 20.0 27 23.3
61-80 12 19.7 10 18.2 22 19.0
81-100 9 14.8 8 14.5 17 14.7
>100 3 4.9 2 3.6 5 4.3
Total 61“ 100 55“ 100 116b 100
°  One missing value, ° two missing values
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There was no significant difference in methadone dose between study groups by 
programme tier (Tier 1, p=0.40; Tier 2, p=0.69; Tier 3; p=0.15). There was no 
significant association between length of time on the programme and methadone dose 
(p=0.50). There was also no association between length of time on the programme and 
whether a participant was on the programme for the first time (p=0.38). These results 
are not tabulated.
4. 6.4: Routine takeaway (TAs) doses
Overall, 56 per cent (n=66) received TAs on a weekly basis with a higher proportion of 
urban participants having access to TAs than rural participants (61% vs. 50%). These 
results are summarised in Table 4.11. Comparison of TAs accessed per week by tier 
found a significant difference between the two study groups for Tier 1, with urban 
people significantly more likely to get routine TAs as compared to rural people 
(p=0.001). There was no significant difference for TA doses accessed per week between 
Tier 2 and Tier 3 clients.
Table 4.11: Routine takeaway doses per week on current methadone programme
ACT SNSW Total
Routine takeaway doses per week N=62 N=56 N=118 p-values
n % n % n % (Pearson X2)
Routine takeaway doses
Yes 38 61.3 28 50.0 66 55.9
No 24 38.7 28 50.0 52 44.1 0.22
Total 62 100 56 100 118 100
Routine takeaway doses by Tier
Tier 1: (n=53)
Yes 9 34.6 0 0.0 9 17.0
No 17 65.4 27 100.0 44 83.0 0.001
Total 26 100 27 100 53 100
Tier 2: (n=34)
Yes 15 71.4 12 92.3 27 79.4
No 6 28.6 1 7.7 7 20.6 0.21 +
Total 21 100 13 100 34 100
Tier 3: (n=31)
Yes 14 93.3 16 100.0 30 96.8
No 1 6.7 0 0.0 1 3.2 0.48+
Total 15 100 16 100 31 100
+Fishers exact test
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The significant difference between study groups for Tier 1 clients in relation to TAs 
accessed per week is most likely due to TA policy differing for Tier 1 between 
programmes. Urban Tier 1 clients had access to TAs once they were eligible13, whereas 
rural Tier 1 clients were not allowed TAs at all. This policy is relevant only to the 
SNSW programme and does not apply to all NSW methadone programmes. This has 
been done as an incentive to encourage clients to move into Tier 2 and Tier 3 to 
minimise dosing in the public programme. Rural Tier 3 clients in my study were likely 
to get more than the prescribed NSW maximum of four TAs per week due to GP 
prescribers having greater autonomy of treatment.
4.6.5: Costs associated with dosing
The cost of methadone was significantly different for participants in the two study 
groups (pO.OOl). The majority of rural clients paid nothing for their methadone or paid 
more than $15.00 per week. The cost of methadone was significantly different between 
study groups by tiers (Tier 1, pO.OOl; Tier 2, pO.OOl; Tier 3, p<0.001). The majority 
of rural participants in Tiers 2 and 3 paid more than $15.00 per week. These results are 
presented in Table 4.12.
13 Four consecutive random urines being drug free after 4 months on programme = 1 TA per week. 
Same criteria in the next 4 months = 2 TAs per week.
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Table 4.12: Cost of methadone per week on the current methadone programme
Cost of methadone/week
ACT
N=62
SNSW
N=56
Total
N=118 p-values 
(Pearson X2)n % n % n %
Overall
No cost 6 9.7 27 49.1 33 28.2
Up to $15.00 50 80.6 2 3.6 52 44.4 <0.001
>$15.00 6 9.7 26 47.3 32 27.4
Total 62 100 55* 100 117* 100
Tier 1: (n=53)
Nothing 6 23.1 27 100.0 33 62.3
Up to $15.00 18 69.2 0 0.0 18 34.0 <0.001
>$15.00 2 7.7 0 0.0 2 3.8
Total 26 100 27 100 53 100
Tier 2: (n=34)
Nothing 0 0.0 0 0.0 0 0.0
Up to $15.00 17 81.0 0 0.0 17 50.0 <0.001
> $15.00 4 19.0 13 100.0 17 50.0
Total 21 100 13 100 34 100
Tier 3: (n=31)
Nothing 0 0.0 0 0.0 0 0.0
Up to $15.00 15 100.0 2 13.3 17 56.7 <0.001
> $15.00 0 0.0 13 86.7 13 43.3
Total 15 100 15' 100 301 100
a One missing value
The significant difference between costs of methadone between tiers can be attributed to 
programme policy within the two areas. In the ACT, all clients in Tier 1 paid $15.00 per 
week for methadone after six months on the treatment and clients in Tiers 2 and 3 were 
to pay $30.00 per week. However, ACT clients were given a subsidy of $15.00 per 
week by the programme, which meant they paid only the remaining $15.00 per week. In 
SNSW, all clients in Tier 1 paid nothing for their weekly methadone, while Tiers 2 and 
3 clients paid the full weekly cost of $35.00 with no subsidy from the programme. Why 
some people (Tier 1: n=2, and Tier 2: n=4) were paying more than $15.00 in the ACT is 
unclear considering the cost per week for methadone does not exceed $15.00 in any of 
the tiers. Similarly, how two people in Tier 3 of SNSW were paying only $15.00 for 
methadone when all others in Tiers 2 and 3 were required to pay $35.00 is unclear. As 
the numbers are small, one possible explanation could be that clients may have provided 
an incorrect response. Another reason could be that they had been dosing elsewhere 
around the time of the study.
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4.6.6: Travel-related issues
The majority of participants travelled less than one hour both ways on dosing days, and 
this was similar for both study groups (p=0.62). However, the financial cost associated 
with travel to dose was significantly different for the two study groups, with a greater 
proportion of rural participants paying more than $5.00 per day as compared to their 
urban counterparts (32% vs. 15% urban, p=0.02). These results are presented in Table 
4.13.
Table 4.13: Time and cost to travel for daily dosing
Characteristic
ACT
N=62
SNSW
N=56
Total
N=118 p-values 
(Pearson X2)n % n % n %
Time travelled to dose (both ways)
< 1 hour to 1 hour 56 90.3 52 92.9 108 91.5
> 1 hour 6 9.7 4 7.1 10 8.5 0.62
Total 62 100 56 100 118 100
Cost to travel to dose (both ways)
<$5.00 53 85.5 38 67.9 91 77.1
> $5.00 9 14.5 18 32.1 27 22.9 0.02
Total 62 100 56 100 118 100
The cost associated with travel being significantly different for both groups could be 
due to reasons such as actual distance travelled, transport means used and cost of 
transport. Unfortunately information regarding transportation used or actual distance 
travelled was not collected and this may need further investigation.
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4.6.7: Clinical assessment and management characteristics
Table 4.14 summarises and compares clinical assessment and management 
characteristics for the participants within the two study groups. There was a significant 
difference (p=<0.001) between participants in the study groups for being allocated a 
case manager. The case manager is separate to the prescriber and manages individual 
client matters apart from prescribing and certain clinical assessments. This can include 
support for related health problems, social support and legal matters. Most rural 
participants (77%, n=43) had a case manager compared to 29 per cent (n=18) of urban 
participants.
As also shown in Table 4.14, all participants were regularly reviewed by their 
methadone prescribers. The majority (82%) did not pay to see their prescriber. There 
was no significant difference between study groups for cost of seeing their prescriber 
(p=0.13), but a higher proportion of urban individuals were represented in this category 
compared to rural individuals (89% vs. 75%).
Costs associated with prescriber visits were compared between study groups by tier as 
the type of prescriber and cost of appointment was based on tier for each study group. 
There was a marginally significant difference (p=0.06) in cost associated with seeing 
the prescriber between Tier 3 clients, with the majority of urban clients not paying to 
see their prescriber (60%, n=9), while the majority of rural clients (81%, n= 13) paid 
$30.00 or more. These results are not tabulated.
All participants saw their prescribers either at monthly, three monthly or six monthly 
intervals for review. The majority saw their prescriber at three monthly intervals (72%, 
n=85). Rural study group participants were significantly more likely to see their 
prescribers more frequently than their urban counterparts (p=0.02). These results are 
presented in Table 4.14.
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When analysed by tiers, the majority of urban Tier 1 participants were significantly 
more likely (p=0.04) to see their prescribers at three monthly intervals (77%, n=20), 
while there was an even spread of rural participants seeing their prescribers at monthly 
or three monthly intervals (monthly: 52%, n=14; three monthly: 48 per cent n=13).
Most urban Tier 2 participants (90%, n=19) saw their prescribers at three monthly 
intervals, while rural Tier 2 participants were once again split between monthly and 
three monthly appointments (monthly: 31%, n=4; three monthly: 69%, n=9). This 
difference was not significant (p=0.09) and may be due to small numbers. There were 
only two participants (one urban and one rural) in Tiers 1 and 2 who saw their 
prescriber at six monthly intervals. All Tier 3 participants saw their prescribers either at 
monthly or three monthly intervals only and there was no significant difference between 
urban and rural study groups. Overall, for both study groups, pregnant clients and new 
clients were likely to see their prescriber at shorter intervals. These results comparing 
prescriber appointments by tier are not tabulated.
Table 4.14: Summary of clinical assessment and management characteristics
Characteristic
n
ACT
N=62
%
SNSW
N=56
n %
Total
N=118
n %
p-values 
(Pearson X2)
Case Manager
Yes 18 29.0 43 76.8 61 51.7
No 44 71.0 13 23.2 57 48.3 <0.001
Total 62 100 56 100 118 100
Cost of prescriber appointments
No cost 55 88.7 42 75.0 97 82.2
Up to $30.00 3 4.8 8 14.3 11 9.3 0.13
> $30.00 4 6.5 6 10.7 10 8.5
Total 62 100 56 100 118 100
Time in between prescriber 
appointments
Once a month or more 10 16.1 21 37.5 31 26.3
3 monthly 50 80.6 35 62.5 85 72.0 0.02
6 monthly 2 3.2 0 0.0 2 1.7
Total 62 100 56 100 118 100
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Differences between urban and rural study groups and between tiers of study groups in 
relation to the factors described above can be attributed to differences in policy and 
service delivery within the programmes (as described in Chapter 2). The significant 
difference between access to case managers is due to the rural programme policy of 
allocating a case manager for all Tier 1 and 2 clients, while in the urban programme, 
case managers are only allocated to people whose management may be complicated.
The significant difference between the two study groups in relation to frequency of 
seeing their prescriber could be attributed to arrangements within each tier. Rural people 
in Tier 1 and Tier 2 could access their prescriber monthly if they chose to, as prescriber 
clinics were run on a monthly basis. In the urban programme, prescriber clinics were not 
run regularly, but people were reviewed as per their needs. If stable, they saw their 
prescriber for a methadone prescription on a three monthly basis.
4.7: Current drug usage and associated risk factors
This section describes and compares drug usage, drug injecting practices, and associated 
risk factors including methadone injecting for urban and rural participants while on their 
current methadone programme in the month prior to interview.
4.7.1: Drug usage
Table 4.15 summarises drug usage by participants in the month prior to interview. All 
participants had been on the programme for more than one month at the time of 
interview; thus all drug use in the last month prior to interview took place while on the 
programme. Overall, the mean number of other drugs used (apart from methadone) was 
3.38 (SD 1.37). The drugs that were used the most frequently in the month prior to 
interview were tobacco, cannabis, heroin, alcohol and tranquillisers (92%, 65%, 36%, 
47% and 47% respectively). Proportions using these drugs in both study groups were 
similar, apart from tranquillisers which seemed to be used more amongst rural 
participants as compared to urban participants (55% vs. 39%), but was not significantly 
different (p=0.14). Only a small proportion used cocaine and this was completely 
restricted to the urban population. There was no significant difference in mean number 
of drugs used or type of drug used between the two study groups.
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These results demonstrate that many people continue to use opioids and other drugs 
while on methadone treatment in keeping with other studies [44, 166, 181]. 
Benzodiazepines have been shown to be one of the more common drugs used amongst 
people on methadone treatment [126, 182]. A recent study showed that benzodiazepine 
intake on a daily basis was significantly more likely in people on methadone or codeine, 
than people using heroin [183]. The difference between cocaine and tranquilliser use 
between urban and rural study groups could be relative to availability of the two drugs 
within urban and rural areas respectively.
Table 4.15: Drugs used in the month prior to interview
Drugs used in the last month 
prior to interview
ACT
N=62*
SNSW
N=56*
Total
N=118* p-values 
(Pearson X2)
n % n % n %
Heroin 23 37.1 19 33.9 42 35.6 0.59
Other opioids 13 21.0 15 26.8 28 23.7 0.50
Alcohol 29 46.8 26 46.4 55 46.6 0.63
Cannabis 38 61.3 39 69.6 77 65.3 0.45
Amphetamines 13 21.0 8 14.3 17.8 21.0 0.39
Cocaine 3 4.8 0 0.0 3 2.5 0.15
Tranquillisers 24 38.7 31 55.4 55 46.6 0.14
Barbiturates 1 1.6 1 1.8 2 1.7 0.63
Hallucinogens 4 6.5 2 3.6 6 5.1 0.49
Inhalants 0 9.0 1 1.8 1 0.8 0.37
T obacco 57 91.9 51 91.1 108 91.5 0.57
Mean number of other drugs used 
in the month prior to interview
3.33 + 1.47 
(n = 61)a
3.43 + 1.26 
(n = 56)
3.38 + 1.37 
(n = 117)a
0.69
*  Total for each drug used does not tally to actual sample numbers as participants could pick more than one option 
a One missing value
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4.7.2: Frequency of injecting drugs
A little over 50 per cent of the total sample had injected drugs in the month prior to 
interview and this was similar for both study groups (p=0.73). Table 4.16 summarises 
frequency of injecting amongst study participants in the month prior to interview. Of all 
the participants who had injected (n=61), 54 per cent (n=33) had done so once a week or 
less, 36 per cent (n=22) had injected more than once a week but not daily, and 10 per 
cent (n=6) had injected more than once a day. Although the results suggest that urban 
people injected more often than rural people (64% injected once a week or less), there 
was no significant difference between the two study groups in terms of frequency of 
injecting (p=0.40).
Table 4.16: Frequency of injecting drugs in the month prior to interview
ACT SNSW Total
Injecting practices in the month 
prior to interview n
N=62
% n
N=56
%
N=118 
n %
p-values 
(Pearson X2)
Injected drugs
Yes 33 53.2 28 50.0 61 51.7
No 29 46.8 28 50.0 57 47.9 0.73
Total 62 100 56 100 118 100
Frequency of injecting (n=61)
Once a week or less 15 45.5 18 64.3 33 54.1
More than once a week but not daily 14 42.4 8 28.6 22 36.1 0.40
Once a day or more 4 12.1 2 7.1 6 9.8
Total 33 100 28 100 61 100
4.7.3: Risk factors and protective behaviours associated with injecting drugs
Of the participants who had injected in the month prior to interview (urban n=33, rural 
n=28), the majority (93%) had not used injecting equipment after someone else. This 
was similar for both study groups (p=0.13). Table 4.17 summarises risk factors and 
protective behaviours associated with injecting drugs in the month prior to interview.
Ninety per cent of participants (n=51) who had injected in the month prior to interview 
had accessed NSPs. A greater proportion of these were urban participants in comparison 
to rural participants (94% vs. 84%), but this difference was not significant (p=0.39) 
(Table 4.17). Overall, 53 per cent (n=59) of study participants had accessed NSPs 
during their injecting careers and this was similar for both study groups (urban: 56%, 
rural: 49%, p=0.39). These results are not tabulated.
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Whether accessing NSPs equates to safer injecting behaviour and using clean equipment 
for each injecting episode cannot be ascertained. Considering the low proportion of 
persons who used equipment after someone else, it would be reasonable to assume that 
most injecting in the month prior to interview was done using clean equipment.
Living with someone who injects drugs has been shown to be a risk factor associated 
with injecting drugs [184-187]. Of all participants (injectors and non-injectors), 60 per 
cent (n= 70) stated that they did not live with someone who injected drugs, 20 per cent 
said they did (n=24), 19 per cent lived by themselves (n=22), and two per cent (n=2) did 
not know if anyone in their household injected. These results are not tabulated.
Of the persons who had injected in the month prior to interview (n=61), 35 per cent 
(n=21) lived with someone who injected drugs. This was similar for the study groups 
(urban: 34%, n=l 1; rural 36%, n=10; p= 0.91). This analysis included those who lived 
alone (in the category of injectors who did not live with someone who injects). These 
results are presented in Table 4.17.
Table 4.17: Injecting risks and NSP access in the month prior to interview
ACT SNSW Total
Characteristic
N=33 N=28 N=61
p-values 
(Pearson X2)
n % n % n %
Injectors who shared injecting 
equipment
0 times 31 93.9 26 92.9 57 93.4 0.13
1-2 times 2 6.1 0 0.0 2 3.3
> 2 times 0 0.0 2 7.1 2 3.3
Total 33 100 28 100 61 100
Injectors who accessed NSPs
Yes 30 93.8 21 84.0 51 89.5
No 2 6.3 4 16.0 6 10.5 0.39+
Total 32“ 100 25b 100 57c 100
Injectors who lived with someone 
who injects
Yes 11 34.4 10 35.7 21 35.0
No (includes people who lived alone) 21 65.6 18 64.3 39 65.0 0.91
Total 32 100 28 100 61 100
°  One missing value h three missing values, cfour missing values. +  Fishers exact test
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I examined if living with someone who injects drugs and having injected drugs in the 
month prior to interview were associated. Analysis included those who lived alone 
(similar to previous analysis). These findings are outlined in Table 4.18. For the overall 
sample, people who lived with someone who injected were significantly more likely to 
have injected drugs (p=<0.001). Eighty eight per cent of all participants who were living 
with someone who injected drugs (21 of 24 people) had injected in the month prior to 
interview as compared to 42 per cent of participants (39 of 92 people) who did not live 
with someone who injected. This association was also found to be statistically 
significant within each study group (urban study group, p=0.009; rural study group 
p=0.004). When people who lived alone were not included in the analysis, the 
significant association still remained (total sample, pO.OOl; urban p=0.009; rural 
p=0.004). These results suggest that people who live with someone who injects drugs 
are more likely to inject drugs and support findings from previous studies.
Table 4.18: Association between living with someone who injects drugs and injecting drugs in the 
month prior to interview
Injected in the
Living with someone who injects drugs
p-values
month prior to interview Yes
(n=24)
No
(n=92)
Total
(n=116)a
(Pearson X2)
n % n % n %
Total sample
Yes 21 87.5 39 42.4 60a 51.7
No 3 12.5 53 57.6 56 48.3 <0.001+
Total 24 100 92 100 116 100
Urban group (ACT)
Yes 11 84.6 21 43.8 32 52.5
No 2 15.4 27 56.3 29 47.5 0.01+
Total 13 100 48 100 61 100
Rural group (SNSW)
Yes 10 90.9 18 40.9 28 50.9
No 1 9.1 26 59.1 55 49.1 0.005+
Total 11 100 44 100 55 100
°  Two missing values-people who did not know if  anyone injected in their household or not, +  Fishers exact test
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4.7.4: Frequency of methadone injecting
Overall, 67 per cent of participants (n=78) had injected methadone while on the current 
programme. This was similar for both study groups (urban=64%, n=39; rural=70%, 
n=39). These results are not tabulated.
Information was collected in relation to when participants had last injected methadone 
and the frequency of injecting methadone while on the current programme. These 
results are presented in Table 4.19. Overall, the majority (71%, n=55) had injected in 
the last year or previous to the last year. Fifteen per cent (n=12) had injected in the last 
week prior to interview, and 14 per cent (n=l 1) in the last month prior to interview but 
not in the last week. Twenty three per cent of urban participants (n=9) had injected in 
the last week prior to interview as compared to only eight per cent of rural participants 
(n=3). These results were not significantly different between the two study groups 
(p=0.17).
Only 55 of 78 participants (70%) who had injected methadone while on the current 
programme indicated their frequency of injecting. Of these, the majority (60%, n=33) 
had injected less than monthly, while 24 per cent (n= 13) had injected weekly or more 
and 16 per cent (n=9) had injected once a month or more, but less than weekly. These 
proportions were similar for both study groups (p=0.91). These results need to be 
interpreted with caution as there were several missing responses.
Table 4.19: Frequency of methadone injecting while on the current programme
ACT
Characteristic ^  ^
SNSW
N=39
Total
N=78 p-values
n % n n %
Last injected methadone
In the last week 9 23.1 3 7.7 12 15.4
In the last month but not in the last week 5 12.8 6 15.4 11 14.1 0.17
In the last year/ Previous to the last year 25 64.1 30 76.9 55 70.5
Total 39 100 39 100 78 100
F r e q u e n c y  o f  i n j e c t in g  m e t h a d o n e
Weekly or more 8 25.8 5 20.8 13 23.6
Monthly/few times per month 5 16.1 4 16.7 9 16.4 0.91
Less than monthly 18 58.1 15 62.5 33 60.0
Total 3 1 “ 100 24b 100 55c 100
°  Eight missing values, b fifteen missing values,c twenty three missing values
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A recent study found that methadone injecting in Australia was associated with the TA 
policy of the State or Territory. There was a positive correlation between a more 
flexible TA policy and methadone injecting (more TAs allowed correlated to increased 
methadone injecting) [93]. I looked at this association in my study sample, and found 
that there was no significant association between the number of TAs and methadone 
injecting (2 or less TAs: p=0.453; 3 TAs: p=0.382). However, there were four 
participants who got more than four TAs per week and all four injected methadone.
4.8: Serological HIV/HCVstatus andHBV vaccination status
HIV serology was available for 109 participants. No one in the urban study group was 
positive for HIV antibodies, while one person in the rural study group returned an 
indeterminate test. Of 110 participants for whom HCV serology was available, 70 per 
cent (n=76) were HCV antibody positive. Of these, 63 per cent (n=36) were urban and 
75 per cent (n=40) were rural. The two study groups did not differ significantly in 
relation to HIV and HCV serological status. The percentage of HIV and HCV antibody 
positive results in my study is consistent with data collected from other studies and 
current published Australian statistics [33, 80-82]. Serological HIV and HCV status and 
relationship to self-reported status are discussed in Chapter 7.
Overall 39 per cent (n=46) of those interviewed self-reported having been immunised 
against HBV. The two study groups differed significantly in relation to self-report of 
HBV vaccination status (p=0.01). A higher proportion of urban participants reported 
that they were vaccinated in comparison to rural participants (urban 50%, n=31; rural 
27%, n=15) and a higher proportion of rural participants reported that they did not know 
their vaccination status in comparison to their urban counterparts (urban 8%, n=5; rural 
23% n=13). These results are not tabulated.
IDUs have been identified as a group for whom HBV vaccination is recommended by 
NHMRC Guidelines as discussed in Chapter 1 [39]. Many programmes make an effort 
to immunise IDUs, but as the vaccine is not routinely funded for adults through the NIP 
or through methadone programmes, the cost of the vaccine has to be borne by the client. 
As discussed in Chapter 1, HBV vaccination has been included in the NIP as a routine 
childhood vaccine as of 2000, but not as a vaccine for adults. For these reasons HBV 
immunisation rates amongst current IDUs can be expected to be low and results from 
my study on self-reported status support this observation.
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4.9: Perceived client outcomes and satisfaction
Perceived client outcomes were measured and compared for the two study groups 
against the five main reasons identified by participants for accessing their current 
methadone programme (financial issues, getting out of the drug scene, health issues, 
stopping drug usage and general relationship issues). Overall 50-70 per cent of 
participants perceived that they had achieved outcomes against the reasons for which 
they had accessed the programme. Table 4.20 outlines these results.
4.9.1: Perceived client outcomes
Of the 82 per cent of participants (n=85) who had stated financial issues as a reason for 
accessing their current methadone programme, 68 per cent (n=57) perceived that their 
financial situation had improved. The rural study group had a higher proportion of 
participants who perceived their financial situation to have improved as compared to 
urban participants, but this difference was not significant (77% vs. 62%, p=0.16). 
Seventy nine per cent of participants (n=80) had accessed their programme to get out of 
the drug scene; of these 60 per cent (n=43) perceived that they had achieved this 
outcome. Once again a higher proportion of rural participants achieved the outcome 
than urban participants, and these proportions were not significantly different 
(67% vs. 54%, p=0.27). Health as a reason for accessing the current programme was 
stated by 76 per cent of participants (n—81); of these, 61 per cent (n=49) perceived that 
their health had improved. This time, urban participants had a higher proportion who 
felt that their health had improved in comparison to rural participants, but were not 
significantly different to the rural study group (63% vs. 57%, p=0.59).
Of those participants who had stated stopping illegal drug usage completely as a reason 
for accessing the methadone programme (71%, n=70), 55 per cent (n=37) stated that 
they had achieved this outcome. Rural participants had a higher proportion who 
perceived achieving this outcome in comparison to their urban counterparts, but there 
was no significant difference between the study groups (57% vs. 52%, p=0.64). Of the 
65 per cent of participants (n=66) who stated improving general relationships as a 
reason, 63 per cent (n=39) perceived that their relationships had improved. Urban 
participants had a higher proportion represented in this group in comparison to rural 
participants, but were not significantly different to the rural group (65% vs. 59%, 
p=0.64).
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For other reasons cited for accessing the programme (to improve employment 
prospects, decrease injecting and decrease criminal activity), level of perceived 
outcomes varied. Employment was not one of the highly ranked reasons for accessing 
the programme (50%, n=48). Urban participants were significantly more likely to have 
stated this to be a reason for accessing the programme in comparison to rural 
participants (61% vs.39%, p=0.03). For those who stated employment as a reason for 
accessing their current programme, 50 per cent (n=22) perceived that they had achieved 
this outcome. As an achieved outcome, there was no significant difference between 
urban and rural study groups (urban=48%, rural=53%, p=0.75). Similar to employment, 
smaller proportions of individuals stated decreasing injecting (48%) and criminal 
activity (45%) as reasons for accessing the programme; this was similar for both study 
groups. Eighty nine per cent (n=32) perceived that they had decreased injecting; a 
higher proportion of urban participants stated they had achieved this in comparison to 
rural participants (93%, vs. 86%), but this was not significantly different (p=0.63). The 
rural study group had a higher proportion of participants who perceived they had 
decreased their criminal activity, but this was once again not significantly different to 
the urban study group (93% vs. 85%, p=0.62).
All those interviewed were asked if they had any specific health concerns and if they 
perceived that they were in better control of their lives (these results have not been 
tabulate). Most participants stated they were worried about their dental health and the 
majority (70%) reported that it had worsened since being on methadone treatment. 
Although there was a higher proportion of rural participants reporting worsened dental 
health, this difference was not significant (77% vs. 66%, p=0.23) Lack of access to 
dental care either through the programme and in general was seen as a major issue. This 
could be worse for rural people and could be contributing to the larger proportion 
affected. Overall, 72 per cent (n=81) stated that their control over their life had 
improved; this was similar for the two study groups (p=0.98). There were a small 
number of people who stated that their control had worsened and this may need to be 
investigated further.
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4.9.2: Client satisfaction with the current methadone programme
Table 4.22 summarises levels of client satisfaction in relation to their programme, 
perceived confidentiality and relationship with programme staff. These results should be 
interpreted with caution as this sample only includes users of the programme. Overall,
71 per cent of the participants (n=79) were satisfied with their current methadone 
programme and 71 per cent stated (n=76) that their confidentiality was maintained.
There was no significant difference between the two study groups for these factors. 
There was a marginally significant difference (p=0.09) between study groups in relation 
to perceived respect from programme staff, with a higher proportion of urban 
participants feeling more respected (85% vs. 72%)
Table 4.21: Client satisfaction with current methadone programme
Characteristic ACT SNSW Total
(N=62) (N=56) (N=l 18) p-values 
(Pearson X2)
n % n % n %
Programme satisfaction
Satisfied 43 74.1 36 66.7 79 70.5
Unsatisfied 15 25.9 18 33.3 33 29.5 0.39
Total 58" 100 54b 100 112C 100
Confidentiality
Yes 43 76.8 33 64.7 76 71.0
No 13 23.2 18 35.3 31 29.0 0.17
Total 56c 100 51' 100 107d 100
Respect from programme staff
Yes 50 84.7 38 71.7 88 78.6
No 9 15.3 15 28.3 24 21.4 0.09
Total 59' 100 56 100 115' 100
Four missing values, h two missing values, c six missing values, "  eleven missing values,e three missing values, 
e five missing values
These results suggest that there were no dissimilarities between urban and rural study 
participants in relation to perceived outcomes achieved and satisfaction with their 
respective programmes.
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4.10: Summary
The two study groups were not significantly different in relation to most socio­
demographic characteristics, previous drug history, prison history or methadone 
treatment history. The two groups were also similar in relation to current drug usage, 
HIV and HCV serological status and perceptions of outcomes achieved. Although there 
was no difference between the two study groups in relation to continued drug usage and 
injecting while on the programme, many participants continued to use heroin and other 
drugs, and practice some risky behaviour such as injecting methadone.
As the two study groups were similar socio-demographically and in relation to previous 
and current risk factors, these factors may not influence differences in health and BBV 
risk outcomes for urban and rural clients in my study. However, as the two recent 
studies by Day and colleagues [141], and Lawrinson and colleagues [67] comparing 
characteristics and risk behaviours for urban and rural IDUs did find differences, these 
factors cannot be discounted. As the study groups were similar in relation to perceived 
outcomes achieved, issues related to outcomes not achieved could be addressed as 
common programme management issues rather than as urban or rural specific issues.
The issue of dental health problems stated by the majority and access for dental health 
care through the programme should be further reviewed.
Most of the significant differences between the two study groups were related to 
programme policy and delivery. This included differences in cost of methadone, cost of 
travel to dose, TA policy, time in between prescriber appointments and access to case 
managers. These differences can be largely attributed to jurisdictional autonomy of 
service delivery due to the Australian health structure. The significant differences in 
reasons for accessing the programme, referral source to the programme, and self- 
reported HBV vaccination status could be related to differing outcomes that urban and 
rural clients wanted to achieve from the programme. These differences could potentially 
affect health and BBV risk outcomes for the two study groups.
The following two Chapters (Chapters 5 and 6) measure and compare health and BBV 
risk for the urban and rural study groups and identify factors significantly associated 
with these outcomes within the study groups. Differences identified in this chapter are 
included in the analysis, and any policy implications that may arise for urban and rural 
methadone clients are discussed in each chapter and conclusively in Chapter 8.
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Chapter 5
Measurement and comparison o f health outcomes
In this chapter I report findings from the measurement and comparison of health 
outcomes (physical and psychological) for urban (ACT) and rural (SNSW) people on 
methadone treatment, and identify factors associated with health outcomes for the two 
population groups. As it has been shown that there is a relationship between opioid use 
and psychopathology, I have included indicators of psychological adjustment as a 
measure of health status in my study, in addition to physical health symptoms [130, 131, 
188],
The literature review in Chapter 2 showed that methadone treatment is effective in 
improving health status of heroin dependent individuals by decreasing use of heroin and 
injecting. However, as discussed in Chapter 1, there are issues related to service 
delivery in rural areas (such as availability, access, cost and confidentiality) that could 
impact on health outcomes for rural people on methadone treatment in comparison to 
urban people. Methadone treatment provision and delivery can also vary between 
jurisdictions due to the Australian health service structure (also discussed in Chapter 1). 
This was supported by results in Chapter 4, where comparison of factors relating to 
programme policy and delivery for the two study groups indicated that there were some 
differences. This could further impact on health outcomes for rural methadone clients.
Improvement in health status is a key reason for individuals accessing the methadone 
programme (supported by results in Chapter 4). Whilst other researchers have shown 
that there are differences between urban and rural IDUs in relation to some socio­
demographic characteristics, risk behaviours and access to harm reduction services in 
Australia, no evaluation assessing outcomes for urban and rural IDUs on methadone 
treatment has been done before [67, 141], It is therefore unknown whether these 
differences can influence outcomes of methadone treatment for the two populations. 
Findings from my study can assist with informing policy and service delivery according 
to needs for urban and rural IDUs to maximise health outcomes achieved from 
methadone treatment programmes.
141
Chapter 5: Measurement and comparison of health outcomes
5.1: Explanation of OTI measurement of health outcomes
Measurement of health status was done using two sections of the OTI (Sections VI and 
VII), incorporated into my questionnaire as Section V and Section VI of the OTI 
(Appendix 2: Part III). Section V measures physical health status, while Section VI (the 
GHQ-28) measures psychological adjustment. I explain the process of measurement of 
health outcomes by the OTI in this section.
5.1.1. Measurement and comparison of physical health status
The OTI measures physical health status by the presence or absence of 
symptomatology in eight health areas/systems mostly in the month prior to interview. 
The eight areas/systems covered are general health issues (which includes general well­
being symptoms such as fatigue, insomnia, appetite, hearing or vision loss), injection 
related problems, cardio-respiratory, genito-urinary, gynaecological, musculo-skeletal, 
neurological and gastro-intestinal systems. Each area/system has a set of symptoms. A 
person can have a 0 or 1 score for each symptom depending on whether or not they 
have experienced the symptom in the month prior to interview (apart from 
gynaecological symptoms which are measured for the last few months). A score can be 
calculated for each of the areas/systems. A Total Health Score (THS) is calculated by 
summing the scores for each area/system. There are 52 symptoms in total within the 
eight areas/systems that can be scored; thus a THS for a person can range from 0-52. 
Group mean scores can be calculated for the THS as well as for each area/system and 
can be compared between study groups. A higher THS or area/system score indicates 
poorer health status [189].
5.1.2: Measurement and comparison of psychological adjustment
The OTI incorporates the GHQ-28 to measure psychological adjustment and any 
existing psychopathology [151]. The GHQ-28 measures psychopathology in four 
symptom areas: somatic, anxiety, social dysfunction and depression. Scores range from 
0-7 in each area and a total psychological adjustment score is calculated by summing 
the scores of the four areas. A total score can range from 0-28. Like the THS, group 
mean scores can be calculated for the total score and within each of the four areas and 
compared for study groups and higher scores indicate greater levels of psychopathology 
[189],
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5.2: Comparison of health outcomes for urban and rural study groups
Group mean scores were calculated and compared for the two study groups for the THS, 
the eight individual health areas/systems scores that made up the THS, and total 
psychological adjustment score (GHQ-28 scores). Gynaecological scores were excluded 
for the THS comparison, as my study sample included both male and female 
participants.
5.2.1: Measurement and comparison of physical health status (THS) for 
urban and rural study groups
Figures 5.1.a and 5.1.b show the distributions of THS for the overall study group and 
for urban and rural study groups. As the underlying distributions were assumed to be 
normal (Figure 5.1.a and b) for reasons explained in Chapter 3, two sample t-tests were 
used to compare mean THS between the two study groups and between programme tiers 
[157],
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Figure 5.1a: Distribution of Total Health Scores for the overall sample14
Number
n=l 16
30.0010.00 20.00
Figure 5.1b: Distribution of Total Health Scores by study group14
Distribution of THS: Urban study group
Numb( r
20.00 30.0010.00
Distribution of THS: Rural study group
Numbt r
5.00 10.00 15.00 20.00 25.00 30.00
14 THS does not include gynaecological scores
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Table 5.1 summarises mean THS comparisons for the two study groups overall, and by 
programme tier. The mean THS for the overall sample was 14.68 (SD 7.61; range 1-35). 
This score was higher than that of the mean THS from the validation research conducted 
towards the development of the OTI (mean 12.60, SD 7.60) and the range was slightly 
narrower (0-42) [189]. The urban study group had a lower mean THS of 13.98 (SD 
7.72, range 1-35) compared to the rural study group mean THS of 15.43 (SD 7.48, 
range 3-32). Mean THS for the three programme tiers were also calculated and 
compared between the two study groups, as service provision and delivery differed 
between programme tiers. There was no significant differences in the mean THS 
between the two study groups (p=0.31) or between programme tiers of the two study 
groups (Tierl: p=0.27; Tier 2: p=0.96; Tier 3: p=0.66).
Table 5.1: Comparison of mean total health scores by study group and by tier
Characteristics Overall sample 
N=118
ACT
N=62
SNSW
N=56
p-values 
(Pearson X2)
Overall sample
n 116a 60 56
Mean score 14.68 13.98 15.43 0.31
SD 7.61 7.72 7.48
Range 1-35 1-35 3-32
Tier 1
n 52b 25b 27
Mean score 14.35 13.08 15.52 0.27
SD 7.91 7.80 7.98
Range 1-32 1-30 3-32
Tier 2
n 33b 20b 13
Mean score 14.76 14.70 14.84 0.96
SD 7.49 8.32 6.32
Range 1-35 1-35 7-29
Tier 3
n 31 15 16
Mean score 15.16 14.53 15.75 0.66
SD 7.42 7.10 7.89
Range 5-30 5-29 6-30
a Two missing values, h one missing value
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5.2.2: Comparison of the eight areas/systems of physical health status for the 
urban and rural study groups
Mean scores for the eight areas/systems that make up THS (general health issues, 
injection related problems, cardio-respiratory, genito-urinary, musculo-skeletal, 
neurological, gastro-intestinal systems and gynaecological) were calculated for the 
overall sample, compared between the two study groups, and between programme tiers. 
These results are presented in Appendix 14; Tables 1-8. Once again two sample t-tests 
were used to compare group mean scores as underlying normal distributions were 
assumed for reasons explained in Chapter 3. There were no significant differences 
(p>0.05) found in the mean scores for the eight areas/systems between the two study 
groups and between programme tiers of the two study groups (p>0.05).
5.2.3: Comparison of psychological adjustment (GHQ-28) for the urban and 
rural study groups
The underlying distribution for the mean scores for psychological adjustment for the 
overall sample and the two study groups were not assumed to be normal. This was 
because there were many participants who did not have symptomatology and thus had 
zero scores in each of the four areas that made up the total psychological adjustment 
score. As seen in Figures 5.2.a (overall sample) and 5.2.b (urban and rural samples), 
these distributions did not approximate a normal distribution. A non-parametric test 
(Mann-Whitney test) was used to compare total psychological adjustment mean scores 
for the two study groups [157].
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Figure 5.2a: Distribution of total psychological adjustment scores (GHQ-28 scores) 
for the overall sample
Overall distribution of psychological adjustment scores
0.00 5.00 10.00 15.00 20.00 25.00 30.00
Total psychoiogcial adjustment scores
Figure 5.2b: Distributions of total psychological adjustment scores by study group
ACT psycohological adjustment scores
0.00 3.00 10.00 15.00 20.00 23.00 30.00
Psychological adjustment score
SNSW psychological adjustment scores
0.00 5.00 10.00 15.00 20.00 25.00
Psychological adjustment score
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Table 5.2 shows total psychological adjustment scores for the overall sample and for the 
two study groups. The group mean score for the overall sample was 8.83 (Cl 7.34- 
10.32, range 0-28). This score and range were very similar to the validation research 
conducted towards the development of the OTI (mean 8.60, SD 7.60, range 0-28) [189]. 
Group mean scores were calculated and compared between the two study groups and 
between programme tiers. There were no significant differences found between the 
psychological total adjustment mean scores for the two study groups (urban: 8.10, 
SD=7.40, range=0-28; rural: 9.61, SD=8.76, range=0-26; p=0.51) or between 
programme tiers.
Table 5.2: Psychological adjustment mean scores for the overall sample and the two study groups
Characteristics Overall sample 
N=118
ACT
N=62
SNSW
N=56
p-values 
(Pearson X2)
Overall sample
n 116a 60a 56
Mean score 8.83 8.10 9.61 0.51
SD 8.09 7.40 8.76
Range 0-28 0-28 0-26
Tier 1
n 53 26 27
Mean score 7.55 6.19 8.85 0.31
SD 7.72 6.69 8.52
Range 0-25 0-21 0-25
Tier 2
n 32a 19a 13
Mean score 9.97 9.58 10.54 0.80
SD 7.79 7.36 8.65
Range 0-28 0-28 0-25
Tier 3
n 31 15 16
Mean score 9.84 9.53 10.13 0.92
SD 8.91 8.33 9.69
Range 0-28 0-28 0-26
a Two missing values
As the final sample size was smaller than the required sample size (n=100 in each study 
group) to elicit a significant difference of 20 per cent between study groups for health 
outcomes (p<0.05, power 0.8), I recalculated the power my study would have to pick 
up a significant difference between study groups with the sample numbers recruited.
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I replaced the standard deviations of mean THS used for initial power calculations (SD 
from ACT 1993 study) with the SDs of mean THS from my study. With the numbers 
recruited, my study had a power of 0.53 to detect a 20 per cent difference (at the p<0.05 
significance level) between mean THS for urban and rural study groups. Any significant 
differences in urban and rural comparisons with the new power of my study are most 
likely due to the actual difference being greater than 20 per cent. Some significant 
differences/associations may also be due to chance. For these reasons results should be 
interpreted with caution.
The comparison of health outcomes for urban and rural methadone participants in my 
study indicated that there was no difference between the two study groups in relation to 
the magnitude of physical and psychological health outcomes (as measured by the THS 
and GHQ-28). There could be two reasons for this result:
1) There is truly no significant difference between urban and rural study groups in 
relation to health outcomes,
2) The numbers recruited into the study did not have enough power to elicit a significant 
difference between the two study groups.
The aim of measuring and comparing health outcomes for urban and rural people on 
methadone treatment was firstly to examine if health outcomes differed in magnitude 
for the two populations, and secondly if any differences between the populations (such 
as socio-demographics, risk behaviours, rural specific issues, programme policy and 
delivery) could influence health outcomes related to methadone treatment. Whilst there 
was no significant difference in the magnitude of health outcomes, factors influencing 
these health outcomes for the two populations could differ as policy and service 
delivery within the two programmes were shown to be different. In addition to 
differences found in my study other recent studies have shown that urban and rural 
IDUs can differ in relation to socio-demographic characteristics and risk behaviours [67, 
141]. My analyses reported in the next section of the chapter aims to identify factors 
that could significantly influence health outcomes related to methadone treatment for 
urban and rural people. The analyses also examine whether these factors differ for the 
two populations and whether they have a beneficial or detrimental effect on health 
outcomes. It is important to identify these factors for appropriate policy development, 
so that programmes can be tailored according to client needs to ensure maximum 
benefit.
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5.3: Factors contributing to health outcomes within urban and rural 
study groups
In this analysis all factors identified as potentially being associated with health 
outcomes related to methadone treatment were included. These were factors identified 
in my rationale and from other studies (summarised in Chapter 3 Fig 3.1), and 
differences identified between the study groups in relation to programme policy and 
delivery in Chapter 4. Factors that were included in this analysis are reiterated below;
1) Sociodemographic characteristics:
Age, gender, education level, employment status, main income source.
2) Previous risk characteristics associated with incarceration and drug use:
Prison history, age first injected drugs, age started injecting regularly.
3) Current programme characteristics:
Programme tier, first time on programme, number of times on programme, length of 
time on programme, methadone dose, travel time to dose, travel cost to dose.
4) Programme policy and service delivery:
Access to routine takeaways, cost of methadone per week, cost per prescriber 
appointment, time in between prescriber appointments, having a case manager.
5) Risk factors while on the programme:
Total number of other drugs used while on the programme, injected in the month 
prior to interview, shared injecting equipment in the month prior to interview, living 
with someone who injects drugs.
6) Client programme satisfaction,
Associations between factors and health outcomes were examined through univariate 
analyses as explained in Chapter 3. Health outcomes as measured by the OTI THS 1? 
were used for this analysis. Psychological adjustment (GHQ-28 scores) was not 
included as GHQ scores cannot be combined with THS scores. Linear regression was 
used for this purpose as THS were measured on a scale that was approximately 
continuous. Factors identified as having a significant association at the p<0.10 level in 
the univariate analysis were entered into a stepwise linear regression model to elicit the 
combination of factors significantly associated (p<0.05) with health outcomes in each 
study group.
15 Poorer health outcomes = higher mean THS. 
Better health outcomes = lower mean THS.
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Tables 5.3.a and 5.3.b present the results of the univariate analyses for the factors that 
were found to have a significant association (p<0.10) with health outcome within urban 
and rural study groups (results of the complete univariate analyses are presented in 
Appendix 15). There were many factors that had more than two categories and LR tests 
were used to determine whether these were significantly associated with health 
outcomes as a whole factor, ß coefficients16 in the model indicate the change in mean 
score of health outcomes (THS) in relation to the factor and the direction of the 
association (positive=detrimental, negative=beneficial). R2 indicates the proportion of 
the variance of health outcomes within the study groups that can be explained by the 
factor.
There were six factors in the urban study group and five factors in the rural study group 
that were significantly associated (p<0.10) with health outcomes in the univariate 
analyses. The one common factor between the two groups was satisfaction level with 
the programme.
For the urban study group the six factors significantly associated with health outcomes 
were:
1) employment status,
2) main income in the last six months,
3) cost of methadone per week,
4) having shared injecting equipment in the month prior to interview,
5) having a case manager,
6) satisfaction with the programme.
For the rural study group the six factors significantly associated with health outcomes 
were:
1) gender,
2) education level,
3) methadone dose,
4) total number of other drugs used in the month prior to interview,
5) satisfaction with the programme.
l6 THS = a + ß x  (factor) + random error
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Chapter 5: Measurement and comparison of health outcomes
For the urban study group, factors that were shown to be significantly associated with 
better health outcomes (negative ß coefficients) were being employed in the month prior 
to interview (ß=-6.33, SE=2.70, p=0.02), and employment being the main source of 
income for the last six months prior to interview (ß=-5.75, SE=2.07, p=0.008). These 
two factors could be related to each other, as employment being a factor contributing to 
better health outcomes, could also be expected to be beneficial as the main source of 
income. LR tests showed that employment as a whole factor was significantly 
associated with health outcomes (p=0.04). An LR test was not needed for the main 
income source as it was a binary variable.
Factors that were found to be significantly associated with poorer health outcomes in 
the urban study group (positive ß coefficients) were methadone cost being greater than 
$15.00 per week (ß= 10.33, SE=4.31, p=0.02), sharing injecting equipment 1-2 times in 
the month prior to interview (ß= 12.35, SE=4.99, p=0.02), having a case manager 
(ß=4.63, SE=2.11, p=0.03) and being unsatisfied with the programme (ß=5.31,
SE=2.27, p=0.002). For the categorical variables, (cost of methadone and sharing 
injecting equipment), LR tests showed that they were significantly associated with 
poorer health outcomes as whole factors (cost of methadone per week p= 0.05, sharing 
injecting equipment p=0.01).
For rural participants, factors that were shown to be significantly associated with better 
health outcomes (negative ß coefficients) were education level and methadone dose. 
With educational level, only completing Year 10 had a beneficial influence (ß=-4.63, 
SE=2.62, p=0.08) while having a tertiary education had a detrimental influence 
(ß= 4.42, SE=2.38, p=0.07). LR tests indicated that education level remained 
significantly associated with health outcomes as a whole factor (p=0.01).
Methadone dose had a linear relationship with health outcomes, with higher doses being 
associated with better health outcomes (increasing negative values of ß coefficients as 
the dose increased). However, only the two highest dose categories were significantly 
associated with better health outcomes (81-100mgs: ß=-5.90, SE=3.52, p=0.10, 
>100mgs: ß=-9.40, SE=5.75, p=0.10). As these categories had very small numbers, I 
combined dose categories to two categories (<40mgs and > 40mgs) to increase the 
power of the analysis. Higher methadone doses were still associated with better health 
outcomes (>40mgs, ß=-3.99, SE=1.98, p=0.05). This analysis has not been presented.
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Factors that were found to be significantly associated with poorer health outcomes in 
the rural study group (positive ß coefficients) were being female (ß=4.98, SE=1.95, 
p=0.01), having a tertiary education (ß=4.42, p=0.07), using a greater number of other 
drugs in the month prior to interview (ß=1.63, SE=0.77, p=0.04) and not being satisfied 
with the programme (ß=4.81, SE=2.08, p=0.03).
Being unsatisfied with the programme was the only common factor for both study 
groups and was associated with poorer health outcomes. The variance (R2) in THS 
scores contributed by each of the factors in the urban study group was between 8-17 per 
cent, while in the rural study group was between 8-19 per cent.
The factors significantly associated with health outcomes in the univariate analyses for 
each study group were entered into multiple linear regression models to establish the 
best combination of factors significantly associated with health outcomes for urban and 
rural clients. Significance level used for these analyses was p<0.05 as these were the 
final models. Programme tier was entered into the models regardless of whether or not it 
was significantly associated with health outcomes in the univariate analyses, as 
programme policy and delivery for the three tiers differed considerably within and 
between the study groups.
Multivariate analyses showed two factors to be significantly associated with health 
outcomes related to methadone treatment for urban clients and four factors for rural 
clients. Tables 5.4.a and 5.4.b outline the results of the multivariate analyses of the two 
study groups.
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Chapter 5: Measurement and Comparison of Health Outcomes
There were only 33 clients in the urban multivariate model as sharing injecting 
equipment was one of the factors entered into the model. This factor was only directed 
at injectors in the study, and in the ACT there were 33 participants who had injected in 
the month prior to interview (Chapter 4, Table 4.16). The two factors significantly 
associated with health outcomes in the final model; were the cost of methadone per 
week and having a case manager. Both these factors contributed to poorer health 
outcomes (ß coefficients were positive).
Participants who paid up to $15.00 per week were significantly more likely to have 
poorer health outcomes than those who did not pay anything (ß=12.00, SE=4.33, 
p=0.01). Those who paid more than $15.00 per week were also more likely to have 
poorer health outcomes (ß=9.50, SE=4.68, p=0.05). All ACT clients were required to 
pay $15.00 per week regardless of the tier they are in. As new Tier 1 clients received 
methadone free of charge for the first six months on the programme, this may explain 
the three participants who paid nothing. The four participants who paid more than 
$15.00 is harder to explain and as discussed in Chapter 4, this could be due to incorrect 
responses or the possibility of having dosed at a non-ACT pharmacy that charges more 
than $15.00 at the time of interview. All in all, having to pay for methadone 
contributed to significantly poorer health outcomes for urban people in my study.
Having a case manager contributing to poorer health outcomes (ß= 10.25, SE=2.85, 
p=0.001) was most likely due to the policy in the ACT, where only clients whose 
management is complex are allocated case managers. These two factors explained 31 
per cent of the total variance of health outcomes (adjusted R2=0.31). Programme tier 
did not show any significant association with health outcomes.
For rural participants, those who used a greater number of other drugs in the month 
prior to interview, were female, and were unsatisfied with their programme, were 
significantly more likely to have poorer health outcomes as indicated by positive 
ß coefficients (> no. of other drugs used: ß=2.47, SE=0.84, p=0.001; female: ß=3.78, 
SE=2.09, p=0.008; unsatisfied with programme: ß=3.96, SE=2.01, p=0.04). Education 
level as a whole factor was still significantly associated with health outcomes (p=0.01). 
Those with a tertiary education were significantly more likely to have poorer health 
outcomes, similar to the univariate analysis (ß=4.71, SE=4.71, p=0.03). However, 
completing Year 10 was no longer significantly associated with better health outcomes.
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Methadone dose was also no longer significantly associated with health outcomes. The 
variance in rural health outcomes explained by this model was 38 per cent (adjusted R2 
=0.38).
The final multivariate models showed that for urban people in my study, the cost of 
methadone was the main factor that was significantly associated with poorer health 
outcomes. For rural people in my study, using a greater number of other drugs in the 
month prior to interview, being female, being unsatisfied with their programme and 
having a higher level of education as a combination of factors were significantly more 
likely to contribute to poorer health outcomes. These results suggest that factors 
significantly associated with health outcomes while on methadone treatment differ for 
urban and rural clients.
5.4: Summary and discussion
The results from comparing and measuring health outcomes for urban and rural 
participants in my study indicated that there was no significant difference in the 
magnitude of outcomes achieved between the two groups while on methadone treatment 
(as measured by THS and the GHQ-28). However, further analysis found that different 
factors were significantly associated with health outcomes (as measured by THS) within 
the two study groups. This could be a reflection of the differences identified between 
the two study groups in Chapter 4, and the differences identified between urban and 
rural IDUs and entrants to methadone treatment in other studies [67, 141].
The final multivariate models to identify factors significantly associated with health 
outcomes within study groups indicated that for urban individuals, having to pay for 
their methadone dose was associated with poorer health outcomes. The cost of 
methadone was shown to differ significantly in my study between urban and rural 
programmes and between tiers of the programmes (Chapter 4), which can be attributed 
to programme policy within the two study groups. Most urban clients (90%, n=56) paid 
$15.00 or more for their methadone (regardless of programme tier), while almost half 
of the rural clients (48%, n=26) paid nothing for their methadone. Rural clients who 
paid for their methadone were in Tiers 2 and 3 of the programme, were more likely to 
be stable, and thus may have had better health outcomes.
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For this reason, cost of methadone may be a significant contributor to health outcomes 
for urban clients in my study (particularly in Tier 1), but may not be a significant 
contributor to health outcomes for rural clients. How generalisable this finding is to 
other urban and rural people on methadone treatment can only be determined by a 
larger comparison study, as these policies may be specific to the ACT and SNSW 
programmes.
The significant association between having a case manager and poorer health outcomes 
for urban individuals can also be explained by ACT programme policy. Only clients 
with complex issues were allocated a case manager, and most of these clients were in 
Tier 1. These individuals could thus be expected to have poorer health outcomes. 
Having a case manager was possibly not a significant factor associated with health 
outcomes for rural clients as all were allocated a case manager.
In the rural study group, female participants being significantly more likely to have 
poorer health outcomes even when gynaecological scores where excluded in the 
calculation of THS was not a surprising finding. This could be associated with greater 
risk taking behaviour amongst rural female IDUs as shown by Lawrinson and 
colleagues [67]. Mondanaro reported findings from several studies that showed that 
women who use illegal drugs are more likely to have poorer health outcomes than their 
male counterparts [190]. She also found that women continued to experience poorer 
health outcomes even while on treatment [191]. This finding should thus be taken into 
account by rural programmes when female clients are enrolled.
Results from Chapter 4 indicated that rural clients were significantly more likely to pay 
more for their travel expenses to dose, which may result in missing a dose. This could 
be a reason for using a greater number of other drugs as a substitute for a missed 
methadone dose amongst rural individuals. Being unsatisfied with the programme 
contributing to poorer health outcomes, could be associated with service delivery 
issues and rapport with staff. This was supported by results in Chapter 4, where 
(although not significantly different), a higher proportion of rural individuals were not 
satisfied with their programme as compared to their urban counterparts (33% vs. 26%, 
p=0.39). A higher proportion also felt they were not respected (28% vs. 15%, p=0.09). 
Tertiary education being significantly associated with poorer health outcomes for rural 
individuals was an interesting finding and could be investigated further.
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5.5: Conclusion
In conclusion, there was no significant difference between urban and rural individuals in 
my study in relation to the magnitude of health outcomes while on their current 
methadone programme. However, factors influencing their health outcomes differed and 
were mainly associated with policy and service delivery within the urban and rural 
programmes. These differences should be considered within the respective programmes 
to inform policy development and service provision to maximise outcomes for 
individuals.
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Chapter 6
Measurement and comparison o f BB V Risk
In this chapter I report findings from the comparison of BBV risk between urban and 
rural methadone clients in my study while on methadone treatment, and the factors 
associated with risk in each group. I will be concentrating on risk associated with 
injecting, as methadone is prescribed in Australia for oral administration, and is thus 
expected to decrease injecting and associated BBV risk. However, studies have shown 
that methadone programme clients continue to inject other drugs while on treatment, 
and sometimes inject their methadone takeaways or illegally acquired methadone [126, 
163, 166, 181, 182, 192, 193]. These findings were supported in my study (Chapter 4). 
These injecting episodes while on methadone treatment could contribute to BBV risk. 
Differences in urban and rural areas in relation to socio-demographic characteristics, 
risk behaviours and methadone programme policy could also contribute to differences 
in magnitude and factors influencing BBV risk in the two areas.
Measurement of BBV risk was done by using the BBV TraQ instead of the OTI and the 
reasons for this are explained in this chapter. A descriptive comparison of the BBV 
TraQ and the OTI in relation to measurement of BBV risk is also presented.
The chapter is presented in two parts. Part A describes the measurement of BBV risk by 
the BBV TraQ and the OTI, and includes a descriptive comparison of the two 
questionnaires. Part B, reports findings of the measurement and comparison of BBV 
risk for the urban and rural study groups, and the factors associated with risk within the 
study groups.
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Part A: Description and comparison of BBV risk measurement by the 
BBVTraQ and OTI
6.1: Background
As noted in Chapter 1, a major objective of methadone treatment is to decrease the 
transmission of BBVs [44]. The BBVs I am interested in for the purpose of my study 
are HIV, HBV and HCV, as injecting drug use has been shown to be a major risk factor 
for transmission of these viruses [17]. HIV prevalence in Australia has been kept low 
amongst IDUs through the introduction of NSPs as a harm minimisation measure when 
HIV was discovered in the early 1980s [44], Australia is considered to be a low 
prevalence zone for HBV, with general population prevalence estimated to be less than 
two per cent [19]. The Australian prevalence of HBV has been estimated to be four 
times higher in IDUs as compared to the general population and different studies have 
showed varying prevalence between 2-30 per cent [19, 84, 194]. HBV transmission can 
still be a problem for IDUs in Australia even though prevalence is low and there is 
immunisation against it available, for reasons explained in Chapter 1 [38, 39, 194, 195]. 
HCV has been prevalent amongst Australian IDUs for many years, is considered to be 
more infectious and more readily transmitted through blood than HIV, and there is no 
immunisation against it [17, 24, 44], People can also be infected more than once as 
there are several genotypes of the virus [83]. Lack of knowledge of HCV aetiology and 
transmission until the late 1980s may also be responsible for the higher prevalence. 
Thus, most methadone clients are already HCV positive when they start on methadone 
treatment (as discussed in Chapter 2).
For the above reasons methadone treatment has been shown to be effective in 
preventing new infections of HIV and HBV (where prevalence is low) related to 
injecting, while it has not been as successful with HCV [24, 44, 55] . For HCV it may 
be effective in preventing further transmission and minimising re-acquisition of a new 
genotype.
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6.2: Measurement of BBV risk by the BBV TraQ
The BBV TraQ (Appendix 2, Part II) was developed with the primary purpose of 
having a standardised assessment tool to measure BBV transmission risk for HIV,
HBV and HCV. The secondary purpose for its development was to understand and 
determine risk practices associated with BBV transmission in order to enhance the on­
going development of preventive strategies. The BBV TraQ has questions relating to 
BBV risk alone and needs to be administered with other validated demographic 
questionnaires. It was developed to be used amongst persons who are considered to be 
current IDUs (defined as having injected drugs in the month prior to interview) [143],
The BBV TraQ measures risk in three domains: risk associated with injecting drugs, 
sexual behaviour and other skin penetration (OSP) practices, such as tattooing and body 
piercing. The BBV TraQ uses a numerical scale to measure risk and there arc four 
scores that can be calculated; risk scores for each of the three domains and a total BBV 
risk score, measured by combining the scores for the three domains. This can be done as 
the questionnaire has been shown to have internal validity and reliability for calculation 
of a score within each domain [196]. Individual and group mean scores can be 
calculated for the three risk domains and for total BBV risk. Risk is measured through a 
series of 34 questions: 20 in the injecting risk domain, eight in the sexual risk domain 
and six in the OSP risk domain. Each question can have a score from 0-5 depending on 
the frequency of the risk behaviour practiced; a higher score indicating greater 
frequency. Scores for an individual can range between 0-100 for injecting risk, 0-40 for 
sexual behaviour risk, 0-30 for OSP practice risk and 0-170 for a total BBV risk score. 
The higher the score the greater risk of BBV transmission.
The BBV TraQ takes into account protective behaviour that may be practiced to 
minimise risk related to injecting. There are nine out of the 20 questions in the 
injecting risk domain that have two parts to it. The first part measures the risk and the 
second part measures any protective behaviour practiced to minimise the risk. A 
combined score of these two parts is the score for the risk behaviour, taking into 
account the protective behaviour practiced. Sexual risk and OSP do not have specific 
items for protective behaviours.
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For the purposes of measuring injecting risk, the BBV TraQ can only be used with 
people who have injected in the month prior to interview; however this is not a 
requirement for measurement of sexual and OSP risk scores (C Fry, [Turning Point 
Drug and Alcohol centre, Fitzroy, Victoria], 1999 pers. comm., 13 November). As 
BBV risk includes injecting risk, total BBV risk score can only be calculated with a 
sample of persons who have injected in the month prior to interview. For injecting risk 
the questionnaire is thus specific to measuring whether or not a BBV risk has occurred 
while the person is injecting. A score of zero for injecting risk for an individual simply 
means that although the person has injected in the month prior to interview, there was 
no BBV risk while injecting.
6.3: Measurement of BBV risk by the OTI
The OTI is a validated questionnaire developed in response to a lack of consistency in 
the definition, measurement and evaluation of opioid treatment outcomes in the early 
1990s. The questionnaire provides a comprehensive and standardised tool for 
measurement of outcomes and evaluation of opioid treatment, both for clinical 
assessment and research purposes [120, 189].
The OTI was developed to be multi-dimensional to include the many facets of opioid 
dependence. It measures outcomes in five domains; Drug use, HIV risk taking 
behaviour, Social functioning, Criminality and Health. The GHQ is administered with 
the OTI to measure psychological adjustment [151]. In contrast, the BBV TraQ 
measures BBV risk only.
The OTI measures BBV risk in two domains; these being injecting risk and sexual risk. 
A total BBV risk score can be calculated by summing the scores of these two domains. 
Individual and group mean scores can be calculated for the two risk domains and for 
total BBV risk. There are six items to measure BBV risk from injecting practice and 
five items to measure BBV risk from sexual practice. Each item has five responses and 
is scored from 0-5. For injecting risk a person can have a score ranging from 0-30, for 
sexual risk from 0-25 and for total BBV risk, a score ranging from 0-55. Each of the 
risk domains have been validated to provide scores within the domain.
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6.4: Comparison of BBV risk measurement by the OTI and the BBV 
TraQ
Table 6.1 at the end of this section summarises the comparison of the two 
questionnaires.
6.4.1: Purpose of the two questionnaires
The primary purpose of the OTI BBV risk section is for use as a clinical assessment 
tool to measure and evaluate opioid treatment in relation to BBV risk behaviour 
change. A secondary purpose is for use in research for the measurement of BBV risk 
amongst relevant populations [189]. In comparison, the BBV TraQ is primarily used 
for measuring and identifying BBV risk for research purposes, and secondarily used to 
identify common BBV risk behaviours to assist with the development of relevant 
preventive strategies [143, 196].
Although the two questionnaires have a commonality of purpose, in that they can be 
used to measure BBV risk for research, the focus of measurement is different. The OTI 
BBV risk measurement section is termed the HIV risk taking behaviour section as it 
was specifically designed to measure behaviour of IDUs in relation to HIV 
transmission. At the time of development of the questionnaire, injecting drug use had 
emerged as a major BBV risk for HIV and this was used as the basis for BBV risk 
measurement in the OTI [197]. Emerging data at that time showed that transmission of 
HIV from IDUs to the general population through unsafe sexual practice was a risk as 
well. HIV transmission risk through sexual practice was therefore included in 
determination of total BBV risk [198, 199]. The BBV TraQ in comparison measures 
BBV risk associated not only with HIV, but also with HBV and HCV.
6.4.2: Comparison of domains and scales of measurement of the two 
questionnaires
The OTI measures BBV risk in two domains only, while the BBV TraQ measures risk 
in three domains. The two domains that the OTI measures risk in are injecting and 
sexual practices; the BBV TraQ measures risk in these two domains as well as with 
OSP. Apart from the difference in the number of domains within which BBV risk is 
measured, the two questionnaires are similar in relation to method of measurement.
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The time period of measurement of BBV risk for both the OTI and BBV TraQ is the 
month prior to interview. Both questionnaires use a numerical scale for measuring risk. 
Risk scores can be calculated within domains and a total risk score combines scores 
from all domains. A score of zero indicates no risk, while any score above zero 
indicates risk, and the higher the score the greater the risk. Group mean score can be 
calculated for the two domains (injecting and sexual risk) and a group mean score for 
total BBV risk. Thus method of measurement of BBV risk by the OTI is very similar to 
the BBV TraQ.
6.4.3: Administration and eligible populations for use of the two 
questionnaires
The OTI and BBV TraQ differ in mode of administration: the BBV TraQ is self- 
administered with an interviewer present, while the OTI is interviewer administered.
The OTI can be administered to two subpopulations to measure BBV risk. The first is 
those accessing opioid treatment, and the OTI is used to evaluate outcomes of 
treatment in relation to BBV risk behaviour change. Persons participating do not need 
to have injected in the month prior to interview. The second set is amongst people with 
BBV risk practices to measure risk at one point in time for research purposes [189]. In 
comparison, the BBV TraQ can only be administered to people who are current 
injectors and have had a history of injecting in the month prior to interview. It is used 
to research BBV risk behaviours amongst IDUs to assist with developing preventive 
strategies.
6.4.4: Measurement of BBV risk due to injecting
Measurement of BBV risk due to injecting by the OTI and the BBV TraQ differ. The 
OTI recognises the act of injecting as a BBV risk whether or not transmission risk has 
occurred during the process. Both injectors and non-injectors are therefore included in 
calculation of a BBV risk score due to injecting. A zero score only indicates that a 
person has not injected. The BBV TraQ measures BBV risk due to injecting only 
amongst current injectors. A zero score thus indicates that although a person has 
injected the process was not associated with a BBV risk. BBV TraQ risk scores reflect 
true BBV risk that may have occurred while injecting. To summarise, a zero OTI 
injecting risk score indicates that a person has not injected and thus has no BBV risk 
due to injecting; the BBV TraQ zero injecting score indicates that a person has not had a
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BBV risk while injecting. Another major difference between the OTI and the BBV 
TraQ in relation to the measurement of BBV risk due to injecting is that the BBV TraQ 
has included the practice of protective behaviours to minimise a BBV risk in its 
calculation.
The OTI measures BBV risk due to injecting that is specifically related to needle and 
syringe sharing, re-use and cleaning. The reason for this is that BBV risk measurement 
by the OTI is specific to HIV. At the time of development of the OTI, HIV 
contaminated blood had been shown to be transmitted effectively though sharing 
injecting equipment, and thorough cleaning of injecting equipment with bleach before 
re-use was being promoted to kill the virus and prevent transmission [197, 200]. The 
BBV TraQ measures BBV risks that the OTI measures, but also includes risk from other 
external factors associated with the process of injecting. These include risks associated 
with indirect blood contamination (such as the act of drawing up of drugs from a 
common container, sharing of tourniquets, cleaning of the injecting site, assistance from 
another injector). HBV and HCV have been shown to be effectively transmitted through 
indirect blood contamination in comparison to HIV [24, 44], As the BBV TraQ 
includes measurement of HBV and HCV transmission risk, these other risk factor 
measurements have been included in the questionnaire.
Measurement of BBV risk due to sexual practice is more similar between the OTI and 
BBV TraQ. For the BBV TraQ, sexual risk measurement is not dependent on whether a 
person has had a sexual encounter unlike injecting risk. For both questionnaires a zero 
score can indicate not having any sexual contact at all. The sexual risk section of the 
BBV TraQ does not measure protective behaviour practices as is done for injecting risk.
In summary, although the OTI and the BBV TraQ can both be used in research to 
measure BBV transmission risk, the two questionnaires achieve this differently. The 
questionnaires differ in terms of purpose, outcomes measures, population groups to 
which they can be administered to, and measurement of outcomes.
Table 6.1 summarises this comparison of the BBV TraQ and the OTI.
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Table 6.1: Comparison of the OTI and BBV TraQ measurement of BBV risk due to injecting
Characteristic BBV TraQ* OTI+
Purpose • Research tool to measure BBV risk • Research tool to measure HIV risk
• Tool to identify BBV risks to develop • Evaluation tool for opioid treatment to
strategies for prevention measure HIV risk behaviour change
Outcome measure • HIV, HBV, HCV risk behaviours • HIV risk behaviours
Target group • Current injectors (persons who injected • Persons on opioid treatment (for
in the month prior to interview) clinical assessment)
• Persons at risk of HIV transmission
Administration • Self-administered • Interviewer administered
Risk measurement • Month prior to interview • Month prior to interview
period
Measurement • Injecting practice • Injecting practice
Domains • Sexual practice • Sexual practice
• OSP risk
Measurement • Injecting risk score: 0-100 • Injecting risk score: 0-30
scores • Sexual risk score: 0-40 • Sexual risk score: 0-25
• OSP risk score: 0-30 • Total BBV risk score: 0-55 (sum of
• Total BBV risk score: 0-170 (sum of injecting and sexual risk scores)
injecting, sexual and OSP risk scores)
Measurement • Numerical rating scale; higher the • Numerical rating scale; higher the
method score greater the risk score greater the risk
Measurement of • Risk associated with direct blood • Risk associated with direct blood
risks contamination (needle sharing, re-use contamination (needle sharing, re-use
and cleaning) and cleaning)
• Risk associated with indirect blood
contamination (e.g. drawing up drugs,
cleaning injection site)
Measurement of • Yes (for injecting risk) • No
protective
behaviours
*  The Blood Borne Virus Transmission Risk Assessment Questionnaire 
*The Opiate Treatment Index
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6.5: Reasons for using the BBV TraQfor measurement of BBV risk
Based on the comparison of the two questionnaires, I chose the BBV TraQ over the OTI 
to measure and compare BBV risk between urban and rural methadone programmes in 
my study; specific reasons are detailed below.
• The BBV TraQ measures BBV risk related to HIV, HBV and HCV, while the OTI 
targets HIV risk specifically. As my study was aimed at measuring and comparing 
BBV risk due to injecting for HBV and HCV in addition to HIV, the BBV TraQ was 
the more appropriate instrument.
• The BBV TraQ includes measurement of external risk factors (indirect blood 
contamination) associated with the process of injecting, which have been shown to 
be effective in the transmission of HBV and HCV. This is in addition to direct risk 
factors such as sharing injecting equipment. The OTI only measures BBV risk 
associated with direct risk factors.
• The BBV TraQ measures actual BBV risk associated with injecting and does not 
take into account the process of injecting as a BBV risk, while the OTI does.
• The BBV TraQ takes into account protective behaviours that may have been 
practised while injecting, while the OTI does not. The OTI may therefore be 
overestimating risk by not accounting for protective behaviours practised.
For these reasons I considered the BBV TraQ to be a more specific and robust tool for 
measuring and comparing BBV risk in my study.
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Part B: Measurement and comparison of urban and rural BBV risk 
6.6: Analyses outline
Analysis to measure and compare BB V  risk between the two study groups was 
conducted at three levels. Figure 6.1 outlines the analyses plan and structure.
Figure 6.1: Analyses plan and structure
Level 1 analysis
Overall sample (N=l 18)
▼
Comparison o f urban/rural participants who injected 
while on treatment
Urban (N=62) Proportions of injectors/non-injectors Rural (N=56)
Factors associated with injecting
Those who did not inject in the 
month prior to interview, (n=57)
Those who injected in the month prior to interview (N=61)
Level 2 analysis Comparison o f urban/rural BB V risk amongst injectors
Urban (n=32a) Total BBV risk (group mean scores) Rural (n=28)
Injecting risk (group mean scores)
Sexual risk (group mean scores)
OSP risk (group mean scores)
Level 3 analysis Comparison o f urban/rural participants who injected 
with and without a BBV risk
Urban (n=32*) Proportions of Injectors with BBV risk (Yes/No) Rural (n=28)
No risk Risk Risk No risk
(n=12) (n=20) (n=19) (n=9)
Mean score comparison of injecting with BBV risk 
Factors associated with injecting with BBV risk
°  One missing value
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While methadone treatment aims to minimise risk of BBV transmission through risky 
injecting behaviour, it also aims to reduce other health problems associated with 
unhygienic and unsafe injecting practice (e.g. localised infections around the injecting 
site, collapsed veins and emboli) as described in Chapter 2. For this reason I started my 
analysis by comparing the risk of the physical act of injecting, amongst injectors and 
non-injectors in my two study groups in the month prior to interview. This analysis 
also identified factors significantly associated with injecting within the two study 
groups and examined if they differed. As the BBV TraQ does not include a question 
about whether a person had injected in the month prior to interview, the OTI drug use 
section was used to identify injectors and non-injectors in the study.
My second level of analysis measured and compared total BBV risk and BBV risk 
from the three domains between the two study groups using the BBV TraQ. This 
analysis was only amongst injectors and was done using total group mean risk scores, 
which included zero scores. The main comparison was for injecting risk, however, I 
also measured and compared risk from sexual practice and OSP and calculated total 
BBV risk contributed by the three domains. This was done to examine if total BBV 
risk for urban and rural clients could vary due to risk from exposures other than risky 
injecting practice. I also compared BBV risk for participants in my study to those of 
the BBV TraQ validation study.
The third level of analysis was amongst those who injected with a BBV risk (score>0) 
and had the following aims:
1) To compare proportions of injectors who injected with a BBV risk and without a 
BBV risk between urban and rural study groups.
2) To measure and compare the magnitude of BBV risk for those who injected with 
risk behaviour between urban and rural study groups.
3) To identify and compare the factors associated with injecting with a BBV risk 
between urban and rural study groups.
For the first aim, proportions of individuals who injected with BBV risk (risk score>0) 
and no risk (risk score= 0) were compared between the two study groups. For aim two, 
I measured and compared injecting risk mean scores for those who injected with risk 
behaviour (risk score>0) between the two study groups. For the last aim, I identified 
factors that were significantly associated with injecting with a BBV risk (risk score>0) 
within the two study groups and examined if these differed.
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By measuring and comparing proportions of injectors, factors significantly associated 
with injecting and factors significantly associated with BBV risk while injecting within 
the two study groups, I aim to make a useful contribution towards methadone treatment 
policy and service delivery within urban and rural areas to decrease BBV risk associated 
with injecting while on treatment.
6.7: Level 1 Analysis: Factors associated with injecting in urban and 
rural study groups
Fifty two per cent (n=61) of the total sample had injected in the month prior to 
interview. There was no significant difference between the proportion of injectors 
amongst urban and rural study groups (p=0.73), with 53 per cent (n=33) of urban 
participants and 50 per cent (n=28) of rural participants having injected in the month 
prior to interview. These results are presented in Table 6.2 and were also presented in 
Chapter 4, for comparison of current risk factors while on the current programme.
Table 6.2: Comparison of urban and rural proportions of injectors and non-injectors in the month 
prior to interview
Characteristic Total (N=118) 
n %
ACT (N=62)
n %
SNSW (N=56)
n %
p-value 
(Pearson X2)
Injectors 61 51.7 33 53.2 28 50.0
0.73
Non-Injectors 57 47.9 29 46.8 28 50.0
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Factors included in the analysis to identify significant associations with injecting in the 
two study groups were those that were identified in my rationale, through previous 
studies and differences identified between study groups in Chapter 4 (similar to 
potential factors associated with health outcomes). These were;
1) Sociodemographic characteristics:
age, gender, level of education, employment status, main income source in the six 
months prior to interview, prison history.
2) Current programme characteristics:
programme tier, length of time on current methadone programme, daily methadone 
dose, time taken to travel to dose, cost of travel to dose.
3) Programme policy and service delivery:
cost of methadone per week, access to routine takeaway doses, number of takeaway 
doses, having a case manager.
4) Risk factors while on the programme:
total number of other drugs used in the month prior to interview, living with 
someone who injects drugs.
5) Client programme satisfaction.
Methods used for this analysis were similar to those used to identify factors associated 
with health outcomes in the urban and rural study group and were explained in detail in 
the methods chapter (Chapter 3). In summary, univariate analysis was used to test 
associations of potential significant factors with injecting in each area at the p<0.10 
level. Significant factors were entered into multivariate regression models (backward 
stepwise elimination) to identify the combination of factors significantly associated 
(p<0.05) with injecting within each study group. Logistic regression was used for both 
univariate and multivariate analysis as the outcome was binary (i.e. injected or not).
Tables 6.3.a and 6.3.b present factors that were significantly associated (p<0.10) with 
injecting within the two study groups in this analysis. There were seven factors found 
to be significantly associated with injecting for urban individuals and four factors for 
rural individuals in the univariate analyses (p<0.10). Appendix 16 presents the complete 
univariate analyses done to test for associations between all potential factors and 
injecting within the two study groups.
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Table 6.3a: Factors significantly associated with injecting in the urban (ACT) study group 
(univariate analysis)
Factors
ACT (N=62)
n OR Cl p-value LR test 
(p-value)
Pseudo
R2
Total no. of other drugs used in 61* 2.43 1.43-4.12 0.001 NA 0.19the month prior to interview
Living with someone who injects
No* 37 1.00
Yes 13 8.07 1.56-41.73 0.01 NA 0.12
Total 50b
Main income in the last 6 months
Other* 43 1.00
Employment 18 3.28 0.99-10.84 0.05 NA 0.05
Total 61a
Case manager
No* 44 1.00
Yes 18 3.12 0.95-10.25 0.06 NA 0.04
Total 62
Time travelled to dose
< Ihr to 1 hr* 52 1.00
> Ihr 4 0.15 0.02-1.37 0.09 NA 0.04
Total 56c
Methadone dose ( mgs)
1-20* 10 1.00
21-40 14 6.00 0.89-40.31 0.07 0.55 0.06
41-60 11 3.33 0.60-18.54 0.17
61-80 10 2.00 0.33-11.97 0.45
81-100 8 1.60 0.24-10.81 0.63
>100 2 1.00 0.06-25.99 1.00
Total 55d
*  Reference category, a one missing value, 12 people lived alone or did not know if someone in their household 
injected,c six missing values, J seven missing values
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In the urban study group (as shown in Table 6.3a), those who used a greater number of 
drugs in the month prior to interview were almost two and half times more likely to 
have injected than those who did not (OR=2.43, Cl: 1.43-4.12, p=0.001), which could 
be expected. Individuals living with someone who injected drugs were eight times more 
likely to have injected than those who did not live with someone who injected drugs 
(OR=8.07, Cl: 1.56-41.73, p=0.01). This correlates with findings from other studies 
[185, 187, 201], Those whose main source of income was through employment were a 
little over three times more likely to have injected than those who had other sources of 
employment (OR=3.28, Cl: 0.99-10.84, p=0.05). This could either be due to not being 
able to make clinic or pharmacy dosing times or could be associated with having 
disposable income to spend on other drugs. Individuals with case managers were three 
times more likely to inject than those who did not have case managers (OR=3.12, Cl: 
0.95-10.25, p=0.06). This is most likely due to only high risk patients being allocated a 
case manager in the ACT (similar to contributing to poorer health outcomes). 
Interestingly the time travelled to dose being greater decreased the chances of injecting 
(OR=0.15, Cl: 0.02-1.37, p=0.09), but was marginally significant. This association is 
difficult to explain.
Methadone dose showed a linear relationship with injecting. There was a decreased risk 
of injecting with higher methadone doses (decreasing ORs as methadone dose 
increased). However, only one category was significantly associated with injecting 
(methadone dose 21-40mgs: OR= 6.00, Cl: 0.89-40.31, p=0.07). An LR test revealed 
that as a whole factor, methadone dose was not significantly associated (p=0.55) with 
injecting. This result may be due to the lower power of my study to pick up any 
significant associations.
The variance in injecting explained by each of these six factors was between 
4-19 per cent (as explained by the Pseudo R2), with number of other drugs used and 
living with someone who injected contributing the highest percentage.
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Table 6.3b: Factors significantly associated with injecting in the rural (SNSW) study group 
(univariate analysis)
Factors
SNSW (N=56)
n OR Cl p-value LR test 
(p-value)
Pseudo
R2
Total no of other drugs used in
the month prior to interview 56 2.60 1.47-4.58 0.001 NA 0.19
Living with someone who injects
No* 33 1.00
Yes 11 15.3 1.75- 0.01 NA 0.19
Total 44“ 8 134.87
Employment status
Unemployed* 13 1.00
Employed 10 0.08 0.01-0.56 0.01 0.06 0.11
Student 3 0.15 0.01-2.29 0.17
Other (pension, home duties, sick 30 0.30 0.07-1.31 0.11
leave)
Total 56
Programme Tier
Tier 1 * 27 1.00
Tier 2 13 0.26 0.06-1.07 0.06 0.15 0.05
Tier 3 16 0.46 0.12-1.61 0.22
Total 56
*  Reference category, NA: Not Applicable, a 12 people lived alone or did not know if  someone in their household
injected
For rural participants (as shown in Table 6.3b), of the four factors significantly 
associated with injecting in the month prior to interview, two were common to the urban 
study group. These were the total number of drugs used in the month prior to interview 
and living with someone who injected. Participants who used a greater number of other 
drugs in the month prior to interview were over two and half times more likely to inject 
(OR=2.60, Cl: 1.47-4.58, p=0.001), while those who lived with someone who injected 
were a little over 15 times more likely to have injected than those who did not 
(OR=15.38, Cl: 1.75-134.87, p=0.01). Like the urban area these associations could be 
expected. The other two factors significantly associated were employment status and 
programme tier, both of which had only one category significantly associated with 
injecting. Participants who were employed were less likely to inject than those who 
were unemployed (OR=0.08, Cl: 0.01-0.56, p=0.01). Those who were in Tier 2 were 
also less likely to inject than those in Tier 1 (OR=0.26, Cl: 0.06-1.07, p=0.06). LR tests 
showed that as whole factors employment status was significantly associated with 
injecting (p=0.06), while programme tier was not (p=0.15). The variance in injecting 
explained by each of these four factors was between 5-19 per cent.
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As there were common factors significantly associated with injecting within the urban 
and rural study groups in the univariate analysis, I combined the two study groups for 
the multivariate analysis and included all significant factors in the univariate analysis 
into one regression model. By doing this I was increasing the power to elicit significant 
associations that may have otherwise have been missed due to smaller sample size. 
Programme area (i.e. urban or rural) was included as a factor in the model to establish if 
being an urban or rural client significantly affected risk of injecting while adjusting for 
the other factors. Programme tier was entered into the model regardless of its level of 
significance in the univariate analysis as policy between tiers differed (as was done for 
health outcomes). Factors included in this multivariate analysis were programme area, 
programme tier, total number of other drugs used in the month prior to interview, living 
with someone who injected, main income source in the last six months, having a case 
manager, the time travelled to dose, and employment status. Significance level was set 
at p=0.05 as this was the final model.
Table 6.4 summarises the results of the multivariate analysis and the final combination 
of factors that were significantly associated with injecting in the month prior to 
interview. There were only 92 clients in this analysis. These were the number of 
participants who lived with someone who injected and could indicate whether they had 
injected or not in the month prior to interview.
Table 6.4: Combination of factors significantly associated with injecting in the combined sample 
(multivariate analysis)
Factor
Total sample (ACT and SNSW: n=92)
n OR Cl p-value
Total no. of other drugs used in the month
prior to interview 92 4.29 2.24-8.19 <0.0001
Living with someone who injects drugs
No* 23 1.00
Yes 69 23.80 4.08-138.91 <0.0001
Total 92
Main income in the last 6 months
Other* 68 1.00
Employment 14 7.86 1.71-36.24 0.01
Total 92
' Reference category, Pseudo R -  0.43
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The multivariate analysis determined three factors to be significantly associated with 
injecting in the month prior to interview (as shown in Table 6.4). These were the total 
number of other drugs used, living with someone who injected drugs, and main income 
source being employment. The odds of injecting were a little over four times greater 
amongst participants who used a greater number of other drugs in the month prior to 
interview (OR=4.29, Cl; 2.24-8.19, p<0.0001), almost 24 times greater amongst 
participants who lived with someone who injected drugs (OR=23.80, Cl: 4.08-138.91, 
pO.OOOl), and almost eight times greater amongst those whose main income source 
was employment (OR=7.86, Cl: 1.71-36.24, p=0.01). The confidence interval was quite 
wide for the OR associated with living with someone who injects and could either be 
associated with the small numbers in this group or a large variance in injecting. This 
combination of factors explained 43 per cent of variance in injecting in the month prior 
to interview for all participants in my study (pseudo R2=0.43). Interestingly being an 
urban or rural individual did not influence risk of injecting while on treatment.
I decided to explore if the effect of these three factors on injecting differed between 
urban and rural individuals, even though programme area was not a factor significantly 
associated with injecting. To do this, I used statistical methods to create interaction 
terms [157] between each of these factors and programme area (i.e. programme area and 
total number of other drugs used, programme area and living with someone who 
injected, programme area and main income source in the last six months prior to 
interview). These new interaction factors if significantly associated with injecting would 
indicate that there was a difference in effect of the factors on injecting for urban and 
rural individuals. The three factors significantly associated with injecting and the three 
new interaction factors were entered into the combined model. Programme area was 
also entered in the model (as this was the factor with which interaction was being 
determined). None of the interaction factors were significantly associated with injecting 
(p<0.05) (these results have not been tabulated). This suggests that there was no 
difference in the effect of the three factors on injecting between urban and rural 
individuals. The initial three factors still remained significantly associated with injecting 
and programme area continued to be not significantly associated.
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These results suggest that being an urban or rural client is not significantly associated 
with injecting while on methadone treatment. Factors that were associated with 
injecting were mainly influenced by clients’ circumstances (i.e. living with someone 
who injected and having employment as a main source of income). There may be a 
small influence of programme policy, in that use of greater number of other drugs could 
be related to not being able to access the dosing centre. This could also be affecting 
those employed as the dosing time may be inconvenient. Other factors related to policy 
such as programme tier or having a case manager did not influence risk of injecting.
6.8: Level 2 Analysis: Comparison of urban and rural BBV risk (Total 
BB V risk, Injecting risk, Sexual risk and OSP risk)
The BBV TraQ was used for the second level of analysis to measure and compare BBV 
risk between urban and rural study groups. Group means scores (including zero scores) 
were used to measure total BBV risk, injecting risk, sexual risk and OSP risk for urban 
and rural study groups, and t-tests were used to compare scores between the two study 
groups. As the BBV TraQ requires that injecting risk and total BBV risk be calculated 
only amongst current injectors, this analysis was only amongst participants who had 
injected in the month prior to interview (urban=33, rural=29). Although measurement 
of sexual risk and OSP risk does not need to be done only amongst injectors, I chose to 
measure it amongst injectors in my study, as I compared the results of my study to 
those of the BBV TraQ validation study which was conducted amongst injectors only. 
These results are presented in Table 6.5.
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Table 6.5: Group-mean scores comparison for BBV risk for urban (ACT) and rural (SNSW) study 
groups
Characteristics Overall sample 
(N=61)
ACT
(N=33)
SNSW
(N=28)
p-value 
(Pearson X2)
Total BBV risk
n 60a 32a 28
Mean score 14.20 12.75 15.85
SD 13.33 13.62 13.04 0.37
Range 0-65 0-65 0-45
Injecting risk
n 60a 32a 28
Mean score 6.70 5.78 7.75 0.42
SD 9.26 8.93 9.68
Range 0-42 0-42 0-38
Sexual risk
n 59b 32a 27a
Mean score 5.22 4.41 6.19 0.36
SD 7.37 6.20 8.58
Range 0-30 0-22 0-30
OSP risk
n 59b 32a 2T
Mean score 2.42 2.59 2.22 0.65
SD 3.13 3.66 2.41
Range 0-16 0-16 0-8
a One missing valuedtw o missing values
The overall total BBV risk score was 14.20 (SD 13.33), with the rural study group 
having a higher score than the urban study group, but this difference was not 
significant (rural: 15.85, SD 13.04; urban: 12.75, SD 13.62, p=0.37). The group mean 
scores for injecting was higher amongst rural participants but not significantly different 
to urban participants (rural: 7.75, SD 9.68; urban: 5.78, SD 8.93; p=0.42). Sexual risk 
was also higher for rural participants in comparison to urban participants but once 
again not significantly different (rural 6.19, SD 8.58; urban: 4.41, SD 6.20; p=0.36). 
OSP risk was slightly higher in urban participants, but not significantly different to 
rural participants (urban: 2.59, SD 3.66; rural: 2.22, SD 2.41; p=0.65). The range of 
scores for all four risk groups for rural participants was narrower than their urban 
counterparts.
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The total BBV risk score for both urban and rural individuals in my study was largely 
contributed through injecting and sexual risk practices. Injecting risk scores contributed 
the highest proportion towards total BBV risk scores overall as well as within urban 
and rural study groups, but was not much higher than the contribution made by sexual 
risk scores. OSP risk scores contributed to a smaller extent.
Not finding a significant difference between the two study groups in relation to 
injecting risk and total BBV risk could be due to there actually being no significant 
difference or a reflection of sample numbers. The study did recruit an adequate sample 
size to pick up a 20 per cent significant difference between mean scores for total BBV 
risk (required n=20 per study group) and injecting risk (n=24 per study group). The 
recruited sample size may, however, have been too small as the SDs used for sample 
size calculations (ACT 1993 study OTI injecting risk SDs) were quite small. These 
SDs may not have been truly representative of that expected in methadone clients who 
inject. SDs in my study for this group were found to be higher. I recalculated power to 
pick up a 20 per cent significant difference at the p<0.05 level using sample numbers 
and standard deviations from my study. For total BBV risk, the sample numbers 
recruited had only 40 per cent power to pick up a significant difference of 20 per cent 
at the p<0.05 level. For injecting risk, power to pick up a significant difference of 20 
per cent was 25 per cent at the p<0.05 level. Thus, sample numbers recruited into my 
study may have been too low to elicit significant differences between study groups for 
injecting and total BBV risk.
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6.8.1: Comparison of BBV risk scores in my study to BBV TraQ validation 
study scores
The group mean scores for total BBV risk and the three domains (injecting risk, sexual 
risk and OSP) in my study in comparison to the risk scores from the BBV TraQ 
validation study are outlined in Table 6.6 [143]. The mean scores for total BBV risk 
and injecting risk in the BBV TraQ validation study were much higher than the scores 
in my study. The scores for sexual risk and OSP were also higher. The higher injecting 
risk and total BBV risk is most likely due to the sample population of the BBV TraQ 
validation study being IDUs who were not on methadone treatment. This comparison 
provides further evidence that methadone treatment decreases the frequency of 
injecting, thus contributing to lower BBV risk. The lower sexual risk and OSP risk 
scores in my study population can not be explained.
Table 6.6: Comparison of BBV risk scores from current study to validation study of BBV TraQ
Characteristics ACT
(N=33)
SNSW
(N=28)
BBV TRAQ 1143]
Total BBV risk
n 32a 28 209
Mean score 12.75 15.85 29.41
SD 13.62 13.04 21.22
Injecting risk
n 32a 28 209
Mean score 5.78 7.75 16.11
SD 8.93 9.68 14.84
Sexual risk
n 32a 27a 209
Mean score 4.41 6.19 9.23
SD 6.20 8.58 9.67
OSP risk
n 32a 2 T 209
Mean score 2.59 2.22 4.16
SD 3.66 2.41 3.88
a One missing value
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6.9: Level 3 Analyses: Comparison of BBV risk due to injecting and 
identification of factors associated with a risk within the two study 
groups
Of the 61 participants who had injected in the month prior to interview, one participant 
in the urban study group did not indicate whether they injected with a BBV risk or not. 
This made the total sample size for this analysis 60, with 32 individuals in the urban 
group and 28 in the rural group. A large proportion of these individuals (64%, n=39) 
had injected with a risk (injecting risk score >0). Fifty one per cent (n=20) were urban 
and 49 per cent (n= 19) were rural. Of the 21 participants who did not have a BBV risk 
while injecting (injecting risk score=0), 57 per cent (n= 12) were urban and 43 per cent 
(n=9) were rural. These results were presented in Fig 6.1 in the Level 3 analysis section.
6.9.1: Comparison of proportions of urban and rural participants with BBV 
risk due to injecting.
Amongst participants who injected with a risk (injecting risk score >0), there was a 
slightly higher proportion of rural participants as compared to urban participants 
(rural=70%, urban=63%), but these proportions were not significantly different. These 
results are presented in Table 6.7.
Table 6.7: Proportions of urban and rural participants with and without BBV risk due to injecting
BBV risk 
due to
Total (n=61) ACT (n=33) SNSW (n=28) p-value 
(Pearson X2)
injecting n % n % n %
Yes 39 65.0 20 62.5 19 67.9
0.66
No 21 35.0 12 37.5 9 32.1
Total 60“ 100 32" 100 28 100
° One missing value
183
Chapter 6: Measurement and Comparison of BBV Risk
6.9.2: Comparison of urban and rural injecting risk scores for those who 
had a BBV risk while injecting
Group mean scores for injecting with a BBV risk (injecting risk scores>0) were 
compared for urban and rural participants using a t-test. These results are presented in 
Table 6.8. Mean scores were slightly higher for the rural group (rural: 11.42, SD 9.81; 
urban: 9.25, SD 9.81) but were not significantly different to the urban group (p=0.49). 
These mean scores were higher than the scores for all participants (injectors with and 
without risk, Table 6.4) as would be expected.
Table 6.8: Comparison of injecting risk scores for urban (ACT) and rural (SNSW) study groups
Characteristics Overall sample ACT injectors SNSW injectors p-value
with BBV risk with BBV risk with BBV risk (Pearson X2)
Injecting risk
0.49n 39 20 19
Mean score 10.30 9.25 11.42
SD 9.74 9.81 9.81
Range 1-42 2-42 1-42
These results indicate that there was no significant difference between the two study 
groups in relation to the proportions of urban and rural injectors who injected with a 
BBV risk. In addition, there was no difference detected in the magnitude of BBV risk 
due to injecting between study groups (as measured by the injecting risk score).
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6.9.3: Factors associated with BBV risk due to injecting17 within urban and 
rural study groups.
Whilst there was no significant difference between urban and rural participants in 
magnitude of BBV risk due to injecting, due to reasons explained in the rationale for the 
study and differences identified in Chapter 4, the factors influencing risk could differ (as 
with health outcomes). My analysis in this section aimed to identify factors that were 
significantly associated with injecting with a BBV risk for urban and rural individuals 
and compare them to determine if they differed. Differences identified in Chapter 4, and 
factors associated with BBV risk due to injecting identified in previous studies and in 
my rationale, were included in this analysis. These were the same factors used in the 
analysis to identify significant associations with injecting (Section 6.7). A few 
additional factors that could potentially influence injecting with a risk were included. 
These were frequency of injecting in the month prior to interview and participants self- 
reported HCV status.
The methods used for this analysis were similar to those used for the Level 1 analysis to 
identify factors associated with injecting and to identify factors associated with health 
outcomes'* (described in detail in Chapter 3). Linear regression was used in both the 
univariate and multivariate analysis as injecting risk was measured as a continuous 
variable.
Univariate analysis found that there were seven factors that were significantly 
associated with injecting with a BBV risk (p<0.10) for urban participants and three 
factors for rural participants. These results are tabulated in Tables 6.9a and 6.9b for 
urban and rural groups respectively. Appendix 17 details the complete univariate 
analysis.
17 BBV risk due to injecting = mean injecting risk scores>0 as measured by the BBV TraQ.
Lower BBV risk due to injecting = lower mean injecting risk scores.
Higher BBV risk due to injecting = higher mean injecting risk scores
I!< Univariate analyses were used to identify a subset o f factors significantly associated with BBV risk 
associated with injecting at the p<0.10 level. All factors significantly associated in this analysis were 
entered into multivariate linear regression models. Backward stepwise elimination was used to 
determine the final combination o f factors that were significantly associated (p<0.05) with injecting 
with a BBV risk within the two study groups.
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For urban participants, frequency of injecting in the month prior to interview, older age 
and being educated were significantly associated with lower BBV risk due to injecting 
(as ß coefficients were negative and p<0.01). Although frequency of injecting as a 
whole factor was significantly associated with decreased risk (LR test p=<0.0001), 
results showed that those who injected more (> once a week but < daily) had a slightly 
higher risk than those who injected less (weekly or less) (ß=-10.02, SE=4.60 vs. 
ß=-13.56, SE=4.53). This result is hard to explain, and it is possible that frequency may 
be associated with being a regular injector and thus being more prepared to practice safe 
injecting behaviours. Even though frequency of injecting was associated with lower risk 
those who injected more frequently had a slightly higher risk than those who injected 
less. Age had an inversely significant linear association with BBV risk due to injecting. 
Increasing age significantly contributed to lower risk (ß=-0.37, SE=0.27, p=0.04). Level 
of education as a whole factor also significantly lowered BBV risk due to injecting 
(p=0.10) and any level greater than Year 10 appeared to significantly decrease risk.
Being in programme Tier 2 was significantly associated with increased BBV risk due to 
injecting for urban clients (ß=6.38, SE=3.65, p=0.09). Although not significant, being in 
Tier 3 appeared to decrease risk (ß=-2.74, SE=3.54, p=0.44). As the LR test for 
programme tier showed that it was significant as a whole factor (p=0.05), these results 
suggest that as clients progressed through the programme tiers their risk decreased. 
Access to only up to two TAs was also significantly associated with increased BBV risk 
due to injecting (ß=6.93, SE=3.88, p=0.08). Although not significant, having more than 
two TAs decreased risk (ß=-2.57, SE=3.46, p=0.46). An LR test deemed number of TAs 
as a whole factor to be significantly associated with risk (p=0.07). This suggests that as 
the number of TAs increased the BBV risk due to injecting decreased. These significant 
associations with programme tier and number of TAs could be related as clients in the 
ACT have access to a greater number of TAs as they progress through tiers.
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Missing a greater number of methadone doses per week also had a linear association 
with BBV risk due to injecting amongst urban clients. As the number of doses increased 
(>2), BBV risk significantly increased (ß=7.49, SE=3.98, p=0.07). Although missing 
lower number of doses was not significantly associated in its own right (ß=0.81, 
SE=4.04, p=0.84), LR tests showed that as whole factor the number of doses missed per 
week was significantly associated with risk (p=0.07). This result suggests that as the 
number of missed doses increased, individuals experienced significantly higher BBV 
risk due to injecting. Participants who self-reported a positive HCV status were also just 
significantly more likely to have a BBV risk while injecting (ß=5.99, SE=3.48, p=0.10). 
The variance in BBV risk due to injecting contributed by each of the seven factors in the 
urban study group was between 6-24 per cent. Frequency of injecting contributed the 
highest percentage.
For rural participants the factors significantly associated with BBV risk due to injecting 
were similar to those for urban participants. Once again frequency of injecting was 
significantly associated with decreased risk. This association appeared to be stronger 
than elicited in urban clients as the ß coefficients were larger and the p-values smaller. 
Like the urban study group, greater frequency of injecting was associated with a slightly 
higher risk (weekly or less: ß=-25.61, SE=5.47; >weekly <daily: ß=-23.75, SE=5.80).
As with urban clients BBV risk due to injecting decreased with access to increased 
number of TAs per week. The difference in risk between access to up to two doses and 
greater than two doses was marked (ß=29.76, SE=8.02, vs. ß=-4.75, SE=3.21).
Although only one category of number of TAs (up to 2 doses) was significantly 
associated, LR tests showed the whole factor to be significantly associated with risk 
(p=0.0006). This association also appeared to be stronger than that elicited with urban 
clients. The reasons for these associations are most likely similar to those found in the 
urban study group. A lower daily methadone dose of 21-40mgs was significantly 
associated with increased BBV risk due to injecting (ß=8.30, SE=4.59, p=0.08). 
Methadone dose as a whole factor was shown to be significantly associated as a whole 
factor (LR test; p=0.05). It also had a linear association with risk. As the dose increased 
BBV risk due to injecting decreased. The variance in BBV risk due to injecting 
contributed from each of these factors was between 28-47 per cent. Frequency of 
injecting in the month prior to interview contributed to the highest percentage like the 
urban study group.
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As two of the three factors in the rural study group associated with BBV risk due to 
injecting (frequency of injecting in the month prior to interview and number of TAs per 
week) were common to the urban study group, I combined the two study groups into 
one sample for multivariate analysis. This was similar to the methods used to establish 
the combination of factors associated with injecting (Level 1 analysis, Section 6.7). All 
factors that were significantly associated in the univariate analysis in each study group 
were entered into the model. Programme area was entered into the multivariate model to 
examine if being urban or rural contributed significantly to risk. Programme tier was 
also entered into the model (for reasons explained previously).
Factors entered into the multivariate model were thus, programme area, programme tier, 
frequency of injecting in the month prior to interview, number of TAs per week, 
methadone dose, age, education level, missed doses, and self-reported HCV status. 
Linear regression analysis was used as the outcome was a continuous variable (BBV 
risk due to injecting as measured by mean injecting risk scores). Significance level was 
set at p<0.05 as this was the final model. The final combination of factors significantly 
associated with injecting with a BBV risk is presented in Table 6.10.
There were six factors that contributed significantly to BBV risk due to injecting in the 
final model. These were programme area, age, frequency of injecting, number of TAs 
per week, the number of missed methadone doses per week and methadone dose. 
Education level, programme tier and HCV self-reported status were no longer 
significantly associated.
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Table 6.10: Combination of factors significantly associated with injecting with a BBV risk for the 
combined sample (multivariate analysis)
Factor
Total sample (n=56)
n ß SE p-value LR test
Programme area
Urban 30
Rural 26 5.77 1.81 0 .003 NA
Total 56
Age (yrs) 56 -0.38 0.11 0.001 NA
Freq of injecting in the month prior to
interview
Did not inject* 0
Weekly or less 32 dropped
> weekly but <daily 18 1.48 1.93 0.45 < 0.0001
Once daily or > 6 16.94 2.74 < 0.0001
Total 56
Number of takeaway doses
None* 31
up to 2 doses 7 9.44 2.64 0 .001 < 0 .0001
> 2 doses 18 -2.95 1.89 0.13
Total 56
Missed doses
None* 12
up to 2 doses 20 2.13 2.43 0.39 0 .02
> 2 doses 24 5.09 2.17 0 .02
Total 60
Methadone dose (mgs)
1-20* 8
21-40 17 6.01 2.56 0 .02 0 .03
41-60 15 0.001 2.72 1.00
61-80 10 2.76 2.89 0.35
81-100 5 5.93 3.87 0.13
>100 1 0.60 6.51 0.93
Total 56
* Reference category, Adjusted R =0.62
Rural programme clients were significantly more likely to experience increased BBV 
risk due to injecting compared to urban programme clients (ß=5.77, SE=1.81, p=0.003). 
Older age continued to be significantly associated with lower risk (ß=-.038, SE=0.11, 
p=0.001). Increasing frequency of injecting in the month prior to interview was now 
significantly associated with increased risk as a whole factor (LR test, p=<0.0001), 
(unlike the univariate analysis which showed decreased risk), which could be expected. 
The number of TAs accessed per week was significantly associated as a whole factor 
(LR test, p=<0.0001) and increasing number of TAs significantly decreased risk.
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Increasing numbers of missed methadone doses per week continued to be significantly 
associated with increased BBV risk due to injecting (LR test, p=0.02). Methadone dose 
as a whole factor was significantly associated with increased risk (LR test, p=0.03). The 
lower (21-40mgs) and the higher spectrum of doses (81-100mgs) appeared to contribute 
to higher risk compared to doses in between. This combination of factors explained 62 
per cent of the variance in injecting with a BBV risk for my overall study sample.
6.10: Summary and discussion
In the descriptive comparison of the BBV TraQ and the OTI, the BBV TraQ was found 
to be more comprehensive in measuring BBV risk. The BBV TraQ was designed to 
measure BBV risk in relation to HIV, HBV and HCV, while the OTI only measured risk 
from HIV. The BBV TraQ also had the advantage of including protective measures 
practiced during injecting in the measurement of BBV risk. The OTI includes the 
physical act of injecting as a BBV risk whether risk behaviour has occurred or not. The 
BBV TraQ measures BBV risk from injecting only when risk behaviour has occurred; 
Non-injectors are thus not included in risk measurement by the BBV TraQ. The 
descriptive comparison showed that there were differences between the OTI and BBV 
TraQ in measurement of risk outcomes, but as done in my study the two questionnaires 
can be used complementarily.
In the first level of analyses, a little over half of the people in my study (52%) had 
injected in the month prior to interview. The proportions of injectors in the two study 
groups were similar (urban=53%, rural=50%, p=0.73). There were two common factors 
within the study groups that were significantly associated with injecting while on 
methadone treatment in the univariate analysis (living with someone who injected drugs 
and number of other drugs used in the month prior to interview). Multivariate analysis 
combining both urban and rural study groups showed that there were three factors 
significantly associated with injecting. These were the two common factors from the 
univariate analysis, and the main source of income in the six months prior to interview 
being employment. All three factors increased the risk of injecting for individuals while 
on treatment and all were factors external to the programme and not related to 
programme policy or service delivery. Interestingly, programme area and programme 
tier were not associated with injecting and the effect of the three significant factors on 
injecting did not differ between urban and rural study groups.
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In the second level of analyses, the two study groups did not differ in relation to 
magnitude of total BBV risk, BBV risk due to injecting, sexual or OSP practices. 
Although BBV risk due to injecting was found to be the main contributor towards total 
BBV risk in both study groups, risk from sexual behaviour contributed almost as much 
as injecting risk. It may be useful for methadone programmes to include routine 
education regarding BBV risk related to sexual practice as a part of the programme. In 
comparison to the risk scores of the BBV TraQ validation study, participants in my 
study had lower injecting risk scores. This finding supports the use of methadone 
treatment to decrease BBV risk from injecting. Risk from sexual practice and OSP 
were also lower; whether being on methadone assisted with this is uncertain. As the 
objective of my study was to concentrate on measurement and comparison of BBV risk 
due to injecting between study groups the rest of the discussion is in relation to 
injecting risk.
The third level of analyses, found that there was no difference between urban and rural 
study groups in the proportions of injectors who injected with a BBV risk, even though 
rural injectors had a higher proportion in this group (urban=63%, rural=68%, p=0.66). 
Similar to factors associated with injecting within study groups, univariate analysis 
showed that urban and rural study groups had common factors that were significantly 
associated with injecting with a BBV risk. Frequency of injecting in the month prior to 
interview and access to a lower number of TAs per week were found to be common 
factors associated with increased risk within both study groups. Multivariate analysis 
combining the two study groups showed that these factors continued to be significantly 
associated with increased BBV risk due to injecting. Other factors in the model that 
were significantly associated with increased risk were being a rural programme client, 
being of younger age, missing a greater number of methadone doses per week and 
having lower methadone doses.
Rural clients significantly having a higher BBV risk due to injecting in comparison to 
urban clients is an important finding, particularly as programme area did not influence 
the risk of injecting in the Level 1 analysis. This finding needs to be taken into account 
by methadone programme policy makers. Reasons for the increased risk should be 
determined and addressed within rural programmes. Younger age being associated with 
increased risk could be associated with younger people being known to practice more 
risky behaviours in general [201, 202],
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Frequency of injecting significantly contributing to increased BBV risk while injecting 
could be related to factors associated with injecting in the month prior to interview: i.e. 
living with someone who injected drugs and the number of other drugs used. These 
were common factors for both urban and rural individuals. Greater number of missed 
doses being associated with increased risk and a greater number of TAs being 
associated with decreased risk could be related to dosing access issues. Factors such as 
the cost of travel and restricted dosing times could influence access to dosing and the 
number of missed doses. Similarly, having a greater number of TAs per week could be 
associated with decreased BBV risk, as the number of missed doses would be 
decreased. These two factors may just be a surrogate of a higher risk group defined by 
access issues. Studies have shown that there is an association between methadone dose 
and expected outcomes of methadone treatment including retention [177]. Strain and 
colleagues studied the effect of low to moderate doses of methadone on opioid use 
while on treatment. They conducted a randomised, double-blind, placebo-controlled 
study amongst 247 opioid dependent individuals who were put into three groups and 
prescribed different stable daily doses (50, 20 or 0 mg per day). Only the 50mg 
treatment group showed a significantly reduced rate of opioid use (56.4% vs. 67.6% 
and 73.6% for the 20mg and Omg groups respectively; p < 0.05) [177]. Results in my 
study were similar and suggested that intermediary methadone doses (21-40 and 61- 
80mgs) contributed to lowest BBV risk due to injecting while on the programme.
6.11: Conclusion
A large proportion of methadone clients in my study continued to inject while on the 
programme. The proportions of urban and rural injectors were similar. The factors 
significantly associated with injecting were also similar for both study groups and the 
effect of the factors on injecting did not differ between study groups. All significant 
factors associated with injecting were external to the programme since they were related 
to client environment and behaviour (living with someone who injected, no. of other 
drugs used). In contrast, factors related to programme policy were the main factors that 
significantly influenced injecting with a BBV risk (number of TAs, methadone dose, 
and missed methadone doses). Rural programme clients were significantly more likely 
to inject with a BBV risk than urban programme clients. This could be related to access 
issues and could thus affect client behaviour (such as frequency of injecting).
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Chapter 7
Validity o f HCV self-reported status
In this chapter I address the second aim of my study. I report findings from my analysis 
aimed at determining the validity of HCV self-reported status for urban and rural IDUs 
by comparing self-report to serum antibody status (referred to as serology from here 
onwards). Validity measures used are explained in this chapter and summarised in 
Appendix 1. Serology was done at the time of interview through a finger prick blood 
spot (as described in Methods, Chapter 3) and used as the gold standard to establish true 
HCV status of participants. HIV self-report validity was used as a comparator. Validity 
of HCV and HIV self-reported status was measured for the overall sample and 
compared between urban and rural study groups.
In this chapter I also report findings from analysis conducted to identify factors 
significantly associated with HCV status as determined by serology. I also examined if 
significant risk factor associations established with HCV serological status differed to 
that elicited through serology. These analyses were done for the whole sample 
combining urban and rural study groups. Reasons for this were explained in the 
methods chapter; Chapter 3.
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7.1: Background
HCV has emerged as a major health issue amongst IDUs as it is mainly transmitted 
through blood. Research findings published prior to commencement of my study, 
suggested that the validity of HCV self-reported status is poor [56, 57, 88-90]. Results 
of the NSW methadone injectors study in 1999 suggested that validity of HCV self- 
report was also poor among rural IDUs ( as described in Chapter 2) [58, 192]. The 
research opportunity presented through my PhD allowed me to investigate the validity 
of HCV self-report amongst IDUs further.
As discussed in my rationale and literature review (Chapters 1 and 2), HCV continues to 
be highly prevalent amongst IDUs [24, 44], This was supported from results in my 
study (Chapter 4). Although IDUs should practice safe injecting behaviours to minimise 
BBV transmission risk and other harms associated with injecting, my results suggest 
that risky behaviours while injecting continue to occur (Chapter 4). Accurate knowledge 
of HCV status amongst IDUs may promote safer injecting behaviour and thus decrease 
the chances of HCV transmission. Accurate knowledge of status may also assist with 
seeking treatment, support services, and making relevant work choices. In addition,
HCV self-report has been used as the indicator of HCV status in research to identify risk 
factors associated with HCV. It is thus important for self-reported status to be accurate 
for research integrity.
Many studies have shown that methadone programme clients continue to inject drugs 
while on treatment [14, 81, 126, 203], In my study approximately 50 per cent of 
participants had injected in the month prior to interview (Chapter 4). Of the 64 rural 
individuals in the NSW methadone injectors study, 73 per cent (n=47) were on 
methadone treatment [58]. Most people on methadone are also HCV positive from their 
previous injecting careers when they access treatment (as discussed in Chapter 2). A 
study in Australia conducted between January 2002 and June 2003, examined HCV 
sero-prevalence amongst 178 IDUs receiving opioid replacement therapy. HCV 
prevalence was found to be 75 per cent [45] Another study in 1995 amongst 116 
methadone clients in one clinic in New Zealand, found that HCV antibodies were 
detected in 84 per cent of the sample [14]. A US study in 2001, found 87 per cent of 
methadone treatment clients to be HCV positive [204]. These rates are similar to those 
amongst IDUs not in methadone treatment [17, 20].
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7.2: Validity measures used to establish accuracy of HCV and HIV self- 
reported status
Validity measures are used to establish the accuracy of a screening test. Screening tests 
are used as early detectors of markers of a disease or the disease itself. If a positive 
screening test has good accuracy, then a person with a positive test has a high likelihood 
of having the markers of the disease or early stages of the disease itself. Conversely if a 
negative screening has good accuracy then a person with a negative test will most likely 
not have the disease [79, 205]. Epidemiological validity measures examine the 
reliability of a screening test to detect early markers of disease and minimise the need to 
conduct complicated or invasive diagnostic tests unless indicated. In my study, HCV 
and HIV self-reported status were demarcated as the screening tests. Their validity was 
tested against HCV and HIV serological status, which were the gold standards used to 
indicate true disease.
As was done in Chapter 2 ,1 used sensitivity, specificity, PPVs and NPVs, PLRs and 
NLRs to measure the validity of HCV self-reported status as an accurate indicator of 
true HCV status. Sensitivity, PPV and PLR measure the validity of positive self-reports, 
while specificity, NPV and NLR measure the validity of negative self-reports. PLRs and 
NLRs are newer validity measures and test the odds of a correct self-report in people 
with HCV and without HCV, thus combining the effect of sensitivity and specificity 
[205]. As Likelihood ratios (LRs) combine sensitivity and specificity measurements, 
they are dependent on the magnitude of these measures. As LRs are ratios, they have an 
added advantage of not being dependent on disease prevalence in the population.
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7.3: HCV and HIV self-reported and serological status
Overall, 91 per cent of the sample provided a self-reported status for HCV. There was a 
higher proportion of urban participants providing a report, but this difference was not 
significant (urban=94%, n=58; rural=88%, n=49; p=0.35). The number of participants 
who provided self-reports for HCV and HIV are presented in Table 7.1. For HIV, 92 per 
cent of the overall sample provided a self-report. A higher proportion of urban 
participants provided a report, once again this difference was not significant 
(urban=95%, n=59; rural=88%, n=49; p=0.19).
7.1: Number of self reports (HCV and HIV) provided for whole sample and the two study groups
ACT SNSW Total p-values
Self-report (N=62) (N=56) (N=118) (Pearson X2)
n % n % n %
HCV
Provided* 58 93.5 49 87.5 107 90.7 0.35
Not provided+ 4 6.5 7 12.5 11 9.3
Total 62 100.0 56 100.0 118 100.0
HIV
Provided* 59 95.2 49 87.5 108 91.5 0.19
Not provided* 3 4.8 7 12.5 10 8.5
Total 62 100.0 56 100.0 118 100.0
*  Results=positive, negative, don't know
* Results=m is sing, no previous test
As shown in Table 7.2, a large proportion (98%, n=l 15) of the overall sample agreed to 
have a finger prick blood test done for HCV and HIV serology. There were similar 
proportions in the urban and rural study groups (urban=97%, n=60; rural=98%, 0=55;
p=1.00).
Table 7.2: Serology testing for HCV and HIV in urban and rural study groups
Serology (HCV & 
HIV)
ACT
(N=62)
SNSW
(N=56)
Total
(N=118)
p-values 
(Pearson X2)
n % n % n %
Yes 60 96.8 55 98.2 115 97.5
1.00
No 2 3.2 1 1.8 3 2.5
Total 62 100.0 56 100.0 118 100.0
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7.3.1: Previous serological testing for HCV and HIV
Table 7.3 presents the numbers of urban and rural people who stated they were 
previously tested for HCV and HIV. Overall, 92 per cent (n=108) stated they were 
previously tested for HCV. Of these, 95 per cent of urban individuals (n=59) said they 
were previously tested as compared to 88 percent of their rural counterparts (n=49); this 
difference was not significant (p=0.19). For HIV, 94 per cent (n=l 11) of the overall 
sample stated that they were previously tested. Like HCV, urban individuals were more 
likely to have been tested as opposed to rural individuals (urban 98%, n=61; rural 89%, 
n=50), but once again this difference was not significant (p=0.10). There was a small 
proportion of people who did not know whether they had been tested previously for 
both HCV and HIV. There were more rural than urban people in this category.
Table 7.3: Previous serology testing for HIV/HCV for the overall sample and the two study groups
Previously tested
ACT
(N=62)
SNSW
(N=56)
Total 
(N=l 18)
p-values 
(Pearson X2)
n % n % n %
HCV
Yes 59 95.2 49 87.5 108 91.5 0.19
No 2 3.2 2 3.6 4 3.4
Don’t know 1 1.6 5 8.9 6 5.1
Total 62 100.0 56 100.0 118 100.0
HIV
Yes 61 98.4 50 89.3 111 94.1 0.10
No 0 0.0 2 3.6 2 1.7
Don’t know 1 1.6 4 7.1 5 4.2
Total 62 100.0 56 100.0 118 100.0
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7.3.2: HCV and HIV self-report
Although self-reports were collected for HCV, HIV, HBV and Hepatitis A Virus 
(HAV), only results for HCV and HIV self-report are presented as these were the BBV 
of interest for this research question. In addition, serology testing was available only for 
these two viruses. Table 7.4 presents results of self-reported status for HCV and HIV. 
Overall, of those who provided a self-report for HCV (n=107), 71 per cent (n=76) 
reported a positive status. There was no significant difference between urban and rural 
self-reports (p=0.64), even though rural individuals reported a higher percentage of 
positive self-reports (rural 76%, n=37, urban 67%, n=39). Similar but smaller 
proportions of participants in both study groups reported not knowing their status.
Overall, 108 participants provided a self-report of HIV status. Of these 98 per cent 
(n=106) reported their status to be negative. All urban individuals (n=59) reported their 
status to be negative, while two rural individuals reported their status as unknown.
Table 7.4: HCV and HIV status as per self-report
Self-reported status
ACT
(N=62)
SNSW
(N=56)
Total 
(N=l 18)
p-values 
(Pearson X2)
n % n % n %
HCV
Positive 39 67.2 37 75.5 76 71.0 0.64
Negative 16 27.6 10 20.4 26 24.3
Don’t know 3 5.2 2 4.1 5 4.7
Total 58" 100.0 49b 100.0 107c 100.0
HIV
Positive 0 0.0 0 0.0 0 0.0 0.12
Negative 59 100.0 47 95.9 106 98.1
Don’t know 0 0.0 2 4.1 2 1.9
Total 59d 100.0 49* 100.0 108f 100.0
Three no previous test and one missing value, b seven no previous tests, c ten no previous tests and one 
missing value, J one no previous test and two missing values, e six no previous tests and one missing 
value, *seven no previous tests and three missing values
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7.3.3: HCV and HIV serology
Of 115 blood samples collected, there were five (2 urban and 3 rural) that did not yield a 
result (due to a poor sample). Table 7.5 outlines the results of HCV and HIV serology 
for the overall sample, and urban and rural study groups. Overall, of 110 individuals for 
whom serology was available 69 per cent (n=76) tested positive for HCV. A higher 
proportion of rural people tested positive as opposed to urban (rural=76%, urban=63%), 
but this was not significantly different (p=0.16).
For those for whom serology was available for HIV (n=l 10), all urban participants 
tested negative (n=57). All but one rural individual tested negative. This individual had 
an indeterminate result. The result was cross-checked with the person’s self-report to 
see if they had reported their status as unknown. The indeterminate result had been 
reported as a negative self-report. As I did not know the identity of participants it was 
impossible to contact this person to be retested, and the result was recorded as 
indeterminate for the purposes of the study.
Table 7.5: HCV and HIV status as per serology
Serology Result
ACT
N=62
SNSW
N=56
Total
N=118
p-values 
(Pearson X2)
n % n % n %
HCV *’ +
Positive 36 63.2 40 75.5 76 69.1 0.16
Negative 21 36.8 13 24.5 34 30.9
Total 57* 100.0 53b 100.0 110d 100.0
HIV * +
Positive 0 0.0 0 0.0 0 0.0 0.48
Negative 57 100.0 52 98.1 109 99.1
Total 57* 100.0 52c 100.0 109e 100.0
ACT: two not tested, three poor samples, + Rural: one not tested, two poor samples, one indeterminate 
a five missing values, b three missing values, c four missing values, d eight missing values e nine missing 
values
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7.4: Validity of HCV and HIV self-report
In order to calculate validity of HCV and HIV self-report, only positive and negative 
self-reports and serological results were used. Self-reports where status was reported as 
unknown, serology results that were indeterminate and missing (including persons who 
were not tested and poor blood samples) have been excluded.
7.4.1: Validity of HCV self-report (comparison of HCV self-reported status 
to serological status)
Table 7.6 represents a two by two table of positive and negative HCV self-reports 
tabulated against HCV serological results for the overall sample and the two study 
groups. Overall, there were 94 participants for whom both HCV serological and self- 
reported status were available (of 102 participants who provided self reports and 110 
participants who had serology done). Of these, 50 were urban individuals and 44 were 
rural individuals. This formed the sample for which validity of HCV self-report was 
calculated. Of the 94 individuals, 74 (79%) provided a correct self-report (positive and 
negative). Fifty per cent (n=37) were urban and fifty per cent (n=37) were rural.
Table 7.7 presents the results of validity measurement of HCV self-reported status.
Table 7.6: Cross tabulation of HCV positive and negative self-reports and serology
HCV
self-reports
ACT (n=50) 
Sero +ve Sero -ve
SNSW (n 
Sero +ve
=44) 
Sero -ve
Total (n 
Sero +ve
=94) 
Sero -ve
Self-rep +ve 27 8 31 3 58 11
Self-rep -ve 5 10 4 6 9 16
Total 32 18 35 9 67 27
Table 7.7: Comparison of HCV self-report validity between study groups
Validity Overall sample Urban (ACT) Rural (SNSW) p=value
measure measure (Cl) measure (Cl) measure (Cl)
Sensitivity 0.87 (0.76-0.94) 0.84 (0.67-0.95) 0.89 (0.73-0.97) 0.73
Specificity 0.59 (0.39-0.78) 0.56 (0.31-0.80) 0.67 (0.30-0.93) 0.69
PPV 0.84 (0.73-0.92) 0.77 (0.60-0.90) 0.91 (0.76-0.98) 0.19
NPV 0.64 (0.43- 0.82) 0.67 (0.38-0.88) 0.60 (0.26-0.89) 1.00
PLR 2.12 (1.34-3.38) 1.90 (1.11-3.25) 2.66(1.05-6.75) 0.53
NLR 0.23 (0.11-0.45) 0.28 (0.11-0.70) 0.17(0.06-0.48) 0.48
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Sensitivity of self-report for the overall sample indicated that 87 per cent of the 
participants who actually had HCV had reported a positive status. The rural study group 
had higher sensitivity than the urban study group, but the difference between the two 
study groups was not significant (urban=84%; rural= 89%; p=0.73). The PPV for the 
overall sample indicated that 84 per cent of participants who reported a positive self- 
report were correct. The rural study group had a higher PPV than urban study groups, 
but the difference was not significant (urban= 77%; rural=91%; p=0.19). For the overall 
sample, the PLR indicated that participants with HCV were 2.12 times more likely to 
report a positive status as opposed to those without HCV. Again the rural study group 
had a higher PLR, but the difference between the groups was not significant 
(urban=1.90, rural=2.66; p=0.53). These results measured the validity of HCV positive 
self-reports and indicate that over 80 per cent of the sample was sure of their HCV 
positive status. Rural individuals were more likely to report their status correctly.
Specificity of HCV self-report for the whole sample was relatively low at 59 per cent. 
This indicated that only 59 per cent of the sample who reported their status as negative 
actually did not have HCV. The specificity for the urban study group was relatively 
lower than the rural study group, but the difference was not significant (urban=56%; 
rural=67%; p=0.69). The NPV indicated that only 64 per cent of all participants who 
reported a negative status were correct. The urban study group had a higher proportion 
of correct negative self-reports than the rural study group in this instance, but this 
difference was not significant (urban=67%; rural=60%; p=1.00). The NLR indicated 
that the likelihood of a negative self-report in persons who were HCV positive in 
comparison to those who were HCV negative was approximately one in four (0.23). 
This is quite a high proportion of incorrect negative self-reports. The likelihood was 
higher for urban participants in comparison to rural, but were not significantly different 
(0.28 vs. 0.17, p=0.48). These results measured the validity of HCV negative self- 
reports and indicate that validity was quite poor.
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7.4.2: Validity of HIV self-report (comparison of HIV self-reported status 
with serological status)
For HIV, of 106 individuals who provided positive or negative self reports and of 109 
individuals who had positive or negative serology, 97 had both available (54 urban and 
43 rural). Of these 97 individuals, all (both urban and rural) reported their negative 
status correctly. These results indicate that validity of HIV self-reported status was high 
and accurate amongst participants in my study.
7.5: Duration between last serological test and validity of HCV self- 
reports
As information regarding the time of last serological test was collected in the study, I 
conducted further analysis to examine if the duration between last serological tests for 
study participants affected validity of HCV self-reported status. Duration since last 
serological test could affect validity of negative self-reports particularly, as a person 
may have had a risk exposure and seroconverted since the last test. The window period 
for seroconversion from time of exposure for a HCV serum antibody test (anti-HCV 
EIA-3) to be positive is between 1-3 months (mean=2.2 months). Lower validity of 
negative self-reports in my study could thus be related to seroconversion since the last 
test if it was done more than three months prior to self-report in my study. Duration of 
time since last test could also affect validity of positive self-reports through bias related 
to recall of test result. Analysis to examine if duration since last serological test was 
related to validity of self-report was done for the overall sample and compared for urban 
and rural study groups. These results are presented in Table 7.8.
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Table 7.8: Duration between current self-report and last stated serology
Self-report N Mean time since last 
serology (Yrs)
SD (yrs) Range (Yrs)
Correct -i-ve self-report
Overall 58 6.2 3.9 0.2-14.1
ACT 27 7.2 3.9 0.3-14.1
SNSW 31 5.2 3.6 0.2-12.6
Correct -ve self-report
Overall 16 1.1 1.3 0.1-3.9
ACT 10 0.9 1.2 0.1-3.9
SNSW 6 1.5 1.4 0.2-3.3
Incorrect +ve self-report
Overall 11 8.3 5.1 0.5-15.3
ACT 8 8.0 5.9 0.5-15.3
SNSW 3 9.0 3.0 6.5-12.3
Incorrect -ve self-report
Overall 9 1.0 0.8 0.3-2.1
ACT 5 1.1 0.9 0.3-2.0
SNSW 4 0.8 0.9 0.3-2.1
There was a total of 58 participants who had provided a correct positive self-report. The 
mean time since their last serological test was just over six years (74 months). The 
range was large with serological testing having been done from between two months to 
14 years prior to self-report in my study. The mean time for last serological test for rural 
individuals was almost two years less than for urban individuals (urban=7.2 years, 
rural=5.2 years). This shorter mean time could be associated with greater validity of 
positive self-reports (sensitivity, PPV and PLR) for rural individuals.
For the 16 participants who had correct negative self-reports, the mean time from last 
serology was just over one year (13 months) with a range of 1 month to 4 years. This 
mean time was much less than that related to correct positive self-reports. The mean 
time since last serology for urban individuals was a little over six months less than their 
rural counterparts (urban=0.9 years, rural=1.5 years). This could be associated with 
urban participants having a higher number of correct negative reports reflected in the 
higher NPV (urban= 67%, rural= 60%).
205
Chapter 7: Validity o f  HCV self-reported status
Although urban participants had a higher NPV, the proportion who reported their status 
as negative but truly did not have HCV (specificity) was lower than that of rural 
participants (urban=56%, rural=67%). This is also reflected in the incorrect positive 
self-reports, where there was a higher number of urban individuals (urban=8, rural=3). 
Even though urban individuals had poorer specificity, for those who had an incorrect 
positive self-report their mean time since last serology was a year shorter than that of 
their rural counterparts (urban=8.0, rural=9.0).
Overall, there were nine participants who provided incorrect negative self-reports. The 
mean time between the last serological tests and the incorrect negative self-reports 
provided at the time of my study was one year with a range between three months to 
two years. Validity of negative self-reports (specificity, NPV and NLR) was quite poor 
for both urban and rural individuals. This may be associated with seroconversion since 
their last serological test. For all participants with incorrect negative reports, the time 
between last serological tests and self-reports in my study was greater than three 
months. The number of urban and rural individuals who provided incorrect negative 
self-reports did not differ greatly (urban=5, rural=4). This is reflected in the sensitivity 
of HCV self-report, where although rural participants had a higher sensitivity, the 
difference was not great (urban=84%, rural=89%). The mean time between last 
serological tests and incorrect negative self-reports for urban and rural individuals was 
also not very different (urban=l.l years, rural=0.8 years).
These results suggest that the duration between a person’s last serological test and 
providing a correct HCV self-report could potentially influence validity of self-report. 
Shorter time frames between last serological test and self-report appeared to provide 
better validity of self-report. Rural individuals had shorter mean time-frames and this 
may be reflected in them having better validity of HCV self-report (both positive and 
negative). Other factors influencing validity of self-report could be the knowledge that 
HCV prevalence is high amongst IDU, which could be associated with the higher 
validity of positive self-reports, whilst the high HCV incidence in IDU could be related 
to poor validity of negative self-reports.
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7.6: Factors significantly associated with HCV status identified through 
serology and comparison to those identified through self-reported status
This analysis aimed to identify factors significantly associated with HCV status (as 
diagnosed through serology) in my study. It also compared significant risk factor 
associations determined through HCV serology to those elicited through self-report to 
examine if they differed. Factors tested for their association with HCV serology and 
HCV self-report were those identified as possible risk factors in the methods chapter 
(Chapter 3). These factors included sociodemographic characteristics, previous and 
current risk factors, and relevant current methadone programme characteristics. Urban 
and rural samples were combined for these analyses as validity of HCV self-reported 
status was not different between the two study groups, and for reasons explained in the 
methods chapter (Chapter 3). Only sample results that were positive or negative were 
included in the analysis.
7.6.1: Factors significantly associated with HCV status as determined 
through serology
Univariate analyses were conducted to establish a subset of factors significantly 
associated with HCV serological status at the p<0.10 using Pearson’s X2 tests. These 
were entered into a stepwise (backward elimination) multiple regression model to 
establish the final combination of factors significantly associated with HCV serological 
status at the p<0.05 level (as this was the final model). Logistic regression analysis was 
used as the outcome of interest (HCV serological status) was a binary variable
Tables 7.9a and 7.9b present results of the univariate analyses. Table 7.9a presents 
sociodemographic factor associations with HCV serological status while Table 7.9b 
presents associations of previous and current risk factors, and relevant current 
methadone programme characteristics with HCV serological status.
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Table 7.9a: Sociodemographic factors associated with HCV serological status (univariate analysis)
Factor
HCV
(n=3
n
-ve
4)
%
HCV +ve 
(n=76)
n %
Total
(n=110)
n %
p-values 
(Pearson X2)
Age group
<20 0 0.0 1 100.0 1 100.0 0.02
20-29 years 12 46.2 14 53.8 26 100.0
30-39 years 17 37.0 29 63.0 46 100.0
40 + 4 11.4 31 88.6 35 100.0
Total 33* 30.6 75“ 69.4 108b 100.0
Gender
Male 18 28.6 45 71.4 63 100.0 0.54
Female 16 34.0 31 66.0 47 100.0
Total 34 30.9 76 69.1 110 100.0
Education level§
< YrlO 3 11.1 24 88.9 27 100.0 0.03
Year 10 12 48.0 13 52.0 25 100.0
Year 12 7 36.8 12 63.2 19 100.0
Tertiary 10 27.8 26 72.2 36 100.0
Total 32b 29.9 75* 70.1 107c 100.0
Employment status
Unemployed 8 33.3 16 66.7 24 100.0 0.97
Employed 7 28.0 18 72.0 25 100.0
Student 1 25.0 3 75.0 4 100.0
Other (pensioners, sick leave, home 
duties) 18 31.6 39 68.4 57 100.0
Total 34 30.9 76 69.1 110 100.0
Main income in the last 6 months
Paid employed (part time/full-time) 8 33.3 16 66.7 24 100.0 0.80
Other (pension, student, home duties) 26 30.6 59 69.4 85 100.0
Total 34 31.2 75* 68.8 109* 100.0
* Mutually exclusive categories, a one missing value, b two missing values, c three missing values
Sociodemographic factors significantly associated with HCV serological status in the 
univariate analyses were age group of study participants and level of education. HCV 
prevalence was statistically significantly higher in the 30-39 years and >40 year age 
groups (p=0.02). Individuals who had only completed year 10 and those who had a 
tertiary education also had significantly higher HCV prevalence in comparison to other 
education levels (p=0.03). Gender, current employment status and main source of 
income in the last six months were not significantly associated with HCV serological 
status.
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Table 7.9b: Previous and current risk factors and relevant current methadone programme 
characteristics associated with HCV serological status (univariate analysis)
Factor
HCV -ve  
(n=34)
HCV +ve 
(n=76)
Total
(n=110) p-values 
(Pearson X2)
n % n % n %
Ever injected methadone
Yes 17 23.6 55 76.4 72 100.0 0.04
No 16 43.2 21 56.8 37 100.0
Total 33" 30.3 76 69.7 109“ 100.0
Previous imprisonment
Yes (n=53) 11 20.8 42 79.2 53 100.0 0.03
No 22 40.0 33 60.0 55 100.0
Total 33“ 30.6 75“ 69.4 108b 100.0
MTP in prison (n=53)
Yes 9 36.0 16 64.0 25 100.0 0.02*
No 2 7.1 26 92.9 28 100.0
Total 11 20.8 42 79.2 53 100.0
Injected in prison (n=53)
Yes 3 21.4 11 78.6 14 100.0 1.00*
No 8 20.5 31 79.5 39 100.0
Total 11 20.8 42 79.2 53 100.0
Tattooed in prison (n=53)
Yes 1 8.3 11 91.7 12 100.0 0.42*
No 10 24.4 31 75.6 41 100.0
Total 11 20.8 42 79.2 53 100.0
Programme area (urban or rural)
Urban (ACT) 21 36.8 36 63.2 57 100.0 0.16
Rural (SNSW) 13 24.5 40 75.5 53 100.0
Total 34 30.9 76 69.1 110 100.0
Living with someone who injects 
drugs (n=94)
Yes 7 33.3 14 66.7 21 100.0 0.73
No 20 29.4 48 70.6 68 100.0
Total 27 100.0 62 100.0 89c 100.0
Routine takeaways
Yes 22 35.5 40 64.5 62 100.0 0.24
No 12 25.0 36 75.0 48 100.0
Total 34 30.9 76 69.1 110 100.0
Case manager
Yes 16 28.1 41 71.9 57 100.0 0.50
No 18 34.0 35 66.0 53 100.0
Total 34 100.0 76 100.0 110 100.0
* Fishers exact test, ° one missing value, b two missing values,c five missing values
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Previous and current risk factors, and relevant current methadone treatment programme 
characteristics established as being significantly associated with HCV serological status 
in the univariate analyses were; having injected methadone, previous incarceration, and 
methadone treatment in prison. HCV prevalence was significantly higher amongst 
individuals who had ever injected methadone and were previously imprisoned (ever 
injected methadone: p=0.04, previously imprisoned: p=0.03). Methadone treatment in 
prison was significantly associated with lower HCV prevalence (p=0.02). Interestingly, 
having injected or being tattooed in prison was not significantly associated with HCV 
serological status. Programme area, living with someone who injected drugs, access to 
routine TAs and having a case manager were also not significantly associated with HCV 
serological status (p<0.05).
Factors found to be significantly associated with HCV serological status in the 
univariate analyses were entered into a multiple regression model. Table 7.9c (next 
page) presents the results of this analysis and the final combination of factors 
significantly associated with HCV serological status. This analysis had a sample size of 
n=53, as it only included people who had been in prison. Of the five factors entered in 
the multiple regression model, one factor was dropped due to collinearity (previous 
imprisonment). Of the remaining four factors, being on methadone treatment in prison 
and education level remained significantly associated with HCV serological status and 
had a protective effect.
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Table 7.9c: Factors significantly associated with HCV serological status (multivariate analysis)
Factors
All participants (N=53 )
n OR Cl p-value LR test 
(p-value)
MTP in prison
No* 28
Yes 25 0.11 0.02-0.74 0.02 NA
Total 53
Education level§
< YrlO* 12
Year 10 15 7.84-09 9.98‘l0-6.17^8 <0.001 0.03
Year 12 7 8.82'09 8.06'10-9.64'08 <0.001
Tertiary 19 dropped
Total 53
' Mutually exclusive categories, * Reference category, A 5 missing values, Pseudo R = 0.39
Individuals who had methadone treatment in prison were 10 times less likely to be HCV 
sero-positive compared to those who were not on treatment (OR=0.11, 0=0.02-0.74, 
p=0.02). Education level as a whole factor remained significantly associated with HCV 
serological status (LR test: p=0.03).
Having completed Year 10 and Year 12, had a highly significant protective effect with 
individuals in this group less likely to be HCV sero-positive (Year 10: OR= 7.84-09, 
CI=9.98'10-6.17'08, p=<0.001; Year 12: OR=8.82'09, CI=8.06‘10-9.64 08, p=<0.001).
Having ever injected methadone remained marginally significantly associated with 
HCV serological status. The odds of being HCV sero-positive for those who had ever 
injected methadone was five times greater than those who had not injected methadone 
(OR=5.28, CI=0.91-30.72: p=0.06).
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7.6.2: Comparison of factors significantly associated with HCV self-reported 
status and serological status
Univariate analyses to identify significant associations of possible risk factors with 
HCV self-reported status were also conducted, to examine if the associations differed to 
those established with HCV serological status. Tables 7.10a and 7.10b present results of 
this analysis. Table 7.10a presents sociodemographic factor associations, while Table 
7.10b, presents associations of previous and current risk factors, and relevant current 
methadone programme characteristics with HCV self-reported status.
Table 7.10a: Sociodemographic factors associated with HCV self-reported status (univariate 
analysis)
Factor
HCV -ve  
(n=26)
HCV +ve 
(n=76)
Total
(n=102) p-values 
(Pearson X2)
n % n % n %
Age group
<20 0 0.0 1 100.0 1 100.0 0.004
20-29 years 12 44.4 15 55.6 27 100.0
30-39 years 13 29.5 31 70.5 44 100.0
40 + 1 3.4 28 96.6 29 100.0
Total 26 25.7 75* 74.3 101* 100.0
Gender
male 13 22.4 45 77.6 58 100.0 0.41
female 13 29.5 31 70.5 44 100.0
Total 26 25.5 76 74.5 102 100.0
Education level8
< YrlO 6 21.4 22 78.6 28 100.0 0.69
Year 10 5 25.0 15 75.0 20 100.0
Year 12 3 17.6 14 82.4 17 100.0
Tertiary 11 31.4 24 68.6 35 100.0
Total 25“ 25.0 75’ 75.0 100b 100.0
Employment status
unemployed 4 16.0 21 84.0 25 100.0 0.57
employed 6 33.3 12 66.7 18 100.0
student 1 20.0 4 80.0 5 100.0
Other (pensioners, sick leave, home 
duties) 15 27.8 39 72.2 54 100.0
Total 26 25.5 76 74.5 102 100.0
Main income in the last 6 months
Paid employed (part time/full-time) 9 47.4 10 52.6 19 100.0 0.02
Other (pension, student, home duties 17 20.7 65 79.3 82 100.0
Total 26 100.0 75“ 100.0 101“ 100.0
'  Mutually exclusive categories, a one missing value, b two missing values
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Table 7.10b: Previous and current risk factors and relevant current methadone programme 
characteristics associated with HCV self-reported status (univariate analysis)
Factor
HCV
(n=2
-ve
6)
HCV +ve 
(n=76)
Total
(n=102) p-values 
(Pearson X2)
n % n % n %
Routine takeaways
Yes 20 35.7 36 64.3 56 100.0 0.009
No 6 13.0 40 87.0 46 100.0
Total 26 25.5 76 74.5 102 100.0
Ever injected methadone
Yes 16 22.5 54 77.1 70 100.0 0.51
No 9 29.0 22 71.0 31 100.0
Total 25* 24.8 76 75.2 101“ 100.0
Previous imprisonment
Yes (n=53) 9 17.3 43 82.7 52 100.0 0.06
No 16 33.3 32 66.7 48 100.0
Total 25* 25.0 75' 75.0 100b 100.0
MTP in prison (n=53)
Yes 5 20.0 20 80.0 25 100.0 0.72*
No 4 14.8 23 85.2 27 100.0
Total 9 17.3 43 82.7 52* 100.0
Injected in prison (n=53)
Yes 2 12.5 14 87.5 16 100.0 0.70*
No 7 19.4 29 80.6 36 100.0
Total 9 17.3 43 82.7 52' \00.0
Tattooed in prison (n=53)
Yes 1 7.1 13 92.9 14 100.0 0.09*
No 9 23.1 30 76.9 39 100.0
Total 10 18.9 43 81.1 53 100.0
Area (urban or rural)
Urban (ACT) 16 29.1 39 70.9 55 100.0 0.37
Rural (SNSW) 10 21.3 37 78.7 47 100.0
Total
Living with someone who injects 
drugs (n=94)
26 25.5 76 74.5 102 100.0
1.00“Yes 4 20.0 16 80.0 20 100.0
No 14 23.7 45 76.3 59 100.0
Total 18 22.8 61 77.2 79c 100.0
Case manager
Yes 10 18.9 43 81.1 53 100.0 0.11
No 16 32.7 33 67.3 49 100.0
Total 26
TT.
25.5 76 74.5 102 100.0
* Fishers exact test, a one missing value, b two missing values,L fifteen missing values
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As can be seem from Table 7 .10a the two sociodemographic factors that were 
significantly associated with HCV self-reported status were age group and main income 
source in the six months prior to interview (age group=0.0004; main income: p=0.02). 
Age group was also associated with HCV serological status, but main income source 
was not. Similar to the association with HCV serological status, HCV self-reported 
prevalence was statistically significantly higher in the 30-39 years and >40 year age 
groups (p=0.004). HCV self-reported prevalence was statistically significantly higher 
amongst those whose main source of income in the last six months was not through paid 
employment (p=0.02). Education level, although significantly associated with HCV 
serological status, was not associated with HCV self-reported status. Gender and 
employment at the time of interview were not significantly associated with HCV self- 
reported status. This was similar to the association found with HCV serological status.
Of previous and current risk factors, and relevant current methadone programme 
characteristics, only one factor was significantly associated with HCV self-reported 
status as presented in Table 7.10b. This factor was whether or not individuals had 
access to routine TAs (p=0.009). HCV self-reported prevalence was statistically 
significantly higher amongst those who did not have access to routine TAs. This 
association did not exist with HCV serological status.
Having injected and being tattooed in prison, programme area, living with someone 
who injected drugs and having a case manager were factors that were not significantly 
associated with HCV self-reported status (p>0.05). This is similar to the association 
found with HCV serological status. There were three other factors significantly 
associated with HCV serological status: previous imprisonment, having been on 
methadone treatment in prison and having injected methadone. Previous imprisonment 
was marginally significantly associated with HCV self-reported status (p=0.06). The 
other two factors were not.
These results suggest that risk factors associated with HCV serological status and self- 
reported status vary. This could affect the validity of studies conducted to identify risk 
factors associated with HCV status.
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7. 7: Summary and discussion
HCV antibody positivity amongst methadone clients in my study (69%) was within the 
range of that found in other Australian studies conducted amongst IDUs (65-90%) [20, 81, 
82]. It was lower than that found in the Australian study amongst 178 IDUs receiving 
opioid replacement therapy between January 2002 and June 2003 (75%) [45]. It was also 
lower than the other two validity studies of HCV self-reported status conducted amongst 
methadone treatment clients (UK=84% and US=89%) [56, 57]. HCV positivity for rural 
individuals in my study (76%) was higher than that found amongst rural participants in the 
NSW methadone injectors study (65%) [58]. In comparison, less than one per cent in both 
study groups was HIV positive, which suggests that methadone continues to be effective in 
preventing HIV transmission. All but one participant who had serology done for HIV in my 
study were negative, but it was disturbing to note that some (even though numbers were 
small) were unsure whether they had been previously tested for HIV.
There were a few important sociodemographic characteristics, risk factors and programme 
related characteristics that were significantly associated with being HCV serological status. 
Individuals with a secondary school education (Year 10 and 12) and individuals who were 
on methadone treatment in prison were significantly less likely to be HCV sero-positive. 
Ever having injected methadone being marginally significantly associated with higher HCV 
sero-prevalence is an important finding for policy makers to consider. The marginality of 
the results may be due to a small sample size.
Validity measurements for the whole sample and for the two study groups suggested that a 
correct positive self-report in people with HCV was more likely than a correct negative 
self-report in people without HCV. This result could be a reflection of knowledge that 
prevalence of HCV amongst IDUs is high, rather than knowledge of actual positive status. 
The proportion of incorrect negative self-report was quite high and was more likely than 
incorrect positive self-report. Validity of self-reported status for rural people being better 
than for urban people (even if not statistically significant) may be a reflection of some rural 
programme management characteristics (such as every client being allocated a case 
manager and having access to their methadone prescriber on a monthly basis if they 
wished). Validity measurements in my study were compared to those calculated for the 
studies reviewed in Chapter 2 [56-58, 88, 89]. This comparison is presented in Table 7.11.
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Validity of positive self-report in my study was relatively high and compared well with 
the first five studies reviewed in general. It was very comparable to the two studies 
amongst methadone clients in the US and UK, and higher than that of the rural 
methadone injectors study. Validity of negative self-reports in my study was relatively 
low and validity results were comparable to the NSW rural methadone injectors study.
The sensitivity and PPVs were greater than 75 per cent in my study and in four of the 
six studies reviewed [56, 57, 89, 90]. The NSW prisoners and rural methadone 
injectors’ studies had values lower than this. Results from my study and reviewed 
studies where sensitivity was greater than 75 per cent, suggest that people who were 
actually HCV positive are more likely to report their status correctly. However, this still 
leaves 10-40 per cent of a high risk population for HCV unaware of their correct 
positive status. The low validity of positive self-report in the NSW prison study and 
rural methadone injectors study also raises some doubt as to the robustness of positive 
self-report [58, 88]. Whether the low values are just an artefact of those particular 
studies or whether they are a true reflection of the validity of positive self-report can 
only be determined by further research. It is difficult to compare the PLRs, as these 
were not calculable for two of the studies. From results where they were calculable, the 
PLRs were higher in the studies that had higher sensitivity. This suggested that the 
likelihood of correctly self-reporting a positive status while actually positive as 
compared to when actually negative is quite high. The PLR in my study was more 
comparable to that of the NSW rural methadone injectors study. These results suggest 
that validity of positive HCV self-reported status is relatively good, but due to lower 
validity in some studies, it should be investigated further.
There was a small proportion of people in my study who reported their positive status 
incorrectly (reported positive while serologically negative). It is highly unlikely that a 
person who was serologically positive could test negative the next time. Serological 
tests to establish HCV status are conducted through identifying antibodies against the 
virus. Twenty five per cent of persons exposed may clear the virus, but antibodies still 
remain in the system [17]. Thus conversion from a positive HCV antibody test to a 
negative one is highly unlikely. These people, who are actually negative but think they 
are positive, may face unnecessary stigmatisation and discrimination in society due to 
inaccurate knowledge of status.
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Results from testing validity of negative HCV self-reported status in my study and for 
the six studies reviewed suggested that it was poor. The NPVs were low for all studies 
and particularly so for the two methadone treatment programme studies in the US and 
the UK [56, 57]. These results were comparable to my study. The NLR for four of five 
the studies where it was calculable were also comparable to my study [56, 57, 89, 90]. 
The NLR for the rural methadone injectors study was much greater in comparison. It 
indicated that the likelihood of a negative self-report in persons who were HCV positive 
in comparison to those who were HCV negative was approximately three in four (0.74) 
as compared to one in four (0.23) in my study. Although, the specificity for four of five 
studies reviewed where it was calculable was greater than 80 per cent, the specificity for 
the rural methadone injectors study and my study were lower than 60 per cent. The low 
NPVs and the relatively high NLRs in all studies (particularly the rural methadone 
injectors’ study) suggest that negative HCV self-reported status is not a good indicator 
of a truly negative status. This may relate in part to the high HCV incidence amongst 
IDU and testing intervals being longer than the window period for seroconversion. The 
lower specificity in my study and the NSW rural injectors study suggested that validity 
of negative self-reports in these studies were poorer than the other five studies.
Since the commencement of my PhD in 2000 and data collection in 2002, there were 
two more studies conducted in the US investigating the accuracy of HCV self-reported 
status amongst IDUs [206, 207]. The first study by Schlicting and colleagues was 
conducted in 2003, amongst 653 IDUs who were part of a project designed to evaluate 
the effectiveness of a needle exchange programme in decreasing BBVs. The researchers 
used similar methodology to my study and tested the validity of self-reported HCV 
status, by calculating the sensitivity and specificity of self-report against serology (as 
the gold standard) [206]. They also calculated the validity of HAV and HBV self- 
reported status. Of the 653 participants, 558 had serology for HCV. Of these, 74 
individuals self-reported as being HCV positive (13%), but serology found 293 
individuals to be positive (53%). The sensitivity of HCV self-report was reported as 24 
per cent, while specificity was reported at 98 per cent. The sensitivity from this study 
was much lower than my study and the other six studies reviewed. The specificity was 
much higher than my study but within the range of that found in the other studies.
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The second study was conducted in 2005 by Weaver and colleagues, and assessed 
prevalence of HCV self-report versus serology amongst 276 methadone treatment 
clients in a clinic in Richmond, Virginia [207], A self-administered questionnaire was 
used to gather information regarding HCV self-reported status, knowledge about risk 
factors for transmission, treatment options, and interest in receiving more information. 
Of the 276 clients in the clinic, 200 completed the questionnaire and provided a self- 
reported status for HCV. The self-reported prevalence of HCV was found to be 34 per 
cent. When a chart review of serological status was done for all 276 clinic clients at the 
clinic, it was found that HCV prevalence was 70 per cent. These results need to be 
interpreted with caution as self-reported status for 76 clients was not available and 
hence not included in calculation of self-reported HCV prevalence (as they had not 
participated). They were, however, included in the estimates of HCV serological 
prevalence. Actual numbers of participants who reported their status correctly (positive 
or negative) were not presented in published findings. Thus, validity of self-reported 
status (sensitivity and specificity) could not be calculated. As the findings from this 
study are not comparable to mine, they will not be considered in my conclusions and 
recommendations.
Results from my study suggest that validity could be affected by the duration between 
last serological tests and provision of self-reports in my study. This may particularly 
have affected validity of negative self-reports as seroconversion may have occurred 
since the last serological test. The mean time since last serological test to provision of 
incorrect negative self-reports was greater than the mean time of two months required 
for seroconversion. This, however, cannot be taken to be the conclusive reason for poor 
validity of negative HCV self-report. Even if this were the case, it implies that there 
may not be sufficient knowledge or awareness on the part of the individual to have 
practiced safe injecting behaviour or to seek another test when a risk exposure occurred.
The validity of rural participants HCV self-report being greater than that of urban (even 
if not significantly different), may also be associated with mean time since the last 
serological test. Results suggest that rural participants had shorter mean times than their 
urban counterparts since their last serological test.
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The comparison of significant associations of risk factors related to HCV serological 
status and self-reported status showed that different risk factors emerged as being 
significantly associated with HCV status. This is an important issue and needs to be 
examined further as many studies use self-reported status to identify risk factors 
associated with HCV.
7.8: Conclusion
My research investigating the validity of HCV self-reported status has indicated that 
validity of self-report is poor amongst IDUs, who are a high-risk group for HCV 
transmission. The results supported limited findings from previous studies and need to 
be investigated more conclusively.
For individuals in my study it appeared that duration between last serological test and 
provision of self-report may be related to validity of self-reported status. This indicates 
the need for better testing criteria and education strategies to seek testing when 
appropriate. It would be useful to investigate reasons for inaccurate knowledge of HCV 
status to enable development of targeted strategies to improve validity. Very little is 
also known about whether or not validity of self-reported status influences risk 
behaviour and further research towards this may be warranted.
It was reassuring that HIV seroprevalence was almost zero and that validity for both 
positive and negative self-reports was close to 100 per cent. This indicated a very 
accurate knowledge of status amongst people in my study. The applicability and 
adaptability of HIV education strategies to improve knowledge about HCV could be 
reviewed and considered.
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Chapter 8
Major findings, policy implications and recommendations
In this chapter I bring together the results of my study to draw out possible policy and 
service delivery implications for urban and rural methadone treatment programmes and 
for improving knowledge of HCV status amongst IDUs. A major strength of this study 
is the use of primary data collected from urban and rural methadone clients.
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8.1: Background
Research from overseas and Australia has shown that rural populations can have poorer 
general health outcomes due to access, cost, and confidentiality issues associated with 
health service provision and delivery (as discussed in Chapters 1 & 2). There has been 
limited research comparing outcomes for urban and rural people on methadone 
treatment and whether differences in urban and rural health service provision can affect 
the outcomes. Two recent studies have shown that rural IDUs and entrants to 
methadone treatment have greater injecting risks and poorer access to harm 
minimisation services [67, 141]. This could impact on outcomes for urban and rural 
people on methadone treatment. Literature reviewed suggests that there has been 
limited evaluation of outcomes of methadone treatment policy and service delivery (as 
opposed to effectiveness of methadone treatment) and basically no research at all to 
compare urban and rural outcomes.
Reviewing the history, development and the delivery of methadone treatment in 
Australia revealed that programmes can be subject to jurisdictional differences. Health 
service structure in Australia comprises of the Commonwealth and State health systems, 
with policy development being the responsibility of the Commonwealth Government 
and service delivery being the responsibility of State and Territory Governments. Based 
on this structure, there are policy structures and guidelines in place to ensure that the 
philosophy and goals of methadone treatment are met by all programmes; however, 
level of service provision and delivery can differ between jurisdictions. This has both 
advantages and disadvantages. As an advantage, methadone treatment provision and 
delivery can be tailored according to individual and community needs within urban and 
rural areas. As a disadvantage, methadone programmes may be given lower priority in 
areas where resources are stretched.
Transmission of HCV amongst IDUs in Australia continues to occur even with 
availability of harm minimisation services (as discussed in Chapter 1 and 2). Previous 
available research amongst at-risk groups (such as IDUs, prisoners and methadone 
treatment clients) suggests that knowledge of HCV status was poor (as discussed in 
Chapter 2 and 7). This lack of accurate knowledge may affect HCV transmission risk 
and treatment seeking behaviour amongst IDUs and research that uses HCV self- 
reported status as an indicator of HCV status.
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For these reasons, I aimed to compare health outcomes and BBV risks due to injecting 
for urban and rural people on methadone treatment to determine if they differed. I also 
aimed to identify the factors influencing these outcomes and whether they were 
associated with programme policy and service delivery within the areas. Validity of 
HCV self-reported status for urban and rural IDUs was also examined.
8.2: Major findings, policy implications and recommendations
Results from my study indicated that there were differences in policy and service 
delivery of methadone treatment in the ACT and SNSW. These differences may have 
influenced health outcomes and BBV risk due to injecting for urban and rural 
individuals in my study. Validity of HCV self-reported status was also found to be poor. 
Results suggested that it was better for rural IDUs in comparison to their urban 
counterparts. In the following sections, I summarise the major findings, discuss possible 
policy implications and put forward some recommendations.
8.2.1: Programme management and service delivery differences between 
urban and rural study groups and implications for policy
Evaluation and comparison of the urban and rural methadone programmes in my study 
indicated that the programmes within the two areas reflected the policy and service 
delivery arrangements of the Australian health structure. Both programmes used the 
four guiding principles (availability, access, acceptability, and quality of care) outlined 
in the National Policy on Methadone Treatment as the basis for treatment provision 
[13]. In terms of availability both programmes had a combination of public and private 
services. The services included medical assessment on entry to the programme and 
access to regular reviews. Both programmes catered for treatment of clients on different 
tiers of the programme, and in general seemed to be acceptable to clients. There 
appeared to be an accepted level of quality of care in relation to provision of 
information and ensuring client confidentiality.
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Results in Chapter 4 indicated that urban and rural individuals did not differ in relation 
to individual characteristics such as sociodemographics, previous drug use, BBV risk 
factors and previous methadone treatment history. Study groups differed, however, in 
relation to aspects of service provision and delivery. This may have contributed to 
differing levels of availability and access, and may have influenced acceptability and 
quality of care within the two programmes. These differences may have also affected 
health and BBV risk outcomes for individuals in the two areas.
Differences between programme policy and service delivery affecting availability and 
access for the two study groups were reflected in differences in costs associated with 
treatment and access to support services within the programmes. For example, provision 
of private methadone treatment services (Tier 3) for the two programmes differed.
Tier 3 rural clients had to negotiate these services directly with GP prescribers rather 
than being registered through the Area programme, unlike Tier 3 urban clients. This 
difference had implications for Tier 3 rural clients in relation to cost of GP prescriber 
appointments and access to support services (such as case managers and counselling), 
which were organised through the programme for Tier 1 and Tier 2 clients. Tier 1 and 
Tier 2 rural clients were also bulk-billed through the Medicare system for their medical 
care and had routine access to case managers.
Programme policy in relation to access to dosing facilities was also different for urban 
and rural study groups. For urban clients who dosed through the public system (Tier 1) 
there was only one public dosing centre available in the ACT. Urban clients who had to 
travel for longer than one hour to dose being significantly more likely to inject was 
possibly related to this. For rural clients, although there were eight public dosing centres 
to cater for wider population spread; seven of the eight were based in CHCs. This may 
have compromised confidentiality of clients which was reflected in smaller proportions 
of rural participants stating that they perceived their confidentiality was maintained. 
Poorer availability of services may have been a reason for rural clients being 
significantly more likely to pay more than $5.00 for travel expenses to dose. The 
increased cost of travel may also be associated with poorer confidentiality reflected in 
clients travelling to dosing centres further away where they would be anonymous to the 
local community. Cost of methadone was also significantly different for urban and rural 
clients who dosed privately through community pharmacies (Tier 2 and Tier 3). Most 
rural clients paid greater than $15.00.
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Some policy and service delivery differences were in favour of rural clients (e.g. case 
managers for all Tier 1 and 2 clients), while others were in favour of urban clients (e.g. 
TA for clients in all Tiers). All Tier 1 and 2 rural clients had access to case managers, 
whilst only urban clients with complicated treatment needs had access to case managers. 
Rural clients in Tier 1 and Tier 2 also had the option to see their prescribers at shorter 
intervals if they wished, as prescriber appointments were available at monthly intervals 
as opposed to three monthly for urban clients. Even though not statistically significant, 
these differences may have resulted in a higher proportion of rural clients achieving the 
outcomes against the reasons for which they had accessed their current programme, and 
having greater validity of HCV self-reports as compared to urban clients.
A programme policy in favour of urban clients was that clients in all tiers had access to 
TAs dependent on their stability. In comparison, only rural clients in Tier 2 and 3 had 
access to TAs; clients in Tier 1 did not have access to any TAs regardless of stability. 
This may have been associated with rural individuals using a greater number of other 
drugs and injecting more frequently (in the month prior to interview) being significantly 
more likely to have poorer health outcomes and increased BBV risk respectively.
The two study groups also differed significantly in relation to reasons for accessing the 
programme and referral sources. Based on these reasons, urban and rural programmes 
could identify treatment needs of their IDU populations and tailor their programmes 
accordingly. Programmes should also be flexible to adapt to changing needs, which 
should be reviewed periodically. The differences also suggest the need for individual 
goal setting and case management within programmes to maximise outcomes for the 
individual client as well as the programme.
Overall, only 39 per cent of individuals in my study stated they were immunised against 
HBV, with rural people significantly less likely to have been immunised than urban 
clients (p=0.01). This could be a reflection of poorer access to these services in rural 
areas. The NHMRC has identified IDUs as a high risk group for HBV immunisation, 
but these results suggest that this service is not being delivered through either 
programme. Methadone treatment programmes need to consider routine provision of 
HBV vaccination to clients to minimise transmission and to decrease the risk of co­
morbidities with HCV.
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Results from my study suggest that programme policy and service delivery differed 
between the urban and rural study group. This may have impacted on availability 
access, acceptability and quality of care for urban and rural individuals in these 
programmes. These differences could influence outcomes of methadone treatment 
differently for urban and rural individuals. Based on these findings, I put forward my 
first two recommendations for Australian methadone programme policy makers.
Recommendation 1:
Methadone programmes should regularly evaluate needs of urban and rural 
clients to assist with relevant policy development and service delivery. This 
should be done to maximise the outcomes achieved for people on methadone.
Recommendation 2:
HBV immunisation strategies for IDUs should be reviewed (particularly for rural 
IDUs). Methadone treatment programmes should consider providing HBV 
vaccination to all clients as part of the treatment programme.
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8.2.2: Comparison of health and BBV risk outcomes for urban and rural 
study groups and implications for programme policy
There was no significant difference between urban and rural study groups in relation to 
the magnitude of health outcomes while on their current methadone programme as 
measured by the OTI. However, the factors influencing health outcomes for the two 
areas differed. For urban clients they were related to programme policy (paying for 
methadone and having a case manager). For rural clients, factors included a 
combination of individual characteristics (being female), possible access issues 
(reflected in the greater number of other drugs used) and service delivery issues (lack of 
satisfaction with their programme). It would be useful for urban and rural programmes 
to take these differences into account in planning and policy development to maximise 
benefits at the individual client level and to enhance overall effectiveness of their 
respective programmes.
A little over 50 per cent of participants had injected while on the programme in the 
month prior to interview. The proportions of injectors in the urban and rural study 
groups were similar. This result supports findings from other studies and is of concern, 
as one of the main objectives of methadone treatment is to prevent injecting and risks 
associated with it. Factors significantly associated with injecting while on treatment in 
the two study groups were similar and included the number of drugs used in the month 
prior to interview, living with someone who injected drugs and having employment as 
the main source of income in the six months prior to interview. These factors are 
external to the programme and mainly related to individual client characteristics and 
risk practices, and cannot be influenced by programme policy. However, they should be 
considered as possible risk factors when clients enrol into the programme and taken into 
account during management and review. As the risk factors were the same for urban and 
rural individuals they should be considered for all methadone treatment clients.
Overall for those who injected, there was no difference between the proportions of 
participants who injected with and without a BBV risk; this was similar for urban and 
rural study groups. The two study groups also did not differ in the magnitude of BBV 
risk due to injecting (as measured by the BBV TraQ injecting risk score).
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Factors influencing injecting with a BBV risk were similar for both study groups and 
were mainly related to programme policy (lower number of TAs per week, greater 
number of missed doses per week and lower daily methadone dose). There were a few 
external factors to the programme and these included frequency of injecting and 
younger age. Interestingly, rural clients were significantly more likely to inject with a 
BBV risk, even though being rural was not in itself significantly associated with 
injecting.
Factors associated with injecting with a BBV risk should be considered specifically 
within rural programmes as rural clients were significantly more likely to be affected. 
These factors although associated with policy could also be affected by individual 
circumstances; for example distance from dosing centre and dosing centre times would 
affect the number of doses missed and frequency of injecting. As increased risk could 
be due to a combination of policy and individual circumstances, programmes could 
consider a multi pronged approach to reduce BBV risk due to injecting for clients. This 
could include reviewing and adapting policy according to client needs (e.g. tailoring 
dosing times to miss fewer doses, flexibility with TAs according to immediate 
circumstances), as well as targeted education to assist individuals in managing risk 
factors at the time of enrolment and while on treatment. Once again individual case 
management for all clients could assist in identifying circumstantial needs, which in 
turn would minimise BBV risk and achieve better outcomes from methadone treatment.
BBV risk associated with sexual practice almost equally contributed to Total BBV risk 
as risk associated with injecting practice. This finding has implications for methadone 
programme policy and delivery, particularly for HIV and HBV, where sexual 
transmission is important. Methadone treatment programmes could consider amore 
holistic approach to include management of sexual behaviour risk amongst clients. 
Some sexual and reproductive health components such as education and support for 
minimising sexually transmitted infections, and information and access to contraception 
could be incorporated into programmes.
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The findings from my study indicate that health and BBV risk outcomes from 
methadone treatment for urban and rural people can be affected by programme policy 
and service delivery, as well as individual characteristics and risk behaviours. 
Programmes may thus need to consider a combination of strategies to improve 
outcomes. This could include tailoring policy and service delivery according to 
identified area needs and taking into account individual risk factors.
Based on these findings, I put forward my third, fourth and fifth recommendations for 
Australian methadone programme policy makers. These recommendations should be 
considered in conjunction with my first recommendation, which will assist in 
identifying programme needs to allow for appropriate policy development and service 
delivery.
Recommendation 3:
As there was a combination of policy-related and external factors associated 
with health and BBV risk outcomes an holistic approach to managing clients 
receiving methadone treatment should be considered. Holistic care could be 
supported by allocating case managers for individual clients to assist with 
identification of needs and risk factors, and goal setting. Continuing case 
management will assist in identifying circumstantial needs, reviewing progress 
against goals, and providing support for reintegration into the general 
community.
Recommendation 4:
Methadone treatment programmes should consider a more flexible approach to 
Takeaway Dose policies and dosing times to accommodate for individual 
clients’ circumstantial needs to minimise risk taking behaviour associated with 
access issues.
Recommendation 5:
Methadone treatment programmes should incorporate education and harm 
minimisation strategies aimed at decreasing sexual transmission of HIV and 
HBV.
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8.2.3: Validity of HCV self-reported status and policy implications
Validity of HCV self-reported status in comparison to serological status in my study 
was found to be poor. Overall, the validity of positive HCV self-report was relatively 
better than the validity of negative self-report. In comparison, HIV validity was close to 
100 per cent. This could be an indication of the enormous effort put into education 
campaigns in the 1980s in Australia, which included promoting harm minimisation 
strategies and awareness of the serious consequences associated with HIV and AIDS 
(including the shorter life expectancy and high mortality).
Results from my study in relation to accuracy of HCV self-reported status supported 
findings from the five studies conducted prior to my study [56, 57, 89, 90, 195], and the 
more recent study by Schlicting and colleagues [206]. Although the sampling 
population, sample size and sampling strategy in these studies and my study were 
different, participants in the studies were all at high-risk for transmission of HCV. A 
common theme emerging from the findings in these studies and my study was the poor 
validity of negative HCV self-reported status. Although validity of positive self- 
reported status appeared to be better, there were between 10-40 per cent of participants 
in these studies who had an incorrect self-report. These results suggest that IDUs who 
are at most risk of being infected with HCV are poorly informed of their actual status.
Results suggested that time between last serological test and provision of self-report 
may be associated with validity of HCV self-report. Longer mean time periods since 
last serological testing were noted for participants who provided incorrect positive self- 
reports. The mean time period since last serological test and provision of incorrect 
negative self-reports was greater than the mean period for seroconversion, suggesting 
that these participants had seroconverted since their last test. These results support the 
need for more frequent HCV testing and education about risk exposure.
Validity of self-report amongst rural individuals in my study appeared to be greater than 
that of urban individuals. This finding may be related to HCV education and testing 
policies in the rural programme. The mean time between last serological test and 
provision of self-report in my study was shorter for rural individuals than for their urban 
counterparts. This finding could be investigated further towards determining reasons for 
better validity.
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With the growing epidemic of HCV and HCV related liver disease amongst injecting 
drug users, and the lack of success of harm minimisation services such as NSPs in 
decreasing incidence in Australia it is important for IDUs to have accurate knowledge 
of their status [24, 53, 54], As discussed, lack of accurate knowledge of HCV status 
may affect injecting practices, treatment seeking behaviour and quality of life for IDUs. 
As validity of HCV self-report was particularly low amongst the two studies conducted 
in Australian methadone programmes (my study and NSW rural methadone injectors 
study), it is important for Australian methadone treatment programmes to review their 
education and testing strategies in relation to HCV.
Hallinan and colleagues have recently suggested an integrated model of care within 
opioid replacement therapy services to decrease HCV incidence and increase treatment 
uptake. This model includes the provision of HCV-specific harm reduction strategies, 
regular HCV testing, clinical assessment and determination of need for HCV treatment 
referral [47]. Methadone treatment programmes would be well placed to establish this 
integrated model as clients access the service on a regular basis and there are full-time 
clinical practitioners on-site who could provide regular education, testing and 
assessment.
Reasons for inaccurate knowledge of HCV status were not investigated in any of the 
studies that examined accuracy of HCV self-report. There were some possible reasons 
cited, and these included:
• people not being informed of their status,
• not knowing the meaning of their result,
• confusion with other hepatitis viruses,
• denial,
• fear of reporting correct status in case they are discriminated against [206, 207].
Further research may be warranted into investigating reasons for levels of HCV status 
knowledge amongst at-risk groups and whether knowledge of status influences BB V 
risk behaviour and seeking treatment. It may be useful to conduct this study specifically 
amongst IDUs not on treatment as they are more likely to practise risk behaviours in 
comparison to IDUs on treatment. This study amongst methadone treatment clients may 
actually be overestimating validity as being on a treatment programme may mean better 
access to information and testing.
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It may also be useful to further compare HCV self-report validity and its association 
with information provision and testing policies between programmes, as results from 
my study suggest that clients on programmes with better support services have better 
validity (i.e. rural study groups had better validity which could be related to all 
participants having case managers). This could be extended to comparison with HCV 
testing and management policies in other countries. The study amongst US methadone 
clients reviewed suggests better validity of HCV self-reported status [56], and reasons 
for this could be explored.
Factors that were significantly associated with being HCV positive for all participants in 
my study (as measured by serology) were being older, having a tertiary education, 
having injected methadone, previous incarceration and not being on a prison methadone 
programme. These findings are relevant for all methadone service treatment 
programmes to minimise HCV transmission and could be addressed through targeted 
education for the at-risk populations. A seamless transition for treatment between prison 
and community programmes may also assist.
Factors significantly associated with HCV self-reported status differed to those 
associated with HCV serological status. This finding suggests that the use of HCV self- 
reported status as an indicator of HCV status in research may be inappropriate.
Based on these findings, I put forward my sixth and seventh recommendations. These 
recommendations are aimed at improving accuracy of knowledge on HCV status and 
risk exposures to have an impact on HCV transmission and treatment uptake.
Recommendation 6:
The poor validity of HCV self-reported status and the high prevalence of HCV 
amongst study participants indicate a need for methadone treatment services to 
promote and support HCV education and prevention strategies and testing 
processes within programmes. Consideration should also be given to providing 
support to individuals to enabie them to access HCV treatment services.
Recommendation 7:
Further studies should be conducted to determine reasons for poor validity of 
HCV self-reported status and whether it influences risk taking behaviour. This 
will assist in developing targeted strategies to improve knowledge, minimise risk 
behaviours and increase uptake of treatment for HCV.
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8.3: Relevance of methods used for future AOD research
I designed a random sampling strategy to minimise selection bias and to ensure 
representativeness of urban and rural methadone treatment client populations in the 
study. This was done with the aim of increasing generalisability of results to other urban 
and rural methadone treatment programmes. Although every effort was made to 
maintain random selection of participants into the study, due to logistic issues within 
programmes, unreliability of clients to keep appointments and the design of the 
sampling strategy to ensure continuing recruitment, proper randomisation was not 
achieved. This highlights the difficulties in using methods to increase representativeness 
of samples in AOD research, which are mainly associated with difficulty in accessing 
clients and unreliability of clients in keeping appointments. Logistic issues that 
contributed to not being able to randomise and recruit sufficient numbers included the 
lack of sufficient client numbers on the programmes and the quick turnover of ACT 
programme co-ordinators.
A major issue in AOD research is that participants are asked about illegal behaviours 
that may affect outcomes (e.g. use of licit and illicit drugs, crime, and income through 
illegal sources). Due to anxiety of being identified and repercussions associated with 
admitting to illegal behaviours, participants may sometimes not provide accurate 
information. The use of de-identified databases and gaining verbal consent without 
identification of participants in my study may have assisted with decreasing inaccurate 
responses and increasing validity of results.
Aspects of the study design also assisted in fulfilling Ethics Committee requirements. 
Obtaining verbal consent with a witness present rather then signed consent fulfilled the 
three HRECs requirement of gaining informed consent but not retaining any identifying 
details of participants. The use of a cross-sectional study design further assisted with 
accommodating this requirement. Information was collected at one point in time with no 
client follow-up required and thus there was no need to retain identifying details of 
clients for future contact.
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Cohort studies are the ideal study design to establish causality and a temporal 
relationship [79]. Most AOD research, however, uses convenience samples due to 
recruitment and identification issues and difficulty in following up participants for the 
required time frame. Many people who take part in AOD research are very mobile and 
change contact details often as seen in my study. Using convenience samples can lead to 
selection bias and decreased generalisability of research results. A cohort study would 
be the most effective study design as a follow-up to my study. It would be able to 
establish causality of significant factors influencing outcomes in urban and rural 
methadone treatment clients, and reasons for poor validity of HCV self-reported status. 
However, it may be difficult to conduct for reasons stated.
The instruments (OTI and BBV TraQ) used to measure health and BBV risk outcomes 
in this study were validated tools designed specifically to measure the outcomes of 
interest. A descriptive comparison of the two questionnaires found that they defined and 
measured BBV risk differently and the study population criteria for the questionnaires 
differed. The comparison suggested that the BBV TraQ is a more robust tool to measure 
BBV risk due to injecting as it only measures risk when it actually occurs and includes 
measurement of protective practises to minimise the risk. It does not include the 
physical act of injecting as a BBV risk, while the OTI does. The two questionnaires can 
be used in conjunction with each other in relation to investigating harm from injecting 
drugs as undertaken in my study, as the process should include both the physical act of 
injecting and associated BBV risk.
8.4: Limitations of the study
The study may not be completely representative of urban and rural methadone clients’ 
health and BBV risk outcomes as random sampling was not achieved to its fullest. 
However, 13 per cent of the targeted study population was recruited into the study (10% 
ACT methadone clients and 23% SNSW methadone clients). This proportion should 
provide a reasonable representation of the overall Australian methadone treatment 
programme population. Not being able to recruit sufficient numbers into the study may 
have decreased the power of the study to be able to pick up significant differences in 
outcomes for study groups.
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Although a cross-sectional study design may have assisted with greater validity of 
results by not having to identify clients, it only assisted with generating hypotheses in 
relation to differences in urban and rural health and BBV risk outcomes and factors 
affecting these outcomes. Furthermore, the study design was only able to measure 
validity of HC V self-reported status at one point in time for a sample population but 
was unable to establish reasons for poor validity. Validity of HCV self-report in my 
study may actually be overestimated, as participants being on a treatment programme 
may have been better informed of their status due to having better access to information 
and testing.
Another probable limitation is that the data for the study was collected five years ago. 
Needs of clients within urban and rural programmes and factors affecting outcomes may 
have changed. There have also been more recent studies conducted in relation to 
validity of HCV self-reported status; however, findings from these studies are 
supportive of the findings in my study.
Despite these limitations, results from my study indicate that there are differences in 
urban and rural methadone treatment client outcomes that need to be considered in 
programme policy and service delivery. The findings can be used as a baseline to 
inform programme planning as well as further studies for evaluating outcomes related to 
urban and rural programmes. The results also support the need to investigate the validity 
of HCV self-report further and the reasons for it, which may assist with decreasing 
current rates of HCV transmission.
8.5: Generalisability of study results
Some results from my study in relation to individual client characteristics associated 
with health and BBV risk outcomes may be generalisable to other urban and rural 
methadone clients in Australia. This is because the two study groups were socio- 
demographically similar to clients on other Australian AOD services as seen in the 
1998, 2001 and 2004 surveys [4-6]. Other results in relation to policy and service 
delivery are not generalisable as they are specific to the programme areas in this study.
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8.6: Conclusions
In conclusion, there were no significant differences (p>0.05) in relation to magnitude of 
outcomes for health and BBV risk due to injecting for urban and rural clients 
methadone treatment in my study. The factors that significantly contributed (p<0.05) to 
poorer health outcomes within the urban and rural programmes differed and were 
related to policy within programmes. These factors should be considered within urban 
and rural programme policy and service delivery to assist with improving health 
outcomes. Factors that significantly contributed (p<0.05) to increased BBV risk due to 
injecting were similar for the two study groups and were related to individual client 
characteristics. These factors would be better addressed on an individual client level 
within all methadone programmes.
Although the two study groups differed in relation to some outcomes, an interesting 
finding was that the two study groups were in fact very similar in relation to many 
socio-demographic characteristics, programme related characteristics and risk taking 
behaviours. There were several instances where results were not significant but showed 
trends towards significance and this may have been due to the small sample size. It 
would be useful to consider a similar study on a larger scale to further help address the 
question of whether or not outcomes for urban and rural methadone clients are 
significantly different or in fact very similar.
Validity of HCV self-reported status as elicited in this study suggests that it is poor and 
more research in specific high-risk populations may be warranted. The findings indicate 
a need for harm minimisation and treatment programmes to develop better education 
and testing strategies to improve knowledge of HCV status amongst high risk groups. 
This may assist with decreasing transmission and enhancing treatment seeking 
behaviours. It is also important for policy makers and service providers to take into 
account significant client characteristics and risk factors associated with HCV status in 
the development of strategies to minimise and prevent HCV transmission.
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The findings from my research conducted for this PhD suggests that methadone 
treatment policy and delivery can affect outcomes for clients. It supports the need for 
regular evaluation of programmes to assist with development of policy to provide 
services as needed and as appropriate. By examining the validity of HCV self-reported 
status, the research has also provided further information about the accuracy of 
knowledge of HCV status in a high risk population.
By conducting this research, I consider that I have been able to provide valuable input 
into health and BBV risk outcomes related to urban and rural methadone treatment 
programmes. The study has generated findings that have important implications for 
harm minimisation programmes in relation to HCV transmission.
Initial findings have been disseminated to the ACT and SNSW methadone programmes 
and final recommendations will also be disseminated in the hope of improving 
outcomes for urban and rural people on methadone treatment.
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250
Appendices
Appendix 1
Appendix 1: Explanation o f validity measures used in the study
Two by two table for calculation of validity measures
Reports
(self-report /serology)
Disease 9 +ve 
(serology +ve)
Disease -ve
(serology -ve)
Totals
Screening test +ve 
(self-report +ve)
a b a+b
Screening test-ve  
(self report -ve)
c d c+d
Totals a+c b+d a+b+c+d
a=no. o f true positive self-reports, b=no. o f false positive self-reports, 
c=no. offalse negative self-reports, d=no. o f true negative self-reports
Validity measures used and what it measures in my study20,21
Validity measures used What it measures in my study
Sensitivity=a/(a+c)
Proportion of people who have a positive screening 
test amongst those who truly have disease.
Specificity=d/(b+d)
Proportion of people who have a negative screening 
test amongst those truly do not have disease.
PPV=a/(a+b)
The proportion of those who truly have disease with 
a positive screening test.
NPV=d/(c+d)
The proportion of those who did not have disease 
with a negative screening test
PLR=(a/[a+c|)/(b/[b+d])
The likelihood of a positive test in someone with the 
disease compared to someone without the disease
NLR=(c/[a+c])/(d/[b+d])
The likelihood of a negative test in someone with the 
disease compared to someone without the disease.
The proportion of participants who provided a positive 
self-report amongst those who were serologically positive.
The proportion of participants who provided a negative 
self-report amongst those who were serologically 
negative.
The proportion of participants whose positive 
self-report was correct.
The proportion of participants whose negative 
self-report was correct.
The proportion of participants who were serologically 
positive and had a positive self-report, compared to the 
proportion of participants who were serologically negative 
and had a positive self report.
The proportion of participants who were serologically 
positive and had a negative self-report, compared to the 
proportion of participants who were serologically negative 
and had a negative self-report.
19 The word disease is used as per definitions in Epidemiology textbooks (below) to explain validity measures used 
for screening.
20 79. Hennekens CH and Buring JE, Epidemiology in Medicine. 1987, Boston/Toronto: Little Brown 
and Company.
21 205. Sackett LD, et al., Evidence-Based Medicine; How to Practice and Teach EBM. second ed, ed. 
Churchill-Livingston. 2000, London.
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Appendix 2
Comparison of Outcomes for Methadone 
Treatment Program Clients
Questionnaire
2002
The National Centre for Epidemiology and Population Health
Australian National University
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R ecord  num ber:
Date: / /
A rea code:
(A C T  =  1)
( S N S W  =  2 )
Interview er:
PARTI
GENERAL QUESTIONS
The National Centre for Epidemiology and Population Health
Australian National University
Appendix 2
Please write responses if space is provided or highlight options or place a tick in 
boxes. Pick only one response unless otherwise specified.
Section 1: General Questions
Q1. How many months have you been on this program?______________ Months
Q2. How did you get on the program?
GP referral 1 court order 2 drug worker 3 self-referred 4
Other so (please specify)_____________________________
Q3. Why did you go onto this methadone program? (For each statement tick 
one box)
No Yes Don’t
Know
Not
Applicable
Because of my relationships □ o □ 90 □ 0 0
Because of my children □ c □ , □ 9 0 □ 0 0
Because of money □ o □ 9 0 □ 0 0
Because of employment □ o □ , □ 9 0 □ 0 0
Because of study □ o □ , D 90 □ 0 0
Because of my health □ o □ 9 0 □ 0 0
Had a court appearance □ o □ 9 0 O o o
Ordered by court □ o □ l □ 9 0 □ 0 0
To cut down/stop criminal activity □ o □ l □ 0 0
To get out of the illegal drug scene □ o □  90 □ 0 0
To manage tolerance □ o □ , □  90 □ 0 0
To get off illegal drugs completely □ o □ l □  90 □ 0 0
To cut down use of illegal drugs □ o □ , □  90 □ 0 0
To stop using for a while □ o □  90 ° o o
To cut down the number of times I 
inject
□ o D 90 □ 0 0
Other80 (please specify)
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Q4. How many doses per week do you get at your dosing center?
If more than 7 times, please specify reason_____________________
Q5. Do you get routine takeaways?
Noo Yes 1
I
(Go to Q 7)
Q6. How many takeaway doses do you get per week?
'll 22 33 44 more than 45
Q7. What is your current methadone dose?
1-20 mgs-i 21-40 mgs2 41-60mgs3 61-80mgs4 81-100mgs5 >100mgs6
Q8. Do you give random urines?
No o Yes ^
Q9. Thinking of all the times you were on methadone, what is the most number of 
days you have missed dosing in a week?
0 o 1i 22 33 44 55 66 7?
Q10. How long do you have to travel to get dosed?
Less than V2 an hour, Vi an hour to 1 hour 2 1 to V/2 half hours
V/2 hours to 2 hours 4 > 2 hours 5
Q11. How much does it cost per day for travel expenses to get dosed?
Nothingo $1 -5, $6 -  102 $ 1 1 - 153 $15 -  204 > $ 20 5
Q12. How often do you see your methadone prescriber?
W e e k l y F o r t n i g h t l y  2 monthly 3 3monthly 4 6monthly 5 > 6monthly 6
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Q13. How far do you have to travel to see your methadone prescriber?
Less than 1/2 an houri 'A an hour to 1 hour 2 1 to VA half hours 3
VA hours to 2 hours 4 more than 2 hours 5
Q14. How much do you have to pay for each consultation with your prescriber?
Nothing o $1 .00 -30 .00 ! $31.00 -  60.00 2 more than $60.00 3
Q15. How far do you have to travel to see your case manager?
< 1/ 2 an hour! 'A an hour to 1 hour2 1 to 1A half hours3
11/2 hours to 2hours4 > 2hours 5 Not applicable 0o (if no case manager)
Q16. Which of the following categories does the person who doses you fit into? 
(Can highlight more than one option)
Unknown prior to program! Relative 2 Family friend 3 Work mate 4
Acquaintance 5 Other 8o (please specify)________________________________
Q17. How much does methadone cost you per week?
Nothing o $1.00-15 .00 i $16.00 -  30.002 $30.00 -  45.00 3 > $45.00 4
Q18. How long do you expect to be on methadone?
< 1yn 1yr2 2yrs3 3yrs4 4yrs5 5yrs6 > than 5yrs 7 
Don’t Knowgo
Q19. Is this the first time you have been on a methadone program?
N^o Yesi
(Go to Q 23)
Q20. How many other times have you been on a methadone program?
Q21. When was the last time you were on a methadone program before this one?
__________ Year
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Q22. Why did you leave the last program? (Can highlight more than one option)
Too far to travel 1 Too expensive2 Confidentiality 3 Did not suit me 4
Did not fit my schedule 5 Other 80 (Please specify)
Q23. Which of the following would best describe your program?
(Ask interviewer for definition)
Public 1 Partly public/partly private 2___________ Private 3___________ Don’t know 90
Q24. Where do you get dosed?
Clinic i Pharmacy 2 hospital 3 GP surgery4
Other so_______________
Q25. How satisfied are you with this program?
Very satisfied t Satisfied 2 Unsatisfied 3 Very unsatisfied
4Don't know 90
Q26. Since being on methadone (For each statement tick one box)
Stayed Don’t Not
Improved
Applicable
the same Worsened Know
My health has □  , □  2 □ 3 C U o □ 0 0
The state of my teeth has □  1 □  2 □ 3 □  90 □  00
My relationships have □  , □  2 □ 3 Q  90 □ 0 0
My relationships with my children □  , □ 2 □ 3 □ 9 0 □  00
have
My financial situation has □  , □ 2 □ 3 □ 9 0 □ 0 0
My employment situation has □  1 □ 2 □ 3 □ 9 0 d o o
My options for study have □  1 □  2 □ 3 □ 9 0 □ 0 0
My control over my life has □ 1 □  2 □ 3 □ 9 0 □ 0 0
My management of tolerance has □  1 □ 2 □ 3 □ 9 0 □ 0 0
My ability to think clearly has □  , □  2 □ 3 □ 9 0 □ 0 0
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Q27. Since being on methadone I have found that (For each statement tick one 
box)
The staff treat me with respect
My confidentiality is respected
I can get away from other users 
if I want to
I am off illegal drugs completely 
I have cut down my illegal drug 
use
I stopped using for a while
My court case was helped
I didn’t have to go to jail
I cut down/ stopped criminal 
activity
I have less problems with the 
police
I have stopped injecting 
completely
I have cut down the number of 
times I inject
I am out of the illegal drug 
scene
I use more pills 
I drink more alcohol 
Other80 (please specify)
Don't
A g r e e D i s a g r e e k n o w IS
□ , □ , □ » □ o o
□ , □ , □ « , □ o o
□ 1 □, □ o o
□ , □ , □ o o
□ , □ , □ . □ o .
□ , □ 2 □ s o □ o o
□ , □ , □ s o □ o o
□ , □ , □ s o □ o o
□ , □ , □ s o □ o o
□ , □ , □ s o □ o o
□ , □ , □ s o □ o o
□ , □2 □ s o □ o o
□ , □ 2 □ s o □ o o
□ , □2 □ s o □ o o
□ , □ 2 □ s o □ o o
NA
Q28. What other types of drug treatment have you had in the past? 
(You can tick more than one box)
None ever □
Detoxification □
Narcotics anonymous □
Drug counseling □
In-patient rehabilitation □
Other 80 (please specify)
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Q29. The methadone program would work better for me if there were.
(For each statement tick one box)
Longer opening hours
More counselling
Crisis counselling available
Easier transfers to other clinics
More take-aways
Emergency take-aways
A needle and syringe exchange
A disposal bin for fits
Support groups for coming off methadone
injectabie methadone
Less urinalysis
More urinalysis
Ways to appeal against decisions made 
about me
Reward for abstinence 
Help in developing my long term goals 
More notice taken of my personal goals 
A dispensing site closer to home
More information about drugs and 
pregnancy
More information about the effects of 
methadone
More information about the effects of 
illegal drugs
More information about prescription drugs 
Help in dealing with my childhood abuse 
Help for domestic violence
Don't
No Yes know NA
□ o □ o o □ o o
□ o □ , □ o o □ o o
□ c □ o o □ o o
□ o □ s o □ o o
□ o □ o o □ o o
□ o □ , □ o o □ o o
□ o □ l □ o o □ „ 0
□ o □ o o □ o o
□ o □ , C2 90 □ o o
□ o □ , □ o o
□
1---1 00
□ o □ o o □ o o
□ o □ o o
□ o □ , □ o o □  00
□ o □ - □ o o
□ o □ l □ . □ o o
□ o □ o o □ o o
□ o □ l □ o o
□ o □ l □  oo □ o o
o
□
□ l □ o o □ o o
o
□
□ o o □ o o
□ o □ o o □ o o
□ o □ l □ o o □ o o
□ o □ l □ « □ o o
Other so (please specify)
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Q 30. Do you access Needle and Syringe Outlets?
No o Yes -I
▼
(Go to question 33)
Appendix 2
Q31. How often do you access the needle and syringe outlets?
Every day! 2-3 times a week 2 Once a week 3 Once a month 4
> once a months
Q32. What do you get from the needle and syringe outlets?
(Can highlight more than one option)
Injecting equipment -i sterile water 2 condoms 3 information 4
Other so (please specify)_________________________________________________
Q33. What sex are you?
Male! Female2 Transexual3
Q34. How old are you? Years
Q35. What is the highest level of education you have completed? (Tick one box)
Postgraduate qualification 
Bachelor degree 
TAFE certificate (eg. trade)
High school certificate (year 12)
Leaving/school certificate (year 10)
Left high school before leaving certificate (before year 10)
Did not attend high school 
Completed primary school 
Attended primary school
□  i
□  2 
□ 3  
□4 
□5 
□ 8
□ 7
□e
□9
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Q36. How are you employed at the moment?
Unemployed 1 Full-time2 Part-time/casual3 StudenU Home duties5 
Other80 (please specify)________________________________________________
Q37. During the last 6 months what were your sources of income?
(Can highlight more than one option)
Paid employment, Self-employed 2 Government benefits 3 
Illegal sources 4 Other 8o (please specify)
Q38. Which was your main source of income in the last 6 months?
Paid employmenti Self-employment 2 Government benefits3
Illegal sources 4 Other 80 (please specify)
Q39. In what country were you born? _______________________________
Q40. Do you identify as an Aboriginal or Torres Strait Islander?
No o Yes 1
Q41. How many children are financially dependent on you
a) Living with you _________________________
b) Not living with you _________________________
c) Not applicable0o
Q42. What is your current marital status?
Never marriedi Married/Defacto2 Separated3 Divorced4 Widowed5 
Other eo (please specify)_____________________________________________
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Q43. Where do you live?
ACT 1 NSW 2
Q44. What is your residential postcode? ________________
Q45. What is your accommodation type at the moment?
Own accommodation-i Rented accommodation 2 Boarding house3 
Homeless 4 Other 80 (please specify)______________________________________
Q46. Who do you live with at the moment? (Can highlight more than one option)
Live alone! Live with parents2 Live with partner3 Share with others 4
Other80 (please specify)___________________________________________________
Q47. Do any of the people you currently live with inject illegal drugs?
No o Yes t Don’t know 90
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Section 2: Prison History
Q48. Have you ever been in prison? (Including remand/police cells)
fJo0 Yes!
(Go to next section)
Q49. If yes, when was the last time you were in prison?________________Year
Q50. How many times have you been in prison? ________________
Q51. How long were you in prison the last time? ________________Months
Q52; Did you inject drugs while in prison?
No0 Yes ,
Q53. Did you get tattooed while in prison?
No o Yes 1
Q54. Were you on a methadone program whilst in prison?
No o Yes!
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Section 3: Drug History
Q55. At what age did you first inject drugs? Years
Q56. What drug did you first inject? (Tick one box only)
Heroin
□ ,
Methadone
□  .
Other opioids (eg; codeine, morphine, opium)
□  3
Amphetamines (eg; speed, MDMA)
□  <
Cocaine
Hallucinogens (LSD)
□  .
Ecstasy
Benzodiazepines (normison, footies, rohypnol, mogadon, 
temazepam, valium, serapax) □  .
Steroids
o>
□
Other so (please specify)
Q57. At what age did you first start to inject regularly?_________________ Years
(Regular = at least once a week)
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Q58. What drug(s) were you injecting at that time?
(You can tick more than one box)
Heroin
□ 1
Methadone
□  a
Other opioids (eg; codeine, morphine, opium)
□  3
Amphetamines (speed, MDMA)
□  3
Cocaine
□  .
Hallucinogens (LSD)
□  .
Ecstasy
□  a
Benzodiazepines (normison, footies, rohypnol, mogadon, 
temazepam, valium, serapax) □  .
Steroids
□  .
Other bo (please specify)
Q59. Who have you been injected by in the last month? (Can highlight more than 
one option)
Sel^ Partner Friend3 Stranger4 Dealer5
Not applicable 0o Other 8o (please specify)_________________________________
Q60. Who has prepared/mixed the drugs you injected in the last month? 
(Can highlight more than one option)
Selfi Partner 2 Friend 3 Stranger 4 Dealer 5
Not applicable 0o Other 8o (please specify)__________________________
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Q 61. Who injects/injected you most often? (Circle one option only)
Selfi Partner 2 Friend 3 Stranger4 Dealers
Other 80 (please specify)_______________________________________________
Q62. Who mostly prepared/mixed the drugs you inject? (Circle one option only)
Self-i Partner 2 Friend 3 Stranger 4 Dealer 5
Other ec (please specify)___________________________________________________
Q63. Have you ever injected methadone?
No o Y e s !
(Go to next section)
Q64. If yes, when
In the last week ■, In the last month 2 In the last year 3 
Previous to the last year 4
Q65. How often do you inject methadone?
Daily 1 Weekly 2 monthly 3 Other80
Q66. How many times per week would you inject methadone?
1i 22 33 44 55 66 77 >7  times8
Other80______________________________________________
Q67. Which of the following methadone did/do you inject?
(Can highlight more than one option)
Regular dosei Takeaways2 Friends/partners takeaways3 Buy it 4
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Section 4: Serostatus:
Q68. Have you ever been tested for HIV?
No o Don’t know 90 Yes !
(Go to question 72)
Q69. What was the result of that test?
Negative o Positive! Don’t know90
Q70. If positive, when were you told this result?______________________Month
_______________________Year
Q71. If negative, when was your last test? ______________________Month
______________________Year
Q72. Have you ever been tested for the hepatitis C virus?
No o Don’t know 90 Yes 1
(Go to question 76)
Q73. What was the result of that test?
Negative o Positive! Don’t know 90
Q74. If positive, when were you told this result?______________________Month
______________________Year
Q75. If negative, when was your last test? Month
Year
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Q76. Have you ever been tested for the hepatitis B virus?
No o Don’t know 90 Yes i
(Go to question 80)
Q77. What was the result of that test?
Negative 0 Positive 1 Don’t know 90
Q78. If positive, when were you told this result?____________________ Month
_______________________Year
Q79. If negative, when was your last test? Month
Year
Q80. Have you ever been vaccinated for the hepatitis B virus?
No o Don’t know 90 Yes •,
(Go to Q 81)
If yes First injection: Month Year
Second injection Month Year
Third injection Month Year
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Q81. Have you ever been tested for the hepatitis A virus?
No o Don’t know 90 Yes 1
(Go to question 85)
Q82. What was the result of that test?
Negative 0 Positive 1 Don’t know 90
Q83. If positive, did you have the illness, if so when?__________________Month
__________________ Year
Q84. If negative when was your last test?  Month
________ Year
Q85. Have you ever been vaccinated for the hepatitis A virus?
No o Don’t know 90 Yes ^
If yes First injection: Month Year
Second injection: Month Year
Third injection Month Year
End of Part I
Please continue with Part II
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PART II
BBV-TRAQ
Blood Borne Virus 
Transmission Risk Assessment 
Questionnaire
Turning Point Alcohol and Drug Centre Inc. 1998
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Instructions to participants
Appendix 2
• Please consider the following questions carefully and answer each one as 
accurately and truthfully as you can. All questions refer to your behaviour in the 
past MONTH / 4 week period.
• Try and remember that the only correct answer is an accurate and honest answer.
• Remember that the information you provide will remain completely confidential.
SECTION 1 - INJECTING PRACTICES
Record your responses to each of the following questions by highlighting/circling the
answer option that you think is most relevant to you.
86. In the last month, how many times have you handled another person’s used 
needle/syringe (eg. to dispose, to break-off needle) at a time when you had cuts, 
sores or lesions on your fingers and hands?
No times o Once! Twice 2 3 -5 tim e s 3 6 -10 times 4 >10 times 5
87. In the last month, how many times have you sucked or licked left-over drugs from 
a spoon or other mixing container which had been used by another person?
No times o Once! Twice 2 3 -5 t im e s 3 6 -10 times 4 >10 times 5
88. In the last month, how many times have you sucked or licked a filter which had 
been used by another person?
No times o Once i Twice 2 3 -5 t i m e s 3 6 -10  times 4 >10 times 5
89. In the last month, how many times have you sucked or licked a plunger after 
using it in a mix which has been used by another person?
No times o Once i Twice 2 3 -5 t i m e s 3 6 -1 0  times 4 >10 times 5
90. In the last month, how many times have you injected a drug that was filtered 
through another person’s filter?
No times o Once i Twice 2 3 -5 t i m e s 3 6 -1 0  times 4 >10 times 5
91a. In the last month, how many times have you injected a drug that was prepared in 
another person’s used spoon or mixing container?
No times o Once i Twice 2 3 -5 t im e s 3 6 -1 0  times 4 >10 times 5
4 »
(Go to Question 92)
91b. On those occasions how often did you clean the spoon or mixing container 
before using it?
Never 0 Rarely i Sometimes 2 Often 3 Every time 4
92. In the last month, how many times have you injected a drug prepared with water, 
which had been used by another person?
No times o Once i Twice 2 3 -5  times 3 6 -10  times 4 >10 times 5
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93. In the last month, how many times have you injected a drug, which had come into 
contact with another person’s used needle/syringe?
No times o Once i Twice 2 3 - 5 times 3 6 -10  times 4 >10 times 5
94a. In the last month, how many times have you injected a drug that you prepared 
immediately after ‘assisting’ another person with their injection (eg. injecting 
them, holding their arm, handling their used needle/syringe; touching their 
injection site to feel for a vein, to wipe away blood, or to stop bleeding)?
No times o Once! Twice 2 3 - 5 times 3 6 -10  times 4 >10 times 5
(Go to Question 95a)
94b. On those occasions, how often did you wash your hands before preparing your 
mix?
Never 0 Rarely i Sometimes 2 Often 3 Every time 4
95a. In the last month, how many times have you injected a drug that was prepared by 
another person who had already injected or assisted in someone else’s injection?
No times o Once! Twice 2 3 - 5 times 3 6 -10 times 4 >10 times 5
(Go to Question 96a)____________________________________________________________
95b. On those occasions, how often did the person preparing the mix wash their 
hands before preparing the mix?
Never 0 Rarely! Sometimes 2 Often 3 Every time 4
96a. In the last month, how many times have you been injected by another person who 
had already injected or assisted in someone else’s injection?
No times o Once! Twice 2 3 - 5 times 3 6 -10  times 4 >10 times 5
I
(Go to Question 97a)____________________________________________________________
96b. On those occasions, how often did the person injecting you wash their hands 
before injecting you?
Never o Rarely i Sometimes 2 Often 3 Every time 4
97a. In the last month, how many times have you injected with a needle/syringe which 
had been handled or touched by another person who had already injected?
No times o Once! Twice 2 3 - 5 times 3 6 -10  times 4 >10 times 5
(Go to Question 98a)____________________________________________________________
97b. On those occasions, how often did they wash their hands prior to handling the 
needle/syringe that you used?
Never 0 Rarely i Sometimes 2 Often 3 Every time 4
98a. In the last month, how many times have you injected with another person’s used 
needle/syringe?
No times o Once i Twice 2 3 - 5 t i me s 3 6-10 times 4 >10 times 5
(Go to Question 99)____________________________________________________________
98b. On those occasions, how often did you rinse it with a combination of full-strength 
bleach and water (ie. the ‘2x2x2’ method) before you used it?
Never 0 Rarely i Sometimes 2 Often 3 Every time 4
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99. In the last month, how many times have you injected with a needle/syringe after 
another person has already injected some of its contents?
No times 0 Once 1_____ Twice 2 3 - 5 times 3 6 -1 0  times 4 >10 times 5
100a. In the last month, how many times have you touched your own injection site (eg. 
to feel for a vein, to wipe away blood, or to stop bleeding) soon after ‘assisting’ 
another person with their injection (eg. injecting them, holding their arm, 
handling their used needle/syringe; touching their injection site to feel for a vein, 
to wipe away blood, or to stop bleeding)?
No times o Once! Twice 2 3 - 5 times 3 6 -10  times 4 >10 times 5
(Go to Question 101a)
100b. On those occasions, how often did you wash your hands before touching your 
own injection site?
Never 0 Rarely! Sometimes 2 Often 3 Every time 4
101a. In the last month, how many times has another person touched your injection site 
(eg. to feel for a vein, to wipe away blood, or to stop bleeding)?
No times o Once! Twice 2 3 - 5 times 3 -10 times 4 >10 times 5
(Go to Question 102)_________________________________________________ __________
101b. On those occasions, how often did the person wash their hands before they 
touched your injection site?
Never 0 Rarely i Sometimes 2 Often 3 Every time 4
102. In the last month, how many times have you wiped your own injection site with an 
object (eg. swab, tissue, hanky, towel, etc) which had been used by another 
person
No times 0 Once !_____Twice 2 3 -5  times 3_____6- 10  times 4 >10 times 5______
103. In the last month, how many times have you used a tourniquet (eg. medical 
tourniquet, belt, rope, tie, cord, etc), which had been used by another person?
No times o Once i Twice 2 3 - 5 times 3 6 -10 times 4 >10 times 5
104. In the last month, how many times have you received an accidental needle-
stick/prick from another person’s used needle/syringe?
No times 0 Once 1 Twice 2 3 - 5 times 3 6 -1 0  times 4 >10 times 5
105a. In the last month, how many times have you re-used a needle/syringe taken out of 
a shared disposal/sharps container?
No times 0 Once 1 Twice 2 3 - 5 times 3 6 -10 times 4 >10 times 5
*
(Go to SECTION 2)
105b. On those occasions, how often did you rinse it with full-strength bleach before 
you re-used it?
Never 0 Rarely 1 Sometimes 2 Often 3 Every time 4
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SECTION 2 - SEXUAL PRACTICES
Record your responses to each of the following questions by circling the answer option
that you think is most relevant to you.
106. In the last month, how many times have you engaged in unprotected vaginal sex 
with another person (ie. penetration of the vagina with the penis)?
No times o Once! Twice 2 3 - 5 times 3 6-10 times 4 >10 times 5
107. In the last month, how many times have you engaged in unprotected vaginal sex 
with another person (ie. penetration of the vagina with the penis) during 
menstruation?
No times o Once! Twice 2 3 - 5 times 3 6 -10  times 4 >10 times 5
108. In the last month, how many times have you engaged in unprotected vaginal sex 
with another person (ie. penetration of the vagina with the penis) without 
lubrication?
No times o Once i Twice 2 3 - 5 times 3 6-10 times 4 >10 times 5
109. In the last month, how many times have you engaged in unprotected anal sex 
with another person (i.e. penetration of the anus with the penis)?
No times o Once 1 Twice 2 3 - 5 times 3 6 -10 times 4 >10 times 5
110. In the last month, how many times have you engaged in unprotected oral sex with 
another person (i.e. lips and tongue come into contact with the vagina, penis 
and/or anus)?
No times o Once i Twice 2 3 - 5 times 3 6-10 times 4 >10 times 5
111. In the last month, how many times have you engaged in unprotected manual sex 
with another person (i.e. fingers and hands come into contact with the vagina, 
penis and/or anus) during menstruation?
No times o Once i Twice 2 3 - 5 times 3 6-10 times 4 >10 times 5
112. In the last month, how many times have you engaged in unprotected manual sex 
with another person (fingers and hands come into contact with the vagina, penis 
and/or anus) after injecting?
No times o Once i Twice 2 3 - 5 times 3 6-10 times 4 >10 times 5
113. In the last month, how many times have you engaged in unprotected manual sex 
with another person (fingers and hands come into contact with the vagina, penis 
and/or anus) without lubrication?
No times o Once i Twice 2 3 - 5 times 3 6-10 times 4 >10 times 5
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SECTION 3 - OTHER SKIN PENETRATION PRACTICES
Record your responses to each of the following questions by circling the answer option
that you think is most relevant to you.
114. In the last month, how many times have you come into contact with another 
person’s blood (eg. through fights, slash-ups, self-mutilation, accidents, blood- 
sports, occupational, pimples, blood nose, etc)?
No times o Once! Twice 2 3 -5 tim e s 3 6 -10  times 4 >10 times 5
115. In the last month, how many times have you been tattooed by someone who was 
not a professional tattooist?
No times o Once! Twice 2 3 -5 tim e s 3 6 -1 0  times 4 >10 times 5
116. In the last month, how many times have you been pierced (eg. ear or body) by 
someone who was not a professional piercer?
No times o Once! Twice 2 3 - 5 times 3 6 -10 times 4 >10 times 5
117. In the last month, how many times have you used another person’s used razor 
(eg. disposable razors, razor-blades)?
No times o Once i Twice 2 3 - 5 times 3 6 -10 times 4 >10 times 5
118. In the last month, how many times have you used another person’s toothbrush?
No times o Once i Twice 2 3 -5 tim e s 3 6 -10 times 4 >10 times 5
119. In the last month, how many times have you used another person’s personal 
hygiene equipment (eg. nail file, nail scissors, nail clippers, tweezers, comb, 
brush)?
No times o Once i Twice 2 3 -5 tim e s 3 6 -10 times 4 >10 times 5
End o f Part II
The next part is to be filled in by the interviewer
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SECTION I: DRUG USE
First, I'm going to ask you some questions on your use of drugs. I'll emphasise again that the 
information you give me is completely confidential.
NB: For all categories, If the subject responds that their last use of the drug was more than a 
month ago, score zero for that category. Do not include use on day of interview.
Heroin
Now I'm going to ask you some questions about heroin (smack, hammer, horse, scag).
1. On what day did you last use heroin?_____________________________
2. How many hits/smokes/snorts did you have on that day?______________
3. On which day before that did you use heroin?______________________
4. And how many hits/smokes did you have on that day?________________
5. And when was the day before that?_______________________________
(ql= ,q2= ,tl= ,t2=) ______
Other opiates
These questions are about your use of opiates other than heroin (e.g. street 
methadone/done, morphine, pethidine, codeine).
6. On what day did you iast use opiates other than heroin? (do not include legally
obtained methadone)_____________________ ____________________
7. How many pills, doses etc. did you have on that day?_____________
8. On which day before that did you use opiates other than heroin?______
9. And how many pills, doses etc. did you have on that day?___________
10. And when was the day before that?____________________________
(ql= ,q2= ,tl= ,t2=)
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Alcohol
These questions are about your use of alcohol.
11. On what day did you last drink alcohol?_____
12. How much alcohol did you drink on that day?
NO. STAND 
DRINKS
Wine Spirits Beer Fortified Wine
Wine Gl. Nips
(30ml)
Middies
(285ml)
Port Gl.
Bottles
(750ml) Doubles
Schooners
(425ml)
Bottles
Flagons Bottles
(750ml)
Cans/Stubbies
(375ml)
Flagons
Casks 
- lit.
Bottles
(750ml)
TOTAL STANDARD DRINKS___________________
13. On which day before that did you drink alcohol?
14. And how much did you drink on that day?____
NO. STAND 
DRINKS
Wine Spirits Beer Fortified Wine
Wine Gl. Nips Middies Port Gl.
(120ml) (30ml) (285ml) (60ml)
Bottles
(750ml) Doubles
Schooners
(425ml)
Bottles
(750ml)
Flagons Bottles Cans/Stubbies Flagons
(1.5lit.) (750ml) (375ml) (1.51 it.)
Casks 
( _  Nt.)
Bottles
(750ml)
TOTAL STANDARD DRINKS____________________
15. And when was the day before that?__________
(ql= ,q2= ,tl= ,t2= ) Q
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Cannabis
These questions are about your use of marijuana (dope, grass, hash, pot).
16. On what day did you last use marijuana ?_______________________
17. How many joints, bongs, etc. did you have on that day?____________
18. On which day before that did you use marijuana?_________________
19. And how many joints, bongs, etc. did you have on that day?________
20. And when was the day before that?____________________________
(ql= ,q2= ,tl= ,t2= ) Q
Amphetamines
These questions are about your use of amphetamines (speed).
21. On what day did you last use amphetamines?___________________
22. How many tablets, snorts, hits etc. did you have on that day?_______
23. On which day before that did you use amphetamines?____________
24. And how many tablets, snorts, hits, etc., did you have on that day?__
25. And when was the day before that?___________________________
(ql= ,q2= ,tl= ,t2=) Q
Cocaine
These questions are about your use of cocaine (coke, snow, crack).
26. On what day did you last use cocaine?________________________
27. How many snorts, hits, smokes etc. did you have on that day?_____
28. On which day before that did you use cocaine?_________________
29. And how many snorts, hits, smokes etc. did you have on that day?_
30. And when was the day before that?__________________________
(ql= ,q2= ,tl= ,t2=) Q
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Tranquillisers
These questions are about your use of tranquillisers (e.g. Serepax, Rohypnol, 
Mogadon, Valium).
31. On what day did you last use tranquillisers?________________________
32. How many pills did you have on that day?_________________________
33. On which day before that did you use tranquillisers?_________________
34. And how many pills did you have on that day?______________________
35. And when was the day before that?______________________________
(ql= ,q2= ,tl= ,t2= ) Q
Barbiturates
These questions are about your use of barbiturates (e.g. Nembutal, Seconal).
36. On what day did you last use barbiturates?________________________
37. How many pills did you have on that day?_________________________
38. On which day before that did you use barbiturates?_________________
39. And how many pills did you have on that day?_____________________
40. And when was the day before that?______________________________
(ql= ~q2= ,tl= ,t2= ) Q
Hallucinogens
These questions are about your use of hallucinogens (e.g. LSD/acid, ecstasy, 
magic magic mushrooms).
41. On what day did you last use hallucinogens?_______________________
42. How many tabs, pills, etc. did you have on that day?_________________
43. On which day before that did you use hallucinogens?________________
44. And how many tabs, pills, etc. did you have on that day?_____________
45. And when was the day before that?______________________________
(ql= ,q2= ,tl= ,t2=) Q ------
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Inhalants
These questions are about your use of inhalants (e.g. amyl nitrite/rush, glue, 
laughing gas, aerosols, petrol).
46. On what day did you last use inhalants? (do not include asthma
sprays)_____________________________________________________
47. How many sniffs did you have on that day?________________________
48. On which day before that did you use inhalants?___________________
49. And how many sniffs did you have on that day?____________________
50. And when was the day before that?_____________________________
(ql= ,q2= ,ti= ,t2= ) Q
Tobacco
Finally, these questions are about your use of cigarettes.
51. On what day did you last use tobacco?___________
52. How many cigarettes did you have on that day?____
53. On which day before that did you use tobacco?____
54. And how many cigarettes did you have on that day?.
55. And when was the day before that?_____________
(ql= ,q2= ,tl= ,t2= ) Q
General Comments On Drug Use
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DRUG USE SUMMARY
H e ro in  U se  
T o ta l
P o ly -d ru g  
U se  T o ta l
POLY-DRUG USE
O th e r  O p ia te s T ra n q u ill is e rs
A lc o h o l B a rb itu ra te s
C a n n a b is H a llu c in o g e n
s
A m p h e ta m in e
s
In h a la n ts
C o c a in e T o b a c c o
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SECTION II: INJECTING AND SEXUAL PRACTICES
These questions are about the way you use drugs, and your recent sexual behaviour. 
I emphasise again that any information that you give me is completely confidential.
DRUG USE
1. How many times have you hit up (i.e. injected any drugs) in the last month?
Hasn't hit u p ..........................................0
Once a week or less..............................1
More than once a week.........................2
(but less than once a day)
Once a day............................................ 3
2-3 times a day.....................................4
More than 3 times a day....................... 5
If subject hasn't injected in the last month, score zero for the Drug Use section, and go to 
question 7.
2. How many times in the last month have you used a needle after someone else had
already used it?
No times...................................................0
One time...................................................1
Two times.................................................2
3-5 times..................................................3
6-10 times................................................4
More than 10 times.................................. 5
3. How many different people have used a needle before you in the last month?
None......................................................... 0
One person................................................ 1
Two people................................................2
3-5 people.................................................3
6-10 people................................................4
More than 10 people................................ 5
4. How many times in the last month has someone used a needle after you have used it?
No tim es................................................. 0
One tim e ....................................................1
Two times.................................................. 2
3-5 tim es.................................................3
6-10 tim es................................................4
More than 10 tim es.................................. 5
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5. How often, in the last month, have you cleaned needles before re-using them ?
Doesn't re-use.........................................0
Every time............................................... 1
Often....................................................... 2
Sometimes............................................. 3
Rarely.....................................................4
Never.....................................................5
6. Before using needles again, how often in the last month did you use bleach to dean
them?
Doesn't re-use.....................................0
Every tim e ...........................................1
Often................................................... 2
Sometimes........................................... 3
Rarely.................................................. 4
Never .................................................5
Drug Use Sub-total 
SEXUAL BEHAVIOUR
7,How many people, including clients, have you had sex with in the last month?
None.......................................................0
One person..............................................1
Two people............................................. 2
3-5 people............................................... 3
6-10 people........................................... 4
More than 10 people...............................5
If no sex in the last month, score zero for Sexual Behaviour section, and go to Section IV.
8. How often have you used condoms when having sex with your regular partners) in the
last month?
No reg. partner/No penetrative sex.......... 0
Every tim e................................................. 1
Often....................................................... 2
Sometimes................................................3
Rarely........................................................ 4
Never........................................................5
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9. How often did you use condoms when you had sex with casual partners in the last 
month?
No cas. partners/No penetrative sex............ 0
Every tim e.....................................................1
Often.............................................................2
Sometimes ...................................................3
Rarely............................................................4
Never..............................................................5
10. How often have you used condoms when you have been paid for sex in the last
month?
No paid sex/No penetrative sex.....................0
Every tim e ................................................... 1
Often.............................................................2
Sometimes ...................................................3
Rarely...........................................................4
Never............................................................5
11. How many times did you have anal sex in the last month?
No times.......................................................0
One time.........................................................1
Two tim es...................................................... 2
3-5 times...................................................... 3
6-10 times....................................................... 4
More than 10 times.........................................5
Sexual Behaviour Sub-total=
TOTAL SCORE=
(Drug Use Sub-total + Sexual Behaviour Sub-total)=
General Comments on HIV Risk-taking Behaviour
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SECTION III: SOCIAL FUNCTIONING
These next few questions concern the social aspects of your life (things like jobs, friends, etc).
1. How many different places have you lived in over the last six months?
O ne..................................................0
Two................................................... 1
Three................................................. 2
Four................................................... 3
Five or more...................................... 4
2. How much of the last six months have you been unemployed?
All of the tim e.................................... 4
Most of the tim e................................ 3
Half of the tim e................................. 2
Some of the tim e...............................1
None of the tim e ............................... 0
3. How many different full-time jobs have you had in the last six months?
O ne...................................................0
Two................................................... 1
Three................................................. 2
Four...................................................3
Five or more......................................4
4. How often in the last six months have you had conflict with your relatives?
Very often.....................................4
Often............................................. 3
Sometimes.....................................2
Rarely.............................................1
Never............................................. 0
N/A.................................................0
5. How often in the last six months have you had conflict with your partner(s)?
Very often.....................................4
Often............................................. 3
Sometimes.....................................2
Rarely............................................ 1
Never............................................. 0
N/A.................................................0
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6 How often in the last six months have you had conflict with your friends?
Very often......................................4
O ften............................................ 3
Sometimes....................................2
Rarely........................................... 1
Never............................................0
N/A.............................................. 4
7. About how many close friends would you estimate that you have? (INCLUDE
PARTNER)
None............................................... 4
O ne ................................................. 3
Two.................................................. 2
Three................................................ 1
Four or more.................................. 0
8. When you are having problems, are you satisfied with the support you get from your
friends?
Very satisfied.................................... 0
Satisfied........................................... 1
Reasonably O K ................................ 2
Not satisfied......................................3
Very unsatisfied................................4
N/A.....................................................0
9. About how often do you see your friends?
Very Often...................................... 0
Often.............................................. 1
Sometimes.....................................2
Rarely............................................. 3
Never............................................... 4
N/A..................................................4
10. How many of the people you hang around with now have you known for more than
six months?
None ....................................................4
Less than ha lf.........................................3
About a ha lf............................................ 2
More than half.........................................1
All of them ...............................................0
N/A...........................................................4
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11. How much of the last six months have you been living with anyone who uses heroin?
All of the tim e........................... 4
Most of the tim e....................... 3
Half of the tim e........................ 2
Some of the tim e .......................1
None of the tim e ...................... 0
12. How many of the people you hang around with now are users? (INCLUDE
PARTNER)
None .......................................0
Less than half.......................... 1
About a half.............................2
More than half.......................... 3
All of them ...............................4
SOCIAL TOTAL=
General Comments on Social Functioning
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SECTION IV: CRIME
In this section I am interested in any crimes that you may have committed. Any 
information that you give here is completely confidential.
Property Crime
First, I am going to ask you some questions on property crime. By property crime I mean 
things such as break and enter, robbery without violence, shoplifting, stealing a 
prescription pad, stealing a car, or receiving stolen goods. I am interested in the number of 
times that you committed a property crime, not the number of times you've been caught.
1. How often, on average, during the last month have you committed a property 
crime? (READ OPTIONS)
No property crime.................................0
Less than once a week.........................1
Once a week.........................................2
More than once a week........................3
(but less than daily)
Daily.................................................... 4
Dealing
Now I am going to ask you some questions about dealing. By dealing I mean selling drugs 
to someone. I am interested in the number of times that you've dealt drugs, not the 
number of times you've been caught.
2. How often, on average, during the last month have you sold drugs to someone?
No drug dealing...........................................0
Less than once a week............................ 1
Once a week............................................. 2
More than once a week............................3
(but less than daily)
Daily........................................................4
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Fraud
Now I am going to ask you some questions about fraud scams. By fraud I mean things 
such as forging cheques, forging prescriptions, social security scams, or using someone 
else's credit card. I am interested in the number of times that you've committed fraud, not 
the number of times that you've been caught.
3. How often, on average, during the last month have you committed a fraud?
No fraud...............................................0
Less than once a week........................ 1
Once a week..........................................2
More than once a week..........................3
(but less than daily)
Daily........................................................ 4
Crimes Involving Violence
Finally, I am going to ask you some questions about crimes involving violence. By crimes 
involving violence I mean things such as using violence in a robbery, armed robbery, 
assault, rape, etc. I am interested in the number of times that you've committed a crime 
involving violence, not the number of times that you've been caught.
4. How often, on average, during the last month have you committed a crime involving
violence?
No violent crime........................................... 0
Less than once a week.................................1
Once a week.................................................2
More than once a week
(but less than daily)...................................... 3
Daily..............................................................4
CRIME TOTAL=
General Comments on Crime
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SECTION V: HEALTH
These questions are about your health. I am going to read out a list of health 
problems. Please answer 'Yes' if you have had any of these problems over the last 
month.
General
fatigue/energy loss
poor appetite
weight loss/underweight
trouble sleeping
fever
night sweats
swollen glands
jaundice
bleeding easily
teeth problems
eye/vision problems
ear/hearing problems
cuts needing stitches
TOTAL
Injection Related Problems
overdose
abscesses/infections from injecting
dirty hit (made feel sick)
prominent scarring/bruising
difficulty injecting
TOTAL
Cardio/Respiratory
persistent cough
coughing up phlegm
coughing up blood
wheezing
sore throat
shortness of breath
chest pains
heart flutters/racing
swollen ankles
TOTAL
Genito-urinary
painful urination
loss of sex urge
discharge from penis/vagina
rash on/around penis/vagina
TOTAL
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Gynaecological
(WOMEN ONLY) (in the last few Months;
irregular period
miscarriage
TOTAL
Musculo-skeletal
Joint pains/stiffness
Broken bones
muscle pain
TOTAL
Neurogical
headaches
blackouts
tremors (shakes)
numbness/tingling
dizziness
fits/seizures
difficult walking
head injury
forgetting things
TOTAL
Gastro-intestinal
nausea
vomiting
stomach pains
constipation
diarrhoea
TOTAL
HEALTH TOTAL
General Comments on Health
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SECTION VI: PSYCHOLOGICAL ADJUSTMENT 
GENERAL HEALTH QUESTIONNAIRE
Please read this carefully:
I should like to know if you have had any medical complaints, and how your health has 
been in general over the past few weeks. Please answer ALL the questions on the 
following pages simply by circling the answer that you think most nearly applies to you. 
Remember that we want to know about present and recent complaints, not those that you 
had in the past.
HAVE YOU RECENTLY:
1. Been feeling well Better Same Worse Much worse
and in good health? than usual as usual than usual than usual
2. Been feeling in Not No more Rather more Much more
need of a pick at all than usual than usual than usual
me up?
3. Been feeling run Not No more Rather more Much more
down and out of at all than usual than usual than usual
sorts?
4. Felt that you are Not No more Rather more Much more
ill? at all than usual than usual than usual
5. Been getting any Not No more Rather more Much more
pains in your head? at all than usual than usual than usual
6. Been getting a Not No more Rather more Much more
feeling of tightness at all than usual than usual than usual
or pressure in your
head?
7. Been having hot Not No more Rather more Much more
or cold spells? at all than usual than usual than usual
8. Lost much sleep Not No more Rather more Much more
over worry? at all than usual than usual than usual
9. Had difficulty Not No more Rather more Much more
in staying asleep at all than usual than usual than usual
once you are off?
10. Felt constantly Not No more Rather more Much more
under strain? at all than usual than usual than usual
11. Been getting edgy Not No more Rather more Much more
and bad tempered? at all than usual than usual than usual
12. Been getting Not No more Rather more Much more
scared or panicky at all than usual than usual than usual
for no good reason?
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13. Found everything 
getting on top of 
you?
Not 
at all
No more 
than usual
Rather more 
than usual
Much more 
than usual
14. Been feeling 
nervous and strung 
up all the time?
Not 
at all
No more 
than usual
Rather more 
than usual
Much more 
than usual
15. Been managing 
to keep busy and 
occupied?
More so 
than usual
Same 
as usual
Rather less 
than usual
Much less 
than usual
16. Been taking 
longer over the 
things you do?
Quicker 
than usual
Same 
as usual
Longer 
than usual
Much longer 
than usual
17. Felt on the 
whole you were 
doing things well?
Better 
than usual
About 
the same
Less well 
than usual
Much 
less well
18. Been satisfied 
with the way you've 
carried out your 
task?
More
satisfied
About 
the same
Less
than usual
Much less 
satisfied
19. Felt that you 
are playing a 
useful part in 
things?
More so 
than usual
Same 
as usual
Less useful 
than usual
Much less 
useful
20. Felt capable of 
making decisions 
about things?
More so 
than usual
Same 
as usual
Less so 
than usual
Much less 
capable
21. Been able 
to enjoy your 
normal day to 
day activities?
More so 
than usual
Same 
as usual
Less so 
than usual
Much less 
than usual
22. Been thinking 
of yourself as a 
worthless person?
Not 
at all
No more 
than usual
Rather more 
than usual
Much more 
than usual
23. Felt that life 
is entirely 
hopeless?
Not 
at all
No more 
than usual
Rather more 
than usual
Much more 
than usual
24. Felt that life 
is not worth living?
Not 
at all
No more 
than usual
Rather more 
than usual
Much more 
than usual
25. Thought of the 
possibility that
Definitely
not
I don't 
think so
Has crossed 
my mind
Definitely
have
you might do away 
with yourself?
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26. Found at times 
that you couldn't 
do anything because 
your nerves were so 
bad?
Not 
at all
No more 
than usual
Rather more 
than usual
Much more 
than usual
27. Found yourself 
wishing you were 
dead and away from 
it all?
Not 
at all
No more 
than usual
Rather more 
than usual
Much more 
than usual
28. Found that the 
idea of taking your
Definitely
not
1 don't 
think so
Has crossed 
my mind
Definitely
has
own life kept coming 
into your mind?
GHQ SUMMARY DATA
A B C D TOTAL
General Comments on Health
301
Appendix 2
OPIATE TREATMENT INDEX SCORE SHEET 
SCALES
D ru g  use  
(P o ly )
H IV  risk S o c ia l C rim e H e a lth G H Q
In itia l
F /up  1
F /up  2
DRUG USE SCORES
In itia l F /u p  1 F /u p  2
H e ro in
O th e r o p ia te s
A lc o h o l
C a n n a b is
A m p h e ta m in e s
C o ca in e
T ra n q u illiz e rs
B a rb itu ra te s
H a llu c in o g e n s
In h a la n ts
T o b a c c o
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Appendix 3
• Section I: Demographics and drug treatment history
This section is not used for the purposes of this study as socio-demographic 
characteristics and drug treatment histories are covered as a separate section in Part 
1 of the questionnaire, for which specific questions were developed.
• Section II: Drug Use
This domain measures the use of illegal and legal drugs by an individual in eleven 
drug classes: heroin, other opioids, alcohol, cannabis, amphetamines, cocaine, 
tranquillisers, barbiturates, hallucinogens, inhalants and tobacco. For each drug 
used, episodes of use are measured rather than the quantity used, due to the 
difficulty associated with measuring the actual amount of drug used in any given 
instance. A score for each category of drug used is calculated through a simple 
formula {the total number o f use episodes in the two most recent days o f use, divided 
by the total time interval between the days o f use, within the month prior to 
interview). There are two main scores that can be calculated from this section, the 
first being a poly drug use total, which is a total of the number of drugs used in the 
month prior to the interview and the second being the drug use risk score, which 
totals the scores for each drug used in the month prior to the interview. The poly 
drug use total score is the one used in the OTI total score. A higher score in either of 
the sections indicates greater risk.
• Section III: Injecting and Sexual Practices
This section measures risk for an individual associated with injecting and sexual 
risk behaviour, in the last month prior to interview through a series of 11 questions. 
Each question has a rating from 0-5, zero indicates no risk from that particular 
behaviour, while any score above zero indicates risk, and the higher the score the 
greater the risk. This section measures an injecting risk score and a sexual risk 
score, and the total of these two produce a total BBV risk score, which can range 
from 0-55.
• Section IV: Social Functioning
This section has 12 questions that measure social adjustment in the last six months 
prior to interview, under the broad headings of employment, accommodation and 
personal relationships. Each question is scored from 0-4, with zero indicating no 
dysfunction in that particular section. The question scores are summed to elicit a 
total social function score that can range from 0-48.
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• Section V: Crime
This section measures criminal activity of an individual in the month prior to 
interview in four classes of crime; property crime, drug dealing, fraud and crimes 
involving violence. Each class is scored from 0-4, zero indicating no crime 
committed in that class. Score for the four classes are summed to elicit a total score 
that can range from 0-16.
• Section VI: Health
In this section health status of an individual is measured by the presence or absence 
of symptomatology in eight health areas mostly in the month prior to interview.
The eight areas covered are general health, injection related problems, 
cardio/respiratory, genito-urinary, gynaecological, musculo-skeletal, neurological 
and gastro-intestinal systems. Gynaecological symptoms are measured for a few 
months prior to interview. There are 52 symptoms scored in total over the eight 
areas. A person can have a 0 or 1 score for each of these symptoms depending on 
whether or not they have experienced the symptom generally in the month prior to 
interview. Scores for each system are summed to provide a total health score that 
can range from 0-52. The greater the section score or total health score, the poorer 
the health outcomes.
• Section VII: Psychological adjustment as measured by the General Health 
Questionnaire
This section incorporates the General Health Questionnaire-28 (GHQ-28) and 
measures psychopathology through four classes: somatic symptoms, anxiety, social 
dysfunction and depression. Scores range from 0-7 in each class and total scores 
from the four classes can range from 0-28. A higher score indicates greater 
dysfunction.
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Appendix 4
THE AUSTRALIAN NATIONAL UNIVERSITY 
ACT COMMUNITY CARE 
SOUTHERN AREA HEALTH SERVICE
NATIONAL CENTRE FOR EPIDEMIOLOGY AND POPULATION HEALTH Page 1 of 2
MEASURING OUTCOMES FOR METHADONE PROGRAM CLIENTS 
Information Sheet & Consent Form
About the study
The purpose of this study is to look at outcomes such as general health, other drug use, 
risk of contracting HIV, hepatitis B (HB V) and hepatitis C (HCV) and integration into 
the community for people on the methadone program. By speaking with people on the 
methadone program directly, it is hoped that outcomes based on your perception will be 
gathered. The researchers envisage that the results will be used to inform the future 
planning and delivery of services for methadone program clients.
There are three components to the study, the first will compare outcomes between urban 
and rural clients, the second will compare outcomes over time for clients in the 
Australian Capital Territory (ACT) and the third will compare self-report of HIV, HBV 
and HCV with blood test results.
How the study will be conducted
You will be asked to fill in a questionnaire after which a trained interviewer will ask 
you a few more questions and the same person will collect a finger prick blood sample. 
The interview will take approximately one hour including the finger prick blood test, 
which is a minor procedure, with very little discomfort, and there are no recorded 
adverse effects.
Confidentiality and anonymity
The questionnaire will be completely anonymous. There will be no identifying details 
put on the questionnaire. The questionnaire will have a record number, which will be 
linked to the blood spot. We cannot provide individual test results because finger prick 
testing in Australia is used only for research and cannot be used for clinical or 
diagnostic purposes. If you wish to know your HIV, hepatitis B or hepatitis C status, the 
interviewer administering the questionnaire can organize this for you. Only the research 
team will have access to the information collected. No publications from this research 
will identify any individuals.
Storing of Information
All the information from this research will be kept under lock and key, and only the 
principal investigator will have direct access to it.
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Feedback
You can access results of this study, once completed through a report that will be made 
available at methadone clinics and dosing centres. You can also contact the National 
Centre for Epidemiology and Population Health (details listed below) and arrangements 
will be made to forward a report to you directly.
Inquiries
Any inquiries can be directed to the principal investigator Geetha Isaac-Toua on (02) 
6125 5602, at the National Centre of Epidemiology and Population Health, the 
Australian National University.
Further inquiries may be directed to Mrs. Sylvia Deutsch, Human Ethics Officer, 
Research Services Office, Australian National University on (02) 6125 2900 or 
e-mail, Human.Ethics.Officer@anu.edu.au.
Your consent to participate in this research is by verbal consent, witnessed by an agency 
staff member and the researcher. This is to protect your confidentiality and provide 
anonymity to the information you provide. If you do agree to the interview, you are free 
to discontinue the discussion at any time. You will be given $15.00 at the completion of 
the interview to reimburse you for your time and any out of pocket expenses.
The record number below is the number recorded on your questionnaire and blood 
sample. If you wish to withdraw from the study please contact Geetha Isaac-Toua or 
Sylvia Deutsche and mention the record number and any information relating to this 
record number will be destroyed. You can withdraw from the study at any time without 
giving a reason and without penalty. You will be given a copy of this information sheet 
with your record number for your records.
Although all possible precautions will be taken to protect the confidentiality of the 
information you give, there is no legal protection of this information. No information 
about you will be given to anyone else unless you decide that you are in need of 
assistance.
Your participation would be extremely helpful, but there is no pressure on you to take 
part and your access to services will not be affected if you decline. If you have any 
questions relating to this research or participation in the research study please contact 
Geetha Isaac-Toua or Sylvia Deutsche.
Record number:
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Appendix 5
Comparison of Outcomes for Methadone 
Treatment Program Clients
Non respondent Questionnaire
R ecord  num ber:
Date: / /
A rea code:
(A C T  =  1)
( S N S W  =  2 )
Interview er:
2002
The National Centre for Epidemiology and Population Health
Australian National University
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Q1. How old are you?
Q1. What sex are you?
Male1 Female2
Years
Transexual3
Q3. What is the highest level of education you have completed? (Tick one box)
Postgraduate qualification 
Bachelor degree 
TAFE certificate (eg. trade)
High school certificate (year 12)
Leaving/school certificate (year 10)
Left high school before leaving certificate (before year 10)
Did not attend high school 
Completed primary school 
Attended primary school
•— 1 3 
□ 4 
□ 5  
□e
□ 7
□ .
Q4. How are you employed at the moment?
Unemployed 1 Full-time 2 Part-time/casual 3
Home duties 5 Other 80 (please specify) ___________
Student
Q5. What is your current marital status?
Never married 1 Married/Defacto 2 Separated 3 Divorced 4
Widowed Other so (please specify)
Q6. Have you ever been in prison? (Including remand/police cells)
No0 Yesi
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Q7. Do you identify as an Aboriginal or Torres Strait Islander?
No o Yes ^
Q8. How many months have you been on this program?_____________Months
Q9. Is this the first time you have been on a methadone program?
No o Yes i
Q10. Which of the following would best describe your program?
Public ■, Partly public/partly private 2 Private 3 Don’t know 90
Q11. How satisfied are you with this program?
Very satisfied•, Satisfied 2 Unsatisfied 3 Very unsatisfied 4
Don’t know 90
Q12. What is your residential Post-code? _________________
Q13. Why don’t you want to take part in the study?
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Appendix 6
April/May 2002
ATTENTION ALL METHADONE TREATMENT 
PROGRAM CLIENTS
STUDY ON
Methadone Program Treatment Outcomes
You maybe approached by your methadone program coordinator 
in the next month or so, to participate in a study looking at 
outcomes for people on the program. This study is being carried 
out to find out how well the program works from your 
perspective. It will look at expenses associated with the program, 
service provided, convenience relating to clinic times, travel 
distances, and whether the program has helped you to achieve 
outcomes to improve your quality of life. The study will also 
compare the ACT Program with the Southern New South Wales 
program to look at differences.
The study is completely independent of the Health Service and is 
being carried out by qualified researchers from the Australian 
National University. It is completely anonymous and confidential 
and interviews will be conducted outside the clinic. There will be 
no information kept that will link your true identity to information 
provided by you for the study.
By participating in this study, you will be available to provide 
valuable information regarding whether the program suits you or 
not, and how it could be better improved to assist with your life.
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Appendix 7: Recruitment sheet for methadone coordinators
Tier 1
Number from database Sample number Yes/No
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Appendix 9: Recruitment Sheet: Tiers 2 and 3
N u m b e r  on  d a tab ase S a m p le  N u m b er P h a rm a cy
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Appendix 10: Recruitment sheet by pharmacy
Pharmacy: (eg: Devlins* City Pharmacy)
Number from 
database
Name of client Sample number Yes/No
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Appendix 11: Information sheet for ACT participants recruited through community 
pharmacies
THE AUSTRALIAN NATIONAL UNIVERSITY 
ACT COMMUNITY CARE 
SOUTHERN AREA HEALTH SERVICE
NATIONAL CENTRE FOR EPIDEMIOLOGY AND POPULATION HEALTH
MEASURING OUTCOMES FOR METHADONE PROGRAM CLIENTS 
(Information sheet for ACT participants recruited through pharmacies)
You have been randomly selected to participate in the methadone program outcomes 
study and you may have already been asked if you wish to participate. The interview 
will take about an hour and you will be re-imbursed $ 15.00 for your time and out of 
pocket expenses.
If you wish to participate please contact Angie Creed on 6205 1000 or Geetha on 0414 
695 840 to make a time for the interview. You can meet the interviewer either at the 
Griffin Center at Civic or at the Drug and Alcohol Clinic at Woden.
You need to make an appointment by the 28th of June 2002 to be eligible to participate. 
All information regarding the study has been outlined on the attached information sheet.
Please mention your sample number................ .. and not your name, when you make
your appointment.
Your participation is much appreciated and the information provided will be used 
towards trying to improve the programme as per your needs.
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Appendix 12: Information sheet for SN SW participants recruited through community 
pharmacies
THE AUSTRALIAN NATIONAL UNIVERSITY 
ACT COMMUNITY CARE 
SOUTHERN AREA HEALTH SERVICE
NATIONAL CENTRE FOR EPIDEMIOLOGY AND POPULATION HEALTH
Page 1 of 2
MEASURING OUTCOMES FOR METHADONE PROGRAM CLIENTS
(Information sheet for SNSW participants recruited through pharmacies)
You have been randomly selected to participate in the methadone program outcomes 
study. The interview will take about an hour and you will be re-imbursed $15.00 for 
your time and out of pocket expenses.
If you wish to participate please contact Geetha on 0414 695 840 to make a time and 
place for the interview. You have also been given a phone card to enable you to make 
the phone call without any out of pocket expenses. We are also available on weekends, 
to enable to fit into your work or other commitments.
You need to make an appointment by the 27th October 2002 to be eligible to participate. 
All information regarding the study has been outlined on the attached information sheet.
Please mention your sample number................ , and not your name, when you make
your appointment.
Your participation is much appreciated and the information provided will be used 
towards trying to improve the programme as per your needs.
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Appendix 13: Information and interview schedule for selected rural Tier 3 clients
THE AUSTRALIAN NATIONAL UNIVERSITY 
ACT COMMUNITY CARE 
SOUTHERN AREA HEALTH SERVICE
NATIONAL CENTRE FOR EPIDEMIOLOGY AND POPULATION HEALTH
Page 1 of 2
MEASURING OUTCOMES FOR METHADONE PROGRAM CLIENTS
(Interview details)
(Information and interview schedule for selected rural Tier 3 clients, 
given at GP practices)
Thank you for agreeing to participate in the methadone program outcomes study. The 
interview will take about an hour and you will be re-imbursed $15.00 for your time and 
out of pocket expenses.
Your interview date is: ...................................................
Your interview time is: ...................................................
Your interview venue: ...................................................Community Health Center
Your study sample number: ..................................................
All information regarding the study has been outlined on the attached information sheet. 
Please mention your sample number only and not your name, when you come for your 
interview.
If you need to change times or are unable to attend for unforeseen reasons please 
contact Geetha on 0414 695 840
Your participation is much appreciated and the information provided will be used 
towards trying to improve the programme as per your needs.
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Appendix 14: Tables comparing mean score for eight areas/systems ofphysical health 
status
Table 1: Comparison of general health issue mean scores: Overall sample & 
by tier
Characteristics Overall sample 
N=118
ACT
N=62
SNSW
N=56
p-values 
(Pearson X2)
Total sample
n 116a 60a 56
Mean score 5.06 4.92 5.21 0.52
SD 2.48 2.48 2.50
Range 0-11 0-11 0-11
Tier 1
n 52b 25b 27
Mean score 5.15 4.84 5.44 0.44
SD 2.80 2.41 3.13
Range 0-11 1-10 0-11
Tier 2
n 33b 20b 13
Mean score 5.09 5.00 5.23 0.79
SD 2.40 2.87 1.54
Range 0-11 0-11 3-8
Tier 3 
n 31 15 16
Mean score 4.87 4.93 4.81 0.87
SD 2.03 2.19 1.94
Range 1-9 1-8 2-9
°  Two missing values, b one missing value
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Table 2: Comparison of injecting problems mean scores: Overall sample 
& by tier
Characteristics Overall sample ACT SNSW p-values
N=118 N=62 N=56 (Pearson X2)
Total
sample 116a
n 0.43
Mean score 0.83
SD
Range
0-3
Tier 1
n 52b
Mean score 0.40
SD 0.80
Range 0-3
Tier 2 
n 33b
Mean score 0.36
SD 0.90
Range 0-3
Tier 3
n 31
Mean score 0.55
SD 0.81
Range 0-3
60a 56
0.43 0.43 0.97
0.85 0.81
0-3 0-3
25b 27
0.36 0.44 0.46
0.86 0.75
0-3 0-2
20b 13
0.40 0.31 0.74
0.94 0.85
0-3 0-3
15 16
0.60 0.50 0.48
0.74 0.89
0-2 0-3
a Two missing values,h one missing value
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Table 3: Comparison of cardio-rcspiratory problem mean scores: Overall 
sample & by tier
Characteristics Overall sample 
N=118
ACT
N=62
SNSW
N=56
p-values 
(Pearson X2)
Total sample
n 116a 60a 56
Mean score 2.90 2.78 3.02 0.45
SD 2.33 2.44 2.22
Range 0-9 0-9 0-8
Tier 1
n 52b 25b 27
Mean score 2.87 2.48 3.22 0.22
SD 2.16 2.18 2.12
Range 0-7 0-6 0-7
Tier 2
n 33b 20b 13
Mean score 2.79 3.10 2.31 0.52
SD 2.45 2.81 1.75
Range 0-9 0-9 0-5
Tier 3
n 31 15 16
Mean score 3.06 2.87 3.25 0.75
SD 2.54 2.45 2.70
Range 0-8 0-7 0-8
°  Two missing values, b one missing value
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Table 4: Comparison of genito-urinary problems mean scores: Overall 
sample & by tier
Characteristics Overall sample 
N=118
ACT
N=62
SNSW
N=56
p-values 
(Pearson X2)
Total sample
n 116a 60a 56
Mean score 0.70 0.68 0.71 0.93
SD 0.76 0.72 0.80
Range 0-4 0-3 0-4
Tier 1
n 52a 25a 27
Mean score 0.62 0.76 0.48 0.21
SD 0.75 0.83 0.64
Range 0-3 0-3 0-2
Tier 2 
n 33a 20a
0
13
Mean score 0.64 0.60 0.69 0.94
SD 0.70 0.60 0.85
Range 0-2 0-2 0-2
Tier 3
n 31 15 16
Mean score 0.90 0.67 1.13 0.11
SD 0.83 0.72 0.89
Range 0-4 0-2 0-4
a Two missing values, bone missing value
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Table 5: Comparison of musculo-skcletal problems mean scores: Overall 
sample & by tier
Characteristics Overall sample 
N=118
ACT
N=62
SNSW
N=56
p-values 
(Pearson X2)
Total sample
n 116a 60a 56
Mean score 1.17 1.03 1.32 0.07
SD 0.87 0.90 0.81
Range 0-3 0-3 0-2
Tier 1
n 52b 25b 27
Mean score 1.19 1.08 1.30 0.36
SD 0.91 0.95 0.87
Range 0-3 0-3 0-2
Tier 2 
n 33b 20b 13
Mean score 1.09 0.95 1.31 0.25
SD 0.84 0.89 0.75
Range 0-2 0-2 0-2
Tier 3 
n 31 \5 16
Mean score 1.23 1.07 1.38 0.32
SD 0.84 0.88 0.81
Range 0-2 0-2 0-2
a Two missing values,h one missing value
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Table 6: Comparison of neurological problems mean scores: Overall sample 
& by tier
Characteristics Overall sample 
N=118
ACT
N=62
SNSW
N=56
p-values 
(Pearson X2)
Total sample
n 116a 60a 56
Mean score 2.53 2.35 2.73 0.31
SD 1.94 1.91 1.98
Range 0-7 0-7 0-7
Tier 1
n 52b 25b 27
Mean score 2.50 2.20 2.78 0.25
SD 1.96 1.91 1.99
Range 0-7 0-6 0-7
Tier 2
n 33b 20b 13
Mean score 2.73 2.55 3.00 0.49
SD 1.88 1.96 1.78
Range 0-6 0-6 1-6
Tier 3 
n 31 15 16
Mean score 2.39 2.33 2.44 0.97
SD 2.04 1.95 2.19
Range 0-7 0-7 0-7
°  Two missing values, h one missing value
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Table 7: Comparison of gastro-intestinal problems mean scores: Overall 
sample & by tier
Characteristics Overall sample 
N=118
ACT
N=62
SNSW
N=56
p-values 
(Pearson X2)
Total sample
n 116a 60a 56
Mean score 1.89 1.78 2.00 0.50
SD 1.58 1.55 1.62
Range 0-5 0-5 0-5
Tier 1
n 52a 25a 27
Mean score 1.62 1.36 1.85 0.30
SD 1.55 1.50 1.59
Range 0-5 0-5 0-5
Tier 2
n 33a 20a 13
Mean score 2.06 2.10 2.00 0.76
SD 1.69 1.62 1.87
Range 0-5 0-5 0-5
Tier 3
n 31 15 16
Mean score 2.16 2.07 2.25 0.75
SD 1.49 1.49 1.53
Range 0-5 0-5 0-5
a Two missing values, b one missing value
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Table 8: Comparison of gynaecological problems mean scores: Overall 
sample & by tier (females only)
Characteristics Overall sample 
N=49
ACT
N=27
SNSW
N=22
p-values 
(Pearson X2)
Total sample
n 49 27 22
Mean score 0.63 0.67 0.59 0.61
SD 0.57 0.55 0.59
Range 0-2 0-2 0-2
Tier 1
n 23 13 10
Mean score 0.52 0.62 0.40 0.32
SD 0.51 0.51 0.52
Range 0-1 0-1 0-1
Tier 2
n 10 7 3
Mean score 0.80 0.86 0.67 0.70
SD 0.63 0.69 0.58
Range 0-2 0-2 0.70
Tier 3
n 16 7 9
Mean score 0.69 0.57 0.78 0.55
SD 0.60 0.53 0.67
Range 0-2 0-1 0-2
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